0001839998-24-000040.txt : 20240515 0001839998-24-000040.hdr.sgml : 20240515 20240515172120 ACCESSION NUMBER: 0001839998-24-000040 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 84 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240515 DATE AS OF CHANGE: 20240515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: American Oncology Network, Inc. CENTRAL INDEX KEY: 0001839998 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40177 FILM NUMBER: 24952642 BUSINESS ADDRESS: STREET 1: 14543 GLOBAL PKWY #110 CITY: FORT MYERS STATE: FL ZIP: 33913 BUSINESS PHONE: 833-886-1725 MAIL ADDRESS: STREET 1: 14543 GLOBAL PKWY #110 CITY: FORT MYERS STATE: FL ZIP: 33913 FORMER COMPANY: FORMER CONFORMED NAME: Digital Transformation Opportunities Corp. DATE OF NAME CHANGE: 20210111 10-Q 1 aonc-20240331.htm 10-Q aonc-20240331
00018399982024Q112-31FALSEhttp://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesCurrentP1YP10Dxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesaonc:practiceaonc:statexbrli:pureaonc:segmentaonc:personaonc:office00018399982024-01-012024-03-310001839998us-gaap:CommonClassAMember2024-01-012024-03-310001839998us-gaap:WarrantMember2024-01-012024-03-310001839998us-gaap:CommonClassAMember2024-05-140001839998us-gaap:CommonClassBMember2024-05-1400018399982024-03-3100018399982023-12-310001839998us-gaap:SeriesAPreferredStockMember2024-03-310001839998us-gaap:SeriesAPreferredStockMember2023-12-310001839998us-gaap:CommonClassAMember2024-03-310001839998us-gaap:CommonClassAMember2023-12-310001839998us-gaap:CommonClassBMember2024-03-310001839998us-gaap:CommonClassBMember2023-12-310001839998us-gaap:RelatedPartyMember2024-03-310001839998us-gaap:RelatedPartyMember2023-12-310001839998aonc:PatientServiceMember2024-01-012024-03-310001839998aonc:PatientServiceMember2023-01-012023-03-310001839998us-gaap:ProductAndServiceOtherMember2024-01-012024-03-310001839998us-gaap:ProductAndServiceOtherMember2023-01-012023-03-3100018399982023-01-012023-03-310001839998us-gaap:RelatedPartyMember2024-01-012024-03-310001839998us-gaap:RelatedPartyMember2023-01-012023-03-310001839998us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-12-310001839998us-gaap:CommonClassBMemberus-gaap:CommonStockMember2023-12-310001839998us-gaap:AdditionalPaidInCapitalMember2023-12-310001839998us-gaap:TreasuryStockCommonMember2023-12-310001839998us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-12-310001839998us-gaap:NoncontrollingInterestMember2023-12-310001839998us-gaap:RetainedEarningsMember2023-12-310001839998us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-01-012024-03-310001839998us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-01-012024-03-310001839998us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001839998us-gaap:TreasuryStockCommonMember2024-01-012024-03-310001839998us-gaap:NoncontrollingInterestMember2024-01-012024-03-310001839998us-gaap:RetainedEarningsMember2024-01-012024-03-310001839998us-gaap:CommonClassBMemberus-gaap:CommonStockMember2024-01-012024-03-310001839998us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-03-310001839998us-gaap:CommonClassBMemberus-gaap:CommonStockMember2024-03-310001839998us-gaap:AdditionalPaidInCapitalMember2024-03-310001839998us-gaap:TreasuryStockCommonMember2024-03-310001839998us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-03-310001839998us-gaap:NoncontrollingInterestMember2024-03-310001839998us-gaap:RetainedEarningsMember2024-03-310001839998us-gaap:CapitalUnitClassAMemberus-gaap:MemberUnitsMember2022-12-310001839998aonc:CapitalUnitClassA1Memberus-gaap:MemberUnitsMember2022-12-310001839998us-gaap:MemberUnitsMemberus-gaap:CapitalUnitClassBMember2022-12-310001839998us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001839998us-gaap:RetainedEarningsMember2022-12-3100018399982022-12-310001839998us-gaap:RetainedEarningsMember2023-01-012023-03-310001839998us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001839998us-gaap:CapitalUnitClassAMemberus-gaap:MemberUnitsMember2023-03-310001839998aonc:CapitalUnitClassA1Memberus-gaap:MemberUnitsMember2023-03-310001839998us-gaap:MemberUnitsMemberus-gaap:CapitalUnitClassBMember2023-03-310001839998us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001839998us-gaap:RetainedEarningsMember2023-03-3100018399982023-03-310001839998aonc:AONLLCMember2023-09-200001839998aonc:DigitalTransformationOpportunitiesCorpDTOCMemberus-gaap:CommonClassBMember2023-09-200001839998us-gaap:CommonClassAMember2023-09-202023-09-200001839998aonc:AONLLCMemberaonc:LegacyAONShareholdersMember2023-09-200001839998aonc:NewAONAONIncMemberaonc:AONLLCMember2023-09-200001839998us-gaap:SeriesAPreferredStockMemberaonc:NewAONAONIncMemberaonc:AONLLCMember2023-09-200001839998aonc:AONLLCMemberus-gaap:CommonClassAMember2023-09-200001839998aonc:DTOCUnredeemedShareholdersMemberus-gaap:CommonClassAMember2023-09-200001839998aonc:DTOCSponsorMemberus-gaap:CommonClassAMember2023-09-200001839998us-gaap:CommonClassBMemberaonc:LegacyAONShareholdersMember2023-09-200001839998us-gaap:SeriesAPreferredStockMemberaonc:AEAGrowthManagementLPMember2023-09-200001839998aonc:ClassBPrefundedWarrantsMemberaonc:LegacyAONShareholdersMember2023-09-200001839998aonc:DTOCSponsorMemberaonc:PublicWarrantMember2023-09-200001839998aonc:DTOCSponsorMemberaonc:PublicWarrantMemberus-gaap:CommonClassAMember2023-09-200001839998aonc:DTOCSponsorMemberaonc:PublicWarrantMember2023-09-202023-09-200001839998aonc:DTOCSponsorMemberaonc:PrivatePlacementWarrantsMember2023-09-200001839998aonc:AONLLCMemberaonc:ClassBPrefundedWarrantsMember2023-09-200001839998aonc:AONLLCMemberaonc:ClassBPrefundedWarrantsMemberus-gaap:CommonClassBMember2023-09-200001839998aonc:AONLLCMemberus-gaap:CommonClassBMember2023-09-200001839998aonc:AONLLCMember2024-01-012024-03-310001839998aonc:NewAONAONIncMember2024-01-012024-03-310001839998aonc:AONLLCMember2023-01-012023-03-310001839998aonc:NewAONAONIncMember2023-01-012023-03-310001839998aonc:ParticipatingThreshold1Member2024-03-310001839998aonc:ParticipatingThreshold2Member2024-03-310001839998aonc:ParticipatingThreshold3Member2024-03-310001839998aonc:AONLLCMemberus-gaap:SeriesAPreferredStockMember2024-03-310001839998aonc:AONLLCMemberaonc:NewAONAONIncMember2024-01-012024-03-310001839998aonc:LegacyAONShareholdersMemberaonc:AONLLCMember2023-09-212023-09-300001839998aonc:LegacyAONShareholdersMemberaonc:AONLLCMember2023-01-012023-03-310001839998aonc:MIBAMember2023-05-012023-05-310001839998aonc:PatientVisitsMember2024-01-012024-03-310001839998aonc:PatientVisitsMember2023-01-012023-03-310001839998aonc:ClinicalTrialsMember2024-01-012024-03-310001839998aonc:ClinicalTrialsMember2023-01-012023-03-310001839998aonc:OCPManagementArizonaLLPMember2023-01-012023-01-310001839998aonc:OCPManagementArizonaLLPMember2023-01-310001839998us-gaap:PreferredClassAMember2024-01-012024-03-3100018399982023-01-012023-12-3100018399982023-01-012024-03-310001839998us-gaap:ProfessionalMalpracticeLiabilityMember2024-01-012024-03-310001839998us-gaap:DirectorsAndOfficersLiabilityInsuranceMember2024-01-012024-03-310001839998aonc:PublicWarrantMember2024-03-310001839998aonc:PrivatePlacementWarrantsMember2024-03-310001839998us-gaap:MeasurementInputExpectedDividendRateMemberaonc:PrivatePlacementWarrantsMember2024-03-310001839998us-gaap:MeasurementInputPriceVolatilityMemberaonc:PrivatePlacementWarrantsMember2024-03-310001839998us-gaap:MeasurementInputRiskFreeInterestRateMemberaonc:PrivatePlacementWarrantsMember2024-03-310001839998us-gaap:MeasurementInputExpectedTermMemberaonc:PrivatePlacementWarrantsMember2024-03-310001839998aonc:AONIncMember2024-03-310001839998aonc:AONCommonUnitholdersMember2024-03-3100018399982023-09-2000018399982023-09-202023-09-200001839998aonc:PublicAndPrivateWarrantsMember2023-09-212023-09-300001839998aonc:AONCentralMemberaonc:PhysiciansMember2024-01-012024-03-310001839998aonc:AONCentralMember2024-01-012024-03-310001839998aonc:MIBAMember2023-04-012023-06-300001839998us-gaap:VariableInterestEntityPrimaryBeneficiaryMemberaonc:MIBAMember2023-04-012023-06-300001839998us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2024-03-310001839998us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-12-310001839998us-gaap:FairValueInputsLevel1Memberaonc:OvernightRepurchaseAgreementsMember2024-03-310001839998us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2024-03-310001839998us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2024-03-310001839998us-gaap:FairValueInputsLevel1Member2024-03-310001839998us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel2Member2024-03-310001839998us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2024-03-310001839998us-gaap:FairValueInputsLevel2Member2024-03-310001839998us-gaap:FairValueInputsLevel1Memberaonc:OvernightRepurchaseAgreementsMember2023-12-310001839998us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2023-12-310001839998us-gaap:FairValueInputsLevel1Member2023-12-310001839998us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001839998us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMember2023-12-310001839998us-gaap:FairValueInputsLevel2Member2023-12-310001839998aonc:IntravenousDrugsMember2024-03-310001839998aonc:IntravenousDrugsMember2023-12-310001839998aonc:OralPharmaceuticalsMember2024-03-310001839998aonc:OralPharmaceuticalsMember2023-12-310001839998us-gaap:LeaseholdImprovementsMember2024-03-310001839998us-gaap:LeaseholdImprovementsMember2023-12-310001839998aonc:FurnitureFixturesAndEquipmentMember2024-03-310001839998aonc:FurnitureFixturesAndEquipmentMember2023-12-310001839998aonc:MedicalEquipmentMember2024-03-310001839998aonc:MedicalEquipmentMember2023-12-310001839998us-gaap:ComputerEquipmentMember2024-03-310001839998us-gaap:ComputerEquipmentMember2023-12-310001839998aonc:SignsMember2024-03-310001839998aonc:SignsMember2023-12-310001839998us-gaap:AutomobilesMember2024-03-310001839998us-gaap:AutomobilesMember2023-12-310001839998us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2024-03-310001839998us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-12-310001839998us-gaap:ConstructionInProgressMember2024-03-310001839998us-gaap:ConstructionInProgressMember2023-12-310001839998us-gaap:LineOfCreditMemberaonc:PNCLoanFacilityMember2024-03-310001839998us-gaap:LineOfCreditMemberaonc:PNCLoanFacilityMember2023-12-310001839998us-gaap:LineOfCreditMemberaonc:PNCLoanFacilityMember2021-04-302021-04-300001839998aonc:AlternateBaseRateMemberaonc:PNCLoanFacilityMemberus-gaap:LineOfCreditMember2021-04-302021-04-300001839998us-gaap:LineOfCreditMemberaonc:PNCLoanFacilityMember2021-04-300001839998aonc:DebtInstrumentThresholdLimitPeriodOneMemberaonc:PNCLoanFacilityMemberus-gaap:LineOfCreditMember2021-04-302021-04-300001839998aonc:DebtInstrumentThresholdLimitPeriodTwoMemberaonc:PNCLoanFacilityMemberus-gaap:LineOfCreditMember2021-04-302021-04-300001839998us-gaap:RevolvingCreditFacilityMemberaonc:PNCLineOfCreditMemberus-gaap:LineOfCreditMember2021-04-300001839998us-gaap:RevolvingCreditFacilityMemberaonc:PNCLineOfCreditMemberaonc:LondonInterbankOfferedRateLIBOR1Memberus-gaap:LineOfCreditMember2021-04-302021-04-300001839998us-gaap:RevolvingCreditFacilityMemberaonc:PNCLineOfCreditMemberaonc:AlternateBaseRateMemberus-gaap:LineOfCreditMember2021-04-302021-04-300001839998us-gaap:RevolvingCreditFacilityMemberaonc:PNCLineOfCreditMemberus-gaap:LineOfCreditMember2021-04-302021-04-300001839998us-gaap:RevolvingCreditFacilityMemberaonc:PNCLineOfCreditMemberus-gaap:LineOfCreditMember2024-01-012024-03-310001839998us-gaap:RevolvingCreditFacilityMemberaonc:PNCLineOfCreditMemberus-gaap:LineOfCreditMember2023-01-012023-12-310001839998us-gaap:LineOfCreditMemberaonc:PNCLoanFacilityMember2021-07-290001839998us-gaap:LineOfCreditMemberaonc:PNCLoanFacilityMember2022-02-140001839998us-gaap:RevolvingCreditFacilityMemberaonc:PNCLineOfCreditMemberus-gaap:LineOfCreditMember2022-02-140001839998us-gaap:RevolvingCreditFacilityMemberaonc:PNCLineOfCreditMemberaonc:BloombergShortTermBankYieldIndexMemberus-gaap:LineOfCreditMember2022-02-142022-02-140001839998us-gaap:LineOfCreditMemberaonc:PNCLoanFacilityMember2022-02-142022-02-140001839998us-gaap:RevolvingCreditFacilityMemberaonc:PNCLineOfCreditMemberus-gaap:LineOfCreditMember2022-08-150001839998us-gaap:LineOfCreditMemberaonc:PNCLoanFacilityMember2023-06-300001839998aonc:DebtInstrumentThresholdLimitPeriodOneMemberaonc:PNCLoanFacilityMemberus-gaap:LineOfCreditMember2023-06-012023-06-300001839998aonc:A2024NotesReceivableNote2Member2024-03-310001839998aonc:A2024NotesReceivableNote2Member2023-12-310001839998aonc:A2024NotesReceivableNote2Member2019-05-010001839998aonc:A2024NotesReceivableNote3Member2024-03-310001839998aonc:A2024NotesReceivableNote3Member2023-12-310001839998aonc:A2024NotesReceivableNote3Member2019-06-010001839998aonc:A2025NotesReceivableNote8Member2024-03-310001839998aonc:A2025NotesReceivableNote8Member2023-12-310001839998aonc:A2025NotesReceivableNote8Member2020-05-010001839998aonc:SubsidiaryUnderCommonControlOfClassA1MemberMemberus-gaap:RelatedPartyMember2024-01-012024-03-310001839998aonc:SubsidiaryUnderCommonControlOfClassA1MemberMemberus-gaap:RelatedPartyMember2023-01-012023-03-310001839998aonc:SubsidiaryUnderCommonControlOfClassA1MemberMemberus-gaap:RelatedPartyMemberus-gaap:CostOfGoodsTotalMemberus-gaap:SupplierConcentrationRiskMember2024-01-012024-03-310001839998aonc:SubsidiaryUnderCommonControlOfClassA1MemberMemberus-gaap:RelatedPartyMemberus-gaap:CostOfGoodsTotalMemberus-gaap:SupplierConcentrationRiskMember2023-01-012023-03-310001839998aonc:SubsidiaryUnderCommonControlOfClassA1MemberMemberus-gaap:RelatedPartyMember2024-03-310001839998aonc:SubsidiaryUnderCommonControlOfClassA1MemberMemberus-gaap:RelatedPartyMember2023-12-310001839998aonc:SubsidiaryUnderCommonControlOfClassA1MemberMemberus-gaap:RelatedPartyMemberus-gaap:AccountsPayableMemberus-gaap:SupplierConcentrationRiskMember2024-01-012024-03-310001839998aonc:SubsidiaryUnderCommonControlOfClassA1MemberMemberus-gaap:RelatedPartyMemberus-gaap:AccountsPayableMemberus-gaap:SupplierConcentrationRiskMember2023-01-012023-12-310001839998us-gaap:EmployeeStockMemberaonc:A2023IncentiveEquityPlanMember2024-03-310001839998us-gaap:EmployeeStockMemberaonc:A2023IncentiveEquityPlanMember2024-01-012024-03-310001839998us-gaap:RestrictedStockMember2024-01-012024-03-280001839998us-gaap:RestrictedStockMember2023-12-310001839998us-gaap:RestrictedStockMember2024-01-012024-03-310001839998us-gaap:RestrictedStockMember2024-03-310001839998us-gaap:RestrictedStockMembersrt:MinimumMember2024-01-012024-03-310001839998us-gaap:RestrictedStockMembersrt:MaximumMember2024-01-012024-03-310001839998us-gaap:CommonClassAMemberaonc:AONLLCMember2022-12-310001839998aonc:CommonClassA1Memberaonc:AONLLCMember2022-12-310001839998us-gaap:CommonClassBMemberaonc:AONLLCMember2023-12-310001839998us-gaap:CommonClassBMemberaonc:AONLLCMember2022-01-012022-12-310001839998us-gaap:CommonClassAMember2022-12-310001839998us-gaap:CommonClassAMember2023-01-012023-03-310001839998us-gaap:CommonClassAMember2023-03-310001839998aonc:CommonClassA1Member2022-12-310001839998aonc:CommonClassA1Member2023-01-012023-03-310001839998aonc:CommonClassA1Member2023-03-310001839998us-gaap:CommonClassBMember2022-12-310001839998us-gaap:CommonClassBMember2023-01-012023-03-310001839998us-gaap:CommonClassBMember2023-03-310001839998aonc:CommonStockClassB1Member2023-06-012023-07-310001839998us-gaap:SeriesAPreferredStockMemberaonc:AEAGrowthManagementLPMember2023-09-202023-09-200001839998us-gaap:CommonClassCMember2024-01-012024-03-310001839998us-gaap:SeriesAPreferredStockMember2024-01-012024-03-310001839998us-gaap:SeriesAPreferredStockMember2023-09-202023-09-200001839998aonc:StockholdersMemberus-gaap:SeriesAPreferredStockMember2024-03-310001839998aonc:StockholdersMemberus-gaap:SeriesAPreferredStockMember2024-01-012024-03-310001839998aonc:NewAONAONIncMember2024-03-310001839998aonc:NewAONAONIncMember2024-01-012024-03-310001839998us-gaap:SeriesAPreferredStockMemberaonc:DividendsPaidEventPriorToJune72024Member2024-01-012024-03-310001839998us-gaap:SeriesAPreferredStockMemberaonc:DividendsPaidEventPriorToJune72025AfterJune72024Member2024-01-012024-03-310001839998aonc:DividendsPaidEventPriorToJune72026AfterJune72025Memberus-gaap:SeriesAPreferredStockMember2024-01-012024-03-310001839998us-gaap:SeriesAPreferredStockMemberaonc:DividendsPaidEventPriorToJune72027AfterJune72026Member2024-01-012024-03-310001839998us-gaap:SeriesAPreferredStockMemberaonc:DividendsPaidEventPriorToJune72028AfterJune72027Member2024-01-012024-03-310001839998us-gaap:SeriesAPreferredStockMemberaonc:DividendsPaidEventAfterJune72028Member2024-01-012024-03-310001839998us-gaap:CommonClassAMember2020-03-042020-03-040001839998aonc:CommonClassA1Member2020-03-042020-03-040001839998us-gaap:CommonClassAMember2023-06-072023-06-070001839998aonc:CommonClassA1Member2023-06-072023-06-070001839998us-gaap:SeriesAPreferredStockMember2024-01-012024-03-310001839998us-gaap:CommonClassBMember2024-01-012024-03-310001839998aonc:ClassBPrefundedWarrantsMember2024-01-012024-03-310001839998aonc:PublicAndPrivateWarrantsMember2024-01-012024-03-310001839998us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001839998aonc:LegacyAONShareholdersMemberaonc:AONLLCMember2024-03-310001839998aonc:LegacyAONShareholdersMemberaonc:AONLLCMember2024-01-012024-03-310001839998aonc:AONLLCMemberaonc:NewAONAONIncMember2023-12-310001839998aonc:LegacyAONShareholdersMemberaonc:AONLLCMember2023-12-310001839998aonc:AONLLCMember2023-12-310001839998aonc:AONLLCMemberaonc:NewAONAONIncMember2024-03-310001839998aonc:AONLLCMember2024-03-310001839998aonc:AONLLCMember2024-01-012024-03-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2024
or
oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number 001-04321
American Oncology Network, Inc.
(Exact name of registrant as specified in its charter)
Delaware85-3984427
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
14543 Global Parkway, Suite 110, Fort Myers, Florida
33913
(Address of Principal Executive Offices)(Zip Code)
(833) 886-1725
Registrant's telephone number, including area code
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Class A common stock, par value $0.0001, per shareAONCThe Nasdaq Stock Market LLC
Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per shareAONCWThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.:
Large accelerated fileroAccelerated filero
Non-accelerated filerxSmaller reporting companyx
Emerging growth companyo
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No x
As of May 14, 2024, the registrant had outstanding 13,046,342 shares of Class A common stock, inclusive of the Sponsor Earnout shares, and 23,725,998 shares of Class B common stock.

TABLE OF CONTENTS
 
PAGE

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q (this “Form 10-Q”), including, without limitation, statements under the headings “Management's Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, including statements about the financial condition, results of operations, earnings outlook and prospects of American Oncology Network, Inc. (“AON”, “New AON”, “AON Inc.”, or the “Company”). Any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements are typically identified by words such as “plan,” “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should,” “would” and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements are based on current expectations and projections about future events and various assumptions. AON cannot guarantee that it will actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements and you should not place undue reliance on AON’s forward-looking statements.

These forward-looking statements involve a number of risks, uncertainties (many of which are beyond the control of AON), or other assumptions that may cause actual results or performance to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in AON’s filings with the Securities and Exchange Commission, including “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The risks described in the “Risk Factors” sections are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can AON assess the impact of all such risk factors on the business of AON, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statement. The statements made herein are made as of the date of this press release and, except as may be required by law, AON undertakes no obligation to update them, whether as a result of new information, developments, or otherwise.
i
Part I - Financial Information

Item 1. Financial Statements
American Oncology Network, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
($ in thousands, except share and per share data)
As of March 31,
2024		As of December 31,
2023
Assets
Current assets
Cash and cash equivalents$74,944 $28,539 
Short-term marketable securities30,105 35,389 
Patient accounts receivable, net132,300 129,151 
Inventories44,288 44,569 
Other receivables34,799 34,274 
Prepaid expenses and other current assets5,029 4,277 
Current portion of notes receivable - related parties2,498 1,604 
Total current assets323,963 277,803 
Property and equipment, net40,997 40,439 
Operating lease right-of-use assets, net (1)43,358 43,349 
Notes receivable - related parties157 1,150 
Other assets12,216 7,588 
Goodwill and intangibles, net1,230 1,230 
Deferred tax asset, net- 2,894 
Total assets$421,921 $374,453 
Liabilities, Mezzanine Equity, and Stockholders' Equity
Current liabilities
Accounts payable (2)$188,329 $127,645 
Accrued compensation related costs12,628 11,410 
Accrued other25,186 22,327 
Income tax payable971 971 
Current portion of operating lease liabilities (3)6,715 6,692 
Total current liabilities233,829 169,045 
Long-term debt, net80,856 80,641 
Long-term operating lease liabilities (4)39,786 39,803 
Other long-term liabilities11,342 14,251 
Total liabilities365,813 303,740 
Mezzanine equity
Series A convertible preferred stock; $0.0001 par value; 7,500,000 shares authorized; 6,651,610 issued and outstanding at March 31, 2024 and December 31, 2023, with an aggregate liquidation preference of $69,369,195 and $68,009,015 at March 31, 2024 and December 31, 2023, respectively.
64,986 64,986 
Redeemable noncontrolling interest157,716 167,025 
Stockholders' equity
Class A Common Stock; $0.0001 par value; 200,000,000 shares authorized; 10,334,734 and 9,517,816 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively.
1 1 
Class B Common Stock; $0.0001 par value; 100,000,000 shares authorized; 23,725,998 and 25,109,551 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively.
3 3 
Additional paid-in capital8,164 - 
Treasury stock, at cost, 31,170 shares at March 31, 2024 and 14,729 shares at December 31, 2023
(97)- 
Accumulated other comprehensive income77 81 
Retained deficit(175,594)(161,812)
Total AON stockholders' deficit(167,446)(161,727)
 Noncontrolling interest852 429 
Total deficit$(166,594)$(161,298)
Total liabilities, mezzanine equity, noncontrolling interest, and stockholders' equity$421,921 $374,453 
(1)Includes related party operating right-of-use assets, net of $11,293 and $10,931 at March 31, 2024 and December 31, 2023, respectively
(2)Includes amounts due to related party of $182,697 and $120,857 at March 31, 2024 and December 31, 2023, respectively
(3)Includes related party current portion of operating lease liabilities of $1,971 and $1,888 at March 31, 2024 and December 31, 2023, respectively
(4)Includes related party long-term operating lease liabilities of $9,772 and $9,472 at March 31, 2024 and December 31, 2023, respectively

The accompanying notes are an integral part of these condensed consolidated financial statements.
1
American Oncology Network, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
($ in thousands, except share and per share data)
Three Months Ended March 31,
20242023
Revenue
Patient service revenue, net$361,508 $301,773 
Other revenue2,831 1,958 
Total revenue364,339 303,731 
Costs and expenses
Cost of revenue (1)354,948 278,534 
General and administrative expenses (2)28,277 23,717 
Transaction expenses352 1,971 
Total costs and expenses383,577 304,222 
Loss from operations(19,238)(491)
Other income (expense)
Interest expense(1,763)(1,417)
Interest income793 57 
Other (expense) income, net(1,908)466 
Loss before income taxes, equity loss in affiliate, and noncontrolling interest(22,116)(1,385)
Income tax expense2,894 - 
Loss before equity loss in affiliate and noncontrolling interest(25,010)(1,385)
Equity in loss of affiliate49 (101)
Net loss before noncontrolling interest (24,961)(1,486)
Net income attributable to noncontrolling interest43 - 
Net loss before redeemable noncontrolling interest(25,004)(1,486)
Net loss and noncontrolling interest attributable to Legacy AON Stockholders prior to the reverse recapitalization- (1,486)
Net loss attributable to redeemable noncontrolling interest(17,163)- 
Net loss attributable to Class A Common Stockholders$(7,841)$- 
Loss per share of Class A Common Stock:
Basic$(1.22)$- 
Diluted$(1.22)$- 
Weighted average shares of Class A Common Stock Outstanding:
Basic7,527,882 - 
Diluted7,527,882 - 
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities(22)64 
Other comprehensive gain (loss)(22)64 
Comprehensive loss$(25,026)$(1,422)
Other comprehensive loss attributable to Legacy AON Shareholders— (1,422)
Other comprehensive loss attributable to noncontrolling interests
(17,180)— 
Total comprehensive loss attributable to Class A Common Stockholders
$(7,846)$— 
(1)Includes related party inventory expense of $310,877 and $178,166 for the three months ended March 31, 2024 and 2023, respectively.
(2)Includes related party rent of $706 and $679 for the three months ended March 31, 2024 and 2023, respectively.

The accompanying notes are an integral part of these condensed consolidated financial statements. 
2
American Oncology Network, Inc.
Condensed Consolidated Statements of Mezzanine and Stockholders’ Deficit
(Unaudited)
($ in thousands, except share and per share data)
Mezzanine Equity - Series A Preferred Stock
NCI(1)
Class A Common
 Stock		Class B Common Stock
In thousands (including share and per share data)Stock$$Stock$Stock$
APIC(1)
Treasury Stock
AOCI(1)
Noncontrolling InterestRetained
Deficit		Total
Equity (Deficit)
Three Months Ended March 31, 2024
Balances at December 31, 20236,65264,986$167,025 6,678,441125,109,5513$- - $81 $429 $(161,812)$(161,298)
Other comprehensive loss--(17)----- - (4)- - $(4)
Equity-based compensation and NCI rebalancing--399 2,289,181---9,696 - - - - $9,696 
Repurchases of Class A Common Stock--- (16,441)---- (97)- - - $(97)
Capital contributions from noncontrolling interest member-- - --- -- - - 380 - $380 
Net income (loss)-- (17,163)----- - - 43 (7,842)$(7,799)
Fair value adjustment to redeemable noncontrolling interest--15,636 ----(9,696)---(5,940)$(15,636)
Redemption of Class B Common Stock to Class A Common Stock--(8,164)1,383,553-(1,383,553)-8,164 - - - $8,164 
Balances at March 31, 20246,652$64,986 $157,716 10,334,734 $1 23,725,998 $3 $8,164 $(97)$77 $852 $(175,594)$(166,594)

Class AClass A-1Class B
In thousands (including share and unit data)Units$Units$$
AOCI(1)
Retained
Earnings (Deficit)		Total
Equity (Deficit)
Three Months Ended March 31, 2023
Balances at December 31, 202219,495$7,725 1,843$28,500 $80 $(117)$25,828 $62,016 
Net loss attributable to Legacy AON Shareholders-- -- - - (1,486)(1,486)
Other comprehensive income attributable to Legacy AON Shareholders-- -- - 64 - 64 
Balances at March 31, 202319,495$7,725 1,843$28,500 $80 $(53)$24,342 $60,594 
(1) The acronyms in the table above are defined as follows:
APIC - Accumulated paid in capital
AOCI - Accumulated other comprehensive income
NCI - Mezzanine equity classified noncontrolling interest

The accompanying notes are an integral part of these condensed consolidated financial statements. 
3
American Oncology Network, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
($ in thousands, except share and per share data)
Three Months Ended March 31,
20242023
Cash flows from operating activities
Net loss$(24,961)$(1,486)
Adjustments to reconcile net loss to net cash provided by operating activities
Depreciation and amortization2,506 2,207 
Amortization of debt issuance costs215 176 
Provision for income taxes2,894 - 
Amortization of operating right-of-use assets (1)2,040 2,224 
Changes in fair value adjustments of warrants and derivative liabilities(1,611)- 
Equity-based compensation10,094 - 
Equity in loss of affiliate(49)101 
Gain on sale of property and equipment393 - 
Changes in operating assets and liabilities:
Patient accounts receivable, net(3,149)(16,711)
Inventories (2)281 4,854 
Prepaid expenses and other current assets(752)(342)
Other receivables(525)3,442 
Other assets(4,579)(2,826)
Accounts payable (3)61,675 5,316 
Accrued compensation related costs1,218 2,757 
Accrued other4,241 (296)
Operating lease liabilities (4)(2,042)(1,777)
Other long-term liabilities(2,752)2,032 
Net cash provided by (used in) operating activities45,137 (329)
Cash flows from investing activities
Purchases of property and equipment(4,132)(2,777)
Purchases of marketable securities(7,069)(1,442)
Proceeds from sales of marketable securities12,624 1,423 
Collections on notes receivable - related parties99 153 
Net cash provided by (used in) investing activities1,522 (2,643)
Cash flows from financing activities
Repayments on finance lease liabilities(157)(105)
Repurchases of Class A Common Stock(97)- 
Net cash used in financing activities(254)(105)
Net increase (decrease) in cash and cash equivalents46,405 (3,077)
Cash and cash equivalents
Beginning of period28,539 26,926 
End of period$74,944 $23,849 
Supplemental noncash investing and financing activities
Promissory note issued in connection with acquisition$1,420 $- 
Contribution from noncontrolling interest(380)- 
Right-of-use assets and lease liabilities removed in termination of lease$- $1,023 
Changes in accounts payable for capital additions to property and equipment$(1,055)$- 
(1)Includes related party amortization of operating right-of-use assets of $2,146 and $528 for the three months ended March 31, 2024 and 2023, respectively.
(2)Includes changes in related party balances of ($7,688) and $4,610 for the three months ended March 31, 2024 and 2023, respectively.
(3)Includes changes in related party balances of $80,584 and $3,669 for the three months ended March 31, 2024 and 2023, respectively.
(4)Includes changes in related party balances of ($2,381) and ($797) for the three months ended March 31, 2024 and 2023, respectively.

The accompanying notes are an integral part of these condensed consolidated financial statements.
4
Notes to Consolidated Financial Statements

1.Business

American Oncology Network, Inc. (“AON”, “New AON”, “AON Inc.”, or the “Company”), through its subsidiary companies and variable interest entities (together, “its subsidiaries”), is an alliance of physicians and seasoned healthcare leaders who provide comprehensive oncology services across 32 oncology practices located in nineteen states (Arizona, Arkansas, Florida, Georgia, Iowa, Idaho, Indiana, Louisiana, Maryland, Missouri, Michigan, North Carolina, Nevada, Nebraska, Ohio, South Carolina, Texas, Virginia, Washington, and the District of Columbia). The Company also provides expertise in drug procurement and payor contracting, along with practice diversification through centralized laboratory and pathology services, as well as specialty pharmacy services, clinical research, radiation oncology, and imaging. During the three months ended March 31, 2024 and 2023, the Company entered into affiliation agreements with or acquired the following oncology practices.
Three Months Ended March 31, 2024Three Months Ended March 31, 2023
StateState
Maryland (a)
Texas (a)
(a)The Company entered into affiliation agreements with the physicians for these respective practices. The Company evaluated each of the affiliation agreements and determined that the transactions did not represent a business combination.
The operations of the practices above have been included in the Company’s condensed consolidated financial statements.
Business Combination Agreements

Digital Transformation Opportunities Corp. (“DTOC”), American Oncology Network, LLC (“AON LLC”), GEF AON Holdings Corp. (“AON Class C Preferred Investor”), and DTOC Merger Sub, Inc., a direct, wholly owned subsidiary of DTOC (“Merger Sub”) entered into a Business Combination Agreement (the “Business Combination Agreement”), dated as of June 14, 2023 (which further amended and restated the Business Combination Agreement entered into by DTOC and AON as of October 5, 2022, and amended and restated on January 6, 2023, and April 27, 2023), pursuant to which, among other transactions, on September 20, 2023 (the “Closing Date”), DTOC and AON undertook a series of transactions (the “Business Combination” or “Reverse Recapitalization”) resulting in the organization of the combined post-business combination company as an umbrella partnership C corporation, in which substantially all of the assets and the business of the combined company are held by AON LLC, and DTOC became a member of AON LLC. In connection with the closing of the Business Combination (“the Closing”), DTOC changed its name to “American Oncology Network, Inc.”. The Business Combination was completed on September 20, 2023.

As a result of, and in connection with, the Closing, among other things, (i) AON LLC amended and restated its operating agreement (the “Amended and Restated AON LLC Agreement”) to reclassify its existing Class A units, Class A-1 units and Class B units into a single class of AON LLC common units (“AON LLC Common Units”) that can be exchanged on a one-to-one basis for shares of New AON Class A common stock (“New AON Class A Common Stock”) and its existing AON LLC Class C units into AON LLC Series A preferred units (AON LLC Series A Preferred Units”); (ii) AON LLC converted profit pool units of certain of AON LLC’s subsidiaries into an equal number of AON LLC Common Units and shares of New AON Class B common stock (“New AON Class B Common Stock”), which together are exchangeable into shares of New AON Class A Common Stock (together with the New AON Class B Common Stock, the “New AON Common Stock”); (iii) New AON amended and restated its charter (the “Charter”) to provide for (a) the conversion of all existing shares of DTOC Class B common stock into shares of New AON Class A Common Stock on a one-to-one basis, (b) amendment of the terms
of New AON Class B Common Stock to provide holders voting rights but no economic rights and (c) designation of a new series of New AON preferred stock as Series A convertible preferred stock (the “New AON Series A
Preferred Stock” or “Series A Preferred Stock") with such rights and preferences as provided for in the certificate of designation of the New Aon Series A Preferred Stock (the “New AON Series A Certificate of Designation”); and (iv) among other things, (a) AON LLC issued common units to New AON in exchange for a combination of cash
5
and shares of New AON Class B Common Stock and warrants to acquire shares of New AON Class B Common Stock (the “Class B Prefunded Warrants”), (b) New AON was admitted as a member of AON LLC, (c) AON LLC distributed shares of New AON Class B common stock or Class B Prefunded Warrants, as applicable, to AON LLC equity holders, (d) New AON reserved a specified number of additional shares of New AON Class A Common Stock after the Closing for issuance to eligible participants, (e) Merger Sub merged with and into the AON Class C Preferred Investor whereby the separate existence of Merger Sub ceased and New AON issued a number of shares of New AON Series A Preferred Stock equal to the number of AON LLC Series A preferred units held by the AON Class C Preferred Investor to AEA Growth Management LP, the parent of AON Class C Preferred Investor (“AEA Growth”) in exchange for all the shares of common stock held by AEA Growth in the AON Class C Preferred Investor (the “First Step”), (f) promptly after the First Step, the AON Class C Preferred Investor merged with and into New AON whereby the separate existence of the AON Class C Preferred Investor ceased and New AON held all the AON LLC Series A preferred units and (g) from and after the Closing (but subject to lock-up restrictions), the AON LLC common equity holders (other than New AON), referred to herein as “Legacy AON Shareholders” (former AON LLC Class A, Class A-1, and Class B unit holders), will have the right (but not the obligation) to exchange AON LLC Common Units together with an equal number of shares of New AON Class B Common Stock (whether held directly or indirectly through Class B Prefunded Warrants) for shares of New AON Class A Common Stock.

In addition, in connection with the Closing, DTOC completed the offer to the holders of AON LLC Class B-1 units to exchange their AON LLC Class B-1 units for such number of newly issued shares of New AON Class A Common Stock equal to the ratio set forth in the Business Combination Agreement (such offer, the “Exchange Offer”). DTOC and AON LLC solicited consents from the holders of AON LLC Class B-1 units to make certain amendments to the terms of the awards and the unit grant agreements pursuant to which the AON LLC Class B-1 units were granted, which provided for the automatic exchange, as of immediately prior to the adoption of the Amended and Restated AON LLC Agreement, of all outstanding AON LLC Class B-1 units into shares of New AON Class A Common Stock (collectively, the “Proposed Amendments”). The requisite number of holders of Class B-1 units provided their consent to the Proposed Amendments, and as a result, in connection with the Closing, all AON LLC Class B-1 units were exchanged for an aggregate of 1,047,343 shares of New AON Class A Common Stock.

Upon the consummation of the Business Combination, the outstanding membership units in AON LLC and the outstanding shares in AON Inc. (New AON) are as follows:
•AON LLC Common Units held by the Legacy AON Shareholders - 28,109,796
•AON LLC Common Units held by New AON - 9,532,354
•AON LLC Series A Preferred Units held by New AON - 6,651,610

•Class A Common Stock held by the former AON LLC Class B-1 unit holders - 1,047,343
•Class A Common Stock held by the DTOC unredeemed shareholders - 147,511
•Class A Common Stock held by the DTOC Sponsor and their permitted transferees - 5,498,125(a)
•Class B Common Stock held by Legacy AON Shareholders - 25,109,551(b)
•New AON Series A Preferred Stock held by AEA Growth Management LP - 6,651,610

(a) Sponsor Earnout Shares of 2,839,375 are subject to vesting and forfeiture provisions and are not outstanding for GAAP purposes as of the Closing Date.

(b) Certain Legacy AON Shareholders hold 3,000,245 Class B Prefunded Warrants, which underlying shares of Class B common stock are not outstanding as of the Closing Date.

Warrants

As of the Closing Date, New AON assumed the outstanding warrants (Public Warrants and Private Placement Warrants) that were issued by DTOC as part of DTOC’s IPO. Further, New AON issued the Class B Prefunded Warrants to former Class A-1 unit holders, in lieu of New AON Class B Common Stock. The accounting treatment for the Public Warrants, the Private Placement Warrants, and the Class B Prefunded Warrants, collectively referred to as “the Warrants”, is disclosed in Note 2.

Public Warrants

6
As of the Closing Date, New AON assumed 8,337,500 public warrants (the “Public Warrants”) issued by DTOC in its IPO. Each whole warrant entitles the holder to purchase one share of New AON Class A Common Stock at a price of $11.50 per share, subject to adjustment. The warrants will become exercisable on the later of 12 months from the closing of the DTOC Initial Public Offering or 30 days after the completion of its initial business combination and will expire five years after the Closing of the Business Combination, or earlier upon redemption or liquidation.

Private Warrants

As of the Closing Date, New AON assumed 6,113,333 Private Placement Warrants held by the DTOC Sponsor (the “Private Placement Warrants” or “Private Warrants”). The Private Placement Warrants will be non-redeemable in certain circumstances so long as they are held by the Sponsor or its permitted transferees. The Private Placement Warrants may also be exercised by the Sponsor and its permitted transferees for cash or on a cashless basis. Otherwise, the Private Placement Warrants have terms and provisions that are identical to those of the Public Warrants, including as to exercise price, exercisability, and exercise period.

Class B Prefunded Warrants

As of the Closing Date, New AON issued 3,000,245 of Class B Prefunded Warrants to former AON Class A-1 unitholders. Because the Class B Warrants are prefunded, there was not any cash consideration exchanged as part of the Class B Warrant issuance. Each Class B Prefunded Warrant entitles the holder to purchase one share of New AON Class B common stock at a price of $0.01 per share. The exercise term of the Class B Warrant shall continue indefinitely so long as the holder of the Class B Warrant is also the holder of an AON LLC Common Unit, provided that the number of shares of Common Stock that this Warrant is exercisable for shall not exceed the number of AON LLC Common Units held by holder.

Transaction Expenses

In connection with the Reverse Recapitalization, AON LLC and New AON incurred costs of $0.4 million and $1.9 million during the three months ended March 31, 2024 and 2023, respectively, which were reported as transaction expenses in the condensed consolidated statements of operations and comprehensive loss.
7
2.Basis of Presentation and Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of the Company were prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. Management believes the unaudited condensed consolidated financial statements for the interim periods presented contain all necessary adjustments, of a normal recurring nature, to state fairly, in all material respects, the Company’s financial position, results of operations and cash flows for the interim periods presented. These unaudited condensed consolidated financial statements were prepared on the same basis as and should be read in conjunction with such audited consolidated financial statements and related notes thereto of AON Inc. and its wholly-owned subsidiaries, included in the Annual Report on Form 10-K, dated and filed on March 28, 2024 with the SEC (the “Annual Report 2023"). Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results the Company expects for the entire year.

For the three months ended March 31, 2024, these unaudited condensed consolidated financial statements reflect the consolidated results of operations, comprehensive loss, cash flows and changes in equity of AON Inc. and its wholly-owned subsidiaries. The condensed consolidated balance sheet at March 31, 2024 presents the financial condition of AON Inc. and its consolidated subsidiaries.

For the three months ended March 31, 2023, these unaudited condensed consolidated financial statements present the consolidated results of operations, comprehensive loss, cash flows and changes in equity of AON LLC. The condensed consolidated balance sheet as of December 31, 2023 presents the financial condition of AON Inc. and its consolidated subsidiaries after the Reverse Recapitalization. All intercompany balances and transactions of AON LLC have been eliminated.

In accordance with Accounting Standards Codification (“ASC”) Topic 805, Business Combinations, the historical equity of AON LLC has been recasted in all periods up to the Closing Date, to reflect the number of shares of New AON’s Class A Common Stock and Class B Common Stock issued to Legacy AON Shareholders in connection with the Reverse Recapitalization. The Company recasted the units outstanding related to the historical AON LLC Class A, Class A-1, and Class B units prior to the Reverse Recapitalization (“Historical AON LLC Equity”) as common equity of New AON, equal to the Per Company Class Unit Exchange Ratio, pursuant to the Business Combination Agreement.

The Per Company Unit Exchange Ratio at which AON LLC Class A units and Class A-1 units were reclassified is equal to 2,524 AON Common Units. The Per Company Unit Exchange Ratio at which AON LLC Class B units were reclassified varied depending on participation threshold, and is equal to 2,524, 2,453, or 1,976, AON Common Units. The Per Company Unit Exchange Ratio at which Class C units were reclassified is equal to 2,705 AON LLC Series A Preferred Units.

The condensed consolidated financial statements and related notes thereto give effect to the conversion for all periods presented, without any change to par value or per unit amounts. The condensed consolidated financial statements do not necessarily represent the capital structure of New AON had the Reverse Recapitalization occurred in prior periods. The Company has not made retroactive adjustments related to the historical book values of Historical AON LLC Equity as the adjustments were considered immaterial.

For the three months ended March 31, 2024, $7.8 million of the consolidated net loss of AON LLC were attributable to the Class A Common Stockholders, and reflects the Class A Common Stockholders’ absorption of 23.0% of the consolidated net loss of AON LLC. For the three months ended March 31, 2024, $17.2 million of the consolidated net losses of AON LLC were attributable to noncontrolling interest, and reflects the Legacy AON Stockholders’ absorption of 77.0% of the consolidated net losses of AON LLC.

For the three months ended March 31, 2023, $1.5 million of the consolidated net losses of AON LLC were attributable to the Legacy AON Stockholders, to reflect their absorption of 100% of the consolidated net losses of AON LLC pertaining to the days prior to the Reverse Recapitalization.
8

Principles of Consolidation
For the period of January 1, 2024 through March 31, 2024, the condensed consolidated financial statements include the accounts of the Company, American Oncology Network, LLC (“AON LLC”), and its wholly owned subsidiary American Oncology Management Company, LLC (“AOMC”), and its consolidated variable interest entities (“VIEs”) American Oncology Partners, P.A. (“AON Partners”), American Oncology Partners of Maryland, P.A. (“Partners of Maryland”), AON Central Services, LLC (“AON Central Services”), and Meaningful Insights Biotech Analytics, LLC (“MIBA”). All intercompany accounts and transactions between the entities have been eliminated in consolidation.

The accounting treatment of the Business Combination was a Reverse Recapitalization.

For the periods prior to the Reverse Recapitalization, the consolidated financial statements of the Company comprise the accounts of AON LLC and its wholly-owned subsidiaries. All intercompany accounts and transactions among AON LLC and its consolidated subsidiaries were eliminated.
The Company accounts for American Oncology Network, LLC, AON Partners, Partners of Maryland, AON Central Services, and MIBA in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810, Consolidations. The Company determines whether it has a controlling financial interest in an entity by first evaluating whether the entity is a VIE. A VIE is broadly defined as an entity that has any of the following three characteristics: (i) the equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (ii) substantially all of the entity’s activities either involve or are conducted on behalf of an investor that has disproportionately few voting rights; or (iii) the equity investors as a group lack any of the following, the power through voting or similar rights to direct the activities of the entity that most significantly impact the entity’s economic performance, the obligation to absorb the expected losses of the entity, or the right to receive the expected residual returns of the entity. The Company consolidates a VIE if it has both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and an obligation to absorb losses or the right to receive benefits that could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively, if any.

AON LLC has contractual relationships with AON Partners, Partners of Maryland and AON Central Services and the physician owners through management service agreements (“MSAs”) and other contractual agreements to provide all practice management services outside of medical services provided by the physicians. In addition, despite not being required by the contractual relationships, AON LLC regularly provides funding to support AON Partners and Partners of Maryland’s operations and acquisitions of physician practices. AON Central Services was formed July 15, 2022 and, effective January 1, 2023, entered into an agreement with AOMC to provide qualified non-clinical and non-medical employees to AOMC to support the operation of the physician practices. MIBA was established during the first quarter of 2023 for the purpose of developing intellectual property to synergize the collection, de-identification, and dissemination of the Company’s patient data for sale to external parties for research, development, and clinical decisions. In May 2023, the Company contributed $0.2 million for a 56% interest in the equity of MIBA. As of March 31, 2024, MIBA had no significant operating activity. The Company concluded that AON LLC had a controlling financial interest in MIBA and has consolidated the entity at March 31, 2024 and recorded the noncontrolling interest in equity. 
The Company has concluded that AON Partners, Partners of Maryland, AON Central Services, and MIBA are all VIEs in which AON LLC has the characteristics of a controlling financial interest and is deemed to be the primary beneficiary. The variable interest subjects AON LLC to all potential losses in the entities and, therefore, requires AON LLC, and in turn AON Inc., to consolidate the results of AON Partners, Partners of Maryland, AON Central Services, and MIBA in its condensed consolidated financial statements. 
Refer to Note 4 for further information on the VIEs.
Significant Accounting Policies
The accounting policies included below should be read in conjunction with the annual consolidated financial statements.
9
Accounting Estimates and Assumptions
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.
Segments
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (the “CODM”). The Company’s CODM is its chief executive officer who reviews financial information together with certain operating metrics principally to make decisions about how to allocate resources and to measure the Company’s performance. The Company has one operating segment and one reportable segment that are structured around the organizational management of oncology practice operations. All revenue and assets are in the United States. 
Revenue Recognition
Revenue is recognized under Accounting Standards Update (“ASU”) 2014-09 Revenue from Contracts with Customers (“Topic 606”). The Company determines the transaction price based upon standard charges for goods and services with anticipated consideration due from patients, third-party payors (including health insurers and government agencies) and others. The Company’s revenue is primarily derived from patient service revenues, which encompass oncology services provided during patient visits and shipments of pharmacy prescriptions. Performance obligations for the Company’s services provided to patients and most procedures, are satisfied over the time of visit which is the same day services are performed. Performance obligations relating to pharmacy revenue are considered fully satisfied at a point in time upon the customer receiving delivery of the prescription. Accordingly, the Company does not anticipate a significant amount of revenue from performance obligations satisfied (or partially satisfied) in previous periods, and any such revenue recognized during the three month periods ended March 31, 2024 and 2023 was immaterial. Additionally, the Company does not expect to recognize material revenue in the future related to performance obligations that are unsatisfied (or partially satisfied) as of March 31, 2024 and December 31, 2023. Approximately $246.1 million and $214.3 million and of the Company’s revenues are generated from services performed during patient visits with the remainder primarily generated from shipments of pharmacy prescriptions for the three month periods ended March 31, 2024 and 2023, respectively.
As services are performed and prescriptions are shipped, timely billing occurs for services rendered and prescriptions shipped less discounts provided to uninsured patients and contractual adjustments to third-party payors based upon prospectively determined rates and discounted charges. Payment is requested at the time of service for self-paying patients and for patients covered by third-party payors that are responsible for paying deductibles and coinsurance.
The Company monitors revenue and receivables to prepare estimated contractual allowances for the anticipated differences between billed and reimbursed amounts. Payments from third-party payors and Government programs including Medicare and Medicaid may be subject to audit and other retrospective adjustments. Such amounts are considered on an estimated basis when net patient revenue is recorded and are adjusted as final adjustments are determined. For the three month periods ended March 31, 2024 and 2023, such resulting historic adjustments have been immaterial to the condensed consolidated financial statements. 
In assessing who is the principal in providing patient services and pharmacy prescriptions, the Company considered who controls the provision of services and prescriptions. The Company has determined they are acting as a principal in these relationships. 
In April 2022, the Company entered into a long-term arrangement to sponsor and manage a clinical trial. The Company subsequently contracted with a third-party to provide the clinical research services and is the principal in this arrangement. The performance of clinical research services are considered a single performance obligation because the Company provides a highly-integrated service. Revenue is recognized for the single performance obligation over time due to the Company’s right to payment for work performed to date. The contract provides for invoices based on predetermined milestones. 

The Company uses the cost-to-cost measure of progress for the Company’s contract because it best depicts the transfer of control to the customer as the performance obligation is fulfilled. For this method, the Company
10
compares the contract costs incurred to date to the estimated total contract costs through completion. As part of the client proposal and contract negotiation process, the Company develops a detailed project budget for the direct costs and reimbursable costs based on the scope of the work, the complexity of the study, the geographical location involved and the Company’s historical experience. The estimated total contract costs at the project level are reviewed and revised periodically throughout the life of the contract, with adjustments to revenue resulting from such revisions being recorded on a cumulative basis in the period in which the revisions are identified. Contract costs consist primarily of direct labor and other reimbursable project-related costs such as travel, third-party vendor costs and investigator fees. The Company establishes pricing based on the Company’s internal pricing guidelines, discount agreements, if any, and negotiations with the client. The transaction price is the contractually defined amount. Revenue related to the clinical trial, which is included within other revenue, was $0.5 million and $0 million for the three months ended March 31, 2024 and 2023, respectively. 
The Company has a system and estimation process for recording Medicare net patient service revenue and estimated recoupments as it relates to value-based care (“VBC”) revenue included in patient service revenue in the condensed consolidated statements of operations and comprehensive loss. The Company’s VBC revenue is primarily generated through its participation in the CMS Oncology Care Model (“OCM”) which is an episode-based payment model to promote high-quality cancer care. Participants enter six-month episode periods, and the Company bills a monthly fee during the six-month period based on a fixed rate per participant per month and the total number of participants. Certain quality and compliance metrics are tracked as part of the program and submitted to CMS at the end of the episode period which may result in recoupment of funds. The Company estimates the recoupment amount by developing a recoupment percentage for each period based on historical known recoupment from CMS and applies the recoupment percentage against total fees for the period. Based on the estimate, the Company accrues a liability representing the expected final recoupments based on historical settlement trends.
Short-term Marketable Securities 
Investments in marketable securities consist of corporate bonds and U.S. Treasury securities.
Management determines the appropriate classification of investments at the time of purchase and reevaluates such determination at each balance sheet date. Marketable securities are classified as available-for-sale and are carried at fair value in the consolidated balance sheets. The marketable securities are classified as short-term based on management’s intent to convert such securities within one year and the ability to convert them within two to three days.
Certain of our available-for-sale securities are debt securities. For an available-for-sale debt security with an amortized cost that exceeds its fair value, the Company first determines if it intends to sell or will more-likely-than-not be required to sell the security before the expected recovery of its amortized cost. If it intends to sell or will more-likely-than-not be required to sell the security, then the Company recognizes the impairment as a credit loss in the condensed consolidated statements of operations and comprehensive loss by writing down the security’s amortized cost to its fair value. If it does not intend to sell or it is not more-likely-than-not that it will be required to sell the security before the expected recovery of its amortized cost, the Company recognizes the portion of the impairment that is due to a credit loss, if any, in the condensed consolidated statements of operations and comprehensive loss through an allowance. The portion of the impairment that is due to factors other than a credit loss is recognized in other comprehensive income (loss) in the condensed consolidated statements of operations and comprehensive loss as an unrealized loss.
Equity Investment in Affiliate
In January 2023, the Company contributed noncash consideration, with a fair value of approximately $2.3 million, in return for a 49% equity interest in OCP Management Arizona, LLP. Investments in entities over which the Company has the ability to exercise significant influence but does not control the entity are accounted for using the equity method. Equity method investments are included with other assets in the condensed consolidated balance sheets. The carrying amount of the investment is adjusted to reflect the Company’s proportionate share of the net earnings or losses and reduced by any dividends received. The Company’s share of income or loss related to this investment is reported as an equity in loss of affiliate in the condensed consolidated statements of operations and comprehensive loss.
11
Noncontrolling Interests
The Company consolidates the results of entities in which it has a controlling financial interest. Refer to Note 15 for additional considerations and presentation for noncontrolling interest.
Mezzanine Equity

New AON Series A Preferred Stock is redeemable for cash or the value of the property, rights or securities to be paid or distributed in the event of a Deemed Liquidation Event (which is outside of the Company’s control). As a result, Management has determined that the New AON Series A Preferred Stock should be classified as mezzanine equity. As of March 31, 2024, the Preferred Stock are recorded at their initial carrying value, net of offering costs of $0.8 million. The Series A Preferred Stock are not being accreted to redemption value, as the redemption is not probable. The Series A Preferred Stock are classified outside of members’ equity on the consolidated balance sheets. Refer to Note 14 for mezzanine equity presentation considerations for redeemable noncontrolling interest.
Treasury Stock

We account for treasury stock purchased under the cost method and include treasury stock as a component of
accumulated paid in capital. Treasury stock purchased with intent to retire (whether or not the retirement is actually accomplished) is charged to common stock. The company repurchased 14,729 shares of class A common stock at the spot rate as of each transaction date for a total cost of less than $0.1 million for the year ended December 31, 2023. For the three months ended March 31, 2024 the Company repurchased an additional 16,441 shares of class A common stock at the spot rate as of each transaction date for a total cost of less than $0.1 million. To date, the Company has repurchased a total of 31,170 shares.
Equity-Based Compensation

The Company issues stock-based awards to employees and directors in the form of stock options and restricted stock units. The Company measures and recognizes compensation expense for its stock-based awards granted to its employees and directors based on the estimated grant date fair value in accordance with ASC 718, Compensation-Stock Compensation, and determines the fair value of restricted stock units based on the fair value of its common stock. The Company measures all share-based options granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. Compensation expense of those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company records the expense for awards with service-based conditions using the straight-line method over the requisite service period, net of any actual forfeitures. The Company classifies share-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified.
Business Combinations
The Company evaluates acquired practices in accordance with ASU 2017-01, Business Combinations (Topic 805)-Clarifying the Definition of a Business. This standard clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. Because substantially all of the value of each acquired practice did not relate to a similar group of assets and as each acquired practice contained both inputs and processes necessary to provide economic benefits to the Company, it was determined that each acquisition represents a business combination. Therefore, the transactions have been accounted for using the acquisition method of accounting, which requires, with limited exceptions, that assets acquired, and liabilities assumed be recognized at their estimated fair values as of the acquisition date. Any excess of the consideration transferred over the estimated fair values of the net assets acquired is recorded as goodwill. Transaction costs related to business combinations are expensed in the period in which they are incurred.
Offering Costs
The Company defers specific incremental costs directly attributable to proposed offerings of securities. These costs consist of legal, accounting, and other similar expenses incurred through the balance sheet date that are directly related to a potential offering. If the offering is completed, these costs will be charged against the gross proceeds of the offering. These offering costs will be allocated to the separable financial instruments issued in the transaction on a relative fair value basis of the securities issued, compared to total proceeds received. Offering costs associated
12
with any instruments classified as liabilities will be expensed as incurred, presented as non-operating expenses in the condensed consolidated statement of operations and comprehensive loss.

Professional Liability
The Company maintains insurance policies for exposure to professional malpractice insurance risk. The limits of malpractice insurance provide each physician/advanced practice provider with a dedicated $1.0 million limit per claim and a $3.0 million limit in the aggregate per policy period – on a first dollar basis, as no deductible applies. The policy further then extends coverage to the Company, by providing a $2.0 million limit per claim and a $4.0 million limit in the aggregate per policy period - on a first dollar basis, additionally, as no deductible applies. Reserves are established for estimates of the loss that will ultimately be incurred on claims that have been reported but not paid and claims that have been incurred but not reported. These reserves are established based on consultation with a third-party actuary. The actuarial valuations consider a number of factors, including historical claims payment patterns, changes in case reserves and the assumed rate of increase in healthcare costs. Management believes the use of actuarial methods to account for these reserves provides a consistent and effective way to measure these subjective accruals. However, due to the sensitive nature of this estimation technique, recorded reserves could differ from ultimate costs related to these claims due to changes in claims reporting, claims payment and settlement practices and differences in assumed future cost increases. Accrued unpaid claims and expenses that are expected to be paid within the next twelve months are classified as current liabilities and included in accrued other. All other accrued unpaid claims and expenses are classified as long-term liabilities and included in other long-term liabilities. Insurance recoveries associated with the unpaid claims are classified as long-term assets included in other assets.
Fair Value of Financial Instruments
Fair value is the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.
Accounting guidance establishes a three-level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:
Level 1Inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market.
Level 2Inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model-derived valuations in which all significant inputs are observable for substantially the full term of the asset or liability.
Level 3Inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. 
Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement of assets and liabilities being measured within the fair value hierarchy.
Our financial instruments include cash, short-term marketable securities, accounts receivable, notes receivable, accounts payable, accrued expenses, long-term debt and contractual agreements that resulted in derivative liabilities. Our nonfinancial assets such as property and equipment are not measured at fair value on a recurring basis; however, they are subject to fair value adjustments in certain circumstances, such as when there is evidence that impairment may exist.
The carrying amounts of cash, accounts receivable, accounts payable, notes receivable, and accrued expenses approximate their fair value because of the short-term maturity and highly liquid nature of these instruments. We
13
determine the fair value of long-term debt and marketable securities based on various factors including maturity schedules and current market rates.
See Note 6 for a discussion of the Company’s Level 1 and Level 2 Marketable Securities as of March 31, 2024. See below for a discussion of the Company’s Level 1 and Level 3 warrant liabilities as of March 31, 2024. As of March 31, 2024 and December 31, 2023, there were no Level 3 financial instruments. There were no transfers between any levels of the hierarchy during any periods presented.

Warrant Liabilities

Upon Closing of the Business Combination, on September 20, 2023, the Company evaluated the Public Warrants and Private Placement Warrants and the Class B Prefunded Warrants, collectively referred to herein as “Warrants”, in accordance with ASC 815-40, “Derivatives and Hedging —- Contracts in Entity’s Own Equity”, and concluded that a provision in the warrant agreements related to potential net cash settlement of the warrants upon an exchange or tender offer that may not result in a change in control of the entity precludes the warrants from being accounted for as components of equity. As the Warrants meet the definition of a derivative as contemplated in ASC 815, the Warrants are recorded as current liabilities within accrued other on the condensed consolidated balance sheets and measured at fair value at inception and at each reporting date in accordance with ASC 820, “Fair Value Measurement”, with changes in fair value recognized in other income (expense), net on the condensed consolidated statements of operations and comprehensive loss in the period of change.

As of March 31, 2024, the Public Warrants were trading separately from the Class A Common Stock and the quoted market price was used to establish fair value. As such, the Public Warrants fair value was determined using a Level 1 input. The fair value of the Public Warrants as of March 31, 2024 is $2.8 million and recorded in other long-term liabilities on the condensed consolidated balance sheets.

Management has utilized the public warrant price to value the private warrants and believes the public and private warrants have materially consistent fair values given the existence of the make-whole redemption feature. As of March 31, 2024, a valuation of the private warrants was performed which confirmed the private warrant value was materially consistent with the public warrants. The details of this valuation are included in the paragraph below.

The fair value of the Private Placement warrants was determined using Level 3 inputs. As of March 31, 2024, the fair value of the Private Placement Warrants was estimated to be $2.1 million and recorded in other long-term liabilities on the condensed consolidated balance sheets. The fair value was estimated at March 31, 2024, using the Black-Scholes Option Pricing model using the following assumptions:
Expected annual dividend yield – 0.0%
                Expected volatility – 26.40%
                Risk-free rate of return – 4.31%
                Expected Option Term – 5.0 years
                
The AON Class B Prefunded Warrants are exercisable into one share of New AON Class B Common Stock. A share of New AON Class B Common Stock, together with an AON LLC Common Unit, may be exchanged for one share of New AON Class A Common Stock. Considering New AON Class B Common Stock has no economic rights and limited liquidity or value if the holder does not also possess an AON LLC Common Unit, and because the AON Class B Prefunded Warrants are exercisable into New AON Class B Common Stock, the Company has estimated fair value of the Class B Prefunded Warrants to be immaterial.
Earnings Per Share

The Company recast Historical AON LLC Equity as AON Inc. common equity for all periods prior to the Reverse Recapitalization, refer to Note 2. However, as 100% of the net losses of AON LLC prior to the Reverse Recapitalization were absorbed by the Legacy AON Shareholders, basic and diluted earnings (loss) per share is zero for the three months ended March 31, 2023. Basic and diluted earnings (loss) per share for the three months ended March 31, 2024 represents the period where the Company had earnings (loss) attributable to Class A Common Stockholders. Class B Common Stock does not have economic rights in AON Inc., including rights to dividends or distributions upon liquidation, and as a result, is not considered a participating security for basic and diluted earnings (loss) per share. As such, basic and diluted earnings (loss) per share of Class B Common Stock has not been presented.
14

The Company has issued and outstanding Sponsor Earnouts, which are subject to forfeiture if the achievement of certain stock price thresholds are not met. In accordance with ASC Topic 260, “Earnings Per Share,” the Sponsor Earnouts are excluded from weighted-average shares outstanding to calculate basic earnings (loss) per share as they are considered contingently issuable shares due to their potential forfeiture. Sponsor Earnouts will be included in weighted-average shares outstanding to calculate basic earnings (loss) per share as of the date of their stock price thresholds are met and they are no longer subject to forfeiture.

Basic and diluted earnings (loss) per share is computed by use of the two-class method as a result of outstanding Series A Preferred Stock, which accrue dividends at the annual rate of 8% of the original price per share, participate with common stock on all other dividends, and accordingly have participation rights in undistributed earnings as if all such earnings had been distributed during the period (see Note 12). Under such method income available to common shareholders is computed by deducting both dividends declared or, if not declared, accumulated on Series A Preferred Stock from net income. Loss attributable to common shareholders is computed by increasing net loss by such dividends. Since the participating Series A Preferred Stock has no contractual obligation to share in the losses of the Company, there is no loss allocation between Class A Common Stock and Series A Preferred Stock.

Basic earnings (loss) per share is based on the weighted-average number of shares of Class A Common Stock outstanding during the period. Diluted earnings (loss) per share is based on the weighted-average number of shares of Class A Common Stock used for the basic earnings (loss) per share calculation, adjusted for the dilutive effect of the Public and Private Warrants and Sponsor Earnout, if any, using the “treasury stock” method and the convertible Series A Preferred Stock and, exchangeable Class B Common Stock and Class B Prefunded Warrants, if any, using the “if-converted” method. Net earnings (loss) for diluted loss per share is adjusted for the Company’s share of AON LLC’s consolidated net earnings (loss), net of AON Inc. taxes, after giving effect to the Class B Common Stock and Class B Prefunded Warrants that are exchanged into potential shares of Class A Common Stock, Public and Private Warrants that are liability classified, and Series A Preferred Stock, to the extent it is dilutive.
Recently Adopted Accounting Pronouncements 
In June 2016, the FASB issued ASU 2016-13, ‘‘Financial instruments-Credit Losses’’ (“ASU 2016- 13”). ASU 2016-13 requires entities to report ‘‘expected’’ credit losses on financial instruments and other commitments to extend credit rather than the current ‘‘incurred loss’’ model. These expected credit losses for financial assets held at the reporting date are to be based on historical experience, current conditions, and reasonable and supportable forecasts. This ASU will also require enhanced disclosures relating to significant estimates and judgments used in estimating credit losses, as well as the credit quality. ASU 2016-13 is effective for the Company for annual reporting periods beginning after December 15, 2022. ASU 2016-13 was adopted by the Company effective January 1, 2023, with no material impact on the Company’s consolidated financial statements and related disclosures. 
In October 2021, the FASB issued ASU 2021-08, “Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers”, which provides that an acquirer must recognize, and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606. The guidance is effective for the Company for annual reporting periods beginning after December 15, 2023, with early adoption permitted. The adoption of this standard as of January 1, 2024, did not have a material impact on the Company’s consolidated financial statements and related disclosures.
Recently Issued Accounting Pronouncements

In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” The amendments in this update are intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses. The ASU requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker, a description of other segment items by reportable segment, and any additional measures of a segment's profit or loss used by the chief operating decision maker when deciding how to allocate resources. The ASU also requires all annual disclosures currently required by Topic 280, “Segment Reporting,” to be included in interim periods. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and retrospective application is required for all
15
periods presented. The Company is evaluating the impact this will have on the Company's consolidated financial statements and related disclosures.

In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” The amendments in this upgrade enhance the transparency and decision usefulness of income tax disclosures. This ASU requires disclosures of specific categories and disaggregation of information in the rate reconciliation table. The ASU also requires disclosure of disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit, and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December 15, 2024. Early adoption is permitted and the amendments should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating the effect that ASU 2023-09 will have on its disclosures.

16
3.Reverse Recapitalization

As discussed in Note 1, AON LLC merged with DTOC, with AON LLC surviving the Merger. AON LLC is governed by a board of managers composed of three (3) persons that were designated by New AON and two (2) persons that were designated by holders of a majority of the AON LLC Common Units, held by members of AON LLC other than New AON. Management determined AON LLC was not a variable interest entity (Refer to Note 2), and as result, identified AON LLC as the accounting acquirer of the Merger in accordance ASC Topic 805. Management concluded that AON LLC was the accounting acquirer due to (i) the Legacy AON Shareholders, defined as the former AON Class A, Class A-1, and Class B unit holders, receiving the largest portion of the voting rights in the combined company, New AON, (ii) significantly all of the Legacy AON Shareholders retained their equity interest as stockholders in New AON, (iii) AON LLC’s operations prior to the Reverse Recapitalization comprising the only ongoing operations of New AON, (iv) the Legacy AON Shareholders have the right to appoint a majority of the directors of New AON, (v) the executive management of AON LLC will become the executive management of New AON and (vi) AON LLC is significantly larger than New AON in terms of revenue, total assets, and employees. Therefore, the Merger was accounted for as a reverse recapitalization, with no goodwill or other intangible assets recorded, in accordance with ASC Topic 805. New AON was treated as the “acquired” company for financial reporting purposes, and for accounting purposes, the Reverse Recapitalization was treated as the equivalent of AON LLC issuing stock for the net assets of New AON, accompanied by a recapitalization. The net assets of New AON were recorded at historical cost on the condensed consolidated balance sheet as of September 20, 2023, the Closing Date of the Reverse Recapitalization, with no goodwill or other intangible assets recorded. For additional information on the capitalization of New AON and AON LLC immediately following the Closing of the Reverse Recapitalization, see Note 1.

The following table provides the historical cost of assets and liabilities of AON Inc. as of September 20, 2023.

As of September 20, 2023
Cash and Cash Equivalents$1,493 
Current Liabilities(13,295)
Long Term Liabilities(6,791)
Total Net Liabilities$(18,593)

The Company recorded a Day 1 expense as of the Closing of the Business Combination equal to $18.2 million. Of that total amount, $13.0 million was recorded in transaction expenses on the condensed consolidated statement of operations and comprehensive loss. The remaining $5.2 million was recorded in other income (expense) net on the condensed consolidated statement of operations and comprehensive loss. This amount represented the loss on the issuance of Public and Private Warrants, as of the Closing, net of cash received. The Company also recorded a $4.3 million gain in other income (expense), net related to the change in the fair value of the Public and Private Warrants during the period of September 21, 2023 through September 30, 2023.
17
4.Variable Interest Entities
AOMC is a wholly owned subsidiary of AON LLC and neither AOMC nor AON LLC has ownership interest in AON Partners and Partners of Maryland. Both AON Partners and Partners of Maryland are fully owned by physicians. AON LLC operates its physician practices through the MSAs and other contractual agreements between AOMC, AON Partners, and Partners of Maryland. The responsibilities of AOMC include, but are not limited to, negotiating provider and payor contracts, employment and compensation decisions, billing and collections, furnishing all supplies and equipment necessary for the respective practice’s operations as well as, necessary real estate, contracting on behalf of AON Partners and Partners of Maryland, entering into leases, holding a power of attorney to perform the above activities, preparing, maintaining and administering all accounting records (including financial reporting), expense payment, and maintenance of all information systems/software. AON LLC is paid a management fee to compensate AOMC for the services provided. AON Central Services is 80% physician owned and 20% owned by AON LLC. AOMC entered into an agreement with AON Central Services, effective January 1, 2023, to provide qualified non-clinical and non-medical employees to AOMC to support the operation of the physician practices. AOMC pays a monthly management fee to AON Central Services equal to the aggregate cost of compensation, benefits and all other costs related to these employees. AON LLC invested $0.2 million in MIBA, a newly formed LLC, during the second quarter of 2023 in exchange for 56% equity ownership. The Company evaluated AON LLC’s relationship with MIBA under the VIE model and determined it was a VIE and the Company is the primary beneficiary based on its financial controlling interest.

Based on various quantitative and qualitative factors, including assessment of certain services performed and relationships held above, management has determined that AON Partners, Partners of Maryland, AON Central Services, and MIBA are all variable interest entities and AOMC is the primary beneficiary who holds the decision-making rights over the activities that most significantly impact the economic performance of AON Partners, Partners of Maryland, AON Central Services, and MIBA through the MSAs and other contractual agreements. Accordingly, the results of AON Partners, Partners of Maryland, AON Central Services, and MIBA have been consolidated with the Company for the three month period ended March 31, 2024. The results of AON Partners, Partners of Maryland, and AON Central Services have been consolidated with the Company for the three month period ended March 31, 2023.
The assets of AON Partners, Partners of Maryland, AON Central Services, and MIBA as of March 31, 2024 and December 31, 2023, are as follows:
As of March 31,
2024		As of December 31,
2023
Assets
Cash and cash equivalents$75,796 $26,574 
Accounts receivable132,300 129,151 
Inventories44,288 44,569 
Prepaid expenses and other current assets1,157 895 
Goodwill and intangibles, net180 180 
Other receivables34,297 33,809 
Other assets7,880 2,091 
Total assets$295,898 $237,269 
18
The liabilities of AON Partners, Partners of Maryland, AON Central Services, and MIBA as of March 31, 2024 and December 31, 2023, are as follows:
As of March 31,
2024		As of December 31,
2023
Liabilities
Accounts payable$184,314 $122,324 
Accrued compensation and benefits25,713 21,380 
Accrued other14,972 16,723 
Other long-term liabilities1,078 273 
Due to AON LLC and subsidiaries, net107,144 117,194 
Total liabilities$333,221 $277,894 
All intercompany transactions and balances with the VIEs are eliminated in consolidation.
19
5.Business Combinations
2024 Acquisitions

The Company did not have any ASC 805 acquisitions during the three months ended March 31, 2024.
2023 Acquisitions

The Company did not have any ASC 805 acquisitions during the three months ended March 31, 2023.
20
6.Marketable Securities
The following table summarizes the Company’s marketable securities financial assets that are measured at fair value on a recurring basis:
As of March 31, 2024
Amortized
Cost		Gross Unrealized
Gains		Gross Unrealized
Losses		Estimated Fair
Value
Cash equivalents (1)
Level 1:
Overnight repurchase agreements (2)$73,938 $- $- $73,938 
Money market funds529 - - 529 
U.S. Treasury Bills993 - - 993 
Level 1 total$75,460 $— $— $75,460 
Marketable securities
Level 2:
Corporate bonds14,267 172 (3)14,436 
U.S. Treasury securities15,467 205 (4)15,668 
Level 2 total29,734 377 (7)30,104 
Total$105,194 $377 $(7)$105,564 
As of December 31, 2023
Amortized
Cost		Gross Unrealized
Gains		Gross Unrealized
Losses		Estimated Fair
Value
Cash equivalents (1)
Level 1:
Overnight repurchase agreements (2)$28,593 $- $- $28,593 
Money market funds$723 $- $- $723 
Level 1 total29,316 — — 29,316 
Marketable securities
Level 2:
Corporate bonds13,678 191 (9)13,860 
U.S. Treasury securities21,318 211 21,529 
Level 2 total34,996 402 (9)35,389 
Total$64,312 $402 $(9)$64,705 
(1)Included in cash and cash equivalents in the consolidated balance sheets at March 31, 2024 and December 31, 2023.
(2)Cash equivalents as of March 31, 2024 included U.S. Treasury Bills with an initial maturity of 3 months or less and overnight repurchase agreements in which cash from the Company's main operating checking account is invested overnight in highly liquid, short-term investments sponsored by a large financial institution. The company had overnight repurchase agreements as of March 31, 2024 and December 31, 2023.
The Company uses quoted prices in active markets for identical assets to determine the fair value of its Level 1 investments. The fair value of the Company’s Level 2 investments is determined using pricing based on quoted market prices or alternative market observable inputs. 







21
The fair value of the Company’s marketable securities as of March 31, 2024, by remaining contractual maturities, were as follows:
Corporate BondsU.S. TreasuriesTotal
Due in one year or less$5,886 $11,972 $17,858 
Due in one to five years8,550 3,696 12,246 
Total$14,436 $15,668 $30,104 
22
7. Supplemental Condensed Balance Sheet Information
Other receivables
Other receivables consisted of the following at March 31, 2024 and December 31, 2023:
As of March 31,
2024		As of December 31,
2023
Rebates receivable$34,112 $33,708 
Other687 566 
Total other receivables$34,799 $34,274 
Inventory
Inventory consisted of the following at March 31, 2024 and December 31, 2023:
As of March 31,
2024		As of December 31, 2023
Intravenous drugs$33,972 $32,388 
Oral pharmaceuticals10,316 12,181 
Total inventories$44,288 $44,569 
Property and Equipment, net
Property and equipment, net consisted of the following at March 31, 2024 and December 31, 2023:
As of March 31,
2024		As of December 31,
2023
Leasehold improvements$33,985 $32,490 
Furniture, fixtures and equipment2,750 2,607 
Medical equipment16,310 15,666 
Computer equipment3,395 3,285 
Signs176 153 
Automobiles110 59 
Software9,231 7,829 
Construction-in-progress1,847 2,985 
Property and equipment, gross67,804 65,074 
Accumulated depreciation and amortization(26,807)(24,635)
Property and equipment, net$40,997 $40,439 
Accrued Other

Accrued other consisted of the following at March 31, 2024 and December 31, 2023:
As of March 31,
2024		As of December 31,
2023
Refund liability$12,879 $15,078 
Warrant liability4,913 - 
Excise taxes payable2,700 2,700 
Current portion of finance lease liabilities1,205 1,189 
Other3,489 3,360 
Total accrued other$25,186 $22,327 
23
8. Long-term Debt
Debt consisted of the following at March 31, 2024 and December 31, 2023: 
As of March 31,
2024		As of December 31, 2023
PNC Facility$81,250 $81,250 
Total81,250 81,250 
Unamortized debt issuance costs(394)(609)
Total debt$80,856 $80,641 
Credit Facilities
On April 30, 2021, the Company entered into a Loan Facility with PNC (“PNC Loan Facility”) collateralized by the Company’s assets and outstanding patient accounts receivable. The PNC Loan Facility is guaranteed on a limited basis by the Company and shareholder of AON Partners and Partners of Maryland. $34.6 million of proceeds from the PNC Loan Facility was used to pay off the Company’s previous term loans and revolver with Truist Bank. The remaining funds were made available for working capital and acquisition of additional physician practices.
The PNC Loan Facility is interest-only with total principal due at an initial maturity on April 30, 2024. Interest originally accrued at one-month LIBOR or an alternate base rate plus 1.45%. The maximum balance of the PNC Loan Facility (“Borrowing Base”) is limited to the lesser of the Facility Limit ($65.0 million) or the fair value of the Company’s patient accounts receivable. The Company must maintain a balance of the lesser of the Borrowing Base or 65% of the Facility Limit in the first year and 75% of the Facility Limit in subsequent years (“minimum funding threshold”). The Company can repay the PNC Loan Facility up to the minimum funding threshold at any time without penalty. In accordance with the PNC Loan Facility, the Company pledged $10.0 million of collateral as restricted cash to be released quarterly in increments of $2.5 million. The restricted cash was fully released as of March 31, 2024 and December 31, 2023.
On April 30, 2021, the Company entered into a $5.0 million revolving line of credit agreement (“PNC Line of Credit”). The PNC Line of Credit has an expiration date of April 30, 2024 and originally bore interest at a rate per annum equal to the sum of the daily LIBOR rate plus 1.65% or an alternate base rate plus 0.65% and is due on the first day of each month beginning June 1, 2021. Any outstanding principal and accrued interest will be due on the expiration date. Beginning July 1, 2021, quarterly bank fees equal to 1.65% per day per annum are due in arrears and will continue on the first day of each quarter thereafter. All debt related to the PNC Line of Credit is collateralized by the Company’s assets. As of March 31, 2024 and December 31 2023, no draws had been made on the PNC Line of Credit. The Company is also subject to a 0.20% unused line fee calculated per annum on the unused balance of the PNC Line of Credit. 
On July 29, 2021, the Company amended the PNC Loan Facility increasing the Facility Limit to $75.0 million. On February 14, 2022, the Company further amended the PNC Loan Facility and Line of Credit agreements. The primary changes included an increase of the Facility limit from $75.0 million to $125.0 million, an increase of the PNC Line of Credit availability from $5.0 million to $10.0 million, interest charges to be calculated based on the Bloomberg Short-Term Bank Yield Index plus 1.65% and certain financial covenants. As part of the amendment, the Company drew an additional $16.3 million in proceeds under the Loan Facility. On August 15, 2022, the PNC Loan Facility and Line of Credit agreements were amended again to reduce the availability under the PNC Line of Credit from $10.0 million to $1.0 million. 
Effective November 23, 2022, the Company entered into Waiver and Amendment No. 6 (“Waiver and Amendment”) under its PNC Loan Facility as the Company was not in compliance with the Delinquency Ratio financial covenant for the period ending October 31, 2022 and the requirement to provide certain annual financial statements. The Waiver and Amendment waives each event of default and also revised future delinquency percentages and financial statement requirements. 
On June 30, 2023, the Company entered into Amendment No. 7 (“Amendment 7”) to its PNC Loan Facility which extended the maturity date from April 30, 2024 to June 30, 2026. In connection with Amendment 7, the Company paid additional debt issuance costs of $0.4 million which will be amortized over the revised remaining life of the
24
Loan Facility. In addition, Amendment 7 revised the definition of the minimum funding threshold to limit the threshold multiplier to 65% of the Facility Limit. 

On January 1, 2024, the Company entered into Amendment No. 8 (“Amendment 8”) to its PNC Loan Facility to modify certain definitions such as “change in control”. In addition, the Amendment 8 also amended the delinquency ratio threshold used to calculate certain debt covenants. The effective date of Amendment 8 was January 16, 2024.

On January 16, 2024, the Company also entered into Amendment No. 3 (“Amendment 3”) to its PNC Line of Credit to modify certain definitions such as “change in control”. In addition, the Amendment 3 also amended certain debt covenants, such as EBITDA thresholds. The effective date of Amendment 3 was December 31, 2023.

The PNC Loan Facility and PNC Line of Credit nonfinancial covenants include restrictions related to unpermitted property liens and the requirement of audited financial statements. Both agreements also contain several financial covenants, including the following ratios: accounts receivable default, delinquency, dilution, days sales outstanding, leverage, and fixed charge coverage. As of March 31, 2024, the Company was in compliance with all financial and nonfinancial debt covenants as required by both loan agreements.
25
9. Income Taxes

The Company is a member of American Oncology Network, LLC, which is treated as a partnership for U.S. federal and certain state and local income taxes. As a partnership, American Oncology Network, LLC is not subject to U.S. federal and certain state and local income taxes. Any taxable income or loss generated by American Oncology Network, LLC is passed through to and included in the taxable income or loss of its members, including the Company.

The Company is subject to U.S. federal income taxes, in addition to state and local income taxes with respect to the allocable share of any taxable income of American Oncology Network, LLC. Additionally, other corporate entities within the Company's structure are subject to income taxes. These corporate entities continue to generate losses and continue to maintain a valuation allowance against their net deferred tax assets.

The Company’s effective income tax rate was (13.1)% and —% for the three months ended March 31, 2024 and 2023, respectively. The provision for income taxes was $2.9 million and $0 for the three months ended March 31, 2024 and 2023, respectively.

The change to the income tax provision for the three months ended March 31, 2024 compared to the income tax provision for the three months ended March 31, 2023 was primarily a result of the transaction closing on September 20, 2023, resulting in a portion of the Company's consolidated pre-tax earnings, which were previously not subject to income taxes, flowing into a taxable corporation included in the Company's post transaction structure. As of December 31, 2023, the Company recognized a deferred tax asset related to its investment in the American Oncology Network, LLC partnership. As of March 31, 2024, the Company updated its valuation allowance assessment based on new factors including its year-to-date loss and forecasted loss at the American Oncology Network, LLC partnership legal entity. Based on its updated valuation allowance assessment, the Company recorded a discrete valuation allowance against its investment in partnership deferred tax asset during the three months ending March 31, 2024.

The effective income tax rate for the three months ended March 31, 2024 and 2023 differed from the federal statutory rate primarily due to certain legal entities in the Company's structure being treated as partnerships for income tax purposes and, therefore, a significant portion of its income not being subject to income tax. Additionally, certain corporate entities within the Company's structure continue to maintain a full valuation allowance against their net deferred tax assets.


26
10. Leases
The Company currently leases office facilities and equipment for its practices under noncancelable operating and finance lease agreements expiring on various dates through 2038. Certain of the leases contain renewal options which are exercisable at the Company’s discretion. These renewal options are considered in determining the lease term if it is reasonably certain that the Company will exercise such options. Additionally, the Company leases certain other office and medical equipment under month-to-month lease agreements. 
Right-of-use assets and lease liabilities consist of the following at March 31, 2024 and December 31, 2023:
As of March 31,
2024		As of December 31,
2023
Assets
Operating lease right-of-use assets, net$43,358 $43,349 
Finance lease right-of-use assets, net (included in property and equipment, net)5,513 5,794 
Total right-of-use assets$48,871 $49,143 
Liabilities
Current
Current portion of operating lease liabilities$6,715 $6,692 
Current portion of finance lease liabilities (included in accrued other)1,205 1,189 
Long-term7,920 7,881 
Long-term operating lease liabilities39,786 39,803 
Long-term finance lease liabilities (included in other long-term liabilities)4,239 4,548 
Total lease liabilities$51,945 $52,232 
The components of lease costs recognized in the condensed consolidated statements of operations and comprehensive loss consist of the following for the three month periods ended March 31, 2024 and 2023 and are included in selling, general, and administrative expenses unless otherwise noted:
Three Months Ended March 31,
20242023
Operating lease costs$2,795 $2,870 
Finance lease costs
Amortization of finance lease right-of-use assets281110
Interest on finance lease liabilities (included in interest expense)8617
Variable lease costs586578
Total lease costs$3,748 $3,575 
27
The following table reconciles the undiscounted cash flows expected to be paid in each of the next five years and thereafter recorded in the condensed consolidated balance sheets for operating and finance leases as of March 31, 2024:
Operating
Leases		Finance
Leases
2024 (remainder of year after March 31, 2024)$6,959 $1,132 
202510,014 1,487 
20269,620 1,249 
20278,370 1,185 
20286,271 948 
Thereafter19,147 261 
Total lease payments60,381 6,262 
Less: amount representing interest(13,880)(818)
Present value of lease liabilities46,501 5,444 
Less: current portion of lease liabilities(6,715)(1,205)
Long-term lease liabilities, net of current portion$39,786 $4,239 
The weighted-average remaining lease term as of March 31, 2024 and December 31, 2023 was 4.54 years and 6.93 years for operating leases and 6.84 years and 4.76 years for finance leases, respectively. The weighted-average discount rate as of March 31, 2024 and December 31, 2023 was 6.33% and 6.64% for operating leases and 6.71% and 6.30% for finance leases, respectively.
The cash paid for amounts included in the measurement of lease liabilities for the three months ended March 31, 2024 and 2023 is as follows:
Three Months Ended
March 31,
20242023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$2,799 $2,845 
Operating cash flows from finance leases86 17 
Financing cash flows from finance leases291 105 
ROU assets obtained in exchange for new operating lease liabilities2,048 4,326 

28
11. Related Parties
Transactions Notes Receivable
The Company enters into promissory notes with physicians of the Company. The notes receivable balances are satisfied through cash payments or settlements through the physicians’ compensation as part of their employee agreement. The notes receivable are amortized over a 60-month period as a reduction of compensation. The notes bear interest at the Company’s incremental borrowing rate (7.09% at March 31, 2024 and 7.18% at December 31, 2023, respectively).
As of March 31,
2024		As of
December 31,
2023		Original
Principal		Issue
Date		Maturity
Date
Notes receivable
Note 2$656 $656 $5,355 5/1/20194/30/2024
Note 3- 17 491 6/1/20195/31/2024
Note 81,999 2,081 2,816 5/1/20205/1/2025
Total notes receivables2,655 2,754 
Less:  Current portion of notes receivable$(2,498)(1,604)
Notes receivable, less current portion$157 $1,150 
Leases
The Company has operating leases for thirteen of the office facilities owned by employees of the Company. Total cash was approximately $0.7 million and $0.7 million paid for leases to related parties for the three months ended March 31, 2024 and 2023, respectively.
Inventory Purchases/Concentration Risk
The Company purchases the majority of pharmaceuticals inventory from a subsidiary under common control of a Legacy AON Shareholder. During the three months ended March 31, 2024 and 2023, the Company purchased from the related party approximately $311.0 million and $243.0 million, respectively. These purchases were approximately 88% and 87% as a percentage of cost of revenue for the three months ended March 31, 2024 and 2023, respectively. At March 31, 2024 and December 31, 2023, the Company had $183.0 million and $102.1 million, respectively, included in accounts payable for invoices from the related party, representing 97% of accounts payable at each period-end.
29
12. Equity-Based Compensation

The Company maintains a single equity incentive plan, the “2023 Incentive Equity Plan”, which was adopted by the Board of Directors and approved by stockholders in connection with the Business Combination. A total of 5,300,000 shares were authorized under the 2023 Incentive Equity Plan. The number of shares of common stock available for issuance under the 2023 Incentive Equity Plan will be increased annually on the first day of each fiscal year during the term of the 2023 Incentive Equity Plan by an amount equal to the lesser of (a) 5% of the shares of common stock outstanding on the final day of the immediately preceding calendar year or (b) such smaller number of shares as determined by the Company’s board of directors. At March 31, 2024, 2,044,394 shares were available for grant under the 2023 Incentive Equity Plan. The purpose of the 2023 Incentive Equity Plan is to attract and retain personnel for positions with the Company, to provide additional incentive to employees, directors, and consultants, and to promote the success of the Company’s business. The Plan permits the grant of Incentive Stock Options (“ISO”) to any ISO Employee and the grant of Non statutory stock options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, and Performance Awards to any Service Provider.

Restricted Stock Units

The Company granted 3,759,459 Restricted Stock Units (“RSUs”) to employees during the three months ended March 31, 2024.

A summary of the RSU activity during the three month period ending March 31, 2024 is as follows:

Restricted Stock UnitsWeighted Average Grant Date Fair Value
Outstanding as of December 31, 2023— $— 
Granted3,759,459 $5.73 
Vested(2,289,181)$5.80 
Forfeited— $— 
Outstanding as of March 31, 20241,470,278 $5.67 

The Company recognized $13.3 million in stock-based compensation expense related to outstanding RSUs during the three months ended March 31, 2024.

As of March 31, 2024, there was approximately $8.2 million of total unrecognized compensation expense related to RSUs, which is expected to be recognized over a weighted-average period of approximately 1.7 years.

The fair value of the RSUs is determined on the date of the grant based on the market price of the Company’s common stock on that date. Each RSU represents the right to receive one share of the Company’s common stock, upon vesting. Portions of the RSUs granted vest immediately with others vesting over one to two years following the grant date, subject to the individual’s continued service to the Company through the applicable vesting date, and are subject to the terms and conditions on the Company’s form of RSU agreement under the 2023 Incentive Equity Plan.
30
13. Equity

Prior Period Presentation

For periods prior to the Reverse Recapitalization, AON LLC had equity and stock-based compensation described below authorized, issued and outstanding. As discussed in Note 1, upon the Closing of the Business Combination, Legacy AON Shareholders received Class A Common Stock, Class B Common Stock, or Class B Prefunded Warrants and AON LLC reclassified their existing Class A, Class A-1, and Class B Units into AON LLC Common Units, pursuant to the terms of the Business Combination Agreement.

The Company recasted Historical AON LLC Equity outstanding for the periods prior to the Reverse Recapitalization, equal to the Per Company Unit Exchange Ratio, pursuant to the Business Combination, that was applied to the Class A, Class A-1, and Class B Units. The historical AON LLC units disclosed in this note give effect to the conversion for all periods presented, as follows.

Class A Units

AON LLC had authorized 19,495,376 units of Class A Units, of which 19,495,376 units were issued and were outstanding as of December 31, 2022.

Class A-1 Units

AON LLC had authorized 3,000,245 units of Class A-1 Units, of which 1,842,520 units were issued and were outstanding as of December 31, 2022.

Class B Units (Profit Interest)

The Class B units were issued through the 2017 Profits Interest Plan adopted by the Company in October 2017. The Class B Units represented a non-voting equity interest in AON LLC that entitled the holder to appreciation in the equity value of AON LLC arising after the date of grant and after such time as an applicable hurdle amount is met. AON LLC recognized the cost of services received in exchange for Class B Units based on the grant-date fair value. That cost was recognized over the period during which the service provider is required to provide service in exchange for the award over the requisite service period or based on performance. AON LLC used the Black-Scholes-Merton pricing model to estimate the fair value of profits interest unit awards. On an as converted basis, as of December 31, 2022, AON LLC issued 5,614,176 Class B Units, of which 4,703,628 were vested and outstanding; the remaining 910,548 of Class B units vested upon consummation of the Business Combination.

The following table summarizes the changes to AON LLC’s Class A, Class A-1, and Class B Units for the three months ended March 31, 2023.

31
in thousands, except for share and per share amountsThree Months Ended
March 31, 2023
Class A Units, value
Beginning of Period$7,725 
Issuance of Units— 
Impact of the Reverse Recapitalization— 
End of Period$7,725 
Class A Units, units
Beginning of Period19,495,376 
Issuance of Units— 
Impact of the Reverse Recapitalization— 
End of Period19,495,376 
Class A-1 Units, value
Beginning of Period$28,500 
Issuance of Units— 
Impact of the Reverse Recapitalization— 
End of Period$28,500 
Class A-1 Units, units
Beginning of Period1,842,520 
Issuance of Units— 
Impact of the Reverse Recapitalization— 
End of Period1,842,520 
Class B Units, value
Beginning of Period$80 
Equity based compensation— 
Impact of the Reverse Recapitalization— 
End of Period$80 
Class B Units, units
Beginning of Period4,703,628 
Units Vested— 
Impact of the Reverse Recapitalization— 
End of Period4,703,628 

Class B-1 Units

In June and July of 2023, the Company granted a total of 415 AON LLC Class B-1 Units to certain employees under the 2017 Profits Interest Plan (the “Plan”). Upon the closing of the Business Combination, the vested Class B-1 Units were reclassified to AON LLC Common Units and exchanged for newly issued shares of Class A Common Stock equal to the Per Company Unit Exchange Ratio, pursuant to the Business Combination Agreement, which resulted in the issuance of 1,047,343 shares of New AON Class A Common Stock.

Mezzanine Equity Class C Units

As described in Note 1, the AON LLC Class C Units were converted into AON LLC Series A Preferred Units as of the Closing Date. Concurrently, New AON issued a number of shares of New AON Series A Preferred Stock equal
32
to the number of AON LLC Series A Preferred Units held by the AON Class C Preferred Investor to AEA Growth Management LP, the parent of AON Class C Preferred Investor (“AEA Growth”) in exchange for all the shares of common stock held by AEA Growth in the AON Class C Preferred Investor. Promptly after the First Step, the AON Class C Preferred Investor merged with and into New AON whereby the separate existence of the AON Class C Preferred Investor ceased and New AON held all the AON LLC Series A Preferred Units. On an as converted basis, as of September 20, 2023, 6,651,610 Series A Preferred Stock were issued to AEA Growth Management LP.

The AON LLC Class C Units were contingently redeemable convertible preferred units and classified as mezzanine equity on the condensed consolidated balance sheet as of June 30, 2023 because the units were redeemable five years from the issuance date, at the option of the holder. As of June 30, 2023, the AON LLC Class C Units were recorded at their initial carrying value, net of offering costs. The Class C Units were not being accreted to redemption value, as the redemption was not probable due to the removal of the redemption right pursuant to the Business Combination. See discussion below.

The Class C Units had materially the same rights as the Series A Preferred Stock issued by the Company to AEA Growth Management LP, the parent of the AON Class C Preferred Investor, with the exception of the “AON LLC Class C Unit Redemption Right” and the “Class C Option to Purchase Additional Shares”, discussed below. Further, the Class C Units did not contain a mandatory conversion feature that allowed AON LLC to force the Class C Investor to convert the Class C Units into another equity unit in AON LLC and the Class C Units did not have a one time conversion price adjustment.

Class C Unit Redemption Right

After the fifth anniversary of the Effective Date (June 7, 2028), the holders of a majority of the Class C Units had the right to cause the Company to redeem all of the Class C Units. The redemption price per Class C Unit was equal to the greater of (i) the Class C Liquidation Preference and (ii) the Fair Market Value of a Class C Unit (the “Class C Redemption Price”). The Class C Liquidation Preference is defined as an amount equal to the sum of (a) the Class C Preferred Return of such Class C Member and (b) the amount of such Class C Member’s Net Invested Capital Contributions of $65.0 million. The Class C Unit Preferred Return is defined as the cumulative, semiannually-compounded return of 8% per annum based on the original Net Invested Capital Contributions of $65.0 million. The Class C Unit Redemption Right was removed as of the Closing of the Business Combination.


Series A Preferred Stock (Mezzanine Equity)

New AON Series A Preferred Stock is redeemable for cash or the value of the property, rights or securities to be paid or distributed in the event of a Deemed Liquidation Event (which outside of the Company’s control). As a result, the Company has determined that the New AON Series A Preferred Stock should be classified as mezzanine equity. At the closing of the Business Combination, the Company exchanged existing AON LLC Class C Units for Series A Preferred Stock in the Company. Based on the qualitative changes to the instrument, this exchange is considered an extinguishment for accounting purposes, with the Company recording a deemed dividend of $2.1 million to account for the difference between the carrying value of the Class C Units and the fair value of the Series A Preferred Stock at the transaction date. This amount is reflected in the December 31, 2023 condensed consolidated statements of mezzanine and stockholders’ equity as part of the reverse recapitalization, net. See further discussion on the PIK Dividend discussed below.

The Series A Preferred Stock are not being accreted to redemption value, as the Series A Preferred Stock are not redeemable, nor are they probable of becoming redeemable.

Dividends

The Series A Preferred Stock accrue dividends at a cumulative, semiannually-compounded return of 8% per annum based on the original Net Invested Capital Contributions from the Class C Units of $65.0 million. These dividends may be paid in cash or accumulate into the Accrued Value at the option of New AON. The accrual shall be calculated on June 30 and December 31 and with respect to the semiannually-compounded return, no interest is required to be paid on any present or future Series A Preferred Stock accrued dividends. The Series A Preferred Stock also participate in distributions with the Class A Common stockholders.

33
On September 20, 2023, the Company issued 6,651,610 Series A Preferred Stock to AEA Growth Management LP. The number of Series A Preferred Stock shares issued at the Closing of the Business Combination was equal to the aggregate Class C Liquidation Preference pursuant to the Business Combination Agreement. As a result, the issuance of the Series A Preferred Stock effectively included an in-kind payout (“PIK”) of the accrued dividend since the calculation of the amount issued was based on the Class C Liquidation Preference. As of the Closing, the Company recorded a dividend of 151,610 Series A Preferred Stock PIK shares with respect to the accrued dividends on the Series A Preferred Stock (the "PIK Dividend") in the December 31, 2023 condensed consolidated statements of mezzanine and stockholders’ equity.

Voting

The holders of the Preferred Stock are entitled to elect and appoint one of the directors (“Series A Director”) to the Board of Directors. All other directors are appointed by the Class A and Class B Common stockholders. There are no restrictions on which matters the Series A Preferred stockholders are entitled to vote. The Series A Preferred stockholders are entitled to the number of votes equal to the number of shares of Common Stock into which the Series A Preferred Stock would be convertible on the record date of the vote.

Conversion Rights

The Series A Preferred Stock is convertible, at the option of the holder, at any time, and without the payment of additional consideration by the holder, into such number of fully-paid Class A Common Stock as is determined by dividing the Accrued Value by the Conversion Price in effect at the time of conversion (“Conversion Ratio”). The Accrued Value is the Original Issue Price (which is $10.00 per share of Preferred Stock, as adjusted for any stock split, stock dividend, combination, or other recapitalization) plus any unpaid dividends, compounded semi-annually. The Conversion Price is initially $10.00 per Preferred Share subject to adjustment for dilutive issuances of additional shares, dividends to common stockholders, stock splits, mergers, and a five-year anniversary special adjustment based on the volume weighted average price of the common stock. These dividends may be paid in cash or accumulate into the Accrued Value, at the option of New AON, on June 30 and December 31 of each year. The Conversion Rights shall terminate at the close of business on the day prior to the date of a Change of Control.

If at any time on or after the 30th day after the five-year anniversary of the issue date, any of the Series A Preferred Stock remain outstanding and the 30-Day VWAP of the Common Stock is less than $10.00 (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification), then the Conversion Price shall be adjusted to the greater of (x) the 30-Day VWAP on such date of determination and (y) $5.00 (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification).

New AON also has the right on or after the third-year anniversary of the date of issuance to cause all (but not less than all) of the outstanding shares of Series A Preferred Stock to be converted into shares of Class A Common Stock for each share of Series A Preferred Stock at the Conversion Ratio detailed above. The Company may only convert shares of Series A Preferred Stock into shares of Common Stock if the 30-Day VWAP of the Common Stock immediately prior to the Company Conversion Date is greater than $16.00 (as adjusted for any stock split, stock dividend, combination, or other recapitalization).

Liquidation Preferences

In the event of voluntary or involuntary liquidation, dissolution or winding up of the Company or an Initial Public Offering (IPO) or Exit Event, the Series A Preferred Stock have preferential liquidation rights. If a Deemed Liquidation Event were to occur, each Series A Preferred stockholder is entitled to be paid out of the assets of the Company available for distribution, equal to the greater of the following:

(i) The Original Issue Price of $10 per Series A Preferred Stock multiplied by the Applicable Percentage plus any Accrued Dividends on such share of Series A Preferred Stock; or

(ii) Such amount per share as would have been payable had all shares of Series A Preferred Stock been converted into Common Stock immediately prior to such Deemed Liquidation Event.

The Series A Preferred Stock Applicable Percentage is defined as a percentage equal to (a) one hundred twenty-five percent (125%) if an Exit Event, dissolution, liquidation, or winding-up occurs prior to June 7, 2024, (b) one
34
hundred twenty percent (120%) if an Exit Event, dissolution, liquidation, or winding up occurs after June 7, 2024, but prior to June 7, 2025, (c) one hundred fifteen percent (115%) if an Exit Event, dissolution, liquidation, or winding-up occurs after June 7, 2025, but prior to June 7, 2026, (d) one hundred ten percent (110%) if an Exit Event, dissolution, liquidation, or winding up occurs after June 7, 2026, but prior to June 7, 2027, (e) one hundred five percent (105%) if an Exit Event, dissolution, liquidation, or winding-up occurs after June 7, 2027, but prior to June 7, 2028, (f) one hundred percent (100%) if an Exit Event, dissolution, liquidation, or winding-up occurs after June 7, 2028.

Distributions to Class A and Class A-1 Members

On March 4, 2020, the AON LLC entered into the Second Amended and Restated Limited Liability Agreement (“Second Operating Agreement”) which established another class of equity, Class A-1 Units. The Second Operating Agreement provided, among other things, that the Class A and A-1 Units would receive a cumulative, annually-compounded, preferred return of 8.0% and 4.0%, respectively, on capital contributions when and if distributions are declared by the Board of the Company.

Prior to the issuance of the Class C Units on June 7, 2023 as discussed above, the Class A and A-1 unitholders were paid a cash distribution of $4.0 million and $4.1 million, respectively, representing the cumulative accrued preferred return to June 7, 2023.

On June 7, 2023, in connection with the issuance of the Class C Units, AON LLC entered into the Third Amended and Restated Limited Liability Agreement (“Third Operating Agreement”) which, among other things, eliminated any provisions for future preferred returns on Class A and A-1 units.



35
14. Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per share of Class A Common Stock and represents the period from January 1, 2024 to March 31, 2024, the period where the Company had Class A and Class B common stock outstanding. Class B Common Stock does not have economic rights in AON Inc., including rights to dividends or distributions upon liquidation, and as a result, is not considered a participating security for basic and diluted loss per share. As such, basic and diluted loss per share of Class B Common Stock has not been presented. Series A Preferred Stock are considered participating securities for basic and diluted loss per share, but do not participate in losses. As such, basic and diluted loss per share is computed using the two-class method. For additional information, see Notes 1 and 2.

Basic loss per share is based on the weighted-average number of shares of Class A Common Stock outstanding during the period. Diluted loss per share is based on the weighted-average number of shares of Class A Common Stock used for the basic loss per share calculation, adjusted for the dilutive effect of Public and Private Warrants, Restricted Stock Units, and Sponsor Earnouts, if any, using the “treasury stock” method and the convertible Series A Preferred Stock, Class B Common Stock, and Class B Prefunded Warrants, if any, using the “if-converted” method. Net loss for diluted loss per share is adjusted for the Company’s share of AON LLC’s consolidated net loss, net of AON Inc. taxes, after giving effect to Class B Common Stock and Class B Prefunded Warrants that are exchanged into potential shares of Class A Common Stock, Public and Private Warrants that are liability classified, and Series A Preferred Stock that accrue dividends, to the extent it is dilutive.

Net loss attributable to Class A Common Stockholders for basic and diluted earnings per share$(7,841,000)
Series A Preferred Cumulative Dividends(1,360,180)
Undistributed loss for basic earnings per share$(9,201,180)
Weighted-average shares for basic earnings per share7,527,882 
Basic and Diluted loss per share of Class A Common Stock$(1.22)

The following table details the securities that have been excluded from the calculation of weighted-average shares for diluted loss per share for the period presented as they were anti-dilutive. Note that the Sponsor Earnouts are excluded from the calculation of weighted-average shares for diluted loss per share as the contingency had not been met as of the period end.

Series A Preferred Stock6,651,610 
Class B Common Stock23,725,998 
Class B Prefunded Warrants3,000,245 
Public and Private Warrants14,450,833 
Restricted Stock Units1,470,278 
36
15. Redeemable Noncontrolling Interest

Legacy AON Shareholders own 26,726,243 AON LLC Common Units, equal to a 61.1% of the economic interest in AON LLC. Legacy AON Shareholders also own 23,725,998 shares of Class B Common Stock and 3,000,245 Class B Prefunded Warrants, which, together with the AON LLC Common Units, may be redeemed at the option of the Legacy AON Shareholder on a one-for-one basis for shares of Class A Common Stock or the cash equivalent thereof (based on the market price of the shares of Class A Common Stock at the time of redemption) as determined by New AON. If New AON elects the redemption to be settled in cash, the cash used to settle the redemption must be funded through a private or public offering of Class A Common Stock no later than ten (10) business days after the redemption notice date. Upon the redemption of the AON LLC Common Units and Class B
Common Stock for shares of Class A Common Stock or the equivalent thereof, all redeemed shares of Class B Common Stock will be cancelled. The redemption value is determined based on a five-day volume weighted average price (”VWAP”) of the Class A common shares, subject to customary conversion rate adjustments for share splits, share dividends, and similar events affecting Class A Common Stock.

When applying SEC guidance concerning mezzanine classification, the Company understands that due to the NCI holders having control of the Board, if there is a sequence of remotely possible events that could trigger a redemption, this requires the instrument to be classified as temporary equity, without any regard to probability. Accordingly, though the redemption would require such a remotely possible sequence of events, and such remote sequence of events would also require, in management’s view, the Company to take extraordinary actions in order to allow such sequence of events to be remotely possible, the noncontrolling interest is currently classified as temporary equity. In the event that the Legacy AON Shareholders own less than 50% of the outstanding economic interest in AON LLC Common Units due to future redemptions, the noncontrolling interest will be presented as permanent equity.

The redeemable noncontrolling interest is recognized at the greater of (1) its initial fair value plus accumulated earnings/(losses) associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At March 31, 2024, the redeemable noncontrolling interest was recorded based on its redemption value of $157.7 million which exceeded its carrying value by $15.6 million. This measurement adjustment decreased additional paid in capital by $9.7 million and retained deficit by $5.9 million. At the end of each reporting period, AON LLC equity attributable to AON Inc. and the Legacy AON Shareholders is rebalanced to reflect AON Inc.’s and the Legacy AON Shareholder’s ownership in AON LLC.


The following table summarizes the economic ownership of AON LLC, for the period beginning December 31, 2023 and ending March 31, 2024.

 Period beginning December 31, 2023 and ending March 31, 2024
AON LLC Units
AON Inc.Legacy AON ShareholdersTotal
Beginning of Period13,330,051 28,109,796 41,439,847 
Issuances2,289,181 — 2,289,181 
Repurchases(16,441)— (16,441)
Redemptions 1,383,553 (1,383,553)— 
Total Units Issued16,986,344 26,726,243 43,712,587 
End of Period16,986,344 26,726,243 43,712,587 
Allocation of income to controlling and noncontrolling interests38.9 %61.1 %100 %
Allocation of losses to controlling and noncontrolling interests (1)
23.0 %77.0 %100 %
(1) As discussed in Note 13, Series A Preferred Stock are considered participating securities for basic and diluted loss per share, but do not participate in losses. As a result, the consolidated net loss of AON LLC, during the period of January 1, 2024 through March 31, 2024, were
37
allocated to the NCI to reflect the absorption of the Legacy AON Shareholders to a portion of the consolidated net loss of AON LLC. Net losses were not attributed to Series A Preferred Stock.
38
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis provides information which AON’s management believes is relevant to an assessment and understanding of AON’s results of operations and financial condition. You should read the following discussion and analysis of AON’s financial condition and results of operations together with AON’s condensed consolidated unaudited financial statements as of March 31, 2024 and for the three months ended March 31, 2024 and 2023 that are included in this Quarterly Report. This discussion should be read in conjunction with our audited consolidated financial statements as of and for the years ended December 31, 2023, 2022 and 2021, together with the related notes thereto, found in our Annual Report on Form 10-K, dated and filed with the SEC on March 28, 2024 and which is available on the SEC’s website at www.sec.gov.

In addition, the following discussion and analysis of AON Inc.’s financial condition and results of operations also contains forward-looking statements that involve risks, uncertainties and assumptions. Actual results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. The following should be read in conjunction with the sections titled “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors.”
Unless otherwise indicated or the context otherwise requires, references in this AON Management’s Discussion and Analysis of Financial Condition and Results of Operations section to “AON,”, “AON, Inc.”, “New AON”, “we,” “us,” “our,” the “Company,” and other similar terms refers to American Oncology Network, Inc., its consolidated subsidiaries and variable interest entities.
Overview
Since its inception in 2018, AON has offered an innovative model of physician-led, community-based oncology management. AON preserves and elevates community oncology by helping its physicians navigate the complex healthcare landscape, providing them an efficient platform to work autonomously and thrive, and most importantly, improving the quality of patient care that is being delivered. We are an alliance of physicians and veteran healthcare leaders partnering to ensure the long-term success and viability of oncology diagnosis and treatment in community-based settings. As of March 31, 2024, we have approximately 220 physicians and advanced practice providers across 91 locations in 19 states and the District of Columbia. Our robust platform provides oncology practices with comprehensive support, access to revenue- diversifying adjacent services and practice management expertise to empower physicians to make cancer care better for every patient.
Our mission is to provide high quality, cost effective cancer care close to where patients live and work. We believe the key to accessible and equitable healthcare lies in the strength of community healthcare practices and we are committed to closing the gap in cancer care to ensure every patient has access to the optimal, comprehensive care needed to help in their fight against cancer. To accomplish this, we have practices in some of the most densely populated cities as well as rural areas where medical resources are scarce. We deliver cancer care innovation by bringing new treatments to the forum and also by ensuring access to the necessary adjacent services to provide comprehensive quality cancer care and preserving the delivery of personalized cancer care in the community oncology setting.
Through access to care-enhancing patient services such as a centralized specialty pharmacy, wide ranging clinical lab and pathology services, clinical research, diagnostic imaging, a fully integrated technology platform anchored by an oncology- specific electronic medical record system, as well as a caring management team and a variety of financial assistance programs, our patients receive expert cancer care at each of our clinics.
We provide patients a variety of services to enhance patient care throughout the healthcare journey: high-quality and timely laboratory services for routine and specialized testing; in-house professional and technical pathology services providing complete, accurate and timely pathology reports; in-house specialty pharmacy with patient education, financial assistance, and 24/7 patient assistance; and care management support services including nutrition guidance.
As the future of healthcare continues to transition from volume to value, we are at the forefront of this initiative by ensuring we remain focused on care quality over care quantity and maintaining a patient-first mentality. Through an integrated system of seamless communication, coordination and patient care for better health outcomes, AON practices benefit from decreased expenditures through the implementation of centralized administrative services, processes, and technologies designed to support effective decision- making such as optimal pricing on drugs and medical supplies. Our patients benefit through our 24/7 clinical care support leading to a reduction in unnecessary emergency room visits and admissions and enhanced care quality. Ultimately, the payors benefit from more efficient delivery of high-quality, comprehensive services comparable to any hospital system at a lower cost point.
39
Though our network spans the country, our clinicians are interconnected and focused on driving change not just at their local clinics, but throughout our network. Our Network Practices not only unite in collaboration through a physician advisory board, but they also remain at the forefront of new discoveries and findings by expanding and improving cancer treatment options for every patient through a Pharmacy and Therapeutics Committee that continuously updates its formulary in real time as advanced therapeutics come to market and through participating in clinical research to ensure we remain on the cutting edge of cancer protocols. Patients benefit from convenient access to clinical trials that we participate in without the need to travel to large cities or tertiary cancer care facilities, and personalized care by matching a patient’s cancer to a tailored therapy using molecular profiling.
We have invested significantly in a resilient, integrated technology platform to support the practices which includes a fully integrated electronic health record and a robust decision support tool and analytics engine. Our development of compliance materials ensures consistency and optimal patient experiences that meets or exceeds the Office of Inspector General (“OIG”) guidelines.
We believe that our position in the market and focus on elevating the state of oncology care with our affiliated providers bodes well for future growth. Our proprietary technology platform supports this growth and enables the Network Practices to standardize and deliver consistent care at scale. We believe that our model will support growth into new markets and allow us to continue to service more patients across the United States.

The Business Combination
Digital Transformation Opportunities Corp. (“DTOC”), American Oncology Network, LLC (“AON LLC”), GEF AON Holdings Corp. (“AON Class C Preferred Investor”), and DTOC Merger Sub, Inc., a direct, wholly owned subsidiary of DTOC (“Merger Sub”) entered into a Business Combination Agreement (the “Business Combination Agreement” or “Reverse Recapitalization”), dated as of June 14, 2023 (which further amended and restated the Business Combination Agreement entered into by DTOC and AON as of October 5, 2022, and amended and restated on January 6, 2023, and April 27, 2023), pursuant to which, among other transactions, on September 20, 2023 (the “Closing Date”), DTOC and AON undertook a series of transactions (the “Business Combination”) resulting in the organization of the combined post-business combination company as an umbrella partnership C corporation, in which substantially all of the assets and the business of the combined company are held by AON LLC, and DTOC became a member of AON LLC. In connection with the closing of the Business Combination (“the Closing”), DTOC changed its name to “American Oncology Network, Inc.”. The Business Combination was completed on September 20, 2023.

As a result of, and in connection with, the Closing, among other things, (i) AON LLC amended and restated its operating agreement (the “Amended and Restated AON LLC Agreement”) to reclassify its existing Class A units, Class A-1 units and Class B units into a single class of AON LLC common units (“AON LLC Common Units”) that can be exchanged on a one-to-one basis for shares of New AON Class A common stock (“New AON Class A Common Stock”) and its existing AON LLC Class C units into AON LLC Series A preferred units (AON LLC Series A Preferred Units”); (ii) AON LLC converted profit pool units of certain of AON LLC’s subsidiaries into an equal number of AON LLC Common Units and shares of New AON Class B common stock (“New AON Class B Common Stock”), which together are exchangeable into shares of New AON Class A Common Stock (together with the New AON Class B Common Stock, the “New AON Common Stock”); (iii) New AON amended and restated its charter (the “Charter”) to provide for (a) the conversion of all existing shares of DTOC Class B common stock into shares of New AON Class A Common Stock on a one-to-one basis, (b) amendment of the terms of New AON Class B Common Stock to provide holders voting rights but no economic rights and (c) designation of a new series of New AON preferred stock as Series A convertible preferred stock (the “New AON Series A Preferred Stock” or “Series A Preferred Stock") with such rights and preferences as provided for in the certificate of designation of the New Aon Series A Preferred Stock (the “New AON Series A Certificate of Designation”); and (iv) among other things, (a) AON LLC issued common units to New AON in exchange for a combination of cash and shares of New AON Class B Common Stock and warrants to acquire shares of New AON Class B Common Stock (the “Class B Prefunded Warrants”), (b) New AON was admitted as a member of AON LLC, (c) AON LLC distributed shares of New AON Class B common stock or Class B Prefunded Warrants, as applicable, to AON LLC equity holders, (d) New AON reserved a specified number of additional shares of New AON Class A Common Stock after the Closing for issuance to eligible participants, (e) Merger Sub merged with and into the AON Class C Preferred Investor whereby the separate existence of Merger Sub ceased and New AON issued a number of shares of New AON Series A Preferred Stock equal to the number of AON LLC Series A preferred units held by the AON Class C Preferred Investor to AEA Growth Management LP, the parent of AON Class C Preferred Investor (“AEA Growth”) in exchange for all the shares of common stock held by AEA Growth in the AON Class C Preferred Investor (the “First Step”), (f) promptly after the First Step, the AON Class C Preferred Investor merged with and into New AON whereby the separate existence of the
40
AON Class C Preferred Investor ceased and New AON held all the AON LLC Series A preferred units and (g) from and after the Closing (but subject to lock-up restrictions), the AON LLC common equity holders (other than New AON), referred to herein as “Legacy AON Stockholders” (former AON LLC Class A, Class A-1, and Class B unit holders), will have the right (but not the obligation) to exchange AON LLC Common Units together with an equal number of shares of New AON Class B Common Stock (whether held directly or indirectly through Class B Prefunded Warrants) for shares of New AON Class A Common Stock.

In addition, in connection with the Closing, DTOC completed the offer to the holders of AON LLC Class B-1 units to exchange their AON LLC Class B-1 units for such number of newly issued shares of New AON Class A Common Stock equal to the ratio set forth in the Business Combination Agreement (such offer, the “Exchange Offer”). DTOC and AON LLC solicited consents from the holders of AON LLC Class B-1 units to make certain amendments to the terms of the awards and the unit grant agreements pursuant to which the AON LLC Class B-1 units were granted, which provided for the automatic exchange, as of immediately prior to the adoption of the Amended and Restated AON LLC Agreement, of all outstanding AON LLC Class B-1 units into shares of New AON Class A Common Stock (collectively, the “Proposed Amendments”). The requisite number of holders of Class B-1 units provided their consent to the Proposed Amendments, and as a result, in connection with the Closing, all AON LLC Class B-1 units were exchanged for an aggregate of 1,047,343 shares of New AON Class A Common Stock.
Basis of Presentation

For the three months ended March 31, 2024, these condensed consolidated financial statements reflect the consolidated results of operations, comprehensive income (loss), cash flows and changes in equity of AON Inc. and its wholly-owned subsidiaries. The consolidated balance sheet at March 31, 2024 presents the financial condition of AON Inc. and its consolidated subsidiaries, including AON LLC, and reflects the initial recording of the assets and liabilities of AON Inc. at their historical cost. All intercompany balances and transactions of AON LLC prior to the Reverse Recapitalization have been eliminated. All intercompany balances and transactions of AON Inc. after the Reverse Recapitalization have been eliminated.

For the three months ended March 31, 2024, $7.8 million of the consolidated net loss of AON Inc. were attributable to the Class A Common Stockholders, and reflects the Class A Common Stockholders’ absorption of 23.0% of the consolidated net loss of AON LLC.

For the three months ended March 31, 2024, $17.2 million of the consolidated net losses of AON LLC were attributable to noncontrolling interest, and reflects the Legacy AON Stockholders’ absorption of 77.0% of the consolidated net losses of AON LLC.

For the three months ended March 31, 2023, $1.5 million of the consolidated net losses of AON LLC were attributable to the Legacy AON Stockholders, to reflect their absorption of 100% of the consolidated net losses of AON LLC pertaining to the days prior to the Reverse Recapitalization.
Key Factors Affecting Performance & Non-GAAP Measures
Factors Affecting Our Revenues
There are many factors that drive patient service revenues; however, we focus on certain key metrics such as:
•Total patient encounters which include initial consultations and treatments, new patient encounters, recurring patient encounters and treatments, and cancer vs non cancer patients.
•Patient referrals which are also an important driver of patient service revenue; we manage the referral pipeline locally through the coordinated efforts of our physician liaisons working with our physicians to market our practices by visiting referral sources such as, primary care providers and other medical specialties.
Factors Affecting Our Operating Costs
Operating costs are primarily dependent upon factors such as:
•The cost of prescription drugs used in our treatment plans which include both intravenous and oral oncolytics. The management of these costs are a critical component of our business as it is our single largest expense. We manage
41
this cost by strategic volume purchases and continuously evaluating the most clinically effective drug for cancer type through our Pharmaceutical and Therapeutics Committee.
•Clinical compensation and benefits, including non-medical personnel, represent our second largest operating expense. These costs are impacted by both micro and macro-economic factors as well as local competition for personnel that could impact costs associated with personnel. In particular, in all of our markets, we have seen significant increases in compensation for qualified nursing resources. We continuously monitor wages period over period to mitigate the impact of variations in industry and macro-economic labor conditions.
•We lease all of our facilities, therefore real-estate costs are a significant component of our operating costs. We continuously monitor local and national real estate conditions to actively manage our exposure to fluctuating occupancy costs.
Key Non-GAAP Financial Measures We Use to Evaluate Our Performance
Adjusted EBITDA
This filing includes the non-GAAP financial measure “Adjusted EBITDA”. Management views this metric as a useful way to look at the performance of our operations between periods and to exclude decisions on capital investment and financing that might otherwise impact the review of profitability of the business based on present market conditions. Management believes this measure provides an additional way of viewing aspects of the Company’s operations that, when viewed with the GAAP results, provides a more complete understanding of the Company’s results of operations and the factors and trends affecting the business.
Adjusted EBITDA is defined as net income prior to interest income, interest expense, income taxes, and depreciation and amortization, as adjusted to add back certain other non-cash charges that we may record each year, such as stock-compensation expense, as well as non-recurring charges such as expenses incurred related to major operational transitions and transaction costs. We believe these expenses and non-recurring charges are not considered an indicator of ongoing company performance. The measures are used as a supplement to GAAP results in evaluating certain aspects of our business, as described below. We believe Adjusted EBITDA is useful to investors in evaluating our performance because the measure considers the performance of our operations, excluding decisions made with respect to capital investment, financing, and other non-recurring charges as outlined above.
The Company includes Adjusted EBITDA because it is an important measure upon which our management uses to assess the results of operations, to evaluate factors and trends affecting the business, and to plan and budget future periods. However, non-GAAP financial measures should be considered a supplement to, and not as a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. Non-GAAP financial measures used by management may differ from the non-GAAP measures used by other companies, including the Company’s competitors. Management encourages investors and others to review the Company’s financial information in its entirety, and not to rely on any single financial measure. Adjusted EBITDA should not be considered as an alternative to net income as an indicator of our performance or as an alternative to any other measure prescribed by GAAP as there are limitations to using such non-GAAP measures. We compensate for these limitations by providing disclosure of the differences between Adjusted EBITDA and GAAP results, including providing a reconciliation to GAAP results, to enable investors to perform their own analysis of our operating results.
Components of Results of Operations
Patient Service Revenue, net
The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) pharmacy benefit managers (“PBMs”); (iii) the federal government under the Medicare program administered by the Centers for Medicare and Medicaid Services (“CMS”); (iv) state governments under Medicaid and other programs, including managed Medicare and Medicaid; and (v) individual patients.
The primary elements of patient service revenue are from fee for service (“FFS”) revenue which includes revenue from required patient infusion and injection treatments, as well as oral prescription drugs. FFS revenue comprise revenues in which we bill and collect for medical services rendered by our physicians or nurse practitioners including office visits and consults. FFS revenue also includes infusion therapies and treatment. FFS revenue consists of fees for medical services provided to patients. Payments for services provided are generally less than billed charges. The Company records revenue
42
net of an allowance for contractual adjustments, which represents the net revenue expected to be collected from third-party payors (including managed care, commercial, and governmental payors such as Medicare and Medicaid), and patients.
These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient’s healthcare plan, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries). The recognition of net revenue (gross charges less contractual allowances) from such services is dependent on certain factors, such as, the proper completion of medical charts following a patient encounter, proper medical coding of the charts, and the verification and authorization of each patient’s eligibility at the time services are rendered as to the payor(s) responsible for payment of such services.
Oral prescription drugs comprise revenues from prescriptions written by our doctors to their patients which are dispensed directly by AON’s specialty pharmacy. Revenue for the oral prescription is based on fee schedules set by various PBMs and other third-party payors. The fee schedule is often subject to direct and indirect remuneration (“DIR”) fees, which are based primarily on adherence and other metrics. DIR fees may be significant and may be assessed in the periods after payments are received against future payments. The Company recognizes revenue, net of estimated DIR fees, at the time the patient takes possession of the oral drug.
Other Revenue
Other revenue is primarily generated from service arrangements with various hospitals systems and data contracts as well as through clinical trials.
Cost of Revenue
Cost of services primarily includes chemotherapy drug costs, clinician salaries and benefits, medical supplies, and clinical occupancy costs. Clinicians include oncologists, advanced practice providers such as physician assistants and nurse practitioners, and registered nurses. Specialty pharmacy costs primarily include the cost of oral medications dispensed from the specialty pharmacy including overhead costs for running a free-standing pharmacy and shipping costs to patients.
General and administrative
Our general and administrative expenses include corporate occupancy costs, technology infrastructure, operations, clinical and quality support, finance, legal, human resources, and business development. Depreciation and amortization expenses are also included in general and administrative expenses. The Company expects its general and administrative expenses to increase over time following the consummation of the Business Combination due to the additional legal, accounting, insurance, investor relations and other costs that the Company will incur as a public company, as well as other costs associated with continuing to grow the business. While we expect general and administrative expenses to increase in the foreseeable future, such expenses on average are expected to decrease as a percentage of revenue over the long term, as the company continues to scale its operations.

Transaction Expenses
Transaction expenses consist of legal services, professional fees and other due diligence expenses that were incurred in connection with the Business Combination. These transaction expenses are considered non-recurring and as a result are included as an add-back in the Company’s Adjusted EBITDA calculation.

Results of Operations
Comparison of the Three Months Ended March 31, 2024 and 2023 Revenue

Three Months Ended March 31,Change
(dollars in thousands)20242023$%
Patient service revenue, net$361,508 $301,773 $59,735 19.8 %
Other revenue2,831 1,958 873 44.6 %
Total revenue$364,339 $303,731 $60,608 20.0 %
For the three months ended March 31, 2024 and 2023 revenue increased $60.6 million, or 20.0%, primarily due to a $59.7 million increase in patient service revenue and a $0.9 million increase in other revenue.
43
Patient service revenue, net
For the three months ended March 31, 2024 and 2023 the $59.7 million increase in revenue is largely attributable to an increased revenue per encounter of 12.8% driving $41.0 million of the revenue increase. $18.7 million of increase in patient service revenue was due to increase of patient encounters of 7.1% seen within the period. This revenue growth was constrained in part by approximately $4.1 million of incremental implicit price concessions associated with accounts receivable in our legacy billing system as the Company transitioned its billing and collection efforts to a new billing system in the fourth quarter of 2023.
Other revenue
For the three months ended March 31, 2024 and 2023 other revenue increased $0.9 million due to an increase in service arrangements and data contracts.

Operating Expenses
Three Months Ended March 31,Change
(dollars in thousands)20242023$%
Cost of revenue$354,948 $278,534 $76,414 27.4 %
General and administrative expenses28,277 23,717 4,560 19.2 %
Transaction expenses
352 1,971 (1,619)*
Total costs and expenses$383,577 $304,222 $79,355 26.1 %
* — % not meaningful
For the three months ended March 31, 2024 and 2023, operating expenses increased $79.4 million, or 26.1%, due to a $76.4 million increase in cost of revenue, and a $4.6 million increase in general and administrative expenses offset by a $1.6 million decrease in transaction expenses.
Cost of revenue
For the three months ended March 31, 2024 and 2023, cost of revenue increased $76.4 million which was primarily driven by drug and medical supply costs, due to both increased patient encounters and cost per encounter. The volume of patient encounters at our practices increased cost of revenue by $14.9 million, and the cost per encounter drove a $42.8 million increase. The increased cost of patient encounters was driven by a combination of higher drug and supply costs as well as the drug and service mix patients required. In March 2024, the Company issued Restricted Stock Units (“RSUs”) under the 2023 Equity Incentive Plan to employees of the Company with various vesting periods including RSUs that vest immediately, over a period of one year, and over a period of two years. The Company recognized $13.3 million of equity-based compensation expense associated with the March 2024 grant of RSUs, substantially all of which was related to RSUs that vested immediately upon grant. There was no stock-based compensation expense recognized during the three months ended March 31, 2023. Refer to Note 12, Equity-Based Compensation, for further discussion.
General and administrative expense
For the three months ended March 31, 2024 and 2023, the $4.6 million increase in general and administrative expenses was driven by a $1.1 million increase in revenue cycle costs associated with the Company’s growth and optimization of our revenue cycle function as well as $0.9 million of increase seen in computer expense as a result of Company’s AthenaIDX RCM conversion and dual RCM costs within the quarter. The company saw an increase of $1.4 million in insurance and accounting fees as a result of being publicly traded as well as $1.5 million increase in operating costs related to legal costs, office expenses, contract labor, licenses, and travel expenses relative to Company growth.
Transaction expense
For the three months ended March 31, 2024 and 2023, the Company saw a $1.6 million decrease in transaction expenses driven by the legal, accounting, and consulting fees incurred by the Company due to the Business Combination that closed in September of 2023.

44
Other Income (Expense)
Three Months Ended March 31,Change
(dollars in thousands)20242023$%
Interest expense$(1,763)$(1,417)$(346)24.4 %
Interest income793 57 736 *
Other (expense) income, net(1,908)466 (2,374)*
Total other expense$(2,878)$(894)$(1,984)*
* — % not meaningful
Interest expense
The increase in interest expense for the three months ended March 31, 2024 was due to an increase in interest rates resulting from an increase in the federal funds rate from 4.75% in the first quarter of 2023 to 5.50% in the first quarter of 2024.
Interest income
The increase in interest income for the three months ended March 31, 2024 was due to interest Company earned as a result of investment activity.
Other (expense) income, net
For the three months ended March 31, 2024 and 2023 the increase in other expense is attributable to a non-cash charge of $1.6 million related to the fair value adjustment of the Public and Private Warrant liabilities.
Income taxes
Three Months Ended March 31,Change
(dollars in thousands)20242023$%
Provision for income taxes$2,894 $— $2,894 *
Effective tax rate(13.1)%— %*
* — % not meaningful
The change to the income tax provision for the three months ended March 31, 2024 compared to the income tax provision for the three months ended March 31, 2023 was primarily a result of the transaction closing on September 20, 2023, resulting in a portion of the Company's consolidated pre-tax earnings, which were previously not subject to income taxes, flowing into a taxable corporation included in the Company's post transaction structure. As of December 31, 2023, the Company recognized a deferred tax asset related to its investment in the American Oncology Network, LLC partnership. As of March 31, 2024, the Company updated its valuation allowance assessment based on new factors including its year-to-date loss and forecasted loss at the American Oncology Network, LLC partnership legal entity. Based on its updated valuation allowance assessment, the Company recorded a discrete valuation allowance against its investment in partnership deferred tax asset during the three months ending March 31, 2024.
45
Our Adjusted EBITDA for recent comparative periods is presented as follows:
Comparison of the Three Months Ended March 31, 2024 and 2023
The following table provides a reconciliation of net income, the most closely comparable GAAP financial measure, to Adjusted EBITDA:
Three Months Ended March 31,Change
(dollars in thousands)20242023$%
Net loss$(24,961)$(1,486)$(23,475)*
Interest expense, net970 1,360 (390)(28.7 %)
Depreciation and amortization2,506 2,207 299 13.5 %
Income tax expense
2,894 — 2,894 *
Equity-based compensation 13,353 — 13,353 *
Revenue cycle transformation (a)4,736 — 4,736 *
Gain/loss on derivative liabilities1,590 — 1,590 *
Transaction expenses (b)352 1,971 (1,619)(82.1 %)
Acquisition related costs (c)522 — 522 *
Adjusted EBITDA$1,962 $4,052 $(2,090)(51.6 %)
* — % not meaningful
(a) During the three months ended March 31, 2024, represents approximately $4.1 million of incremental implicit price concessions associated with exiting a legacy billing system which commenced in the fourth quarter, and approximately $0.6 million of duplicative billing system costs as the legacy system is sunset.
(b) Transaction expenses are one-time non-recurring and are a result of expenses incurred in connection with the Business Combination.
(c) Costs associated with activity related to M&A deals that have been completed and/or are to be completed.
Liquidity and Capital Resources 
General
To date, the Company has financed its operations principally through the issuance of membership units and long-term debt, and to a lesser extent, cash flows from operations. As discussed below, on June 7, 2023, the Company entered into an agreement to issue Class C Preferred Units for net proceeds of approximately $64.5 million. As of March 31, 2024, the Company had $74.9 million of cash and cash equivalents, $30.1 million of short-term marketable securities, $80.9 million in outstanding long-term indebtedness, and $1.0 million of availability under its PNC Line of Credit. 
The Company may incur operating losses and generate negative cash flows from operations for the foreseeable future due to the investments management intends to continue making in expanding operations and sales and marketing and due to additional general and administrative expenses management expects to incur in connection with operating as a public company. As a result, the Company may require additional capital resources to execute strategic initiatives to grow the business.
Management believes that the cash on hand, operating cash flows, and availability under PNC Facility will be sufficient to fund the Company’s operating and capital needs for at least the next 12 months. The Company’s actual results may vary due to, and its future capital requirements will depend on, many factors, including its organic growth rate and the timing and extent of acquisitions of new clinics and expansion into new markets. The Company may in the future enter into arrangements to acquire or invest in complementary businesses. The Company could use its available capital resources sooner than management currently expects. The Company may be required to seek additional equity or debt financing. 

Reverse Recapitalization

The Company closed the Business Combination on September 20, 2023 (“the Closing” or the “Closing Date”). As of the Closing, the Company received $1.4 million of the remaining cash held in the Trust Account after all redemptions. On the Closing Date, the Company paid $7.1 million of DTOC transaction expenses incurred as a result of the Business Combination. The Company assumed an additional $6.1 million in liabilities, of which $3.4 million were related to an excise tax and $2.7 million related to unpaid transaction expenses incurred by DTOC as a result of the Business Combination.
46
Significant Financing Transactions
2022 Debt Financing Activity
In 2022, the Company amended the PNC Facility and Line of Credit agreements. The primary changes included an increase of the Facility limit from $75.0 million to $125.0 million, a decrease of the PNC Line of Credit amount from $5.0 million to $1.0 million, interest charges to be calculated based on the Bloomberg Short-Term Bank Yield Index plus 1.65% and certain financial covenants. As part of the amendments, the Company drew an additional $16.3 million in proceeds under the Facility. 
The total amount outstanding under the PNC Facility as of December 31, 2023 was $81.3 million at an interest rate of 7.19%. No amounts were drawn down on the PNC Line of Credit as of December 31, 2023.
2023 Sale of Class C Equity
On April 27, 2023, AON LLC and the AON Class C Preferred Investor entered into a Unit Purchase Agreement, which they subsequently amended and restated on June 7, 2023 (as amended, the “Unit Purchase Agreement”), which provides for an investment of at least $65.0 million with an option to increase the investment to $75.0 million in connection with the issuance of AON Class C Convertible Preferred Units (“AON Class C Units”) to the AON Class C Preferred Investor.
Pursuant to the Unit Purchase Agreement, on June 7, 2023, the AON Class C Preferred Investor purchased, and AON LLC issued and sold to the AON Class C Preferred Investor, 2,459 AON Class C Units at an aggregate purchase price of $65.0 million. Under the Unit Purchase Agreement, the AON Class C Preferred Investor has an option to purchase an additional 378 AON LLC Class C Units until the closing of the Business Combination (the “Closing”), at a purchase price of $26,432 per Unit. This option was not exercised and expired as of the Closing of the Business Combination. In connection with the Class C Unit sale, AON LLC amended and restated its operating agreement, to among other things, authorize 2,837 AON LLC Class C Units of which 2,459 were outstanding as of June 30, 2023 to the AON Class C Preferred Investor. The AON LLC Class C Units were reclassified into AON LLC Series A Preferred Units as of September 20, 2023, the Closing Date. Concurrently, New AON issued a number of shares of New AON Series A Preferred Stock equal to the number of AON Series A Preferred Units held by the AON Class C Preferred Investor to AEA Growth Management LP, the parent of AON Class C Preferred Investor (“AEA Growth”) in exchange for all the shares of common stock held by AEA Growth in the AON Class C Preferred Investor. Promptly after the First Step, the AON Class C Preferred Investor merged with and into New AON whereby the separate existence of the AON Class C Preferred Investor ceased and New AON held all the AON Series A Preferred Units.
2023 Debt Financing Activity
On June 30, 2023, AON entered into Amendment No. 7 to its PNC Loan Facility which primarily extended the maturity date of the Facility from April 30, 2024 to June 30, 2026.
On December 31, 2023, AON entered into Amendment No. 3 to its Line of Credit agreement to modify certain definitions such as “change in control”. In addition, this also amended certain debt covenants, such as the EBITDA thresholds.
2024 Debt Financing Activity
On January 16, 2024, AON entered into Amendment 8 to its PNC Loan Facility in order to modify the agreement to reflect that transfers of AON LLC units between AON LLC members to AON Inc. or the holder of a majority of AON Inc.’s Series A Preferred Stock, do not trigger a change of control, as defined therein, consistent with the intention of the parties to the PNC Loan Facility. In addition, Amendment 8 also amended the delinquency ratio threshold used to calculate certain debt covenants.
Cash Flows
Historical information regarding sources of cash and capital expenditures in recent periods and analysis of those sources and uses is provided below.
47
Cash flows for the three months ended March 31, 2024 and 2023 were as follows:
Three Months Ended March 31,Change
(dollars in thousands)20242023$%
Net cash (used in) provided by operations$45,137 $(329)$45,466 *
Net cash (used in) provided by investing activities1,522 (2,643)4,165 *
Net cash used in financing activities(254)(105)(149)*
* — % not meaningful
Cash flows from operating activities

The primary sources and uses of our operating cash flow are operating income or operating losses, net of any non-cash items such as stock-based compensation, and depreciation and amortization. The timing of collections of accounts receivable and the payment of accounts payable, and other working capital items can also impact and cause fluctuations in our operating cash flow. Cash provided by operating activities increased by $45.5 million during the three-month period ended March 31, 2024 compared to the three month period ended March 31, 2023, primarily due to:

•The comparative provision of cash of $56.4 million from accounts payable, primarily associated with the timing of $48.3 million of vendor payments for drug purchases during the first quarter of 2024 that were deferred until the second quarter of 2024.

•The comparative provision of cash of $13.6 million associated with the timing of collections of patient accounts receivable, net.

•An increase in loss from operations during the three month period ended March 31, 2024, net of changes in non-cash items such as stock compensation, as well as the comparative usage of cash related to other working capital items.
Cash flows from investing activities
Net cash provided by investing activities was $1.5 million for the three months ended March 31, 2024 compared to $2.6 million used in for the comparable period for 2023. The increase in cash provided period over period was primarily attributable to the following:
•Purchases of marketable securities for the three months ended March 31, 2024 of $7.1 million were offset by sales of marketable securities of $12.6 million. Purchases of marketable securities for the three months ended March 31, 2023 were $1.4 million offset by sales of $1.4 million during this period. This difference resulted in approximately a $5.6 million increase in cash provided between periods.
•The $1.4 million increase in purchases of property and equipment during the three months ended March 31, 2024, compared to 2023 further increased the cash provided between periods.
Cash flows from financing activities
Net cash used in financing activities was $0.3 million for the three months ended March 31, 2024 compared to net cash used in financing activities of $0.1 million for the comparable period for 2023.
Off Balance Sheet Arrangements
As of the date of this Quarterly Report on Form 10-Q, AON does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. The term “off-balance sheet arrangement” generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with AON is a party, under which it has any obligation arising under a guarantee contract, derivative instrument or variable interest or a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.
AON does not engage in off-balance sheet financing arrangements.
48
Material Cash Requirements
Based on the Company’s borrowings under the long-term debt arrangement as of March 31, 2024, the Company expects future cash outflows related to interest expense (based on Bloomberg Short-Term Bank Yield Index rate of 7.09% as of March 31, 2024) of $4.3 million for the remainder of 2024 and $5.8 million in 2025.
The Company also expects a cash outflow of $81.3 million related to the repayment of principal when the PNC Loan Facility matures in June of 2026.
The Company expects the following cash flows related to operating leases with third parties: $4.9 million in 2024, $7.4 million in 2025, $6.9 million in 2026, $5.8 million in 2027, $4.4 million in 2028, and $17.4 million thereafter.
The Company expects the following cash flows related to operating leases with related parties: $2.1 million in 2024, $2.7 million in 2025, $2.7 million in 2026, $2.5 million in 2027, $1.8 million in 2028, and $1.7 million thereafter.
Cash outflows related to certain vendor contracts with committed expenditures are expected to total approximately $1.6 million. The timing of the expenditures is as follows: $1.6 million in 2024.
The Company does not have any significant supply or other arrangements which result in material cash requirements other than as described above.
Critical Accounting Policies and Estimates
The accompanying consolidated financial statements have been prepared in accordance with GAAP. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.

Revenue Recognition
Revenue is recognized under Accounting Standards Update (“ASU”) 2014-09 Revenue from Contracts with Customers (“Topic 606”). The Company determines the transaction price based upon standard charges for goods and services with anticipated consideration due from patients, third-party payors (including health insurers and government agencies) and others. The Company’s revenue is primarily derived from patient service revenues, which encompass oncology services provided during patient encounters and shipments of pharmacy prescriptions. Performance obligations for the Company’s services provided to patients and most procedures, are satisfied over the time of visit which is the same day services are performed. Performance obligations relating to pharmacy revenue are considered fully satisfied at a point in time upon the customer receiving delivery of the prescription. Accordingly, the Company does not anticipate a significant amount of revenue from performance obligations satisfied (or partially satisfied) in previous periods.
As services are performed and prescriptions are shipped, timely billing occurs for services rendered and prescriptions shipped less discounts provided to uninsured patients and contractual adjustments to third-party payors based upon prospectively determined rates and discounted charges. Payment is requested at the time of service for self-paying patients and for patients covered by third-party payors that are responsible for paying deductibles and coinsurance.
The Company monitors revenue and receivables to prepare estimated contractual allowances for the anticipated differences between billed and reimbursed amounts. Payments from third-party payors and Government programs including Medicare and Medicaid may be subject to audit and other retrospective adjustments. Such amounts are considered on an estimated basis when net patient revenue is recorded and are adjusted as final adjustments are determined.
The Company has a system and estimation process for recording Medicare net patient service revenue and estimated recoupments as it relates to value-based care (“VBC”) revenue included in patient service revenue on the Consolidated Statements of Operations and Comprehensive Income (Loss). The Company’s VBC revenue is primarily generated through its participation in the Enhancing Oncology Model (“EOM”) which is an episode-based payment model to promote high-quality cancer care. Participants enter six-month episode periods, and the Company bills a monthly fee during the six-month period based on a fixed rate per participant per month and the total number of participants. Certain quality and compliance metrics are tracked as part of the program and submitted to CMS at the end of the episode period which may result in recoupment of funds. The Company estimates the recoupment amount by developing a recoupment percentage for each period based on historical known recoupment from CMS and applies the recoupment percentage against total fees for
49
the period. Based on the estimate, the Company accrues a liability representing the expected final recoupments based on historical settlement trends.
Accounts Receivable
Accounts receivable from patients are carried at the original charge for the services provided, and an adjustment is made to the receivable in a contra account based on the historical collection rate for the provider and payor combination. This adjustment takes into consideration any allowance for doubtful accounts. Management determines the allowance for uncollectible accounts based on historical experience.
Business Combinations
The Company evaluates acquired practices in accordance with ASU 2017-01, Business Combinations (Topic 805) — Clarifying the Definition of a Business. This standard clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. Because substantially all of the value of each acquired practice did not relate to a similar group of assets and as each acquired practice contained both inputs and processes necessary to provide economic benefits to the Company, it was determined that each acquisition represents a business combination. Therefore, the transactions have been accounted for using the acquisition method of accounting, which requires, with limited exceptions, that assets acquired, and liabilities assumed be recognized at their estimated fair values as of the acquisition date. Any excess of the consideration transferred over the estimated fair values of the net assets acquired is recorded as goodwill. Transaction costs related to business combinations are expensed in the period in which they are incurred.
Professional Liability
The Company maintains an insurance policy for exposure to professional malpractice insurance risk beyond selected retention levels. Reserves are established for estimates of the loss that will ultimately be incurred on claims that have been reported but not paid and claims that have been incurred but not reported. These reserves are established based on consultation with a third-party actuary. The actuarial valuations consider a number of factors, including historical claims payment patterns, changes in case reserves and the assumed rate of increase in healthcare costs. Management believes the use of actuarial methods to account for these reserves provides a consistent and effective way to measure these subjective accruals. However, due to the sensitive nature of this estimation technique, recorded reserves could differ from ultimate costs related to these claims due to changes in claims reporting, claims payment and settlement practices and differences in assumed future cost increases. Accrued unpaid claims and expenses that are expected to be paid within the next twelve months are classified as current liabilities and included in accrued other. All other accrued unpaid claims and expenses are classified as long-term liabilities and included in other long-term liabilities. Insurance recoveries associated with the unpaid claims are classified as long-term assets included in other assets.

Item 3. Quantitative and Qualitative Disclosures About Market Risk
Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of exposure due to potential changes in inflation or interest rates. We do not hold financial instruments for trading purposes.
Interest Rate Risk
Certain of AON’s outstanding indebtedness bears interest at a floating rate. As a result, AON may be exposed to fluctuations in interest rates to the extent of its borrowings under these arrangements. AON does not currently engage in any hedging or derivative instruments to attempt to offset this risk. Based on the total amount of variable debt outstanding as of March 31, 2024, if the Bloomberg Short-Term Bank Yield Index increased by 1.0% due to normal market conditions, AON’s interest expense will increase by approximately $0.8 million per annum.
AON had $81.3 million of borrowings under loans with variable rates as of March 31, 2024.
Inflation Risk
The healthcare industry is very labor intensive and salaries and benefits are subject to inflationary pressures, as are drug and medical supplies costs, medical equipment and other costs. The nationwide shortage of nurses and other clinical staff and support personnel has been a significant operating issue facing us and other healthcare providers. In particular, like others in the healthcare industry, we have experienced a shortage of nurses and other clinical staff and support
50
personnel in certain geographic areas, which was largely driven by the COVID-19 pandemic. Nationally, the increase demand for healthcare workers has in some regions, required us to offer one-time retention bonuses, pay premium wages above standard compensation for essential workers, and even utilize higher cost temporary labor. This staffing shortage may require us to further enhance wages and benefits to recruit and retain nurses and other clinical staff and support personnel or require us to hire expensive temporary personnel. We have also experienced cost increases related to the procurement of medical supplies and equipment as well as construction of new facilities and additional capacity added to existing facilities. Our ability to pass on increased costs associated with providing healthcare to Medicare and Medicaid patients is limited due to various federal, state and local laws which have been enacted that, in certain cases, limit our ability to increase prices.
We minimize the impact of inflation on our labor, drug, and supply costs primarily through maintaining strong relationship with our suppliers and GPO and renegotiated contracts with our payors. In addition, AOP has a Pharmacy and Therapeutics Committee (“P&T Committee”) that meets biweekly to evaluate and modify the preferred drug formulary. The P&T Committee considers the following in its formulary recommendations: 1) evidence-based research demonstrating favorable clinical outcomes of such treatment; 2) potential adverse events or side effects of such treatment; and 3) cost of such treatment to the applicable stakeholder (patient and payor).

Item 4. Controls and Procedures
Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2024. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company on the reports that it files or submits under the Exchange Act is accumulated and communicated to management, including, our principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure.

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgement in designing and evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March 31, 2024, our Chief Executive Officer and Chief Financial Officer concluded that, as a result of material weaknesses identified in our internal control over financial reporting, as previously disclosed in our Annual Report on Form 10-K, filed with the SEC on March 28, 2024, our disclosure controls and procedures were not effective as of March 31, 2024. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting as defined under the Exchange Act and by the Public Company Accounting Oversight Board (United States), such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. We are in the process of implementing measures designed to improve our internal control over financial reporting to remediate these material weaknesses.
Changes in Internal Control

There has been no change in our internal control over financial reporting as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.


51
Part II - Other Information

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

In addition to the other information set forth in this Quarterly Report on Form 10-Q (the “Quarterly Report”), you should carefully consider the risk factors previously disclosed in our Annual Report on Form 10-K, dated and filed with the SEC on March 28, 2024, as of and for the year ended December 31, 2023 (the “2023 Annual Report”).

As of the date of the Quarterly Report, there have been no material changes to the risk factors previously disclosed in our 2023 Annual Report. Any of the risks discussed in these reports, as well as additional risks and uncertainties not currently known to us or that we currently deem immaterial, could materially and adversely affect our results of operations, financial condition or prospects.

Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits
31.1
31.2
32.1
32.2
101.INSInline XBRL Instance Document.*
101.SCHInline XBRL Taxonomy Extension Schema Document.*
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.*
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.*
101.LABInline XBRL Taxonomy Extension Label Linkbase Document.*
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.*
104Cover Page Interactive Data File (Embedded within the Inline XBRL document and included in Exhibit)
* Filed herewith
** Furnished herewith
52
Signatures

Pursuant to the requirements of the Securities and Exchange Act 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

AMERICAN ONCOLOGY NETWORK, INC.
By:/s/ Todd Schonherz
Name:Todd Schonherz
Title:Chief Executive Officer
Dated:May 15, 2024




53
 EX-31.1 2 aonc-302certceoexhibit3111.htm EX-31.1 Document

Exhibit 31.1



CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002


I, Todd Schonherz, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of American Oncology Network, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting


May 15, 2024

By: /s/ Todd Schonherz        



Todd Schonherz
Chief Executive Officer

 EX-31.2 3 aonc-302certcfoexhibit3121.htm EX-31.2 Document

Exhibit 31.2



CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002


I, David Gould, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of American Oncology Network, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting


May 15, 2024

By: /s/ David Gould        



David Gould
Chief Financial Officer

 EX-32.1 4 aonc-906certceoexhibit3211.htm EX-32.1 Document

Exhibit 32.1


CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


I, Todd Schonherz, certify that:


To my knowledge, the Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of American Oncology Network, Inc.


May 15, 2024

By: /s/ Todd Schonherz            

Todd Schonherz
Chief Executive Officer


 EX-32.2 5 aonc-906certcfoexhibit3221.htm EX-32.2 Document

Exhibit 32.2


CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


I, David Gould, certify that:


To my knowledge, the Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of American Oncology Network, Inc.


May 15, 2024

By: /s/ David Gould            

David Gould
Chief Financial Officer


 EX-101.SCH 6 aonc-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statements of Mezzanine and Stockholders’ Deficit link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Condensed Consolidated Statements of Cash Flows - Parenthetical link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Business link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Basis of Presentation and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Reverse Recapitalization link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Variable Interest Entities link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Business Combinations link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Supplemental Condensed Balance Sheet Information link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Long-term Debt link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Related Parties link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Equity-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Redeemable Noncontrolling Interest link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Business (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Reverse Recapitalization (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Variable Interest Entities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Supplemental Condensed Balance Sheet Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Long-term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Related Parties (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Equity-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Redeemable Noncontrolling Interest (Tables) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Business (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Reverse Recapitalization - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Reverse Recapitalization - Schedule of Historical Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Variable Interest Entities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Variable Interest Entities - Schedule of Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Marketable Securities - Schedule of Marketable Securities Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Marketable Securities - Schedule of Marketable Securities Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Marketable Securities - Remaining Contractual Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Supplemental Condensed Balance Sheet Information - Schedule of Other Receivables (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Supplemental Condensed Balance Sheet Information - Schedule of Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Supplemental Condensed Balance Sheet Information - Schedule of Property and Equipment, net (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Supplemental Condensed Balance Sheet Information - Schedule of Accrued Other (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Long-term Debt - Schedule of Long-term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Long-term Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Leases - Right-of-use Assets And Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Leases - Lease Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Leases - Maturities of Operating and Financing Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Leases - Maturities of Operating and Financing Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Leases - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Related Parties - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Related Parties - Notes Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Equity-Based Compensation - Summary of RSU Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Equity-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Equity - Schedule of Changes in Units (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Net Loss Per Share - Calculation Of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Net Loss Per Share - Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - Redeemable Noncontrolling Interest - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - Redeemable Noncontrolling Interest - Schedule of Ownership (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 aonc-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 aonc-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 aonc-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Provision for income taxes Deferred Income Taxes and Tax Credits Consolidated Entities [Axis] Consolidated Entities [Axis] Variable Rate [Domain] Variable Rate [Domain] Oral pharmaceuticals Oral Pharmaceuticals [Member] Oral Pharmaceuticals Net income (loss) Net loss attributable to redeemable noncontrolling interest Net Income (Loss) Attributable to Noncontrolling Interest Offering Costs Deferred Charges, Policy [Policy Text Block] Proceeds from sales of marketable securities Proceeds from Sale of Debt Securities, Available-for-Sale Statistical Measurement [Domain] Statistical Measurement [Domain] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Notes receivable - related parties Financing Receivable, after Allowance for Credit Loss, Noncurrent Redemption value of noncontrolling interest Redeemable Noncontrolling Interest, Equity, Redemption Value Units vested upon consummation of business combination (in units) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested Upon Consummation Of Business Combination Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested Upon Consummation Of Business Combination All Award Types Award Type [Domain] Directors and Officers Liability Insurance Directors and Officers Liability Insurance [Member] Investment, Name [Domain] Investment, Name [Domain] Outstanding, beginning period (in shares) Outstanding, ending period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Statement of Stockholders' Equity [Abstract] Investments, Debt and Equity Securities [Abstract] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Revolving Credit Facility Revolving Credit Facility [Member] Variable Interest Entity, Primary Beneficiary Variable Interest Entity, Primary Beneficiary [Member] DTOC Sponsor DTOC Sponsor [Member] DTOC Sponsor Accounts payable Accounts Payable, Current Computer equipment Computer Equipment [Member] Investment, Name [Axis] Investment, Name [Axis] Operating 
Leases Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Measurement Input, Price Volatility Measurement Input, Price Volatility [Member] Supplier [Axis] Supplier [Axis] Equity Equity [Text Block] MIBA MIBA [Member] MIBA Professional Liability Malpractice Loss Contingency, Policy [Policy Text Block] Income Taxes Income Tax Disclosure [Text Block] Business Business Description and Basis of Presentation [Text Block] Variable Interest Entity [Line Items] Variable Interest Entity [Line Items] Ownership [Axis] Ownership [Axis] Physician Owned Physicians [Member] Physician Owned Property and equipment, gross Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Noncontrolling Interest [Abstract] Current liabilities Liabilities, Current [Abstract] Noncontrolling Interest [Table] Noncontrolling Interest [Table] Stockholders' Equity, Conversion Right [Domain] Stockholders' Equity, Conversion Right [Domain] Stockholders' Equity, Conversion Right [Domain] Business Acquisition [Line Items] Business Acquisition [Line Items] Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Earnings (loss) per unit, diluted (in usd per share) Diluted loss per share of Class A Common Stock (in dollars per share) Earnings Per Share, Diluted Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Patient accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Refund liability Customer Refund Liability, Current Threshold stock price, conversion price adjustment (in usd per share) Stockholders' Equity, Conversion, Stock Price Stockholders' Equity, Conversion, Stock Price Schedule of Reverse Recapitalization, Ownership Summary Schedule Of Reverse Recapitalization, Ownership Summary [Table Text Block] Schedule Of Reverse Recapitalization, Ownership Summary Treasury stock, common, shares (in shares) Treasury Stock, Common, Shares Line of Credit Line of Credit [Member] Malpractice insurance, coverage per claim Malpractice Insurance, Maximum Coverage Per Incident Other income (expense) Other Nonoperating Income (Expense) [Abstract] Bloomberg Short-Term Bank Yield Index Bloomberg Short-Term Bank Yield Index [Member] Bloomberg Short-Term Bank Yield Index Redeemable noncontrolling interest Beginning Balance Ending Balance Redeemable Noncontrolling Interest, Equity, Carrying Amount Trading Symbol Trading Symbol Reverse Recapitalization Reverse Recapitalization Disclosure [Text Block] Reverse Recapitalization Disclosure Common Units Member Units [Member] Net income (loss) Net Income (Loss) Schedule of Earnings Per Unit Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block] Total current liabilities Liabilities, Current 2026 Finance Lease, Liability, to be Paid, Year Two Leases Lessee, Operating Leases [Text Block] Corporate bonds Corporate Bond Securities [Member] AON Central AON Central [Member] AON Central Property and equipment, net Property and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Stockholders' equity, conversion, threshold stock price (in dollars per share) (less than) (greater than) Stockholders' Equity, Conversion, Threshold Stock Price Stockholders' Equity, Conversion, Threshold Stock Price Liabilities, Mezzanine Equity, and Stockholders' Equity Liabilities and Equity [Abstract] Employee Stock Employee Stock [Member] Repurchases of Class A Common Stock Stock Repurchased During Period, Value Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Clinical Trials Clinical Trials [Member] Clinical Trials Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Stockholders' equity Equity, Attributable to Parent [Abstract] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Gross Unrealized
Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax AON Inc. AON Inc. [Member] AON Inc. Number of oncology practices Number Of Oncology Practices Number Of Oncology Practices Schedule of Affiliation Agreements Schedule Of Affiliation Agreements [Table Text Block] Schedule Of Affiliation Agreements Vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Class B Common Stock Common Class B [Member] Dividends [Domain] Dividends [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Fair value adjustment to redeemable noncontrolling interest Fair value adjustment to redeemable noncontrolling interest Adjustments To Additional Paid In Capital, Fair Value Adjustment, Redeemable Noncontrolling Interest Adjustments To Additional Paid In Capital, Fair Value Adjustment, Redeemable Noncontrolling Interest Schedule of Property and Equipment, net Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Class B Prefunded Warrants Class B Prefunded Warrants [Member] Class B Prefunded Warrants Number of board of managers designated by company Number Of Board Of Managers Designated By Company Number Of Board Of Managers Designated By Company Number of shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Cash paid for amounts included in the measurement of lease liabilities: Cash Flow, Lessee [Abstract] Cash Flow, Lessee Entity Small Business Entity Small Business Accrued compensation and benefits Employee-related Liabilities Local Phone Number Local Phone Number Patient accounts receivable, net Increase (Decrease) in Accounts Receivable Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share Warrant [Member] Long-term operating lease liabilities Long-term lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Class B-1 Common Stock, Class B-1 [Member] Common Stock, Class B-1 Medical equipment Medical Equipment [Member] Medical Equipment Basis of Presentation and Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Reverse Recapitalization [Abstract] Reverse Recapitalization Restricted Stock Units Restricted Stock Units (RSUs) [Member] Schedule of RSU Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Repurchases of Class A Common Stock Offering costs Payments of Stock Issuance Costs Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Equity-based compensation and NCI rebalancing Redeemable Noncontrolling Interest, Equity Based Compensation Redeemable Noncontrolling Interest, Equity Based Compensation Quarterly collateral released Debt Instrument, Collateral Released, Quarterly Debt Instrument, Collateral Released, Quarterly Schedule of Long-Term Debt Instruments Schedule of Long-Term Debt Instruments [Table Text Block] Public Warrant Public Warrant [Member] Public Warrant Goodwill and intangibles, net Intangible Assets, Net (Including Goodwill) Lessee, Operating Lease, Liability, to be Paid, Maturity Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of Reverse Recapitalization Schedule Of Reverse Recapitalization [Table Text Block] Schedule Of Reverse Recapitalization Cash and cash equivalents and marketable securities, aggregate fair value Cash, Cash Equivalents And Available-For-Sale Debt Securities Cash, Cash Equivalents And Available-For-Sale Debt Securities Measurement Input, Risk Free Interest Rate Measurement Input, Risk Free Interest Rate [Member] Product and Service [Domain] Product and Service [Domain] Series A convertible preferred stock; $0.0001 par value; 7,500,000 shares authorized; 6,651,610 issued and outstanding at March 31, 2024 and December 31, 2023, with an aggregate liquidation preference of $69,369,195 and $68,009,015 at March 31, 2024 and December 31, 2023, respectively. Beginning Balance Ending Balance Temporary Equity, Carrying Amount, Attributable to Parent Total Net Liabilities Reverse Recapitalization, Net Reverse Recapitalization, Net Debt Instrument, Threshold Limit, Period Two Debt Instrument, Threshold Limit, Period Two [Member] Debt Instrument, Threshold Limit, Period Two Lease, Cost Lease, Cost [Table Text Block] Inventories Increase (Decrease) in Inventories Antidilutive shares excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type Award Type [Axis] Granted (in shares) Grants in period (in units) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Plan Name [Domain] Plan Name [Domain] Document Quarterly Report Document Quarterly Report Beginning of Period End of Period Common Unit, Issuance Value Interest expense Interest Expense Changes in accounts payable for capital additions to property and equipment Capital Expenditures Incurred but Not yet Paid Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized ROU assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Related Parties Related Party Transactions Disclosure [Text Block] Note 8 2025 Notes Receivable, Note 8 [Member] 2025 Notes Receivable, Note 8 Less: amount representing interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Accounting Estimates and Assumptions Use of Estimates, Policy [Policy Text Block] Notes receivable, amortization period (in months) Financing Receivable, Amortization Period Financing Receivable, Amortization Period Leases Lessee, Finance Leases [Text Block] Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Current portion of operating lease liabilities Less: current portion of lease liabilities Operating Lease, Liability, Current Interest on finance lease liabilities (included in interest expense) Finance Lease, Interest Expense Reverse Recapitalization, Change In Units [Roll Forward] Reverse Recapitalization, Change In Units [Roll Forward] Reverse Recapitalization, Change In Units Total right-of-use assets Lease, Right-Of-Use Asset Lease, Right-Of-Use Asset Accounts payable Accounts Payable Description Of Business And Significant Accounting Policies [Line Items] Description Of Business And Significant Accounting Policies [Line Items] Description Of Business And Significant Accounting Policies [Line Items] Entity Shell Company Entity Shell Company 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Recently Adopted Accounting Pronouncements  and Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] PNC Line of Credit PNC Line Of Credit [Member] PNC Line Of Credit Note 2 2024 Notes Receivable, Note 2 [Member] 2024 Notes Receivable, Note 2 Counterparty Name [Domain] Counterparty Name [Domain] Other long-term liabilities Increase (Decrease) in Other Operating Liabilities Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Beginning of period End of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Equity, Attributable to Noncontrolling Interest [Roll Forward] Equity, Attributable to Noncontrolling Interest [Roll Forward] Measurement Input, Expected Term Measurement Input, Expected Term [Member] Public and Private Warrants Public And Private Warrants [Member] Public And Private Warrants Interest income Investment Income, Interest Variable lease costs Variable Lease, Cost Operating lease costs Operating Lease, Cost Weighted average shares of Class A Common Stock Outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Dividends Paid, Event Prior to June 7, 2027, After June 7, 2026 Dividends Paid, Event Prior to June 7, 2027, After June 7, 2026 [Member] Dividends Paid, Event Prior to June 7, 2027, After June 7, 2026 Excise taxes payable Sales and Excise Tax Payable Common stock, shares issued (in shares) Common Stock, Shares, Issued Vested (in shares) Units vested (in units) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Bank fee (in percent) Line of Credit Facility, Commitment Fee Percentage Par value (dollars per share) Temporary Equity, Par or Stated Value Per Share Treasury stock, at cost, 31,170 shares at March 31, 2024 and 14,729 shares at December 31, 2023 Treasury Stock, Common, Value Security Exchange Name Security Exchange Name Redemption of Class B Common Stock to Class A Common Stock Stock Redeemed or Called During Period, Value Total debt Long-Term Debt Equity-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Current portion of notes receivable - related parties Less:  Current portion of notes receivable Financing Receivable, after Allowance for Credit Loss, Current Capital Unit, Class [Domain] Capital Unit, Class [Domain] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Common Class A Common Class A Common Class A [Member] Cost not yet recognized, period for recognition (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Redeemable Noncontrolling Interest Noncontrolling Interest Disclosure [Text Block] Total costs and expenses Costs and Expenses Repurchases (in units) Common Unit, Repurchased Common Unit, Repurchased Redemption ratio Stockholders' Equity, Redemption Ratio Stockholders' Equity, Redemption Ratio Maximum Maximum [Member] Unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Document Type Document Type Schedule of Related Party Transactions Schedule of Related Party Transactions [Table Text Block] Minimum funding threshold (in percent) Debt Instrument, Minimum Funding Threshold, Percentage Debt Instrument, Minimum Borrowing Threshold, Percentage Entity Address, Address Line One Entity Address, Address Line One Current Lease Liability, Current [Abstract] Lease Liability, Current Cost of shares repurchased (less than) Treasury Stock, Value, Acquired, Cost Method Entity Address, Address Line Two Entity Address, Address Line Two 2027 Finance Lease, Liability, to be Paid, Year Three Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Redemption of Class B Common Stock to Class A Common Stock Redeemable Noncontrolling Interest, Stock Redeemed Redeemable Noncontrolling Interest, Stock Redeemed Equity-Based Compensation Share-Based Payment Arrangement [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-Sale 2025 Finance Lease, Liability, to be Paid, Year One Income tax payable Taxes Payable, Current Warrant, exercise period, after initial public offering Class Of Warrant Or Right, Exercise Period, After Initial Public Offering Class Of Warrant Or Right, Exercise Period, After Initial Public Offering Allocation of income to controlling and noncontrolling interests (in percent) Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Allocation Of Income Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Allocation Of Income Net loss attributable to redeemable noncontrolling interest Net Income (Loss) Attributable to Redeemable Noncontrolling Interest Temporary equity, redeemable period Temporary Equity, Redeemable Period Temporary Equity, Redeemable Period Due to AON LLC and subsidiaries, net Other Liabilities, Current Mezzanine equity Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract] Variable Rate [Axis] Variable Rate [Axis] Income Statement [Abstract] Inventory [Line Items] Inventory [Line Items] Impact of the Reverse Recapitalization Common Unit, Value, Impact Of The Reverse Recapitalization Common Unit, Value, Impact Of The Reverse Recapitalization Stockholders' equity, conversion period (in years) Stockholders' Equity, Conversion Period Stockholders' Equity, Conversion Period Debt Instrument, Threshold Limit, Period [Domain] Debt Instrument, Threshold Limit, Period [Domain] Debt Instrument, Threshold Limit, Period [Domain] Shares issued (in shares) Stock Issued During Period, Shares, New Issues Title of 12(b) Security Title of 12(b) Security Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Cash and cash equivalents, estimated fair value Cash and Cash Equivalents, Fair Value Disclosure Business Combinations Business Combination Disclosure [Text Block] Other comprehensive loss attributable to noncontrolling interests Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest Related Party, Type [Domain] Related Party, Type [Domain] Number of securities called by each warrant (in shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Mezzanine Equity and Treasury Stock Stockholders' Equity, Policy [Policy Text Block] Invested capital contributions Members' Capital Beginning Balance (usd per share) Ending Balance (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Income Tax Disclosure [Abstract] Series A Preferred Cumulative Dividends Distributed Earnings Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Inventories Inventory, Net Total lease costs Lease, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] Financial Instrument [Axis] Financial Instrument [Axis] Noncontrolling Interests Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block] Entity Interactive Data Current Entity Interactive Data Current Long-term Debt Long-Term Debt [Text Block] Debt Securities, Available-for-Sale [Table] Debt Securities, Available-for-Sale [Table] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Retained deficit Retained Earnings (Accumulated Deficit) Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Capital Unit, Class A Capital Unit, Class A [Member] Class A-1 distribution (in shares) Stock Dividends, Shares Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Note 3 2024 Notes Receivable, Note 3 [Member] 2024 Notes Receivable, Note 3 Current assets Assets, Current [Abstract] Leases [Abstract] Entity Address, State or Province Entity Address, State or Province Counterparty Name [Axis] Counterparty Name [Axis] Warrant Liabilities Derivatives, Policy [Policy Text Block] Total lease payments Finance Lease, Liability, to be Paid Total Units Issued (in units) Limited Liability Company (LLC) Units, Issued Limited Liability Company (LLC) Units, Issued Patient service revenue, net Patient Service [Member] Patient Service Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Operating cash flows from operating leases Payments for operating leases Operating Lease, Payments Unrealized gain (loss) on marketable securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Dividends Dividends Other receivables Other Receivables Capital Unit, Class B Capital Unit, Class B [Member] Redeemable Preferred Stock Increase (Decrease) in Temporary Equity [Roll Forward] Schedule of Variable Interest Entities [Table] Schedule of Variable Interest Entities [Table] Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Alternate Base Rate Alternate Base Rate [Member] Alternate Base Rate Net loss and noncontrolling interest attributable to Legacy AON Stockholders prior to the reverse recapitalization Net loss attributable to Legacy AON Shareholders Net loss and noncontrolling interest attributable to Legacy AON Stockholders prior to the reverse recapitalization Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Before Recapitalization Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Before Recapitalization Earnout shares not outstanding (in shares) Derivative Instrument, Contingent Consideration, Liability, Shares Derivative Instrument, Contingent Consideration, Liability, Shares Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Class of Stock [Domain] Class of Stock [Domain] Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Net loss attributable to Class A Common Stockholders, Basic Net loss attributable to Class A Common Stockholders for basic earnings per share Net Income (Loss) Available to Common Stockholders, Basic Debt Instrument [Axis] Debt Instrument [Axis] Effective income tax rate (in percent) Effective Income Tax Rate Reconciliation, Percent Present value of lease liabilities Operating Lease, Liability Fair value adjustment to redeemable noncontrolling interest Redeemable Noncontrolling Interest, Equity, Fair Value Adjustment Redeemable Noncontrolling Interest, Equity, Fair Value Adjustment Impact of the Reverse Recapitalization (in units) Common Unit, Unit Impact Of The Reverse Recapitalization Common Unit, Unit Impact Of The Reverse Recapitalization 2024 (remainder of year after March 31, 2024) Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Measurement Input Type [Domain] Measurement Input Type [Domain] Capital contributions from noncontrolling interest member Noncontrolling Interest, Increase from Subsidiary Equity Issuance Credit Facility [Axis] Credit Facility [Axis] Total liabilities Liabilities Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets AOCI AOCI Attributable to Parent [Member] Participating Threshold [Axis] Participating Threshold [Axis] Participating Threshold Type and Tier Identifier [Domain] Type and Tier Identifier [Domain] Issuance of units (in units) Issuances (in units) Common Unit, Issued Accounts Payable Accounts Payable [Member] Warrant, exercise period, after business combination Class Of Warrant Or Right Outstanding, Exercise Period, After Business Combination Class Of Warrant Or Right Outstanding, Exercise Period, After Business Combination Plan Name [Axis] Plan Name [Axis] Rebates receivable Rebates Receivable, Current Rebates Receivable, Current Debt Disclosure [Abstract] Related Party Transaction [Domain] Related Party Transaction [Domain] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Number of reportable segments Number of Reportable Segments Loss per share of Class A Common Stock: Earnings Per Share [Abstract] Schedule of Variable Interest Entities Schedule of Variable Interest Entities [Table Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] AON LLC AON LLC [Member] AON LLC Short-term Marketable Securities Marketable Securities, Policy [Policy Text Block] Schedule of Other Receivables Schedule Of Other Receivables [Table Text Block] Schedule Of Other Receivables General and administrative expenses General and Administrative Expense Due in one to five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Organization, Consolidation and Presentation of Financial Statements [Abstract] Amortization of operating right-of-use assets Operating Lease, Right-of-Use Asset, Periodic Reduction Reverse recapitalization, equity conversion ratio Reverse Recapitalization, Equity Conversion Ratio Reverse Recapitalization, Equity Conversion Ratio Accrued other Other Accrued Liabilities Assets Lease, Right-Of-Use Asset [Abstract] Lease, Right-Of-Use Asset Furniture, fixtures and equipment Furniture, Fixtures and Equipment [Member] Furniture, Fixtures and Equipment Ownership interest Limited Liability Company or Limited Partnership, Members or Limited Partners, Ownership Interest Segments Segment Reporting, Policy [Policy Text Block] Total current assets Assets, Current Financing cash flows from finance leases Finance Lease, Principal Payments Finance Lease, Liability, to be Paid, Maturity Finance Lease, Liability, to be Paid, Maturity [Table Text Block] Accounts receivable Accounts Receivable, after Allowance for Credit Loss Supplemental noncash investing and financing activities Supplemental Cash Flow Information [Abstract] Other (expense) income, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category PNC Loan Facility PNC Loan Facility [Member] PNC Loan Facility Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Earnings Per Share Earnings Per Share, Policy [Policy Text Block] Repurchases of Class A Common Stock (in shares) Stock Repurchased During Period, Shares Concentration risk (in percentage) Concentration Risk, Percentage AON Common Unit AON Common Unitholders [Member] AON Common Unitholders Measurement Input, Expected Dividend Rate Measurement Input, Expected Dividend Rate [Member] Other Other Sundry Liabilities, Current Class of warrant outstanding (in shares) Class of Warrant or Right, Outstanding Granted (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Patient Visits Patient Visits [Member] Patient Visits And Shipments Of Prescriptions 2028 Finance Lease, Liability, to be Paid, Year Four Contribution from noncontrolling interest Noncash Contributions From Noncontrolling Interest Noncash Contributions From Noncontrolling Interest Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Number of days after redemption notice date that redemption must be settled Stockholders' Equity, Number Of Days After The Redemption Notice Date For Redemption To Be Settled Stockholders Equity, Number Of Days After The Redemption Notice Date For Redemption To Be Settled Class of Stock [Axis] Class of Stock [Axis] Accrued other Accrued other Other Accrued Liabilities, Current Fair Value Adjustment of Warrants Fair Value Adjustment of Warrants Depreciation and amortization Depreciation, Depletion and Amortization Beginning balance (in units) Ending balance (in units) Common unit, units outstanding (in units) Common Unit, Outstanding Net loss before redeemable noncontrolling interest Net Income (Loss), Including Portion Attributable To Redeemable Noncontrolling Interest Net Income (Loss), Including Portion Attributable To Redeemable Noncontrolling Interest Net income (loss) attributable to common shareholders Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic Accrued compensation related costs Increase (Decrease) in Employee Related Liabilities Statement of Financial Position [Abstract] Cash and cash equivalents and available-for-sale securities, amortized cost Cash, Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Cash, Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Business Combination and Asset Acquisition [Abstract] Total AON stockholders' deficit Equity, Attributable to Parent Total notes receivables Financing Receivable, after Allowance for Credit Loss Participating Threshold [Domain] Participating Threshold [Domain] Participating Threshold [Domain] Current Liabilities Current Liabilities Assumed In Reverse Recapitalization Current Liabilities Assumed In Reverse Recapitalization Beginning balance (in units) Ending balance (in units) Limited Liability Company (LLC), Units, Outstanding Limited Liability Company (LLC), Units, Outstanding Restricted Stock Restricted Stock [Member] Dividends Paid, Event Prior to June 7, 2026, After June 7, 2025 Dividends Paid, Event Prior to June 7, 2026, After June 7, 2025 [Member] Dividends Paid, Event Prior to June 7, 2026, After June 7, 2025 Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Finance 
Leases Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Shares awarded upon vesting of RSUs (in shares) Shares Awarded Upon Vesting Shares Awarded Upon Vesting Concentration Risk Type [Axis] Concentration Risk Type [Axis] Variable Interest Entities Variable Interest Entity Disclosure [Text Block] Warrants, measurement input Warrants and Rights Outstanding, Measurement Input Common unit authorized (in units) Common Unit, Authorized Long-term Lease Liability, Noncurrent [Abstract] Lease Liability, Noncurrent Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Level 2 Fair Value, Inputs, Level 2 [Member] Other comprehensive income attributable to Legacy AON Shareholders Other Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest, Before Recapitalization Other Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest, Before Recapitalization Entity Emerging Growth Company Entity Emerging Growth Company Unamortized debt issuance costs Debt Issuance Costs, Net Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract] Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract] Long Term Liabilities Noncurrent Liabilities Assumed In Reverse Recapitalization Noncurrent Liabilities Assumed In Reverse Recapitalization Gain (Loss) On Reverse Recapitalization Gain (Loss) On Reverse Recapitalization Gain (Loss) On Reverse Recapitalization OCP Management Arizona, LLP OCP Management Arizona, LLP [Member] OCP Management Arizona, LLP Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Period Focus Document Fiscal Period Focus Issuance of Units Common Unit, Units Issued, Value Common Unit, Units Issued, Value 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Antidilutive Securities [Axis] Antidilutive Securities [Axis] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Promissory note issued in connection with acquisition Notes Issued Equity-based compensation Share-Based Payment Arrangement, Noncash Expense Other Other Miscellaneous Receivables, Net, Current Other Miscellaneous Receivables, Net, Current Changes in fair value adjustments of warrants and derivative liabilities Gain (Loss) On Warrant And Derivative, Net Gain (Loss) On Warrant And Derivative, Net Cash and cash equivalents Cash And Cash Equivalents Acquired Through Reverse Recapitalization Cash And Cash Equivalents Acquired Through Reverse Recapitalization Common Stock Common Stock [Member] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Dividends Paid, Event Prior to June 7, 2025, After June 7, 2024 Dividends Paid, Event Prior to June 7, 2025, After June 7, 2024 [Member] Dividends Paid, Event Prior to June 7, 2025, After June 7, 2024 Net Loss Per Share Earnings Per Share [Text Block] Product and Service [Axis] Product and Service [Axis] Equity method investment (in percent) Equity Method Investment, Ownership Percentage Document Fiscal Year Focus Document Fiscal Year Focus Total deficit Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Inventory [Domain] Inventory [Domain] Other comprehensive loss attributable to Legacy AON Shareholders Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest, Before Recapitalization Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest, Before Recapitalization Net income attributable to noncontrolling interest Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest LLC ownership threshold, percentage Limited Liability Company (LLC), Ownership Threshold, Percentage Limited Liability Company (LLC), Ownership Threshold, Percentage Supplier [Domain] Supplier [Domain] Software Software and Software Development Costs [Member] Minimum Minimum [Member] Statement of Cash Flows [Abstract] Assets Assets [Abstract] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Available-for-Sale Securities, Debt Maturities [Abstract] Available-for-Sale Securities, Debt Maturities [Abstract] Operating lease liabilities Increase (Decrease) in Operating Lease Liability Liabilities Liabilities [Abstract] Professional Malpractice Liability Insurance Professional Malpractice Liability Insurance [Member] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Other revenue Product and Service, Other [Member] Unamortized debt issuance costs Debt Issuance Costs, Gross Net loss before noncontrolling interest Net loss before noncontrolling interest Net Income (Loss), Including Portion Attributable to Noncontrolling Interest U.S. Treasury securities US Treasury Securities [Member] Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Deferred tax asset, net Deferred Income Tax Assets, Net Payments to acquire interest in subsidiary Payments to Acquire Interest in Subsidiaries and Affiliates Retained
Earnings (Deficit) Retained Earnings [Member] Total liabilities, mezzanine equity, noncontrolling interest, and stockholders' equity Liabilities and Equity Amortized 
Cost Debt Securities, Available-for-Sale, Amortized Cost Other assets Other Assets, Noncurrent Ownership [Domain] Ownership [Domain] Earnings (loss) per unit, basic (in usd per share) Basic loss per share of Class A Common Stock (in dollars per share) Earnings Per Share, Basic Operating lease right-of-use assets Operating lease right-of-use assets, net Operating Lease, Right-of-Use Asset Schedule of Long-Term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Lessee, Assets And Liabilities Lessee, Assets And Liabilities [Table Text Block] Lessee, Assets And Liabilities Warrant, term (in years) Warrants and Rights Outstanding, Term Number of days after five year anniversary Stockholders' Equity, Conversion, Number Of Days After Five Year Anniversary Stockholders' Equity, Conversion, Number Of Days After Five Year Anniversary Reverse recapitalization costs Reverse Recapitalization Expenses Reverse Recapitalization Expenses Capital Units by Class [Axis] Capital Units by Class [Axis] Undistributed net earnings, basic Undistributed Earnings, Basic 2024 (remainder of year after March 31, 2024) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Net loss attributable to Class A Common Stockholders, Diluted Net loss attributable to Class A Common Stockholders for diluted earnings per share Net Income (Loss) Available to Common Stockholders, Diluted Beginning balance Ending balance Members' Equity Entity Address, City or Town Entity Address, City or Town Related Party Related Party [Member] Inventory, Current [Table] Inventory, Current [Table] Class C Common Class C [Member] Principles of Consolidation Consolidation, Policy [Policy Text Block] Stockholders' Equity, Conversion Right [Axis] Stockholders' Equity, Conversion Rights [Axis] Stockholders' Equity, Conversion Rights Supplemental Condensed Balance Sheet Information Supplemental Balance Sheet Disclosures [Text Block] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Accrued other Increase (Decrease) in Other Accrued Liabilities Document Transition Report Document Transition Report Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Cost of Goods and Service Benchmark Cost of Goods and Service Benchmark [Member] Accounts payable Increase (Decrease) in Accounts Payable Common stock, shares authorized (in shares) Common Stock, Shares Authorized Digital Transformation Opportunities Corp. (“DTOC”) Digital Transformation Opportunities Corp. (“DTOC”) [Member] Digital Transformation Opportunities Corp. (“DTOC”) Collections on notes receivable - related parties Proceeds from Collection of Notes Receivable Short-term marketable securities Estimated Fair
Value Total Debt Securities, Available-for-Sale Document Information [Table] Document Information [Table] Excess redeemable noncontrolling interest over carrying amount Redeemable Noncontrolling Interest, Equity, Excess Over Carrying Amount Redeemable Noncontrolling Interest, Equity, Excess Over Carrying Amount Gross Unrealized
Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Stockholders' equity, conversion, threshold volume weighted average price period Stockholders' Equity, Conversion, Threshold Volume Weighted Average Price Period Stockholders' Equity, Conversion, Threshold Volume Weighted Average Price Period Liquidation preference Temporary Equity, Liquidation Preference Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] ROU assets obtained in exchange for new lease liabilities Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract] Right-Of-Use Asset Obtained In Exchange For Lease Liability Total Long-Term Debt, Gross Adjustments to reconcile net loss to net cash provided by operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Transactions [Abstract] Measurement Input Type [Axis] Measurement Input Type [Axis] Supplier Concentration Risk Supplier Concentration Risk [Member] Allocation of income to controlling and noncontrolling interests (in percent) Allocation of income to controlling and noncontrolling interests Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Ownership Interest Accumulated depreciation and amortization Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization Redemptions (in units) Common Unit, Redemptions Common Unit, Redemptions Common stock, value Common Stock, Value, Outstanding Percentage of outstanding stock maximum (in percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Automobiles Automobiles [Member] AEA Growth Management LP AEA Growth Management LP [Member] AEA Growth Management LP Other comprehensive loss attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Additional paid-in capital Additional Paid in Capital Intravenous drugs Intravenous Drugs [Member] Intravenous Drugs Inventory [Axis] Inventory [Axis] Forfeited (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Document Information [Line Items] Document Information [Line Items] Incremental borrowing rate Financing Receivable, Borrowing Rate Financing Receivable, Borrowing Rate Dividends Paid, Event Prior to June 7, 2024 Dividends Paid, Event Prior to June 7, 2024 [Member] Dividends Paid, Event Prior to June 7, 2024 Gain on sale of property and equipment Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property AON Inc. New AON (AON Inc.) New AON (AON Inc.) [Member] New AON (AON Inc.) Other receivables Increase (Decrease) in Other Receivables Number of board of managers designated by majority common unit holders Number Of Board Of Managers Designated By Majority Common Unit Holders Number Of Board Of Managers Designated By Majority Common Unit Holders Present value of lease liabilities Finance Lease, Liability Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Equity Investment in Affiliate Equity Method Investments [Policy Text Block] Other comprehensive gain (loss) Other Comprehensive Income (Loss), Net Of Tax, Including Redeemable Noncontrolling Interest Other Comprehensive Income (Loss), Net Of Tax, Including Redeemable Noncontrolling Interest Stock price (in usd per share) Share Price Related Party, Type [Axis] Related Party, Type [Axis] Other assets Other Assets Entity Registrant Name Entity Registrant Name Other assets Increase (Decrease) in Other Operating Assets Pledged collateral Debt Instrument, Collateral Amount Fair value of warrants Warrant liability Warrants and Rights Outstanding Noncontrolling interest Equity, Attributable to Noncontrolling Interest Document Period End Date Document Period End Date Proceeds from lines of credit Proceeds from Lines of Credit Accrued dividend rate (in percent) Preferred Stock, Dividend Rate, Percentage London Interbank Offered Rate (LIBOR) 1 London Interbank Offered Rate (LIBOR) 1 [Member] London Interbank Offered Rate (LIBOR) 1 Weighted-average discount rate for finance leases (in percent) Finance Lease, Weighted Average Discount Rate, Percent Long-term finance lease liabilities (included in other long-term liabilities) Long-term lease liabilities, net of current portion Finance Lease, Liability, Noncurrent Treasury Stock Treasury Stock, Common [Member] Entity Central Index Key Entity Central Index Key Dividends Paid, Event After June 7, 2028 Dividends Paid, Event After June 7, 2028 [Member] Dividends Paid, Event After June 7, 2028 Thereafter Lessee, Operating Lease, Liability, to be Paid, Due after Year Four Lessee, Operating Lease, Liability, to be Paid, Due after Year Four 2023 Incentive Equity Plan 2023 Incentive Equity Plan [Member] 2023 Incentive Equity Plan Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Stock compensation expense Share-Based Payment Arrangement, Expense Income tax expense Income Tax Expense (Benefit) Shares authorized (shares) Temporary Equity, Shares Authorized Finance lease right-of-use assets, net (included in property and equipment, net) Finance Lease, Right-of-Use Asset, after Accumulated Amortization Accrued compensation related costs Employee-related Liabilities, Current Repayments on finance lease liabilities Payments of Financing Costs Number of operating segments Number of Operating Segments Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Capital Unit, Class A-1 Capital Unit, Class A-1 [Member] Capital Unit, Class A-1 Schedule of Reverse Recapitalization, Changes in Units Schedule Of Reverse Recapitalization, Changes In Units [Table Text Block] Schedule Of Reverse Recapitalization, Changes In Units Equity [Abstract] Debt Securities, Available-for-Sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Weighted-average remaining lease term for operating leases (in years) Operating Lease, Weighted Average Remaining Lease Term Total lease liabilities Lease, Liability Lease, Liability Private Placement Warrants Private Placement Warrants [Member] Private Placement Warrants Total revenue Revenue Revenue from Contract with Customer, Excluding Assessed Tax Other receivables Other receivables Other Receivables, Net, Current Entity [Domain] Entity [Domain] Reverse Recapitalization, Change In Value Of Units [Roll Forward] Reverse Recapitalization, Change In Value Of Units [Roll Forward] Reverse Recapitalization, Change In Value Of Units Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Recapitalization exchange ratio, units Recapitalization Exchange Ratio, Units Recapitalization Exchange Ratio, Shares Preferred Class A Preferred Class A [Member] Redeemable convertible preferred stock, shares outstanding (in shares) Beginning Balance (in shares) Ending Balance (in shares) Temporary Equity, Shares Outstanding Legal Entity [Axis] Legal Entity [Axis] Current portion of operating and finance lease liabilities Finance and Operating Lease Liability, Current Finance and Operating Lease Liability, Current Money market funds Money Market Funds [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Increase (Decrease) In Noncontrolling Interest [Roll Forward] Increase (Decrease) In Redeemable Noncontrolling Interest [Roll Forward] Increase (Decrease) In Redeemable Noncontrolling Interest Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Weighted-average discount rate for operating leases (in percent) Operating Lease, Weighted Average Discount Rate, Percent Debt Instrument, Threshold Limit, Period One Debt Instrument, Threshold Limit, Period One [Member] Debt Instrument, Threshold Limit, Period One Legacy AON Shareholders Legacy AON Shareholders [Member] Legacy AON Shareholders DTOC Unredeemed Shareholders DTOC Unredeemed Shareholders [Member] DTOC Unredeemed Shareholders Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Equity-based compensation and NCI rebalancing (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Due in one year or less Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Credit Facility [Domain] Credit Facility [Domain] Shares issued (in shares) Temporary Equity, Shares Issued Shares repurchased (in shares) Treasury Stock, Shares, Acquired Signs Signs [Member] Signs Loss before equity loss in affiliate and noncontrolling interest Income (Loss) From Continuing Operations Before Equity Method Investments, Net Of Tax Income (Loss) From Continuing Operations Before Equity Method Investments, Net Of Tax Business Combinations Business Combinations Policy [Policy Text Block] Basis spread (in percent) Debt Instrument, Basis Spread on Variable Rate Long-term debt, net Long-Term Debt, Excluding Current Maturities Weighted-average remaining lease term for finance leases (in years) Finance Lease, Weighted Average Remaining Lease Term Leasehold improvements Leasehold Improvements [Member] Noncash consideration of equity method investment Noncash Consideration, Fair Value Of Consideration For Equity Method Investment Noncash Consideration, Fair Value Of Consideration For Equity Method Investment Weighted average shares for diluted loss per share (in shares) Weighted Average Number of Shares Outstanding, Diluted Subsidiary Under Common Control of Class A-1 Member Subsidiary Under Common Control Of Class A-1 Member [Member] Subsidiary Under Common Control Of Class A-1 Member Malpractice insurance, limit per policy period Malpractice Insurance, Annual Coverage Limit Costs and expenses Operating Expenses [Abstract] Less: amount representing interest Finance Lease, Liability, Undiscounted Excess Amount Transaction expenses Reverse Recapitalization Transaction Costs Reverse Recapitalization Transaction Costs Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Debt Instrument, Threshold Limit, Period [Axis] Debt Instrument, Threshold Limit, Period [Axis] Debt Instrument, Threshold Limit, Period Additional Paid in Capital Additional Paid-in Capital [Member] Total assets Assets Equity in loss of affiliate Equity in loss of affiliate Income (Loss) from Equity Method Investments Issuance of units (in units) Common Unit, Issued During Period Common Unit, Issued During Period Right-of-use assets and lease liabilities removed in termination of lease Lease, Right-Of-Use Asset And Liability Reduction From Lease Terminations Lease, Right-Of-Use Asset And Liability Reduction From Lease Terminations Cover [Abstract] Description Of Business And Significant Accounting Policies [Table] Description Of Business And Significant Accounting Policies [Table] Description Of Business And Significant Accounting Policies [Table] Number of states in which entity operates Number of States in which Entity Operates Equity-based compensation and NCI rebalancing APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Amortization of debt issuance costs Amortization of Debt Issuance Costs Participating Threshold, 3 Participating Threshold, 3 [Member] Participating Threshold, 3 Number of offices with operating lease Number Of Offices With Operating Leases Number Of Offices With Operating Leases Preferred units, outstanding (in units) Preferred Units, Outstanding Series A Preferred Stock Series A Preferred Stock [Member] Operating cash flows from finance leases Finance Lease, Interest Payment on Liability Payments of dividends Payments of Dividends Other long-term liabilities Other Liabilities, Noncurrent Vested (usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Total lease payments Lessee, Operating Lease, Liability, to be Paid Construction-in-progress Construction in Progress [Member] Thereafter Finance Lease, Liability, to be Paid, Due after Year Four Finance Lease, Liability, to be Paid, Due after Year Four Stockholders Stockholders [Member] Stockholders Amortization of finance lease right-of-use assets Finance Lease, Right-of-Use Asset, Amortization Common Class A-1 Common Class A-1 [Member] Common Class A-1 Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Redemption of Class B Common Stock to Class A Common Stock (in shares) Stock Redeemed or Called During Period, Shares Loss before income taxes, equity loss in affiliate, and noncontrolling interest Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Total comprehensive loss attributable to Class A Common Stockholders Comprehensive Income (Loss), Net Of Tax, Attributable To Common Stockholders Comprehensive Income (Loss), Net Of Tax, Attributable To Common Stockholders Equity Component [Domain] Equity Component [Domain] Less: current portion of lease liabilities Current portion of finance lease liabilities (included in accrued other) Less: current portion of lease liabilities Finance Lease, Liability, Current Participating Threshold, 2 Participating Threshold, 2 [Member] Participating Threshold, 2 Original
Principal Financing Receivable, After allowance For Credit Loss, Original Principal Financing Receivable, After allowance For Credit Loss, Original Principal Debt Instrument [Line Items] Debt Instrument [Line Items] Weighted average shares for basic loss per share (in shares) Weighted average shares for basic earnings per share (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Schedule of Other Accrued Liabilities, Current Schedule Of Other Accrued Liabilities, Current [Table Text Block] Schedule Of Other Accrued Liabilities, Current Loss from operations Operating Income (Loss) Dividends Paid, Event Prior to June 7, 2028, After June 7, 2027 Dividends Paid, Event Prior to June 7, 2028, After June 7, 2027 [Member] Dividends Paid, Event Prior to June 7, 2028, After June 7, 2027 Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] AOCI AOCI Including Portion Attributable to Noncontrolling Interest [Member] Insurance Type and Tier Identifier [Axis] Insurance Type and Tier Identifier [Axis] Overnight Repurchase Agreements Overnight Repurchase Agreements [Member] Overnight Repurchase Agreements Revenue Revenues [Abstract] Consolidated Entities [Domain] Consolidated Entities [Domain] Cost of revenue Cost of Revenue Prepaid expenses and other current assets Prepaid Expense and Other Assets Participating Threshold, 1 Participating Threshold, 1 [Member] Participating Threshold, 1 Other comprehensive income (loss): Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Gain (loss) on issuance of warrants Gain (Loss) On Issuance Of Warrants Gain (Loss) On Issuance Of Warrants Related Party Transaction [Axis] Related Party Transaction [Axis] Allocation of losses to controlling and noncontrolling interests (in percent) Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Allocation Of Losses Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Allocation Of Losses Unused line fee (in percent) Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Statement [Line Items] Statement [Line Items] Dividends [Axis] Dividends [Axis] Debt Securities, Available-for-Sale Debt Securities, Available-for-Sale [Table Text Block] Proceeds from facility Proceeds from Long-Term Lines of Credit Liabilities Lease, Liability [Abstract] Lease, Liability Noncontrolling Interest Noncontrolling Interest [Member] EX-101.PRE 10 aonc-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover - shares
 3 Months Ended
Mar. 31, 2024
May 14, 2024
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2024  
Document Transition Report false  
Entity File Number 001-04321  
Entity Registrant Name American Oncology Network, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 85-3984427  
Entity Address, Address Line One 14543 Global Parkway  
Entity Address, Address Line Two Suite 110  
Entity Address, City or Town Fort Myers  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 33913  
City Area Code 833  
Local Phone Number 886-1725  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Central Index Key 0001839998  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
Current Fiscal Year End Date --12-31  
Amendment Flag false  
Common Class A    
Document Information [Line Items]    
Title of 12(b) Security Class A common stock, par value $0.0001, per share  
Trading Symbol AONC  
Security Exchange Name NASDAQ  
Entity Common Stock, Shares Outstanding   13,046,342
Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share    
Document Information [Line Items]    
Title of 12(b) Security Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share  
Trading Symbol AONCW  
Security Exchange Name NASDAQ  
Class B Common Stock    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding   23,725,998
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets    
Cash and cash equivalents $ 74,944 $ 28,539
Short-term marketable securities 30,105 35,389
Patient accounts receivable, net 132,300 129,151
Inventories 44,288 44,569
Other receivables 34,799 34,274
Prepaid expenses and other current assets 5,029 4,277
Current portion of notes receivable - related parties 2,498 1,604
Total current assets 323,963 277,803
Property and equipment, net 40,997 40,439
Operating lease right-of-use assets [1] 43,358 43,349
Notes receivable - related parties 157 1,150
Other assets 12,216 7,588
Goodwill and intangibles, net 1,230 1,230
Deferred tax asset, net 0 2,894
Total assets 421,921 374,453
Current liabilities    
Accounts payable [2] 188,329 127,645
Accrued compensation related costs 12,628 11,410
Accrued other 25,186 22,327
Income tax payable 971 971
Current portion of operating lease liabilities [3] 6,715 6,692
Total current liabilities 233,829 169,045
Long-term debt, net 80,856 80,641
Long-term operating lease liabilities [4] 39,786 39,803
Other long-term liabilities 11,342 14,251
Total liabilities 365,813 303,740
Mezzanine equity    
Series A convertible preferred stock; $0.0001 par value; 7,500,000 shares authorized; 6,651,610 issued and outstanding at March 31, 2024 and December 31, 2023, with an aggregate liquidation preference of $69,369,195 and $68,009,015 at March 31, 2024 and December 31, 2023, respectively. 64,986 64,986
Redeemable noncontrolling interest 157,716 167,025
Stockholders' equity    
Additional paid-in capital 8,164 0
Treasury stock, at cost, 31,170 shares at March 31, 2024 and 14,729 shares at December 31, 2023 (97) 0
Accumulated other comprehensive income 77 81
Retained deficit (175,594) (161,812)
Total AON stockholders' deficit (167,446) (161,727)
Noncontrolling interest 852 429
Total deficit (166,594) (161,298)
Total liabilities, mezzanine equity, noncontrolling interest, and stockholders' equity 421,921 374,453
Common Class A    
Stockholders' equity    
Common stock, value 1 1
Class B Common Stock    
Stockholders' equity    
Common stock, value $ 3 $ 3
[1] Includes related party operating right-of-use assets, net of $11,293 and $10,931 at March 31, 2024 and December 31, 2023, respectively
[2] Includes amounts due to related party of $182,697 and $120,857 at March 31, 2024 and December 31, 2023, respectively
[3] Includes related party current portion of operating lease liabilities of $1,971 and $1,888 at March 31, 2024 and December 31, 2023, respectively
[4] Includes related party long-term operating lease liabilities of $9,772 and $9,472 at March 31, 2024 and December 31, 2023, respectively
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Redeemable convertible preferred stock, shares outstanding (in shares) 6,652,000 6,652,000
Treasury stock, common, shares (in shares) 31,170 14,729
Operating lease right-of-use assets [1] $ 43,358,000 $ 43,349,000
Accounts payable [2] 188,329,000 127,645,000
Current portion of operating lease liabilities [3] 6,715,000 6,692,000
Long-term operating lease liabilities [4] 39,786,000 39,803,000
Related Party    
Operating lease right-of-use assets 11,293,000 10,931,000
Accounts payable 182,697,000 120,857,000
Current portion of operating lease liabilities 1,971,000 1,888,000
Long-term operating lease liabilities $ 9,772,000 9,472,000
Series A Preferred Stock    
Par value (dollars per share) $ 0.0001  
Shares authorized (shares) 7,500,000  
Shares issued (in shares) 6,651,610  
Redeemable convertible preferred stock, shares outstanding (in shares) 6,651,610  
Liquidation preference $ 69,369,195 $ 68,009,015
Common Class A    
Common stock, par value (in usd per share) $ 0.0001  
Common stock, shares authorized (in shares) 200,000,000  
Common stock, shares issued (in shares) 10,334,734 9,517,816
Common stock, shares outstanding (in shares) 10,334,734 9,517,816
Class B Common Stock    
Common stock, par value (in usd per share) $ 0.0001  
Common stock, shares authorized (in shares) 100,000,000  
Common stock, shares issued (in shares) 23,725,998 25,109,551
Common stock, shares outstanding (in shares) 23,725,998 25,109,551
[1] Includes related party operating right-of-use assets, net of $11,293 and $10,931 at March 31, 2024 and December 31, 2023, respectively
[2] Includes amounts due to related party of $182,697 and $120,857 at March 31, 2024 and December 31, 2023, respectively
[3] Includes related party current portion of operating lease liabilities of $1,971 and $1,888 at March 31, 2024 and December 31, 2023, respectively
[4] Includes related party long-term operating lease liabilities of $9,772 and $9,472 at March 31, 2024 and December 31, 2023, respectively
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue    
Total revenue $ 364,339,000 $ 303,731,000
Costs and expenses    
Cost of revenue 354,948,000 278,534,000
General and administrative expenses 28,277,000 23,717,000
Transaction expenses 352,000 1,971,000
Total costs and expenses 383,577,000 304,222,000
Loss from operations (19,238,000) (491,000)
Other income (expense)    
Interest expense (1,763,000) (1,417,000)
Interest income 793,000 57,000
Other (expense) income, net (1,908,000) 466,000
Loss before income taxes, equity loss in affiliate, and noncontrolling interest (22,116,000) (1,385,000)
Income tax expense 2,894,000 0
Loss before equity loss in affiliate and noncontrolling interest (25,010,000) (1,385,000)
Equity in loss of affiliate 49,000 (101,000)
Net loss before noncontrolling interest (24,961,000) (1,486,000)
Net income attributable to noncontrolling interest 43,000 0
Net loss before redeemable noncontrolling interest (25,004,000) (1,486,000)
Net loss and noncontrolling interest attributable to Legacy AON Stockholders prior to the reverse recapitalization 0 (1,486,000)
Net loss attributable to redeemable noncontrolling interest (17,163,000) 0
Net loss attributable to Class A Common Stockholders, Basic (7,841,000) 0
Net loss attributable to Class A Common Stockholders, Diluted $ (7,841,000) $ 0
Loss per share of Class A Common Stock:    
Earnings (loss) per unit, basic (in usd per share) $ (1.22) $ 0
Earnings (loss) per unit, diluted (in usd per share) $ (1.22) $ 0
Weighted average shares of Class A Common Stock Outstanding:    
Weighted average shares for basic loss per share (in shares) 7,527,882 0
Weighted average shares for diluted loss per share (in shares) 7,527,882 0
Other comprehensive income (loss):    
Unrealized gain (loss) on marketable securities $ (22,000) $ 64,000
Other comprehensive gain (loss) (22,000) 64,000
Comprehensive loss (25,026,000) (1,422,000)
Other comprehensive loss attributable to Legacy AON Shareholders 0 (1,422,000)
Other comprehensive loss attributable to noncontrolling interests (17,180,000) 0
Total comprehensive loss attributable to Class A Common Stockholders (7,846,000) 0
Patient service revenue, net    
Revenue    
Total revenue 361,508,000 301,773,000
Other revenue    
Revenue    
Total revenue $ 2,831,000 $ 1,958,000
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Statements of Mezzanine and Stockholders’ Deficit - USD ($)
$ in Thousands
Total
Common Class A
Class B Common Stock
Common Stock
Common Class A
Common Stock
Class B Common Stock
Common Units
Capital Unit, Class A
Common Units
Capital Unit, Class A-1
Common Units
Capital Unit, Class B
AOCI
Additional Paid in Capital
Treasury Stock
AOCI
Noncontrolling Interest
Retained
Earnings (Deficit)
Beginning balance (in units) at Dec. 31, 2022           19,495,000 1,843,000              
Beginning balance at Dec. 31, 2022 $ 62,016         $ 7,725 $ 28,500 $ 80 $ (117)         $ 25,828
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Net loss attributable to Legacy AON Shareholders (1,486)                         (1,486)
Other comprehensive income attributable to Legacy AON Shareholders 64               64          
Ending balance (in units) at Mar. 31, 2023           19,495,000 1,843,000              
Ending balance at Mar. 31, 2023 $ 60,594         $ 7,725 $ 28,500 $ 80 $ (53)         24,342
Beginning Balance (in shares) at Dec. 31, 2023 6,652,000                          
Beginning Balance at Dec. 31, 2023 $ 64,986                          
Ending Balance (in shares) at Mar. 31, 2024 6,652,000                          
Ending Balance at Mar. 31, 2024 $ 64,986                          
Beginning Balance at Dec. 31, 2023 167,025                          
Increase (Decrease) In Noncontrolling Interest [Roll Forward]                            
Other comprehensive loss attributable to noncontrolling interests (17)                          
Equity-based compensation and NCI rebalancing 399                          
Net income (loss) (17,163)                          
Fair value adjustment to redeemable noncontrolling interest 15,636                          
Redemption of Class B Common Stock to Class A Common Stock (8,164)                          
Ending Balance at Mar. 31, 2024 157,716                          
Beginning balance (in shares) at Dec. 31, 2023   9,517,816 25,109,551 6,678,441,000 25,109,551,000                  
Beginning balance at Dec. 31, 2023 (161,298)     $ 1 $ 3         $ 0 $ 0 $ 81 $ 429 (161,812)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                            
Other comprehensive income (loss) (4)                     (4)    
Equity-based compensation and NCI rebalancing (in shares)       2,289,181,000                    
Equity-based compensation and NCI rebalancing 9,696                 9,696        
Repurchases of Class A Common Stock (in shares)       (16,441,000)                    
Repurchases of Class A Common Stock (97)                   (97)      
Capital contributions from noncontrolling interest member 380                       380  
Net income (loss) (7,799)                       43 (7,842)
Fair value adjustment to redeemable noncontrolling interest (15,636)                 (9,696)       (5,940)
Redemption of Class B Common Stock to Class A Common Stock (in shares)       (1,383,553,000) (1,383,553,000)                  
Redemption of Class B Common Stock to Class A Common Stock 8,164                 8,164        
Net loss attributable to Legacy AON Shareholders 0                          
Ending balance (in shares) at Mar. 31, 2024   10,334,734 23,725,998 10,334,734,000 23,725,998,000                  
Ending balance at Mar. 31, 2024 $ (166,594)     $ 1 $ 3         $ 8,164 $ (97) $ 77 $ 852 $ (175,594)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash flows from operating activities    
Net loss before noncontrolling interest $ (24,961) $ (1,486)
Adjustments to reconcile net loss to net cash provided by operating activities    
Depreciation and amortization 2,506 2,207
Amortization of debt issuance costs 215 176
Provision for income taxes 2,894 0
Amortization of operating right-of-use assets [1] 2,040 2,224
Changes in fair value adjustments of warrants and derivative liabilities (1,611) 0
Equity-based compensation 10,094 0
Equity in loss of affiliate (49) 101
Gain on sale of property and equipment 393 0
Changes in operating assets and liabilities:    
Patient accounts receivable, net (3,149) (16,711)
Inventories [2] 281 4,854
Prepaid expenses and other current assets (752) (342)
Other receivables (525) 3,442
Other assets (4,579) (2,826)
Accounts payable [3] 61,675 5,316
Accrued compensation related costs 1,218 2,757
Accrued other 4,241 (296)
Operating lease liabilities [4] (2,042) (1,777)
Other long-term liabilities (2,752) 2,032
Net cash provided by (used in) operating activities 45,137 (329)
Cash flows from investing activities    
Purchases of property and equipment (4,132) (2,777)
Purchases of marketable securities (7,069) (1,442)
Proceeds from sales of marketable securities 12,624 1,423
Collections on notes receivable - related parties 99 153
Net cash provided by (used in) investing activities 1,522 (2,643)
Cash flows from financing activities    
Repayments on finance lease liabilities (157) (105)
Repurchases of Class A Common Stock (97) 0
Net cash used in financing activities (254) (105)
Net increase (decrease) in cash and cash equivalents 46,405 (3,077)
Beginning of period 28,539 26,926
End of period 74,944 23,849
Supplemental noncash investing and financing activities    
Promissory note issued in connection with acquisition 1,420 0
Contribution from noncontrolling interest (380) 0
Right-of-use assets and lease liabilities removed in termination of lease 0 1,023
Changes in accounts payable for capital additions to property and equipment $ (1,055) $ 0
[1] Includes related party amortization of operating right-of-use assets of $2,146 and $528 for the three months ended March 31, 2024 and 2023, respectively.
[2] Includes changes in related party balances of ($7,688) and $4,610 for the three months ended March 31, 2024 and 2023, respectively.
[3] Includes changes in related party balances of $80,584 and $3,669 for the three months ended March 31, 2024 and 2023, respectively.
[4] Includes changes in related party balances of ($2,381) and ($797) for the three months ended March 31, 2024 and 2023, respectively.
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cost of revenue $ 354,948 $ 278,534
General and administrative expenses 28,277 23,717
Related Party    
Cost of revenue 310,877 178,166
General and administrative expenses $ 706 $ 679
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Condensed Consolidated Statements of Cash Flows - Parenthetical - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Amortization of operating right-of-use assets [1] $ 2,040 $ 2,224
Inventories [2] 281 4,854
Accounts payable [3] 61,675 5,316
Operating lease liabilities [4] (2,042) (1,777)
Related Party    
Amortization of operating right-of-use assets 2,146 528
Inventories (7,688) 4,610
Accounts payable 80,584 3,669
Operating lease liabilities $ (2,381) $ (797)
[1] Includes related party amortization of operating right-of-use assets of $2,146 and $528 for the three months ended March 31, 2024 and 2023, respectively.
[2] Includes changes in related party balances of ($7,688) and $4,610 for the three months ended March 31, 2024 and 2023, respectively.
[3] Includes changes in related party balances of $80,584 and $3,669 for the three months ended March 31, 2024 and 2023, respectively.
[4] Includes changes in related party balances of ($2,381) and ($797) for the three months ended March 31, 2024 and 2023, respectively.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Business
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Business Business
American Oncology Network, Inc. (“AON”, “New AON”, “AON Inc.”, or the “Company”), through its subsidiary companies and variable interest entities (together, “its subsidiaries”), is an alliance of physicians and seasoned healthcare leaders who provide comprehensive oncology services across 32 oncology practices located in nineteen states (Arizona, Arkansas, Florida, Georgia, Iowa, Idaho, Indiana, Louisiana, Maryland, Missouri, Michigan, North Carolina, Nevada, Nebraska, Ohio, South Carolina, Texas, Virginia, Washington, and the District of Columbia). The Company also provides expertise in drug procurement and payor contracting, along with practice diversification through centralized laboratory and pathology services, as well as specialty pharmacy services, clinical research, radiation oncology, and imaging. During the three months ended March 31, 2024 and 2023, the Company entered into affiliation agreements with or acquired the following oncology practices.
Three Months Ended March 31, 2024Three Months Ended March 31, 2023
StateState
Maryland (a)
Texas (a)
(a)The Company entered into affiliation agreements with the physicians for these respective practices. The Company evaluated each of the affiliation agreements and determined that the transactions did not represent a business combination.
The operations of the practices above have been included in the Company’s condensed consolidated financial statements.
Business Combination Agreements

Digital Transformation Opportunities Corp. (“DTOC”), American Oncology Network, LLC (“AON LLC”), GEF AON Holdings Corp. (“AON Class C Preferred Investor”), and DTOC Merger Sub, Inc., a direct, wholly owned subsidiary of DTOC (“Merger Sub”) entered into a Business Combination Agreement (the “Business Combination Agreement”), dated as of June 14, 2023 (which further amended and restated the Business Combination Agreement entered into by DTOC and AON as of October 5, 2022, and amended and restated on January 6, 2023, and April 27, 2023), pursuant to which, among other transactions, on September 20, 2023 (the “Closing Date”), DTOC and AON undertook a series of transactions (the “Business Combination” or “Reverse Recapitalization”) resulting in the organization of the combined post-business combination company as an umbrella partnership C corporation, in which substantially all of the assets and the business of the combined company are held by AON LLC, and DTOC became a member of AON LLC. In connection with the closing of the Business Combination (“the Closing”), DTOC changed its name to “American Oncology Network, Inc.”. The Business Combination was completed on September 20, 2023.

As a result of, and in connection with, the Closing, among other things, (i) AON LLC amended and restated its operating agreement (the “Amended and Restated AON LLC Agreement”) to reclassify its existing Class A units, Class A-1 units and Class B units into a single class of AON LLC common units (“AON LLC Common Units”) that can be exchanged on a one-to-one basis for shares of New AON Class A common stock (“New AON Class A Common Stock”) and its existing AON LLC Class C units into AON LLC Series A preferred units (AON LLC Series A Preferred Units”); (ii) AON LLC converted profit pool units of certain of AON LLC’s subsidiaries into an equal number of AON LLC Common Units and shares of New AON Class B common stock (“New AON Class B Common Stock”), which together are exchangeable into shares of New AON Class A Common Stock (together with the New AON Class B Common Stock, the “New AON Common Stock”); (iii) New AON amended and restated its charter (the “Charter”) to provide for (a) the conversion of all existing shares of DTOC Class B common stock into shares of New AON Class A Common Stock on a one-to-one basis, (b) amendment of the terms
of New AON Class B Common Stock to provide holders voting rights but no economic rights and (c) designation of a new series of New AON preferred stock as Series A convertible preferred stock (the “New AON Series A
Preferred Stock” or “Series A Preferred Stock") with such rights and preferences as provided for in the certificate of designation of the New Aon Series A Preferred Stock (the “New AON Series A Certificate of Designation”); and (iv) among other things, (a) AON LLC issued common units to New AON in exchange for a combination of cash
and shares of New AON Class B Common Stock and warrants to acquire shares of New AON Class B Common Stock (the “Class B Prefunded Warrants”), (b) New AON was admitted as a member of AON LLC, (c) AON LLC distributed shares of New AON Class B common stock or Class B Prefunded Warrants, as applicable, to AON LLC equity holders, (d) New AON reserved a specified number of additional shares of New AON Class A Common Stock after the Closing for issuance to eligible participants, (e) Merger Sub merged with and into the AON Class C Preferred Investor whereby the separate existence of Merger Sub ceased and New AON issued a number of shares of New AON Series A Preferred Stock equal to the number of AON LLC Series A preferred units held by the AON Class C Preferred Investor to AEA Growth Management LP, the parent of AON Class C Preferred Investor (“AEA Growth”) in exchange for all the shares of common stock held by AEA Growth in the AON Class C Preferred Investor (the “First Step”), (f) promptly after the First Step, the AON Class C Preferred Investor merged with and into New AON whereby the separate existence of the AON Class C Preferred Investor ceased and New AON held all the AON LLC Series A preferred units and (g) from and after the Closing (but subject to lock-up restrictions), the AON LLC common equity holders (other than New AON), referred to herein as “Legacy AON Shareholders” (former AON LLC Class A, Class A-1, and Class B unit holders), will have the right (but not the obligation) to exchange AON LLC Common Units together with an equal number of shares of New AON Class B Common Stock (whether held directly or indirectly through Class B Prefunded Warrants) for shares of New AON Class A Common Stock.

In addition, in connection with the Closing, DTOC completed the offer to the holders of AON LLC Class B-1 units to exchange their AON LLC Class B-1 units for such number of newly issued shares of New AON Class A Common Stock equal to the ratio set forth in the Business Combination Agreement (such offer, the “Exchange Offer”). DTOC and AON LLC solicited consents from the holders of AON LLC Class B-1 units to make certain amendments to the terms of the awards and the unit grant agreements pursuant to which the AON LLC Class B-1 units were granted, which provided for the automatic exchange, as of immediately prior to the adoption of the Amended and Restated AON LLC Agreement, of all outstanding AON LLC Class B-1 units into shares of New AON Class A Common Stock (collectively, the “Proposed Amendments”). The requisite number of holders of Class B-1 units provided their consent to the Proposed Amendments, and as a result, in connection with the Closing, all AON LLC Class B-1 units were exchanged for an aggregate of 1,047,343 shares of New AON Class A Common Stock.

Upon the consummation of the Business Combination, the outstanding membership units in AON LLC and the outstanding shares in AON Inc. (New AON) are as follows:
•AON LLC Common Units held by the Legacy AON Shareholders - 28,109,796
•AON LLC Common Units held by New AON - 9,532,354
•AON LLC Series A Preferred Units held by New AON - 6,651,610

•Class A Common Stock held by the former AON LLC Class B-1 unit holders - 1,047,343
•Class A Common Stock held by the DTOC unredeemed shareholders - 147,511
•Class A Common Stock held by the DTOC Sponsor and their permitted transferees - 5,498,125(a)
•Class B Common Stock held by Legacy AON Shareholders - 25,109,551(b)
•New AON Series A Preferred Stock held by AEA Growth Management LP - 6,651,610

(a) Sponsor Earnout Shares of 2,839,375 are subject to vesting and forfeiture provisions and are not outstanding for GAAP purposes as of the Closing Date.

(b) Certain Legacy AON Shareholders hold 3,000,245 Class B Prefunded Warrants, which underlying shares of Class B common stock are not outstanding as of the Closing Date.

Warrants

As of the Closing Date, New AON assumed the outstanding warrants (Public Warrants and Private Placement Warrants) that were issued by DTOC as part of DTOC’s IPO. Further, New AON issued the Class B Prefunded Warrants to former Class A-1 unit holders, in lieu of New AON Class B Common Stock. The accounting treatment for the Public Warrants, the Private Placement Warrants, and the Class B Prefunded Warrants, collectively referred to as “the Warrants”, is disclosed in Note 2.

Public Warrants
As of the Closing Date, New AON assumed 8,337,500 public warrants (the “Public Warrants”) issued by DTOC in its IPO. Each whole warrant entitles the holder to purchase one share of New AON Class A Common Stock at a price of $11.50 per share, subject to adjustment. The warrants will become exercisable on the later of 12 months from the closing of the DTOC Initial Public Offering or 30 days after the completion of its initial business combination and will expire five years after the Closing of the Business Combination, or earlier upon redemption or liquidation.

Private Warrants

As of the Closing Date, New AON assumed 6,113,333 Private Placement Warrants held by the DTOC Sponsor (the “Private Placement Warrants” or “Private Warrants”). The Private Placement Warrants will be non-redeemable in certain circumstances so long as they are held by the Sponsor or its permitted transferees. The Private Placement Warrants may also be exercised by the Sponsor and its permitted transferees for cash or on a cashless basis. Otherwise, the Private Placement Warrants have terms and provisions that are identical to those of the Public Warrants, including as to exercise price, exercisability, and exercise period.

Class B Prefunded Warrants

As of the Closing Date, New AON issued 3,000,245 of Class B Prefunded Warrants to former AON Class A-1 unitholders. Because the Class B Warrants are prefunded, there was not any cash consideration exchanged as part of the Class B Warrant issuance. Each Class B Prefunded Warrant entitles the holder to purchase one share of New AON Class B common stock at a price of $0.01 per share. The exercise term of the Class B Warrant shall continue indefinitely so long as the holder of the Class B Warrant is also the holder of an AON LLC Common Unit, provided that the number of shares of Common Stock that this Warrant is exercisable for shall not exceed the number of AON LLC Common Units held by holder.

Transaction Expenses

In connection with the Reverse Recapitalization, AON LLC and New AON incurred costs of $0.4 million and $1.9 million during the three months ended March 31, 2024 and 2023, respectively, which were reported as transaction expenses in the condensed consolidated statements of operations and comprehensive loss.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Basis of Presentation and Significant Accounting Policies
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation and Significant Accounting Policies Basis of Presentation and Significant Accounting Policies
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of the Company were prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. Management believes the unaudited condensed consolidated financial statements for the interim periods presented contain all necessary adjustments, of a normal recurring nature, to state fairly, in all material respects, the Company’s financial position, results of operations and cash flows for the interim periods presented. These unaudited condensed consolidated financial statements were prepared on the same basis as and should be read in conjunction with such audited consolidated financial statements and related notes thereto of AON Inc. and its wholly-owned subsidiaries, included in the Annual Report on Form 10-K, dated and filed on March 28, 2024 with the SEC (the “Annual Report 2023"). Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results the Company expects for the entire year.

For the three months ended March 31, 2024, these unaudited condensed consolidated financial statements reflect the consolidated results of operations, comprehensive loss, cash flows and changes in equity of AON Inc. and its wholly-owned subsidiaries. The condensed consolidated balance sheet at March 31, 2024 presents the financial condition of AON Inc. and its consolidated subsidiaries.

For the three months ended March 31, 2023, these unaudited condensed consolidated financial statements present the consolidated results of operations, comprehensive loss, cash flows and changes in equity of AON LLC. The condensed consolidated balance sheet as of December 31, 2023 presents the financial condition of AON Inc. and its consolidated subsidiaries after the Reverse Recapitalization. All intercompany balances and transactions of AON LLC have been eliminated.

In accordance with Accounting Standards Codification (“ASC”) Topic 805, Business Combinations, the historical equity of AON LLC has been recasted in all periods up to the Closing Date, to reflect the number of shares of New AON’s Class A Common Stock and Class B Common Stock issued to Legacy AON Shareholders in connection with the Reverse Recapitalization. The Company recasted the units outstanding related to the historical AON LLC Class A, Class A-1, and Class B units prior to the Reverse Recapitalization (“Historical AON LLC Equity”) as common equity of New AON, equal to the Per Company Class Unit Exchange Ratio, pursuant to the Business Combination Agreement.

The Per Company Unit Exchange Ratio at which AON LLC Class A units and Class A-1 units were reclassified is equal to 2,524 AON Common Units. The Per Company Unit Exchange Ratio at which AON LLC Class B units were reclassified varied depending on participation threshold, and is equal to 2,524, 2,453, or 1,976, AON Common Units. The Per Company Unit Exchange Ratio at which Class C units were reclassified is equal to 2,705 AON LLC Series A Preferred Units.

The condensed consolidated financial statements and related notes thereto give effect to the conversion for all periods presented, without any change to par value or per unit amounts. The condensed consolidated financial statements do not necessarily represent the capital structure of New AON had the Reverse Recapitalization occurred in prior periods. The Company has not made retroactive adjustments related to the historical book values of Historical AON LLC Equity as the adjustments were considered immaterial.

For the three months ended March 31, 2024, $7.8 million of the consolidated net loss of AON LLC were attributable to the Class A Common Stockholders, and reflects the Class A Common Stockholders’ absorption of 23.0% of the consolidated net loss of AON LLC. For the three months ended March 31, 2024, $17.2 million of the consolidated net losses of AON LLC were attributable to noncontrolling interest, and reflects the Legacy AON Stockholders’ absorption of 77.0% of the consolidated net losses of AON LLC.

For the three months ended March 31, 2023, $1.5 million of the consolidated net losses of AON LLC were attributable to the Legacy AON Stockholders, to reflect their absorption of 100% of the consolidated net losses of AON LLC pertaining to the days prior to the Reverse Recapitalization.
Principles of Consolidation
For the period of January 1, 2024 through March 31, 2024, the condensed consolidated financial statements include the accounts of the Company, American Oncology Network, LLC (“AON LLC”), and its wholly owned subsidiary American Oncology Management Company, LLC (“AOMC”), and its consolidated variable interest entities (“VIEs”) American Oncology Partners, P.A. (“AON Partners”), American Oncology Partners of Maryland, P.A. (“Partners of Maryland”), AON Central Services, LLC (“AON Central Services”), and Meaningful Insights Biotech Analytics, LLC (“MIBA”). All intercompany accounts and transactions between the entities have been eliminated in consolidation.

The accounting treatment of the Business Combination was a Reverse Recapitalization.

For the periods prior to the Reverse Recapitalization, the consolidated financial statements of the Company comprise the accounts of AON LLC and its wholly-owned subsidiaries. All intercompany accounts and transactions among AON LLC and its consolidated subsidiaries were eliminated.
The Company accounts for American Oncology Network, LLC, AON Partners, Partners of Maryland, AON Central Services, and MIBA in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810, Consolidations. The Company determines whether it has a controlling financial interest in an entity by first evaluating whether the entity is a VIE. A VIE is broadly defined as an entity that has any of the following three characteristics: (i) the equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (ii) substantially all of the entity’s activities either involve or are conducted on behalf of an investor that has disproportionately few voting rights; or (iii) the equity investors as a group lack any of the following, the power through voting or similar rights to direct the activities of the entity that most significantly impact the entity’s economic performance, the obligation to absorb the expected losses of the entity, or the right to receive the expected residual returns of the entity. The Company consolidates a VIE if it has both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and an obligation to absorb losses or the right to receive benefits that could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively, if any.

AON LLC has contractual relationships with AON Partners, Partners of Maryland and AON Central Services and the physician owners through management service agreements (“MSAs”) and other contractual agreements to provide all practice management services outside of medical services provided by the physicians. In addition, despite not being required by the contractual relationships, AON LLC regularly provides funding to support AON Partners and Partners of Maryland’s operations and acquisitions of physician practices. AON Central Services was formed July 15, 2022 and, effective January 1, 2023, entered into an agreement with AOMC to provide qualified non-clinical and non-medical employees to AOMC to support the operation of the physician practices. MIBA was established during the first quarter of 2023 for the purpose of developing intellectual property to synergize the collection, de-identification, and dissemination of the Company’s patient data for sale to external parties for research, development, and clinical decisions. In May 2023, the Company contributed $0.2 million for a 56% interest in the equity of MIBA. As of March 31, 2024, MIBA had no significant operating activity. The Company concluded that AON LLC had a controlling financial interest in MIBA and has consolidated the entity at March 31, 2024 and recorded the noncontrolling interest in equity. 
The Company has concluded that AON Partners, Partners of Maryland, AON Central Services, and MIBA are all VIEs in which AON LLC has the characteristics of a controlling financial interest and is deemed to be the primary beneficiary. The variable interest subjects AON LLC to all potential losses in the entities and, therefore, requires AON LLC, and in turn AON Inc., to consolidate the results of AON Partners, Partners of Maryland, AON Central Services, and MIBA in its condensed consolidated financial statements. 
Refer to Note 4 for further information on the VIEs.
Significant Accounting Policies
The accounting policies included below should be read in conjunction with the annual consolidated financial statements.
Accounting Estimates and Assumptions
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.
Segments
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (the “CODM”). The Company’s CODM is its chief executive officer who reviews financial information together with certain operating metrics principally to make decisions about how to allocate resources and to measure the Company’s performance. The Company has one operating segment and one reportable segment that are structured around the organizational management of oncology practice operations. All revenue and assets are in the United States. 
Revenue Recognition
Revenue is recognized under Accounting Standards Update (“ASU”) 2014-09 Revenue from Contracts with Customers (“Topic 606”). The Company determines the transaction price based upon standard charges for goods and services with anticipated consideration due from patients, third-party payors (including health insurers and government agencies) and others. The Company’s revenue is primarily derived from patient service revenues, which encompass oncology services provided during patient visits and shipments of pharmacy prescriptions. Performance obligations for the Company’s services provided to patients and most procedures, are satisfied over the time of visit which is the same day services are performed. Performance obligations relating to pharmacy revenue are considered fully satisfied at a point in time upon the customer receiving delivery of the prescription. Accordingly, the Company does not anticipate a significant amount of revenue from performance obligations satisfied (or partially satisfied) in previous periods, and any such revenue recognized during the three month periods ended March 31, 2024 and 2023 was immaterial. Additionally, the Company does not expect to recognize material revenue in the future related to performance obligations that are unsatisfied (or partially satisfied) as of March 31, 2024 and December 31, 2023. Approximately $246.1 million and $214.3 million and of the Company’s revenues are generated from services performed during patient visits with the remainder primarily generated from shipments of pharmacy prescriptions for the three month periods ended March 31, 2024 and 2023, respectively.
As services are performed and prescriptions are shipped, timely billing occurs for services rendered and prescriptions shipped less discounts provided to uninsured patients and contractual adjustments to third-party payors based upon prospectively determined rates and discounted charges. Payment is requested at the time of service for self-paying patients and for patients covered by third-party payors that are responsible for paying deductibles and coinsurance.
The Company monitors revenue and receivables to prepare estimated contractual allowances for the anticipated differences between billed and reimbursed amounts. Payments from third-party payors and Government programs including Medicare and Medicaid may be subject to audit and other retrospective adjustments. Such amounts are considered on an estimated basis when net patient revenue is recorded and are adjusted as final adjustments are determined. For the three month periods ended March 31, 2024 and 2023, such resulting historic adjustments have been immaterial to the condensed consolidated financial statements. 
In assessing who is the principal in providing patient services and pharmacy prescriptions, the Company considered who controls the provision of services and prescriptions. The Company has determined they are acting as a principal in these relationships. 
In April 2022, the Company entered into a long-term arrangement to sponsor and manage a clinical trial. The Company subsequently contracted with a third-party to provide the clinical research services and is the principal in this arrangement. The performance of clinical research services are considered a single performance obligation because the Company provides a highly-integrated service. Revenue is recognized for the single performance obligation over time due to the Company’s right to payment for work performed to date. The contract provides for invoices based on predetermined milestones. 

The Company uses the cost-to-cost measure of progress for the Company’s contract because it best depicts the transfer of control to the customer as the performance obligation is fulfilled. For this method, the Company
compares the contract costs incurred to date to the estimated total contract costs through completion. As part of the client proposal and contract negotiation process, the Company develops a detailed project budget for the direct costs and reimbursable costs based on the scope of the work, the complexity of the study, the geographical location involved and the Company’s historical experience. The estimated total contract costs at the project level are reviewed and revised periodically throughout the life of the contract, with adjustments to revenue resulting from such revisions being recorded on a cumulative basis in the period in which the revisions are identified. Contract costs consist primarily of direct labor and other reimbursable project-related costs such as travel, third-party vendor costs and investigator fees. The Company establishes pricing based on the Company’s internal pricing guidelines, discount agreements, if any, and negotiations with the client. The transaction price is the contractually defined amount. Revenue related to the clinical trial, which is included within other revenue, was $0.5 million and $0 million for the three months ended March 31, 2024 and 2023, respectively. 
The Company has a system and estimation process for recording Medicare net patient service revenue and estimated recoupments as it relates to value-based care (“VBC”) revenue included in patient service revenue in the condensed consolidated statements of operations and comprehensive loss. The Company’s VBC revenue is primarily generated through its participation in the CMS Oncology Care Model (“OCM”) which is an episode-based payment model to promote high-quality cancer care. Participants enter six-month episode periods, and the Company bills a monthly fee during the six-month period based on a fixed rate per participant per month and the total number of participants. Certain quality and compliance metrics are tracked as part of the program and submitted to CMS at the end of the episode period which may result in recoupment of funds. The Company estimates the recoupment amount by developing a recoupment percentage for each period based on historical known recoupment from CMS and applies the recoupment percentage against total fees for the period. Based on the estimate, the Company accrues a liability representing the expected final recoupments based on historical settlement trends.
Short-term Marketable Securities 
Investments in marketable securities consist of corporate bonds and U.S. Treasury securities.
Management determines the appropriate classification of investments at the time of purchase and reevaluates such determination at each balance sheet date. Marketable securities are classified as available-for-sale and are carried at fair value in the consolidated balance sheets. The marketable securities are classified as short-term based on management’s intent to convert such securities within one year and the ability to convert them within two to three days.
Certain of our available-for-sale securities are debt securities. For an available-for-sale debt security with an amortized cost that exceeds its fair value, the Company first determines if it intends to sell or will more-likely-than-not be required to sell the security before the expected recovery of its amortized cost. If it intends to sell or will more-likely-than-not be required to sell the security, then the Company recognizes the impairment as a credit loss in the condensed consolidated statements of operations and comprehensive loss by writing down the security’s amortized cost to its fair value. If it does not intend to sell or it is not more-likely-than-not that it will be required to sell the security before the expected recovery of its amortized cost, the Company recognizes the portion of the impairment that is due to a credit loss, if any, in the condensed consolidated statements of operations and comprehensive loss through an allowance. The portion of the impairment that is due to factors other than a credit loss is recognized in other comprehensive income (loss) in the condensed consolidated statements of operations and comprehensive loss as an unrealized loss.
Equity Investment in Affiliate
In January 2023, the Company contributed noncash consideration, with a fair value of approximately $2.3 million, in return for a 49% equity interest in OCP Management Arizona, LLP. Investments in entities over which the Company has the ability to exercise significant influence but does not control the entity are accounted for using the equity method. Equity method investments are included with other assets in the condensed consolidated balance sheets. The carrying amount of the investment is adjusted to reflect the Company’s proportionate share of the net earnings or losses and reduced by any dividends received. The Company’s share of income or loss related to this investment is reported as an equity in loss of affiliate in the condensed consolidated statements of operations and comprehensive loss.
Noncontrolling Interests
The Company consolidates the results of entities in which it has a controlling financial interest. Refer to Note 15 for additional considerations and presentation for noncontrolling interest.
Mezzanine Equity

New AON Series A Preferred Stock is redeemable for cash or the value of the property, rights or securities to be paid or distributed in the event of a Deemed Liquidation Event (which is outside of the Company’s control). As a result, Management has determined that the New AON Series A Preferred Stock should be classified as mezzanine equity. As of March 31, 2024, the Preferred Stock are recorded at their initial carrying value, net of offering costs of $0.8 million. The Series A Preferred Stock are not being accreted to redemption value, as the redemption is not probable. The Series A Preferred Stock are classified outside of members’ equity on the consolidated balance sheets. Refer to Note 14 for mezzanine equity presentation considerations for redeemable noncontrolling interest.
Treasury Stock

We account for treasury stock purchased under the cost method and include treasury stock as a component of
accumulated paid in capital. Treasury stock purchased with intent to retire (whether or not the retirement is actually accomplished) is charged to common stock. The company repurchased 14,729 shares of class A common stock at the spot rate as of each transaction date for a total cost of less than $0.1 million for the year ended December 31, 2023. For the three months ended March 31, 2024 the Company repurchased an additional 16,441 shares of class A common stock at the spot rate as of each transaction date for a total cost of less than $0.1 million. To date, the Company has repurchased a total of 31,170 shares.
Equity-Based Compensation

The Company issues stock-based awards to employees and directors in the form of stock options and restricted stock units. The Company measures and recognizes compensation expense for its stock-based awards granted to its employees and directors based on the estimated grant date fair value in accordance with ASC 718, Compensation-Stock Compensation, and determines the fair value of restricted stock units based on the fair value of its common stock. The Company measures all share-based options granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. Compensation expense of those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company records the expense for awards with service-based conditions using the straight-line method over the requisite service period, net of any actual forfeitures. The Company classifies share-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified.
Business Combinations
The Company evaluates acquired practices in accordance with ASU 2017-01, Business Combinations (Topic 805)-Clarifying the Definition of a Business. This standard clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. Because substantially all of the value of each acquired practice did not relate to a similar group of assets and as each acquired practice contained both inputs and processes necessary to provide economic benefits to the Company, it was determined that each acquisition represents a business combination. Therefore, the transactions have been accounted for using the acquisition method of accounting, which requires, with limited exceptions, that assets acquired, and liabilities assumed be recognized at their estimated fair values as of the acquisition date. Any excess of the consideration transferred over the estimated fair values of the net assets acquired is recorded as goodwill. Transaction costs related to business combinations are expensed in the period in which they are incurred.
Offering Costs
The Company defers specific incremental costs directly attributable to proposed offerings of securities. These costs consist of legal, accounting, and other similar expenses incurred through the balance sheet date that are directly related to a potential offering. If the offering is completed, these costs will be charged against the gross proceeds of the offering. These offering costs will be allocated to the separable financial instruments issued in the transaction on a relative fair value basis of the securities issued, compared to total proceeds received. Offering costs associated
with any instruments classified as liabilities will be expensed as incurred, presented as non-operating expenses in the condensed consolidated statement of operations and comprehensive loss.

Professional Liability
The Company maintains insurance policies for exposure to professional malpractice insurance risk. The limits of malpractice insurance provide each physician/advanced practice provider with a dedicated $1.0 million limit per claim and a $3.0 million limit in the aggregate per policy period – on a first dollar basis, as no deductible applies. The policy further then extends coverage to the Company, by providing a $2.0 million limit per claim and a $4.0 million limit in the aggregate per policy period - on a first dollar basis, additionally, as no deductible applies. Reserves are established for estimates of the loss that will ultimately be incurred on claims that have been reported but not paid and claims that have been incurred but not reported. These reserves are established based on consultation with a third-party actuary. The actuarial valuations consider a number of factors, including historical claims payment patterns, changes in case reserves and the assumed rate of increase in healthcare costs. Management believes the use of actuarial methods to account for these reserves provides a consistent and effective way to measure these subjective accruals. However, due to the sensitive nature of this estimation technique, recorded reserves could differ from ultimate costs related to these claims due to changes in claims reporting, claims payment and settlement practices and differences in assumed future cost increases. Accrued unpaid claims and expenses that are expected to be paid within the next twelve months are classified as current liabilities and included in accrued other. All other accrued unpaid claims and expenses are classified as long-term liabilities and included in other long-term liabilities. Insurance recoveries associated with the unpaid claims are classified as long-term assets included in other assets.
Fair Value of Financial Instruments
Fair value is the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.
Accounting guidance establishes a three-level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:
Level 1Inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market.
Level 2Inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model-derived valuations in which all significant inputs are observable for substantially the full term of the asset or liability.
Level 3Inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. 
Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement of assets and liabilities being measured within the fair value hierarchy.
Our financial instruments include cash, short-term marketable securities, accounts receivable, notes receivable, accounts payable, accrued expenses, long-term debt and contractual agreements that resulted in derivative liabilities. Our nonfinancial assets such as property and equipment are not measured at fair value on a recurring basis; however, they are subject to fair value adjustments in certain circumstances, such as when there is evidence that impairment may exist.
The carrying amounts of cash, accounts receivable, accounts payable, notes receivable, and accrued expenses approximate their fair value because of the short-term maturity and highly liquid nature of these instruments. We
determine the fair value of long-term debt and marketable securities based on various factors including maturity schedules and current market rates.
See Note 6 for a discussion of the Company’s Level 1 and Level 2 Marketable Securities as of March 31, 2024. See below for a discussion of the Company’s Level 1 and Level 3 warrant liabilities as of March 31, 2024. As of March 31, 2024 and December 31, 2023, there were no Level 3 financial instruments. There were no transfers between any levels of the hierarchy during any periods presented.

Warrant Liabilities

Upon Closing of the Business Combination, on September 20, 2023, the Company evaluated the Public Warrants and Private Placement Warrants and the Class B Prefunded Warrants, collectively referred to herein as “Warrants”, in accordance with ASC 815-40, “Derivatives and Hedging —- Contracts in Entity’s Own Equity”, and concluded that a provision in the warrant agreements related to potential net cash settlement of the warrants upon an exchange or tender offer that may not result in a change in control of the entity precludes the warrants from being accounted for as components of equity. As the Warrants meet the definition of a derivative as contemplated in ASC 815, the Warrants are recorded as current liabilities within accrued other on the condensed consolidated balance sheets and measured at fair value at inception and at each reporting date in accordance with ASC 820, “Fair Value Measurement”, with changes in fair value recognized in other income (expense), net on the condensed consolidated statements of operations and comprehensive loss in the period of change.

As of March 31, 2024, the Public Warrants were trading separately from the Class A Common Stock and the quoted market price was used to establish fair value. As such, the Public Warrants fair value was determined using a Level 1 input. The fair value of the Public Warrants as of March 31, 2024 is $2.8 million and recorded in other long-term liabilities on the condensed consolidated balance sheets.

Management has utilized the public warrant price to value the private warrants and believes the public and private warrants have materially consistent fair values given the existence of the make-whole redemption feature. As of March 31, 2024, a valuation of the private warrants was performed which confirmed the private warrant value was materially consistent with the public warrants. The details of this valuation are included in the paragraph below.

The fair value of the Private Placement warrants was determined using Level 3 inputs. As of March 31, 2024, the fair value of the Private Placement Warrants was estimated to be $2.1 million and recorded in other long-term liabilities on the condensed consolidated balance sheets. The fair value was estimated at March 31, 2024, using the Black-Scholes Option Pricing model using the following assumptions:
Expected annual dividend yield – 0.0%
                Expected volatility – 26.40%
                Risk-free rate of return – 4.31%
                Expected Option Term – 5.0 years
                
The AON Class B Prefunded Warrants are exercisable into one share of New AON Class B Common Stock. A share of New AON Class B Common Stock, together with an AON LLC Common Unit, may be exchanged for one share of New AON Class A Common Stock. Considering New AON Class B Common Stock has no economic rights and limited liquidity or value if the holder does not also possess an AON LLC Common Unit, and because the AON Class B Prefunded Warrants are exercisable into New AON Class B Common Stock, the Company has estimated fair value of the Class B Prefunded Warrants to be immaterial.
Earnings Per Share

The Company recast Historical AON LLC Equity as AON Inc. common equity for all periods prior to the Reverse Recapitalization, refer to Note 2. However, as 100% of the net losses of AON LLC prior to the Reverse Recapitalization were absorbed by the Legacy AON Shareholders, basic and diluted earnings (loss) per share is zero for the three months ended March 31, 2023. Basic and diluted earnings (loss) per share for the three months ended March 31, 2024 represents the period where the Company had earnings (loss) attributable to Class A Common Stockholders. Class B Common Stock does not have economic rights in AON Inc., including rights to dividends or distributions upon liquidation, and as a result, is not considered a participating security for basic and diluted earnings (loss) per share. As such, basic and diluted earnings (loss) per share of Class B Common Stock has not been presented.
The Company has issued and outstanding Sponsor Earnouts, which are subject to forfeiture if the achievement of certain stock price thresholds are not met. In accordance with ASC Topic 260, “Earnings Per Share,” the Sponsor Earnouts are excluded from weighted-average shares outstanding to calculate basic earnings (loss) per share as they are considered contingently issuable shares due to their potential forfeiture. Sponsor Earnouts will be included in weighted-average shares outstanding to calculate basic earnings (loss) per share as of the date of their stock price thresholds are met and they are no longer subject to forfeiture.

Basic and diluted earnings (loss) per share is computed by use of the two-class method as a result of outstanding Series A Preferred Stock, which accrue dividends at the annual rate of 8% of the original price per share, participate with common stock on all other dividends, and accordingly have participation rights in undistributed earnings as if all such earnings had been distributed during the period (see Note 12). Under such method income available to common shareholders is computed by deducting both dividends declared or, if not declared, accumulated on Series A Preferred Stock from net income. Loss attributable to common shareholders is computed by increasing net loss by such dividends. Since the participating Series A Preferred Stock has no contractual obligation to share in the losses of the Company, there is no loss allocation between Class A Common Stock and Series A Preferred Stock.

Basic earnings (loss) per share is based on the weighted-average number of shares of Class A Common Stock outstanding during the period. Diluted earnings (loss) per share is based on the weighted-average number of shares of Class A Common Stock used for the basic earnings (loss) per share calculation, adjusted for the dilutive effect of the Public and Private Warrants and Sponsor Earnout, if any, using the “treasury stock” method and the convertible Series A Preferred Stock and, exchangeable Class B Common Stock and Class B Prefunded Warrants, if any, using the “if-converted” method. Net earnings (loss) for diluted loss per share is adjusted for the Company’s share of AON LLC’s consolidated net earnings (loss), net of AON Inc. taxes, after giving effect to the Class B Common Stock and Class B Prefunded Warrants that are exchanged into potential shares of Class A Common Stock, Public and Private Warrants that are liability classified, and Series A Preferred Stock, to the extent it is dilutive.
Recently Adopted Accounting Pronouncements 
In June 2016, the FASB issued ASU 2016-13, ‘‘Financial instruments-Credit Losses’’ (“ASU 2016- 13”). ASU 2016-13 requires entities to report ‘‘expected’’ credit losses on financial instruments and other commitments to extend credit rather than the current ‘‘incurred loss’’ model. These expected credit losses for financial assets held at the reporting date are to be based on historical experience, current conditions, and reasonable and supportable forecasts. This ASU will also require enhanced disclosures relating to significant estimates and judgments used in estimating credit losses, as well as the credit quality. ASU 2016-13 is effective for the Company for annual reporting periods beginning after December 15, 2022. ASU 2016-13 was adopted by the Company effective January 1, 2023, with no material impact on the Company’s consolidated financial statements and related disclosures. 
In October 2021, the FASB issued ASU 2021-08, “Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers”, which provides that an acquirer must recognize, and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606. The guidance is effective for the Company for annual reporting periods beginning after December 15, 2023, with early adoption permitted. The adoption of this standard as of January 1, 2024, did not have a material impact on the Company’s consolidated financial statements and related disclosures.
Recently Issued Accounting Pronouncements

In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” The amendments in this update are intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses. The ASU requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker, a description of other segment items by reportable segment, and any additional measures of a segment's profit or loss used by the chief operating decision maker when deciding how to allocate resources. The ASU also requires all annual disclosures currently required by Topic 280, “Segment Reporting,” to be included in interim periods. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and retrospective application is required for all
periods presented. The Company is evaluating the impact this will have on the Company's consolidated financial statements and related disclosures.

In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” The amendments in this upgrade enhance the transparency and decision usefulness of income tax disclosures. This ASU requires disclosures of specific categories and disaggregation of information in the rate reconciliation table. The ASU also requires disclosure of disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit, and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December 15, 2024. Early adoption is permitted and the amendments should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating the effect that ASU 2023-09 will have on its disclosures.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Reverse Recapitalization
 3 Months Ended
Mar. 31, 2024
Reverse Recapitalization [Abstract]  
Reverse Recapitalization Reverse Recapitalization
As discussed in Note 1, AON LLC merged with DTOC, with AON LLC surviving the Merger. AON LLC is governed by a board of managers composed of three (3) persons that were designated by New AON and two (2) persons that were designated by holders of a majority of the AON LLC Common Units, held by members of AON LLC other than New AON. Management determined AON LLC was not a variable interest entity (Refer to Note 2), and as result, identified AON LLC as the accounting acquirer of the Merger in accordance ASC Topic 805. Management concluded that AON LLC was the accounting acquirer due to (i) the Legacy AON Shareholders, defined as the former AON Class A, Class A-1, and Class B unit holders, receiving the largest portion of the voting rights in the combined company, New AON, (ii) significantly all of the Legacy AON Shareholders retained their equity interest as stockholders in New AON, (iii) AON LLC’s operations prior to the Reverse Recapitalization comprising the only ongoing operations of New AON, (iv) the Legacy AON Shareholders have the right to appoint a majority of the directors of New AON, (v) the executive management of AON LLC will become the executive management of New AON and (vi) AON LLC is significantly larger than New AON in terms of revenue, total assets, and employees. Therefore, the Merger was accounted for as a reverse recapitalization, with no goodwill or other intangible assets recorded, in accordance with ASC Topic 805. New AON was treated as the “acquired” company for financial reporting purposes, and for accounting purposes, the Reverse Recapitalization was treated as the equivalent of AON LLC issuing stock for the net assets of New AON, accompanied by a recapitalization. The net assets of New AON were recorded at historical cost on the condensed consolidated balance sheet as of September 20, 2023, the Closing Date of the Reverse Recapitalization, with no goodwill or other intangible assets recorded. For additional information on the capitalization of New AON and AON LLC immediately following the Closing of the Reverse Recapitalization, see Note 1.

The following table provides the historical cost of assets and liabilities of AON Inc. as of September 20, 2023.

As of September 20, 2023
Cash and Cash Equivalents$1,493 
Current Liabilities(13,295)
Long Term Liabilities(6,791)
Total Net Liabilities$(18,593)
The Company recorded a Day 1 expense as of the Closing of the Business Combination equal to $18.2 million. Of that total amount, $13.0 million was recorded in transaction expenses on the condensed consolidated statement of operations and comprehensive loss. The remaining $5.2 million was recorded in other income (expense) net on the condensed consolidated statement of operations and comprehensive loss. This amount represented the loss on the issuance of Public and Private Warrants, as of the Closing, net of cash received. The Company also recorded a $4.3 million gain in other income (expense), net related to the change in the fair value of the Public and Private Warrants during the period of September 21, 2023 through September 30, 2023.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Variable Interest Entities
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Variable Interest Entities Variable Interest Entities
AOMC is a wholly owned subsidiary of AON LLC and neither AOMC nor AON LLC has ownership interest in AON Partners and Partners of Maryland. Both AON Partners and Partners of Maryland are fully owned by physicians. AON LLC operates its physician practices through the MSAs and other contractual agreements between AOMC, AON Partners, and Partners of Maryland. The responsibilities of AOMC include, but are not limited to, negotiating provider and payor contracts, employment and compensation decisions, billing and collections, furnishing all supplies and equipment necessary for the respective practice’s operations as well as, necessary real estate, contracting on behalf of AON Partners and Partners of Maryland, entering into leases, holding a power of attorney to perform the above activities, preparing, maintaining and administering all accounting records (including financial reporting), expense payment, and maintenance of all information systems/software. AON LLC is paid a management fee to compensate AOMC for the services provided. AON Central Services is 80% physician owned and 20% owned by AON LLC. AOMC entered into an agreement with AON Central Services, effective January 1, 2023, to provide qualified non-clinical and non-medical employees to AOMC to support the operation of the physician practices. AOMC pays a monthly management fee to AON Central Services equal to the aggregate cost of compensation, benefits and all other costs related to these employees. AON LLC invested $0.2 million in MIBA, a newly formed LLC, during the second quarter of 2023 in exchange for 56% equity ownership. The Company evaluated AON LLC’s relationship with MIBA under the VIE model and determined it was a VIE and the Company is the primary beneficiary based on its financial controlling interest.

Based on various quantitative and qualitative factors, including assessment of certain services performed and relationships held above, management has determined that AON Partners, Partners of Maryland, AON Central Services, and MIBA are all variable interest entities and AOMC is the primary beneficiary who holds the decision-making rights over the activities that most significantly impact the economic performance of AON Partners, Partners of Maryland, AON Central Services, and MIBA through the MSAs and other contractual agreements. Accordingly, the results of AON Partners, Partners of Maryland, AON Central Services, and MIBA have been consolidated with the Company for the three month period ended March 31, 2024. The results of AON Partners, Partners of Maryland, and AON Central Services have been consolidated with the Company for the three month period ended March 31, 2023.
The assets of AON Partners, Partners of Maryland, AON Central Services, and MIBA as of March 31, 2024 and December 31, 2023, are as follows:
As of March 31,
2024		As of December 31,
2023
Assets
Cash and cash equivalents$75,796 $26,574 
Accounts receivable132,300 129,151 
Inventories44,288 44,569 
Prepaid expenses and other current assets1,157 895 
Goodwill and intangibles, net180 180 
Other receivables34,297 33,809 
Other assets7,880 2,091 
Total assets$295,898 $237,269 
The liabilities of AON Partners, Partners of Maryland, AON Central Services, and MIBA as of March 31, 2024 and December 31, 2023, are as follows:
As of March 31,
2024		As of December 31,
2023
Liabilities
Accounts payable$184,314 $122,324 
Accrued compensation and benefits25,713 21,380 
Accrued other14,972 16,723 
Other long-term liabilities1,078 273 
Due to AON LLC and subsidiaries, net107,144 117,194 
Total liabilities$333,221 $277,894 
All intercompany transactions and balances with the VIEs are eliminated in consolidation.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Business Combinations
 3 Months Ended
Mar. 31, 2024
Business Combination and Asset Acquisition [Abstract]  
Business Combinations Business Combinations
2024 Acquisitions

The Company did not have any ASC 805 acquisitions during the three months ended March 31, 2024.
2023 Acquisitions

The Company did not have any ASC 805 acquisitions during the three months ended March 31, 2023.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Marketable Securities
 3 Months Ended
Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities Marketable Securities
The following table summarizes the Company’s marketable securities financial assets that are measured at fair value on a recurring basis:
As of March 31, 2024
Amortized
Cost		Gross Unrealized
Gains		Gross Unrealized
Losses		Estimated Fair
Value
Cash equivalents (1)
Level 1:
Overnight repurchase agreements (2)$73,938 $- $- $73,938 
Money market funds529 - - 529 
U.S. Treasury Bills993 - - 993 
Level 1 total$75,460 $— $— $75,460 
Marketable securities
Level 2:
Corporate bonds14,267 172 (3)14,436 
U.S. Treasury securities15,467 205 (4)15,668 
Level 2 total29,734 377 (7)30,104 
Total$105,194 $377 $(7)$105,564 
As of December 31, 2023
Amortized
Cost		Gross Unrealized
Gains		Gross Unrealized
Losses		Estimated Fair
Value
Cash equivalents (1)
Level 1:
Overnight repurchase agreements (2)$28,593 $- $- $28,593 
Money market funds$723 $- $- $723 
Level 1 total29,316 — — 29,316 
Marketable securities
Level 2:
Corporate bonds13,678 191 (9)13,860 
U.S. Treasury securities21,318 211 21,529 
Level 2 total34,996 402 (9)35,389 
Total$64,312 $402 $(9)$64,705 
(1)Included in cash and cash equivalents in the consolidated balance sheets at March 31, 2024 and December 31, 2023.
(2)Cash equivalents as of March 31, 2024 included U.S. Treasury Bills with an initial maturity of 3 months or less and overnight repurchase agreements in which cash from the Company's main operating checking account is invested overnight in highly liquid, short-term investments sponsored by a large financial institution. The company had overnight repurchase agreements as of March 31, 2024 and December 31, 2023.
The Company uses quoted prices in active markets for identical assets to determine the fair value of its Level 1 investments. The fair value of the Company’s Level 2 investments is determined using pricing based on quoted market prices or alternative market observable inputs. 
The fair value of the Company’s marketable securities as of March 31, 2024, by remaining contractual maturities, were as follows:
Corporate BondsU.S. TreasuriesTotal
Due in one year or less$5,886 $11,972 $17,858 
Due in one to five years8,550 3,696 12,246 
Total$14,436 $15,668 $30,104 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Supplemental Condensed Balance Sheet Information
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Supplemental Condensed Balance Sheet Information Supplemental Condensed Balance Sheet Information
Other receivables
Other receivables consisted of the following at March 31, 2024 and December 31, 2023:
As of March 31,
2024		As of December 31,
2023
Rebates receivable$34,112 $33,708 
Other687 566 
Total other receivables$34,799 $34,274 
Inventory
Inventory consisted of the following at March 31, 2024 and December 31, 2023:
As of March 31,
2024		As of December 31, 2023
Intravenous drugs$33,972 $32,388 
Oral pharmaceuticals10,316 12,181 
Total inventories$44,288 $44,569 
Property and Equipment, net
Property and equipment, net consisted of the following at March 31, 2024 and December 31, 2023:
As of March 31,
2024		As of December 31,
2023
Leasehold improvements$33,985 $32,490 
Furniture, fixtures and equipment2,750 2,607 
Medical equipment16,310 15,666 
Computer equipment3,395 3,285 
Signs176 153 
Automobiles110 59 
Software9,231 7,829 
Construction-in-progress1,847 2,985 
Property and equipment, gross67,804 65,074 
Accumulated depreciation and amortization(26,807)(24,635)
Property and equipment, net$40,997 $40,439 
Accrued Other

Accrued other consisted of the following at March 31, 2024 and December 31, 2023:
As of March 31,
2024		As of December 31,
2023
Refund liability$12,879 $15,078 
Warrant liability4,913 - 
Excise taxes payable2,700 2,700 
Current portion of finance lease liabilities1,205 1,189 
Other3,489 3,360 
Total accrued other$25,186 $22,327 
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Long-term Debt
 3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Long-term Debt Long-term Debt
Debt consisted of the following at March 31, 2024 and December 31, 2023: 
As of March 31,
2024		As of December 31, 2023
PNC Facility$81,250 $81,250 
Total81,250 81,250 
Unamortized debt issuance costs(394)(609)
Total debt$80,856 $80,641 
Credit Facilities
On April 30, 2021, the Company entered into a Loan Facility with PNC (“PNC Loan Facility”) collateralized by the Company’s assets and outstanding patient accounts receivable. The PNC Loan Facility is guaranteed on a limited basis by the Company and shareholder of AON Partners and Partners of Maryland. $34.6 million of proceeds from the PNC Loan Facility was used to pay off the Company’s previous term loans and revolver with Truist Bank. The remaining funds were made available for working capital and acquisition of additional physician practices.
The PNC Loan Facility is interest-only with total principal due at an initial maturity on April 30, 2024. Interest originally accrued at one-month LIBOR or an alternate base rate plus 1.45%. The maximum balance of the PNC Loan Facility (“Borrowing Base”) is limited to the lesser of the Facility Limit ($65.0 million) or the fair value of the Company’s patient accounts receivable. The Company must maintain a balance of the lesser of the Borrowing Base or 65% of the Facility Limit in the first year and 75% of the Facility Limit in subsequent years (“minimum funding threshold”). The Company can repay the PNC Loan Facility up to the minimum funding threshold at any time without penalty. In accordance with the PNC Loan Facility, the Company pledged $10.0 million of collateral as restricted cash to be released quarterly in increments of $2.5 million. The restricted cash was fully released as of March 31, 2024 and December 31, 2023.
On April 30, 2021, the Company entered into a $5.0 million revolving line of credit agreement (“PNC Line of Credit”). The PNC Line of Credit has an expiration date of April 30, 2024 and originally bore interest at a rate per annum equal to the sum of the daily LIBOR rate plus 1.65% or an alternate base rate plus 0.65% and is due on the first day of each month beginning June 1, 2021. Any outstanding principal and accrued interest will be due on the expiration date. Beginning July 1, 2021, quarterly bank fees equal to 1.65% per day per annum are due in arrears and will continue on the first day of each quarter thereafter. All debt related to the PNC Line of Credit is collateralized by the Company’s assets. As of March 31, 2024 and December 31 2023, no draws had been made on the PNC Line of Credit. The Company is also subject to a 0.20% unused line fee calculated per annum on the unused balance of the PNC Line of Credit. 
On July 29, 2021, the Company amended the PNC Loan Facility increasing the Facility Limit to $75.0 million. On February 14, 2022, the Company further amended the PNC Loan Facility and Line of Credit agreements. The primary changes included an increase of the Facility limit from $75.0 million to $125.0 million, an increase of the PNC Line of Credit availability from $5.0 million to $10.0 million, interest charges to be calculated based on the Bloomberg Short-Term Bank Yield Index plus 1.65% and certain financial covenants. As part of the amendment, the Company drew an additional $16.3 million in proceeds under the Loan Facility. On August 15, 2022, the PNC Loan Facility and Line of Credit agreements were amended again to reduce the availability under the PNC Line of Credit from $10.0 million to $1.0 million. 
Effective November 23, 2022, the Company entered into Waiver and Amendment No. 6 (“Waiver and Amendment”) under its PNC Loan Facility as the Company was not in compliance with the Delinquency Ratio financial covenant for the period ending October 31, 2022 and the requirement to provide certain annual financial statements. The Waiver and Amendment waives each event of default and also revised future delinquency percentages and financial statement requirements. 
On June 30, 2023, the Company entered into Amendment No. 7 (“Amendment 7”) to its PNC Loan Facility which extended the maturity date from April 30, 2024 to June 30, 2026. In connection with Amendment 7, the Company paid additional debt issuance costs of $0.4 million which will be amortized over the revised remaining life of the
Loan Facility. In addition, Amendment 7 revised the definition of the minimum funding threshold to limit the threshold multiplier to 65% of the Facility Limit. 

On January 1, 2024, the Company entered into Amendment No. 8 (“Amendment 8”) to its PNC Loan Facility to modify certain definitions such as “change in control”. In addition, the Amendment 8 also amended the delinquency ratio threshold used to calculate certain debt covenants. The effective date of Amendment 8 was January 16, 2024.

On January 16, 2024, the Company also entered into Amendment No. 3 (“Amendment 3”) to its PNC Line of Credit to modify certain definitions such as “change in control”. In addition, the Amendment 3 also amended certain debt covenants, such as EBITDA thresholds. The effective date of Amendment 3 was December 31, 2023.

The PNC Loan Facility and PNC Line of Credit nonfinancial covenants include restrictions related to unpermitted property liens and the requirement of audited financial statements. Both agreements also contain several financial covenants, including the following ratios: accounts receivable default, delinquency, dilution, days sales outstanding, leverage, and fixed charge coverage. As of March 31, 2024, the Company was in compliance with all financial and nonfinancial debt covenants as required by both loan agreements.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Income Taxes
 3 Months Ended
Mar. 31, 2024
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The Company is a member of American Oncology Network, LLC, which is treated as a partnership for U.S. federal and certain state and local income taxes. As a partnership, American Oncology Network, LLC is not subject to U.S. federal and certain state and local income taxes. Any taxable income or loss generated by American Oncology Network, LLC is passed through to and included in the taxable income or loss of its members, including the Company.

The Company is subject to U.S. federal income taxes, in addition to state and local income taxes with respect to the allocable share of any taxable income of American Oncology Network, LLC. Additionally, other corporate entities within the Company's structure are subject to income taxes. These corporate entities continue to generate losses and continue to maintain a valuation allowance against their net deferred tax assets.

The Company’s effective income tax rate was (13.1)% and —% for the three months ended March 31, 2024 and 2023, respectively. The provision for income taxes was $2.9 million and $0 for the three months ended March 31, 2024 and 2023, respectively.

The change to the income tax provision for the three months ended March 31, 2024 compared to the income tax provision for the three months ended March 31, 2023 was primarily a result of the transaction closing on September 20, 2023, resulting in a portion of the Company's consolidated pre-tax earnings, which were previously not subject to income taxes, flowing into a taxable corporation included in the Company's post transaction structure. As of December 31, 2023, the Company recognized a deferred tax asset related to its investment in the American Oncology Network, LLC partnership. As of March 31, 2024, the Company updated its valuation allowance assessment based on new factors including its year-to-date loss and forecasted loss at the American Oncology Network, LLC partnership legal entity. Based on its updated valuation allowance assessment, the Company recorded a discrete valuation allowance against its investment in partnership deferred tax asset during the three months ending March 31, 2024.

The effective income tax rate for the three months ended March 31, 2024 and 2023 differed from the federal statutory rate primarily due to certain legal entities in the Company's structure being treated as partnerships for income tax purposes and, therefore, a significant portion of its income not being subject to income tax. Additionally, certain corporate entities within the Company's structure continue to maintain a full valuation allowance against their net deferred tax assets.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Leases
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
Leases Leases
The Company currently leases office facilities and equipment for its practices under noncancelable operating and finance lease agreements expiring on various dates through 2038. Certain of the leases contain renewal options which are exercisable at the Company’s discretion. These renewal options are considered in determining the lease term if it is reasonably certain that the Company will exercise such options. Additionally, the Company leases certain other office and medical equipment under month-to-month lease agreements. 
Right-of-use assets and lease liabilities consist of the following at March 31, 2024 and December 31, 2023:
As of March 31,
2024		As of December 31,
2023
Assets
Operating lease right-of-use assets, net$43,358 $43,349 
Finance lease right-of-use assets, net (included in property and equipment, net)5,513 5,794 
Total right-of-use assets$48,871 $49,143 
Liabilities
Current
Current portion of operating lease liabilities$6,715 $6,692 
Current portion of finance lease liabilities (included in accrued other)1,205 1,189 
Long-term7,920 7,881 
Long-term operating lease liabilities39,786 39,803 
Long-term finance lease liabilities (included in other long-term liabilities)4,239 4,548 
Total lease liabilities$51,945 $52,232 
The components of lease costs recognized in the condensed consolidated statements of operations and comprehensive loss consist of the following for the three month periods ended March 31, 2024 and 2023 and are included in selling, general, and administrative expenses unless otherwise noted:
Three Months Ended March 31,
20242023
Operating lease costs$2,795 $2,870 
Finance lease costs
Amortization of finance lease right-of-use assets281110
Interest on finance lease liabilities (included in interest expense)8617
Variable lease costs586578
Total lease costs$3,748 $3,575 
The following table reconciles the undiscounted cash flows expected to be paid in each of the next five years and thereafter recorded in the condensed consolidated balance sheets for operating and finance leases as of March 31, 2024:
Operating
Leases		Finance
Leases
2024 (remainder of year after March 31, 2024)$6,959 $1,132 
202510,014 1,487 
20269,620 1,249 
20278,370 1,185 
20286,271 948 
Thereafter19,147 261 
Total lease payments60,381 6,262 
Less: amount representing interest(13,880)(818)
Present value of lease liabilities46,501 5,444 
Less: current portion of lease liabilities(6,715)(1,205)
Long-term lease liabilities, net of current portion$39,786 $4,239 
The weighted-average remaining lease term as of March 31, 2024 and December 31, 2023 was 4.54 years and 6.93 years for operating leases and 6.84 years and 4.76 years for finance leases, respectively. The weighted-average discount rate as of March 31, 2024 and December 31, 2023 was 6.33% and 6.64% for operating leases and 6.71% and 6.30% for finance leases, respectively.
The cash paid for amounts included in the measurement of lease liabilities for the three months ended March 31, 2024 and 2023 is as follows:
Three Months Ended
March 31,
20242023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$2,799 $2,845 
Operating cash flows from finance leases86 17 
Financing cash flows from finance leases291 105 
ROU assets obtained in exchange for new operating lease liabilities2,048 4,326 
Leases Leases
The Company currently leases office facilities and equipment for its practices under noncancelable operating and finance lease agreements expiring on various dates through 2038. Certain of the leases contain renewal options which are exercisable at the Company’s discretion. These renewal options are considered in determining the lease term if it is reasonably certain that the Company will exercise such options. Additionally, the Company leases certain other office and medical equipment under month-to-month lease agreements. 
Right-of-use assets and lease liabilities consist of the following at March 31, 2024 and December 31, 2023:
As of March 31,
2024		As of December 31,
2023
Assets
Operating lease right-of-use assets, net$43,358 $43,349 
Finance lease right-of-use assets, net (included in property and equipment, net)5,513 5,794 
Total right-of-use assets$48,871 $49,143 
Liabilities
Current
Current portion of operating lease liabilities$6,715 $6,692 
Current portion of finance lease liabilities (included in accrued other)1,205 1,189 
Long-term7,920 7,881 
Long-term operating lease liabilities39,786 39,803 
Long-term finance lease liabilities (included in other long-term liabilities)4,239 4,548 
Total lease liabilities$51,945 $52,232 
The components of lease costs recognized in the condensed consolidated statements of operations and comprehensive loss consist of the following for the three month periods ended March 31, 2024 and 2023 and are included in selling, general, and administrative expenses unless otherwise noted:
Three Months Ended March 31,
20242023
Operating lease costs$2,795 $2,870 
Finance lease costs
Amortization of finance lease right-of-use assets281110
Interest on finance lease liabilities (included in interest expense)8617
Variable lease costs586578
Total lease costs$3,748 $3,575 
The following table reconciles the undiscounted cash flows expected to be paid in each of the next five years and thereafter recorded in the condensed consolidated balance sheets for operating and finance leases as of March 31, 2024:
Operating
Leases		Finance
Leases
2024 (remainder of year after March 31, 2024)$6,959 $1,132 
202510,014 1,487 
20269,620 1,249 
20278,370 1,185 
20286,271 948 
Thereafter19,147 261 
Total lease payments60,381 6,262 
Less: amount representing interest(13,880)(818)
Present value of lease liabilities46,501 5,444 
Less: current portion of lease liabilities(6,715)(1,205)
Long-term lease liabilities, net of current portion$39,786 $4,239 
The weighted-average remaining lease term as of March 31, 2024 and December 31, 2023 was 4.54 years and 6.93 years for operating leases and 6.84 years and 4.76 years for finance leases, respectively. The weighted-average discount rate as of March 31, 2024 and December 31, 2023 was 6.33% and 6.64% for operating leases and 6.71% and 6.30% for finance leases, respectively.
The cash paid for amounts included in the measurement of lease liabilities for the three months ended March 31, 2024 and 2023 is as follows:
Three Months Ended
March 31,
20242023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$2,799 $2,845 
Operating cash flows from finance leases86 17 
Financing cash flows from finance leases291 105 
ROU assets obtained in exchange for new operating lease liabilities2,048 4,326 
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Related Parties
 3 Months Ended
Mar. 31, 2024
Related Party Transactions [Abstract]  
Related Parties Related Parties
Transactions Notes Receivable
The Company enters into promissory notes with physicians of the Company. The notes receivable balances are satisfied through cash payments or settlements through the physicians’ compensation as part of their employee agreement. The notes receivable are amortized over a 60-month period as a reduction of compensation. The notes bear interest at the Company’s incremental borrowing rate (7.09% at March 31, 2024 and 7.18% at December 31, 2023, respectively).
As of March 31,
2024		As of
December 31,
2023		Original
Principal		Issue
Date		Maturity
Date
Notes receivable
Note 2$656 $656 $5,355 5/1/20194/30/2024
Note 3- 17 491 6/1/20195/31/2024
Note 81,999 2,081 2,816 5/1/20205/1/2025
Total notes receivables2,655 2,754 
Less:  Current portion of notes receivable$(2,498)(1,604)
Notes receivable, less current portion$157 $1,150 
Leases
The Company has operating leases for thirteen of the office facilities owned by employees of the Company. Total cash was approximately $0.7 million and $0.7 million paid for leases to related parties for the three months ended March 31, 2024 and 2023, respectively.
Inventory Purchases/Concentration Risk
The Company purchases the majority of pharmaceuticals inventory from a subsidiary under common control of a Legacy AON Shareholder. During the three months ended March 31, 2024 and 2023, the Company purchased from the related party approximately $311.0 million and $243.0 million, respectively. These purchases were approximately 88% and 87% as a percentage of cost of revenue for the three months ended March 31, 2024 and 2023, respectively. At March 31, 2024 and December 31, 2023, the Company had $183.0 million and $102.1 million, respectively, included in accounts payable for invoices from the related party, representing 97% of accounts payable at each period-end.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Equity-Based Compensation
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Equity-Based Compensation quity-Based Compensation
The Company maintains a single equity incentive plan, the “2023 Incentive Equity Plan”, which was adopted by the Board of Directors and approved by stockholders in connection with the Business Combination. A total of 5,300,000 shares were authorized under the 2023 Incentive Equity Plan. The number of shares of common stock available for issuance under the 2023 Incentive Equity Plan will be increased annually on the first day of each fiscal year during the term of the 2023 Incentive Equity Plan by an amount equal to the lesser of (a) 5% of the shares of common stock outstanding on the final day of the immediately preceding calendar year or (b) such smaller number of shares as determined by the Company’s board of directors. At March 31, 2024, 2,044,394 shares were available for grant under the 2023 Incentive Equity Plan. The purpose of the 2023 Incentive Equity Plan is to attract and retain personnel for positions with the Company, to provide additional incentive to employees, directors, and consultants, and to promote the success of the Company’s business. The Plan permits the grant of Incentive Stock Options (“ISO”) to any ISO Employee and the grant of Non statutory stock options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, and Performance Awards to any Service Provider.

Restricted Stock Units

The Company granted 3,759,459 Restricted Stock Units (“RSUs”) to employees during the three months ended March 31, 2024.

A summary of the RSU activity during the three month period ending March 31, 2024 is as follows:

Restricted Stock UnitsWeighted Average Grant Date Fair Value
Outstanding as of December 31, 2023— $— 
Granted3,759,459 $5.73 
Vested(2,289,181)$5.80 
Forfeited— $— 
Outstanding as of March 31, 20241,470,278 $5.67 

The Company recognized $13.3 million in stock-based compensation expense related to outstanding RSUs during the three months ended March 31, 2024.

As of March 31, 2024, there was approximately $8.2 million of total unrecognized compensation expense related to RSUs, which is expected to be recognized over a weighted-average period of approximately 1.7 years.

The fair value of the RSUs is determined on the date of the grant based on the market price of the Company’s common stock on that date. Each RSU represents the right to receive one share of the Company’s common stock, upon vesting. Portions of the RSUs granted vest immediately with others vesting over one to two years following the grant date, subject to the individual’s continued service to the Company through the applicable vesting date, and are subject to the terms and conditions on the Company’s form of RSU agreement under the 2023 Incentive Equity Plan.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Equity
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Equity Equity
Prior Period Presentation

For periods prior to the Reverse Recapitalization, AON LLC had equity and stock-based compensation described below authorized, issued and outstanding. As discussed in Note 1, upon the Closing of the Business Combination, Legacy AON Shareholders received Class A Common Stock, Class B Common Stock, or Class B Prefunded Warrants and AON LLC reclassified their existing Class A, Class A-1, and Class B Units into AON LLC Common Units, pursuant to the terms of the Business Combination Agreement.

The Company recasted Historical AON LLC Equity outstanding for the periods prior to the Reverse Recapitalization, equal to the Per Company Unit Exchange Ratio, pursuant to the Business Combination, that was applied to the Class A, Class A-1, and Class B Units. The historical AON LLC units disclosed in this note give effect to the conversion for all periods presented, as follows.

Class A Units

AON LLC had authorized 19,495,376 units of Class A Units, of which 19,495,376 units were issued and were outstanding as of December 31, 2022.

Class A-1 Units

AON LLC had authorized 3,000,245 units of Class A-1 Units, of which 1,842,520 units were issued and were outstanding as of December 31, 2022.

Class B Units (Profit Interest)

The Class B units were issued through the 2017 Profits Interest Plan adopted by the Company in October 2017. The Class B Units represented a non-voting equity interest in AON LLC that entitled the holder to appreciation in the equity value of AON LLC arising after the date of grant and after such time as an applicable hurdle amount is met. AON LLC recognized the cost of services received in exchange for Class B Units based on the grant-date fair value. That cost was recognized over the period during which the service provider is required to provide service in exchange for the award over the requisite service period or based on performance. AON LLC used the Black-Scholes-Merton pricing model to estimate the fair value of profits interest unit awards. On an as converted basis, as of December 31, 2022, AON LLC issued 5,614,176 Class B Units, of which 4,703,628 were vested and outstanding; the remaining 910,548 of Class B units vested upon consummation of the Business Combination.

The following table summarizes the changes to AON LLC’s Class A, Class A-1, and Class B Units for the three months ended March 31, 2023.
in thousands, except for share and per share amountsThree Months Ended
March 31, 2023
Class A Units, value
Beginning of Period$7,725 
Issuance of Units— 
Impact of the Reverse Recapitalization— 
End of Period$7,725 
Class A Units, units
Beginning of Period19,495,376 
Issuance of Units— 
Impact of the Reverse Recapitalization— 
End of Period19,495,376 
Class A-1 Units, value
Beginning of Period$28,500 
Issuance of Units— 
Impact of the Reverse Recapitalization— 
End of Period$28,500 
Class A-1 Units, units
Beginning of Period1,842,520 
Issuance of Units— 
Impact of the Reverse Recapitalization— 
End of Period1,842,520 
Class B Units, value
Beginning of Period$80 
Equity based compensation— 
Impact of the Reverse Recapitalization— 
End of Period$80 
Class B Units, units
Beginning of Period4,703,628 
Units Vested— 
Impact of the Reverse Recapitalization— 
End of Period4,703,628 

Class B-1 Units

In June and July of 2023, the Company granted a total of 415 AON LLC Class B-1 Units to certain employees under the 2017 Profits Interest Plan (the “Plan”). Upon the closing of the Business Combination, the vested Class B-1 Units were reclassified to AON LLC Common Units and exchanged for newly issued shares of Class A Common Stock equal to the Per Company Unit Exchange Ratio, pursuant to the Business Combination Agreement, which resulted in the issuance of 1,047,343 shares of New AON Class A Common Stock.

Mezzanine Equity Class C Units

As described in Note 1, the AON LLC Class C Units were converted into AON LLC Series A Preferred Units as of the Closing Date. Concurrently, New AON issued a number of shares of New AON Series A Preferred Stock equal
to the number of AON LLC Series A Preferred Units held by the AON Class C Preferred Investor to AEA Growth Management LP, the parent of AON Class C Preferred Investor (“AEA Growth”) in exchange for all the shares of common stock held by AEA Growth in the AON Class C Preferred Investor. Promptly after the First Step, the AON Class C Preferred Investor merged with and into New AON whereby the separate existence of the AON Class C Preferred Investor ceased and New AON held all the AON LLC Series A Preferred Units. On an as converted basis, as of September 20, 2023, 6,651,610 Series A Preferred Stock were issued to AEA Growth Management LP.

The AON LLC Class C Units were contingently redeemable convertible preferred units and classified as mezzanine equity on the condensed consolidated balance sheet as of June 30, 2023 because the units were redeemable five years from the issuance date, at the option of the holder. As of June 30, 2023, the AON LLC Class C Units were recorded at their initial carrying value, net of offering costs. The Class C Units were not being accreted to redemption value, as the redemption was not probable due to the removal of the redemption right pursuant to the Business Combination. See discussion below.

The Class C Units had materially the same rights as the Series A Preferred Stock issued by the Company to AEA Growth Management LP, the parent of the AON Class C Preferred Investor, with the exception of the “AON LLC Class C Unit Redemption Right” and the “Class C Option to Purchase Additional Shares”, discussed below. Further, the Class C Units did not contain a mandatory conversion feature that allowed AON LLC to force the Class C Investor to convert the Class C Units into another equity unit in AON LLC and the Class C Units did not have a one time conversion price adjustment.

Class C Unit Redemption Right

After the fifth anniversary of the Effective Date (June 7, 2028), the holders of a majority of the Class C Units had the right to cause the Company to redeem all of the Class C Units. The redemption price per Class C Unit was equal to the greater of (i) the Class C Liquidation Preference and (ii) the Fair Market Value of a Class C Unit (the “Class C Redemption Price”). The Class C Liquidation Preference is defined as an amount equal to the sum of (a) the Class C Preferred Return of such Class C Member and (b) the amount of such Class C Member’s Net Invested Capital Contributions of $65.0 million. The Class C Unit Preferred Return is defined as the cumulative, semiannually-compounded return of 8% per annum based on the original Net Invested Capital Contributions of $65.0 million. The Class C Unit Redemption Right was removed as of the Closing of the Business Combination.


Series A Preferred Stock (Mezzanine Equity)

New AON Series A Preferred Stock is redeemable for cash or the value of the property, rights or securities to be paid or distributed in the event of a Deemed Liquidation Event (which outside of the Company’s control). As a result, the Company has determined that the New AON Series A Preferred Stock should be classified as mezzanine equity. At the closing of the Business Combination, the Company exchanged existing AON LLC Class C Units for Series A Preferred Stock in the Company. Based on the qualitative changes to the instrument, this exchange is considered an extinguishment for accounting purposes, with the Company recording a deemed dividend of $2.1 million to account for the difference between the carrying value of the Class C Units and the fair value of the Series A Preferred Stock at the transaction date. This amount is reflected in the December 31, 2023 condensed consolidated statements of mezzanine and stockholders’ equity as part of the reverse recapitalization, net. See further discussion on the PIK Dividend discussed below.

The Series A Preferred Stock are not being accreted to redemption value, as the Series A Preferred Stock are not redeemable, nor are they probable of becoming redeemable.

Dividends

The Series A Preferred Stock accrue dividends at a cumulative, semiannually-compounded return of 8% per annum based on the original Net Invested Capital Contributions from the Class C Units of $65.0 million. These dividends may be paid in cash or accumulate into the Accrued Value at the option of New AON. The accrual shall be calculated on June 30 and December 31 and with respect to the semiannually-compounded return, no interest is required to be paid on any present or future Series A Preferred Stock accrued dividends. The Series A Preferred Stock also participate in distributions with the Class A Common stockholders.
On September 20, 2023, the Company issued 6,651,610 Series A Preferred Stock to AEA Growth Management LP. The number of Series A Preferred Stock shares issued at the Closing of the Business Combination was equal to the aggregate Class C Liquidation Preference pursuant to the Business Combination Agreement. As a result, the issuance of the Series A Preferred Stock effectively included an in-kind payout (“PIK”) of the accrued dividend since the calculation of the amount issued was based on the Class C Liquidation Preference. As of the Closing, the Company recorded a dividend of 151,610 Series A Preferred Stock PIK shares with respect to the accrued dividends on the Series A Preferred Stock (the "PIK Dividend") in the December 31, 2023 condensed consolidated statements of mezzanine and stockholders’ equity.

Voting

The holders of the Preferred Stock are entitled to elect and appoint one of the directors (“Series A Director”) to the Board of Directors. All other directors are appointed by the Class A and Class B Common stockholders. There are no restrictions on which matters the Series A Preferred stockholders are entitled to vote. The Series A Preferred stockholders are entitled to the number of votes equal to the number of shares of Common Stock into which the Series A Preferred Stock would be convertible on the record date of the vote.

Conversion Rights

The Series A Preferred Stock is convertible, at the option of the holder, at any time, and without the payment of additional consideration by the holder, into such number of fully-paid Class A Common Stock as is determined by dividing the Accrued Value by the Conversion Price in effect at the time of conversion (“Conversion Ratio”). The Accrued Value is the Original Issue Price (which is $10.00 per share of Preferred Stock, as adjusted for any stock split, stock dividend, combination, or other recapitalization) plus any unpaid dividends, compounded semi-annually. The Conversion Price is initially $10.00 per Preferred Share subject to adjustment for dilutive issuances of additional shares, dividends to common stockholders, stock splits, mergers, and a five-year anniversary special adjustment based on the volume weighted average price of the common stock. These dividends may be paid in cash or accumulate into the Accrued Value, at the option of New AON, on June 30 and December 31 of each year. The Conversion Rights shall terminate at the close of business on the day prior to the date of a Change of Control.

If at any time on or after the 30th day after the five-year anniversary of the issue date, any of the Series A Preferred Stock remain outstanding and the 30-Day VWAP of the Common Stock is less than $10.00 (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification), then the Conversion Price shall be adjusted to the greater of (x) the 30-Day VWAP on such date of determination and (y) $5.00 (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification).

New AON also has the right on or after the third-year anniversary of the date of issuance to cause all (but not less than all) of the outstanding shares of Series A Preferred Stock to be converted into shares of Class A Common Stock for each share of Series A Preferred Stock at the Conversion Ratio detailed above. The Company may only convert shares of Series A Preferred Stock into shares of Common Stock if the 30-Day VWAP of the Common Stock immediately prior to the Company Conversion Date is greater than $16.00 (as adjusted for any stock split, stock dividend, combination, or other recapitalization).

Liquidation Preferences

In the event of voluntary or involuntary liquidation, dissolution or winding up of the Company or an Initial Public Offering (IPO) or Exit Event, the Series A Preferred Stock have preferential liquidation rights. If a Deemed Liquidation Event were to occur, each Series A Preferred stockholder is entitled to be paid out of the assets of the Company available for distribution, equal to the greater of the following:

(i) The Original Issue Price of $10 per Series A Preferred Stock multiplied by the Applicable Percentage plus any Accrued Dividends on such share of Series A Preferred Stock; or

(ii) Such amount per share as would have been payable had all shares of Series A Preferred Stock been converted into Common Stock immediately prior to such Deemed Liquidation Event.

The Series A Preferred Stock Applicable Percentage is defined as a percentage equal to (a) one hundred twenty-five percent (125%) if an Exit Event, dissolution, liquidation, or winding-up occurs prior to June 7, 2024, (b) one
hundred twenty percent (120%) if an Exit Event, dissolution, liquidation, or winding up occurs after June 7, 2024, but prior to June 7, 2025, (c) one hundred fifteen percent (115%) if an Exit Event, dissolution, liquidation, or winding-up occurs after June 7, 2025, but prior to June 7, 2026, (d) one hundred ten percent (110%) if an Exit Event, dissolution, liquidation, or winding up occurs after June 7, 2026, but prior to June 7, 2027, (e) one hundred five percent (105%) if an Exit Event, dissolution, liquidation, or winding-up occurs after June 7, 2027, but prior to June 7, 2028, (f) one hundred percent (100%) if an Exit Event, dissolution, liquidation, or winding-up occurs after June 7, 2028.

Distributions to Class A and Class A-1 Members

On March 4, 2020, the AON LLC entered into the Second Amended and Restated Limited Liability Agreement (“Second Operating Agreement”) which established another class of equity, Class A-1 Units. The Second Operating Agreement provided, among other things, that the Class A and A-1 Units would receive a cumulative, annually-compounded, preferred return of 8.0% and 4.0%, respectively, on capital contributions when and if distributions are declared by the Board of the Company.

Prior to the issuance of the Class C Units on June 7, 2023 as discussed above, the Class A and A-1 unitholders were paid a cash distribution of $4.0 million and $4.1 million, respectively, representing the cumulative accrued preferred return to June 7, 2023.

On June 7, 2023, in connection with the issuance of the Class C Units, AON LLC entered into the Third Amended and Restated Limited Liability Agreement (“Third Operating Agreement”) which, among other things, eliminated any provisions for future preferred returns on Class A and A-1 units.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Net Loss Per Share
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Net Loss Per Share Net Loss Per Share
The following table sets forth the computation of basic and diluted net loss per share of Class A Common Stock and represents the period from January 1, 2024 to March 31, 2024, the period where the Company had Class A and Class B common stock outstanding. Class B Common Stock does not have economic rights in AON Inc., including rights to dividends or distributions upon liquidation, and as a result, is not considered a participating security for basic and diluted loss per share. As such, basic and diluted loss per share of Class B Common Stock has not been presented. Series A Preferred Stock are considered participating securities for basic and diluted loss per share, but do not participate in losses. As such, basic and diluted loss per share is computed using the two-class method. For additional information, see Notes 1 and 2.

Basic loss per share is based on the weighted-average number of shares of Class A Common Stock outstanding during the period. Diluted loss per share is based on the weighted-average number of shares of Class A Common Stock used for the basic loss per share calculation, adjusted for the dilutive effect of Public and Private Warrants, Restricted Stock Units, and Sponsor Earnouts, if any, using the “treasury stock” method and the convertible Series A Preferred Stock, Class B Common Stock, and Class B Prefunded Warrants, if any, using the “if-converted” method. Net loss for diluted loss per share is adjusted for the Company’s share of AON LLC’s consolidated net loss, net of AON Inc. taxes, after giving effect to Class B Common Stock and Class B Prefunded Warrants that are exchanged into potential shares of Class A Common Stock, Public and Private Warrants that are liability classified, and Series A Preferred Stock that accrue dividends, to the extent it is dilutive.

Net loss attributable to Class A Common Stockholders for basic and diluted earnings per share$(7,841,000)
Series A Preferred Cumulative Dividends(1,360,180)
Undistributed loss for basic earnings per share$(9,201,180)
Weighted-average shares for basic earnings per share7,527,882 
Basic and Diluted loss per share of Class A Common Stock$(1.22)

The following table details the securities that have been excluded from the calculation of weighted-average shares for diluted loss per share for the period presented as they were anti-dilutive. Note that the Sponsor Earnouts are excluded from the calculation of weighted-average shares for diluted loss per share as the contingency had not been met as of the period end.

Series A Preferred Stock6,651,610 
Class B Common Stock23,725,998 
Class B Prefunded Warrants3,000,245 
Public and Private Warrants14,450,833 
Restricted Stock Units1,470,278 
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Redeemable Noncontrolling Interest
 3 Months Ended
Mar. 31, 2024
Noncontrolling Interest [Abstract]  
Redeemable Noncontrolling Interest Redeemable Noncontrolling Interest
Legacy AON Shareholders own 26,726,243 AON LLC Common Units, equal to a 61.1% of the economic interest in AON LLC. Legacy AON Shareholders also own 23,725,998 shares of Class B Common Stock and 3,000,245 Class B Prefunded Warrants, which, together with the AON LLC Common Units, may be redeemed at the option of the Legacy AON Shareholder on a one-for-one basis for shares of Class A Common Stock or the cash equivalent thereof (based on the market price of the shares of Class A Common Stock at the time of redemption) as determined by New AON. If New AON elects the redemption to be settled in cash, the cash used to settle the redemption must be funded through a private or public offering of Class A Common Stock no later than ten (10) business days after the redemption notice date. Upon the redemption of the AON LLC Common Units and Class B
Common Stock for shares of Class A Common Stock or the equivalent thereof, all redeemed shares of Class B Common Stock will be cancelled. The redemption value is determined based on a five-day volume weighted average price (”VWAP”) of the Class A common shares, subject to customary conversion rate adjustments for share splits, share dividends, and similar events affecting Class A Common Stock.

When applying SEC guidance concerning mezzanine classification, the Company understands that due to the NCI holders having control of the Board, if there is a sequence of remotely possible events that could trigger a redemption, this requires the instrument to be classified as temporary equity, without any regard to probability. Accordingly, though the redemption would require such a remotely possible sequence of events, and such remote sequence of events would also require, in management’s view, the Company to take extraordinary actions in order to allow such sequence of events to be remotely possible, the noncontrolling interest is currently classified as temporary equity. In the event that the Legacy AON Shareholders own less than 50% of the outstanding economic interest in AON LLC Common Units due to future redemptions, the noncontrolling interest will be presented as permanent equity.

The redeemable noncontrolling interest is recognized at the greater of (1) its initial fair value plus accumulated earnings/(losses) associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At March 31, 2024, the redeemable noncontrolling interest was recorded based on its redemption value of $157.7 million which exceeded its carrying value by $15.6 million. This measurement adjustment decreased additional paid in capital by $9.7 million and retained deficit by $5.9 million. At the end of each reporting period, AON LLC equity attributable to AON Inc. and the Legacy AON Shareholders is rebalanced to reflect AON Inc.’s and the Legacy AON Shareholder’s ownership in AON LLC.


The following table summarizes the economic ownership of AON LLC, for the period beginning December 31, 2023 and ending March 31, 2024.

 Period beginning December 31, 2023 and ending March 31, 2024
AON LLC Units
AON Inc.Legacy AON ShareholdersTotal
Beginning of Period13,330,051 28,109,796 41,439,847 
Issuances2,289,181 — 2,289,181 
Repurchases(16,441)— (16,441)
Redemptions 1,383,553 (1,383,553)— 
Total Units Issued16,986,344 26,726,243 43,712,587 
End of Period16,986,344 26,726,243 43,712,587 
Allocation of income to controlling and noncontrolling interests38.9 %61.1 %100 %
Allocation of losses to controlling and noncontrolling interests (1)
23.0 %77.0 %100 %
(1) As discussed in Note 13, Series A Preferred Stock are considered participating securities for basic and diluted loss per share, but do not participate in losses. As a result, the consolidated net loss of AON LLC, during the period of January 1, 2024 through March 31, 2024, were
allocated to the NCI to reflect the absorption of the Legacy AON Shareholders to a portion of the consolidated net loss of AON LLC. Net losses were not attributed to Series A Preferred Stock.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Basis of Presentation and Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of the Company were prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. Management believes the unaudited condensed consolidated financial statements for the interim periods presented contain all necessary adjustments, of a normal recurring nature, to state fairly, in all material respects, the Company’s financial position, results of operations and cash flows for the interim periods presented. These unaudited condensed consolidated financial statements were prepared on the same basis as and should be read in conjunction with such audited consolidated financial statements and related notes thereto of AON Inc. and its wholly-owned subsidiaries, included in the Annual Report on Form 10-K, dated and filed on March 28, 2024 with the SEC (the “Annual Report 2023"). Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results the Company expects for the entire year.

For the three months ended March 31, 2024, these unaudited condensed consolidated financial statements reflect the consolidated results of operations, comprehensive loss, cash flows and changes in equity of AON Inc. and its wholly-owned subsidiaries. The condensed consolidated balance sheet at March 31, 2024 presents the financial condition of AON Inc. and its consolidated subsidiaries.

For the three months ended March 31, 2023, these unaudited condensed consolidated financial statements present the consolidated results of operations, comprehensive loss, cash flows and changes in equity of AON LLC. The condensed consolidated balance sheet as of December 31, 2023 presents the financial condition of AON Inc. and its consolidated subsidiaries after the Reverse Recapitalization. All intercompany balances and transactions of AON LLC have been eliminated.

In accordance with Accounting Standards Codification (“ASC”) Topic 805, Business Combinations, the historical equity of AON LLC has been recasted in all periods up to the Closing Date, to reflect the number of shares of New AON’s Class A Common Stock and Class B Common Stock issued to Legacy AON Shareholders in connection with the Reverse Recapitalization. The Company recasted the units outstanding related to the historical AON LLC Class A, Class A-1, and Class B units prior to the Reverse Recapitalization (“Historical AON LLC Equity”) as common equity of New AON, equal to the Per Company Class Unit Exchange Ratio, pursuant to the Business Combination Agreement.

The Per Company Unit Exchange Ratio at which AON LLC Class A units and Class A-1 units were reclassified is equal to 2,524 AON Common Units. The Per Company Unit Exchange Ratio at which AON LLC Class B units were reclassified varied depending on participation threshold, and is equal to 2,524, 2,453, or 1,976, AON Common Units. The Per Company Unit Exchange Ratio at which Class C units were reclassified is equal to 2,705 AON LLC Series A Preferred Units.

The condensed consolidated financial statements and related notes thereto give effect to the conversion for all periods presented, without any change to par value or per unit amounts. The condensed consolidated financial statements do not necessarily represent the capital structure of New AON had the Reverse Recapitalization occurred in prior periods. The Company has not made retroactive adjustments related to the historical book values of Historical AON LLC Equity as the adjustments were considered immaterial.

For the three months ended March 31, 2024, $7.8 million of the consolidated net loss of AON LLC were attributable to the Class A Common Stockholders, and reflects the Class A Common Stockholders’ absorption of 23.0% of the consolidated net loss of AON LLC. For the three months ended March 31, 2024, $17.2 million of the consolidated net losses of AON LLC were attributable to noncontrolling interest, and reflects the Legacy AON Stockholders’ absorption of 77.0% of the consolidated net losses of AON LLC.
For the three months ended March 31, 2023, $1.5 million of the consolidated net losses of AON LLC were attributable to the Legacy AON Stockholders, to reflect their absorption of 100% of the consolidated net losses of AON LLC pertaining to the days prior to the Reverse Recapitalization.
Principles of Consolidation
Principles of Consolidation
For the period of January 1, 2024 through March 31, 2024, the condensed consolidated financial statements include the accounts of the Company, American Oncology Network, LLC (“AON LLC”), and its wholly owned subsidiary American Oncology Management Company, LLC (“AOMC”), and its consolidated variable interest entities (“VIEs”) American Oncology Partners, P.A. (“AON Partners”), American Oncology Partners of Maryland, P.A. (“Partners of Maryland”), AON Central Services, LLC (“AON Central Services”), and Meaningful Insights Biotech Analytics, LLC (“MIBA”). All intercompany accounts and transactions between the entities have been eliminated in consolidation.

The accounting treatment of the Business Combination was a Reverse Recapitalization.

For the periods prior to the Reverse Recapitalization, the consolidated financial statements of the Company comprise the accounts of AON LLC and its wholly-owned subsidiaries. All intercompany accounts and transactions among AON LLC and its consolidated subsidiaries were eliminated.
The Company accounts for American Oncology Network, LLC, AON Partners, Partners of Maryland, AON Central Services, and MIBA in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810, Consolidations. The Company determines whether it has a controlling financial interest in an entity by first evaluating whether the entity is a VIE. A VIE is broadly defined as an entity that has any of the following three characteristics: (i) the equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (ii) substantially all of the entity’s activities either involve or are conducted on behalf of an investor that has disproportionately few voting rights; or (iii) the equity investors as a group lack any of the following, the power through voting or similar rights to direct the activities of the entity that most significantly impact the entity’s economic performance, the obligation to absorb the expected losses of the entity, or the right to receive the expected residual returns of the entity. The Company consolidates a VIE if it has both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and an obligation to absorb losses or the right to receive benefits that could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively, if any.

AON LLC has contractual relationships with AON Partners, Partners of Maryland and AON Central Services and the physician owners through management service agreements (“MSAs”) and other contractual agreements to provide all practice management services outside of medical services provided by the physicians. In addition, despite not being required by the contractual relationships, AON LLC regularly provides funding to support AON Partners and Partners of Maryland’s operations and acquisitions of physician practices. AON Central Services was formed July 15, 2022 and, effective January 1, 2023, entered into an agreement with AOMC to provide qualified non-clinical and non-medical employees to AOMC to support the operation of the physician practices. MIBA was established during the first quarter of 2023 for the purpose of developing intellectual property to synergize the collection, de-identification, and dissemination of the Company’s patient data for sale to external parties for research, development, and clinical decisions. In May 2023, the Company contributed $0.2 million for a 56% interest in the equity of MIBA. As of March 31, 2024, MIBA had no significant operating activity. The Company concluded that AON LLC had a controlling financial interest in MIBA and has consolidated the entity at March 31, 2024 and recorded the noncontrolling interest in equity. 
The Company has concluded that AON Partners, Partners of Maryland, AON Central Services, and MIBA are all VIEs in which AON LLC has the characteristics of a controlling financial interest and is deemed to be the primary beneficiary. The variable interest subjects AON LLC to all potential losses in the entities and, therefore, requires AON LLC, and in turn AON Inc., to consolidate the results of AON Partners, Partners of Maryland, AON Central Services, and MIBA in its condensed consolidated financial statements.
Accounting Estimates and Assumptions
Accounting Estimates and Assumptions
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.
Segments
Segments
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (the “CODM”). The Company’s CODM is its chief executive officer who reviews financial information together with certain operating metrics principally to make decisions about how to allocate resources and to measure the Company’s performance. The Company has one operating segment and one reportable segment that are structured around the organizational management of oncology practice operations. All revenue and assets are in the United States.
Revenue Recognition
Revenue Recognition
Revenue is recognized under Accounting Standards Update (“ASU”) 2014-09 Revenue from Contracts with Customers (“Topic 606”). The Company determines the transaction price based upon standard charges for goods and services with anticipated consideration due from patients, third-party payors (including health insurers and government agencies) and others. The Company’s revenue is primarily derived from patient service revenues, which encompass oncology services provided during patient visits and shipments of pharmacy prescriptions. Performance obligations for the Company’s services provided to patients and most procedures, are satisfied over the time of visit which is the same day services are performed. Performance obligations relating to pharmacy revenue are considered fully satisfied at a point in time upon the customer receiving delivery of the prescription. Accordingly, the Company does not anticipate a significant amount of revenue from performance obligations satisfied (or partially satisfied) in previous periods, and any such revenue recognized during the three month periods ended March 31, 2024 and 2023 was immaterial. Additionally, the Company does not expect to recognize material revenue in the future related to performance obligations that are unsatisfied (or partially satisfied) as of March 31, 2024 and December 31, 2023. Approximately $246.1 million and $214.3 million and of the Company’s revenues are generated from services performed during patient visits with the remainder primarily generated from shipments of pharmacy prescriptions for the three month periods ended March 31, 2024 and 2023, respectively.
As services are performed and prescriptions are shipped, timely billing occurs for services rendered and prescriptions shipped less discounts provided to uninsured patients and contractual adjustments to third-party payors based upon prospectively determined rates and discounted charges. Payment is requested at the time of service for self-paying patients and for patients covered by third-party payors that are responsible for paying deductibles and coinsurance.
The Company monitors revenue and receivables to prepare estimated contractual allowances for the anticipated differences between billed and reimbursed amounts. Payments from third-party payors and Government programs including Medicare and Medicaid may be subject to audit and other retrospective adjustments. Such amounts are considered on an estimated basis when net patient revenue is recorded and are adjusted as final adjustments are determined. For the three month periods ended March 31, 2024 and 2023, such resulting historic adjustments have been immaterial to the condensed consolidated financial statements. 
In assessing who is the principal in providing patient services and pharmacy prescriptions, the Company considered who controls the provision of services and prescriptions. The Company has determined they are acting as a principal in these relationships. 
In April 2022, the Company entered into a long-term arrangement to sponsor and manage a clinical trial. The Company subsequently contracted with a third-party to provide the clinical research services and is the principal in this arrangement. The performance of clinical research services are considered a single performance obligation because the Company provides a highly-integrated service. Revenue is recognized for the single performance obligation over time due to the Company’s right to payment for work performed to date. The contract provides for invoices based on predetermined milestones. 

The Company uses the cost-to-cost measure of progress for the Company’s contract because it best depicts the transfer of control to the customer as the performance obligation is fulfilled. For this method, the Company
compares the contract costs incurred to date to the estimated total contract costs through completion. As part of the client proposal and contract negotiation process, the Company develops a detailed project budget for the direct costs and reimbursable costs based on the scope of the work, the complexity of the study, the geographical location involved and the Company’s historical experience. The estimated total contract costs at the project level are reviewed and revised periodically throughout the life of the contract, with adjustments to revenue resulting from such revisions being recorded on a cumulative basis in the period in which the revisions are identified. Contract costs consist primarily of direct labor and other reimbursable project-related costs such as travel, third-party vendor costs and investigator fees. The Company establishes pricing based on the Company’s internal pricing guidelines, discount agreements, if any, and negotiations with the client. The transaction price is the contractually defined amount. Revenue related to the clinical trial, which is included within other revenue, was $0.5 million and $0 million for the three months ended March 31, 2024 and 2023, respectively. 
The Company has a system and estimation process for recording Medicare net patient service revenue and estimated recoupments as it relates to value-based care (“VBC”) revenue included in patient service revenue in the condensed consolidated statements of operations and comprehensive loss. The Company’s VBC revenue is primarily generated through its participation in the CMS Oncology Care Model (“OCM”) which is an episode-based payment model to promote high-quality cancer care. Participants enter six-month episode periods, and the Company bills a monthly fee during the six-month period based on a fixed rate per participant per month and the total number of participants. Certain quality and compliance metrics are tracked as part of the program and submitted to CMS at the end of the episode period which may result in recoupment of funds. The Company estimates the recoupment amount by developing a recoupment percentage for each period based on historical known recoupment from CMS and applies the recoupment percentage against total fees for the period. Based on the estimate, the Company accrues a liability representing the expected final recoupments based on historical settlement trends.
Short-term Marketable Securities
Short-term Marketable Securities 
Investments in marketable securities consist of corporate bonds and U.S. Treasury securities.
Management determines the appropriate classification of investments at the time of purchase and reevaluates such determination at each balance sheet date. Marketable securities are classified as available-for-sale and are carried at fair value in the consolidated balance sheets. The marketable securities are classified as short-term based on management’s intent to convert such securities within one year and the ability to convert them within two to three days.
Certain of our available-for-sale securities are debt securities. For an available-for-sale debt security with an amortized cost that exceeds its fair value, the Company first determines if it intends to sell or will more-likely-than-not be required to sell the security before the expected recovery of its amortized cost. If it intends to sell or will more-likely-than-not be required to sell the security, then the Company recognizes the impairment as a credit loss in the condensed consolidated statements of operations and comprehensive loss by writing down the security’s amortized cost to its fair value. If it does not intend to sell or it is not more-likely-than-not that it will be required to sell the security before the expected recovery of its amortized cost, the Company recognizes the portion of the impairment that is due to a credit loss, if any, in the condensed consolidated statements of operations and comprehensive loss through an allowance. The portion of the impairment that is due to factors other than a credit loss is recognized in other comprehensive income (loss) in the condensed consolidated statements of operations and comprehensive loss as an unrealized loss.
Equity Investment in Affiliate
Equity Investment in Affiliate
In January 2023, the Company contributed noncash consideration, with a fair value of approximately $2.3 million, in return for a 49% equity interest in OCP Management Arizona, LLP. Investments in entities over which the Company has the ability to exercise significant influence but does not control the entity are accounted for using the equity method. Equity method investments are included with other assets in the condensed consolidated balance sheets. The carrying amount of the investment is adjusted to reflect the Company’s proportionate share of the net earnings or losses and reduced by any dividends received. The Company’s share of income or loss related to this investment is reported as an equity in loss of affiliate in the condensed consolidated statements of operations and comprehensive loss.
Noncontrolling Interests
Noncontrolling Interests
The Company consolidates the results of entities in which it has a controlling financial interest. Refer to Note 15 for additional considerations and presentation for noncontrolling interest.
Mezzanine Equity and Treasury Stock
Mezzanine Equity

New AON Series A Preferred Stock is redeemable for cash or the value of the property, rights or securities to be paid or distributed in the event of a Deemed Liquidation Event (which is outside of the Company’s control). As a result, Management has determined that the New AON Series A Preferred Stock should be classified as mezzanine equity. As of March 31, 2024, the Preferred Stock are recorded at their initial carrying value, net of offering costs of $0.8 million. The Series A Preferred Stock are not being accreted to redemption value, as the redemption is not probable. The Series A Preferred Stock are classified outside of members’ equity on the consolidated balance sheets. Refer to Note 14 for mezzanine equity presentation considerations for redeemable noncontrolling interest.
Treasury Stock

We account for treasury stock purchased under the cost method and include treasury stock as a component of
accumulated paid in capital. Treasury stock purchased with intent to retire (whether or not the retirement is actually accomplished) is charged to common stock. The company repurchased 14,729 shares of class A common stock at the spot rate as of each transaction date for a total cost of less than $0.1 million for the year ended December 31, 2023. For the three months ended March 31, 2024 the Company repurchased an additional 16,441 shares of class A common stock at the spot rate as of each transaction date for a total cost of less than $0.1 million. To date, the Company has repurchased a total of 31,170 shares.
Equity-Based Compensation
Equity-Based Compensation

The Company issues stock-based awards to employees and directors in the form of stock options and restricted stock units. The Company measures and recognizes compensation expense for its stock-based awards granted to its employees and directors based on the estimated grant date fair value in accordance with ASC 718, Compensation-Stock Compensation, and determines the fair value of restricted stock units based on the fair value of its common stock. The Company measures all share-based options granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. Compensation expense of those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company records the expense for awards with service-based conditions using the straight-line method over the requisite service period, net of any actual forfeitures. The Company classifies share-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified.
Business Combinations
Business Combinations
The Company evaluates acquired practices in accordance with ASU 2017-01, Business Combinations (Topic 805)-Clarifying the Definition of a Business. This standard clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. Because substantially all of the value of each acquired practice did not relate to a similar group of assets and as each acquired practice contained both inputs and processes necessary to provide economic benefits to the Company, it was determined that each acquisition represents a business combination. Therefore, the transactions have been accounted for using the acquisition method of accounting, which requires, with limited exceptions, that assets acquired, and liabilities assumed be recognized at their estimated fair values as of the acquisition date. Any excess of the consideration transferred over the estimated fair values of the net assets acquired is recorded as goodwill. Transaction costs related to business combinations are expensed in the period in which they are incurred.
Offering Costs
Offering Costs
The Company defers specific incremental costs directly attributable to proposed offerings of securities. These costs consist of legal, accounting, and other similar expenses incurred through the balance sheet date that are directly related to a potential offering. If the offering is completed, these costs will be charged against the gross proceeds of the offering. These offering costs will be allocated to the separable financial instruments issued in the transaction on a relative fair value basis of the securities issued, compared to total proceeds received. Offering costs associated
with any instruments classified as liabilities will be expensed as incurred, presented as non-operating expenses in the condensed consolidated statement of operations and comprehensive loss.
Professional Liability
Professional Liability
The Company maintains insurance policies for exposure to professional malpractice insurance risk. The limits of malpractice insurance provide each physician/advanced practice provider with a dedicated $1.0 million limit per claim and a $3.0 million limit in the aggregate per policy period – on a first dollar basis, as no deductible applies. The policy further then extends coverage to the Company, by providing a $2.0 million limit per claim and a $4.0 million limit in the aggregate per policy period - on a first dollar basis, additionally, as no deductible applies. Reserves are established for estimates of the loss that will ultimately be incurred on claims that have been reported but not paid and claims that have been incurred but not reported. These reserves are established based on consultation with a third-party actuary. The actuarial valuations consider a number of factors, including historical claims payment patterns, changes in case reserves and the assumed rate of increase in healthcare costs. Management believes the use of actuarial methods to account for these reserves provides a consistent and effective way to measure these subjective accruals. However, due to the sensitive nature of this estimation technique, recorded reserves could differ from ultimate costs related to these claims due to changes in claims reporting, claims payment and settlement practices and differences in assumed future cost increases. Accrued unpaid claims and expenses that are expected to be paid within the next twelve months are classified as current liabilities and included in accrued other. All other accrued unpaid claims and expenses are classified as long-term liabilities and included in other long-term liabilities. Insurance recoveries associated with the unpaid claims are classified as long-term assets included in other assets.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
Fair value is the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.
Accounting guidance establishes a three-level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:
Level 1Inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market.
Level 2Inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model-derived valuations in which all significant inputs are observable for substantially the full term of the asset or liability.
Level 3Inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. 
Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement of assets and liabilities being measured within the fair value hierarchy.
Our financial instruments include cash, short-term marketable securities, accounts receivable, notes receivable, accounts payable, accrued expenses, long-term debt and contractual agreements that resulted in derivative liabilities. Our nonfinancial assets such as property and equipment are not measured at fair value on a recurring basis; however, they are subject to fair value adjustments in certain circumstances, such as when there is evidence that impairment may exist.
The carrying amounts of cash, accounts receivable, accounts payable, notes receivable, and accrued expenses approximate their fair value because of the short-term maturity and highly liquid nature of these instruments. We
determine the fair value of long-term debt and marketable securities based on various factors including maturity schedules and current market rates.
Warrant Liabilities
Warrant Liabilities

Upon Closing of the Business Combination, on September 20, 2023, the Company evaluated the Public Warrants and Private Placement Warrants and the Class B Prefunded Warrants, collectively referred to herein as “Warrants”, in accordance with ASC 815-40, “Derivatives and Hedging —- Contracts in Entity’s Own Equity”, and concluded that a provision in the warrant agreements related to potential net cash settlement of the warrants upon an exchange or tender offer that may not result in a change in control of the entity precludes the warrants from being accounted for as components of equity. As the Warrants meet the definition of a derivative as contemplated in ASC 815, the Warrants are recorded as current liabilities within accrued other on the condensed consolidated balance sheets and measured at fair value at inception and at each reporting date in accordance with ASC 820, “Fair Value Measurement”, with changes in fair value recognized in other income (expense), net on the condensed consolidated statements of operations and comprehensive loss in the period of change.

As of March 31, 2024, the Public Warrants were trading separately from the Class A Common Stock and the quoted market price was used to establish fair value. As such, the Public Warrants fair value was determined using a Level 1 input. The fair value of the Public Warrants as of March 31, 2024 is $2.8 million and recorded in other long-term liabilities on the condensed consolidated balance sheets.

Management has utilized the public warrant price to value the private warrants and believes the public and private warrants have materially consistent fair values given the existence of the make-whole redemption feature. As of March 31, 2024, a valuation of the private warrants was performed which confirmed the private warrant value was materially consistent with the public warrants. The details of this valuation are included in the paragraph below.

The fair value of the Private Placement warrants was determined using Level 3 inputs. As of March 31, 2024, the fair value of the Private Placement Warrants was estimated to be $2.1 million and recorded in other long-term liabilities on the condensed consolidated balance sheets. The fair value was estimated at March 31, 2024, using the Black-Scholes Option Pricing model using the following assumptions:
Expected annual dividend yield – 0.0%
                Expected volatility – 26.40%
                Risk-free rate of return – 4.31%
                Expected Option Term – 5.0 years
                
The AON Class B Prefunded Warrants are exercisable into one share of New AON Class B Common Stock. A share of New AON Class B Common Stock, together with an AON LLC Common Unit, may be exchanged for one share of New AON Class A Common Stock. Considering New AON Class B Common Stock has no economic rights and limited liquidity or value if the holder does not also possess an AON LLC Common Unit, and because the AON Class B Prefunded Warrants are exercisable into New AON Class B Common Stock, the Company has estimated fair value of the Class B Prefunded Warrants to be immaterial.
Earnings Per Share
Earnings Per Share

The Company recast Historical AON LLC Equity as AON Inc. common equity for all periods prior to the Reverse Recapitalization, refer to Note 2. However, as 100% of the net losses of AON LLC prior to the Reverse Recapitalization were absorbed by the Legacy AON Shareholders, basic and diluted earnings (loss) per share is zero for the three months ended March 31, 2023. Basic and diluted earnings (loss) per share for the three months ended March 31, 2024 represents the period where the Company had earnings (loss) attributable to Class A Common Stockholders. Class B Common Stock does not have economic rights in AON Inc., including rights to dividends or distributions upon liquidation, and as a result, is not considered a participating security for basic and diluted earnings (loss) per share. As such, basic and diluted earnings (loss) per share of Class B Common Stock has not been presented.
The Company has issued and outstanding Sponsor Earnouts, which are subject to forfeiture if the achievement of certain stock price thresholds are not met. In accordance with ASC Topic 260, “Earnings Per Share,” the Sponsor Earnouts are excluded from weighted-average shares outstanding to calculate basic earnings (loss) per share as they are considered contingently issuable shares due to their potential forfeiture. Sponsor Earnouts will be included in weighted-average shares outstanding to calculate basic earnings (loss) per share as of the date of their stock price thresholds are met and they are no longer subject to forfeiture.

Basic and diluted earnings (loss) per share is computed by use of the two-class method as a result of outstanding Series A Preferred Stock, which accrue dividends at the annual rate of 8% of the original price per share, participate with common stock on all other dividends, and accordingly have participation rights in undistributed earnings as if all such earnings had been distributed during the period (see Note 12). Under such method income available to common shareholders is computed by deducting both dividends declared or, if not declared, accumulated on Series A Preferred Stock from net income. Loss attributable to common shareholders is computed by increasing net loss by such dividends. Since the participating Series A Preferred Stock has no contractual obligation to share in the losses of the Company, there is no loss allocation between Class A Common Stock and Series A Preferred Stock.

Basic earnings (loss) per share is based on the weighted-average number of shares of Class A Common Stock outstanding during the period. Diluted earnings (loss) per share is based on the weighted-average number of shares of Class A Common Stock used for the basic earnings (loss) per share calculation, adjusted for the dilutive effect of the Public and Private Warrants and Sponsor Earnout, if any, using the “treasury stock” method and the convertible Series A Preferred Stock and, exchangeable Class B Common Stock and Class B Prefunded Warrants, if any, using the “if-converted” method. Net earnings (loss) for diluted loss per share is adjusted for the Company’s share of AON LLC’s consolidated net earnings (loss), net of AON Inc. taxes, after giving effect to the Class B Common Stock and Class B Prefunded Warrants that are exchanged into potential shares of Class A Common Stock, Public and Private Warrants that are liability classified, and Series A Preferred Stock, to the extent it is dilutive.
Recently Adopted Accounting Pronouncements  and Recently Issued Accounting Pronouncements
Recently Adopted Accounting Pronouncements 
In June 2016, the FASB issued ASU 2016-13, ‘‘Financial instruments-Credit Losses’’ (“ASU 2016- 13”). ASU 2016-13 requires entities to report ‘‘expected’’ credit losses on financial instruments and other commitments to extend credit rather than the current ‘‘incurred loss’’ model. These expected credit losses for financial assets held at the reporting date are to be based on historical experience, current conditions, and reasonable and supportable forecasts. This ASU will also require enhanced disclosures relating to significant estimates and judgments used in estimating credit losses, as well as the credit quality. ASU 2016-13 is effective for the Company for annual reporting periods beginning after December 15, 2022. ASU 2016-13 was adopted by the Company effective January 1, 2023, with no material impact on the Company’s consolidated financial statements and related disclosures. 
In October 2021, the FASB issued ASU 2021-08, “Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers”, which provides that an acquirer must recognize, and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606. The guidance is effective for the Company for annual reporting periods beginning after December 15, 2023, with early adoption permitted. The adoption of this standard as of January 1, 2024, did not have a material impact on the Company’s consolidated financial statements and related disclosures.
Recently Issued Accounting Pronouncements

In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” The amendments in this update are intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses. The ASU requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker, a description of other segment items by reportable segment, and any additional measures of a segment's profit or loss used by the chief operating decision maker when deciding how to allocate resources. The ASU also requires all annual disclosures currently required by Topic 280, “Segment Reporting,” to be included in interim periods. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and retrospective application is required for all
periods presented. The Company is evaluating the impact this will have on the Company's consolidated financial statements and related disclosures.

In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” The amendments in this upgrade enhance the transparency and decision usefulness of income tax disclosures. This ASU requires disclosures of specific categories and disaggregation of information in the rate reconciliation table. The ASU also requires disclosure of disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit, and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December 15, 2024. Early adoption is permitted and the amendments should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating the effect that ASU 2023-09 will have on its disclosures.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Business (Tables)
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Affiliation Agreements During the three months ended March 31, 2024 and 2023, the Company entered into affiliation agreements with or acquired the following oncology practices.
Three Months Ended March 31, 2024Three Months Ended March 31, 2023
StateState
Maryland (a)
Texas (a)
(a)The Company entered into affiliation agreements with the physicians for these respective practices. The Company evaluated each of the affiliation agreements and determined that the transactions did not represent a business combination.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Reverse Recapitalization (Tables)
 3 Months Ended
Mar. 31, 2024
Reverse Recapitalization [Abstract]  
Schedule of Reverse Recapitalization
The following table provides the historical cost of assets and liabilities of AON Inc. as of September 20, 2023.

As of September 20, 2023
Cash and Cash Equivalents$1,493 
Current Liabilities(13,295)
Long Term Liabilities(6,791)
Total Net Liabilities$(18,593)
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Variable Interest Entities (Tables)
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Variable Interest Entities
The assets of AON Partners, Partners of Maryland, AON Central Services, and MIBA as of March 31, 2024 and December 31, 2023, are as follows:
As of March 31,
2024		As of December 31,
2023
Assets
Cash and cash equivalents$75,796 $26,574 
Accounts receivable132,300 129,151 
Inventories44,288 44,569 
Prepaid expenses and other current assets1,157 895 
Goodwill and intangibles, net180 180 
Other receivables34,297 33,809 
Other assets7,880 2,091 
Total assets$295,898 $237,269 
The liabilities of AON Partners, Partners of Maryland, AON Central Services, and MIBA as of March 31, 2024 and December 31, 2023, are as follows:
As of March 31,
2024		As of December 31,
2023
Liabilities
Accounts payable$184,314 $122,324 
Accrued compensation and benefits25,713 21,380 
Accrued other14,972 16,723 
Other long-term liabilities1,078 273 
Due to AON LLC and subsidiaries, net107,144 117,194 
Total liabilities$333,221 $277,894 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Marketable Securities (Tables)
 3 Months Ended
Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]  
Debt Securities, Available-for-Sale
The following table summarizes the Company’s marketable securities financial assets that are measured at fair value on a recurring basis:
As of March 31, 2024
Amortized
Cost		Gross Unrealized
Gains		Gross Unrealized
Losses		Estimated Fair
Value
Cash equivalents (1)
Level 1:
Overnight repurchase agreements (2)$73,938 $- $- $73,938 
Money market funds529 - - 529 
U.S. Treasury Bills993 - - 993 
Level 1 total$75,460 $— $— $75,460 
Marketable securities
Level 2:
Corporate bonds14,267 172 (3)14,436 
U.S. Treasury securities15,467 205 (4)15,668 
Level 2 total29,734 377 (7)30,104 
Total$105,194 $377 $(7)$105,564 
As of December 31, 2023
Amortized
Cost		Gross Unrealized
Gains		Gross Unrealized
Losses		Estimated Fair
Value
Cash equivalents (1)
Level 1:
Overnight repurchase agreements (2)$28,593 $- $- $28,593 
Money market funds$723 $- $- $723 
Level 1 total29,316 — — 29,316 
Marketable securities
Level 2:
Corporate bonds13,678 191 (9)13,860 
U.S. Treasury securities21,318 211 21,529 
Level 2 total34,996 402 (9)35,389 
Total$64,312 $402 $(9)$64,705 
(1)Included in cash and cash equivalents in the consolidated balance sheets at March 31, 2024 and December 31, 2023.
(2)Cash equivalents as of March 31, 2024 included U.S. Treasury Bills with an initial maturity of 3 months or less and overnight repurchase agreements in which cash from the Company's main operating checking account is invested overnight in highly liquid, short-term investments sponsored by a large financial institution. The company had overnight repurchase agreements as of March 31, 2024 and December 31, 2023.
The fair value of the Company’s marketable securities as of March 31, 2024, by remaining contractual maturities, were as follows:
Corporate BondsU.S. TreasuriesTotal
Due in one year or less$5,886 $11,972 $17,858 
Due in one to five years8,550 3,696 12,246 
Total$14,436 $15,668 $30,104 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Supplemental Condensed Balance Sheet Information (Tables)
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Other Receivables
Other receivables consisted of the following at March 31, 2024 and December 31, 2023:
As of March 31,
2024		As of December 31,
2023
Rebates receivable$34,112 $33,708 
Other687 566 
Total other receivables$34,799 $34,274 
Schedule of Inventory
Inventory consisted of the following at March 31, 2024 and December 31, 2023:
As of March 31,
2024		As of December 31, 2023
Intravenous drugs$33,972 $32,388 
Oral pharmaceuticals10,316 12,181 
Total inventories$44,288 $44,569 
Schedule of Property and Equipment, net
Property and equipment, net consisted of the following at March 31, 2024 and December 31, 2023:
As of March 31,
2024		As of December 31,
2023
Leasehold improvements$33,985 $32,490 
Furniture, fixtures and equipment2,750 2,607 
Medical equipment16,310 15,666 
Computer equipment3,395 3,285 
Signs176 153 
Automobiles110 59 
Software9,231 7,829 
Construction-in-progress1,847 2,985 
Property and equipment, gross67,804 65,074 
Accumulated depreciation and amortization(26,807)(24,635)
Property and equipment, net$40,997 $40,439 
Schedule of Other Accrued Liabilities, Current
Accrued other consisted of the following at March 31, 2024 and December 31, 2023:
As of March 31,
2024		As of December 31,
2023
Refund liability$12,879 $15,078 
Warrant liability4,913 - 
Excise taxes payable2,700 2,700 
Current portion of finance lease liabilities1,205 1,189 
Other3,489 3,360 
Total accrued other$25,186 $22,327 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Long-term Debt (Tables)
 3 Months Ended
Mar. 31, 2024
Debt Disclosure [Abstract]  
Schedule of Long-Term Debt Instruments
Debt consisted of the following at March 31, 2024 and December 31, 2023: 
As of March 31,
2024		As of December 31, 2023
PNC Facility$81,250 $81,250 
Total81,250 81,250 
Unamortized debt issuance costs(394)(609)
Total debt$80,856 $80,641 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Leases (Tables)
 3 Months Ended
Mar. 31, 2024
Leases [Abstract]  
Lessee, Assets And Liabilities
Right-of-use assets and lease liabilities consist of the following at March 31, 2024 and December 31, 2023:
As of March 31,
2024		As of December 31,
2023
Assets
Operating lease right-of-use assets, net$43,358 $43,349 
Finance lease right-of-use assets, net (included in property and equipment, net)5,513 5,794 
Total right-of-use assets$48,871 $49,143 
Liabilities
Current
Current portion of operating lease liabilities$6,715 $6,692 
Current portion of finance lease liabilities (included in accrued other)1,205 1,189 
Long-term7,920 7,881 
Long-term operating lease liabilities39,786 39,803 
Long-term finance lease liabilities (included in other long-term liabilities)4,239 4,548 
Total lease liabilities$51,945 $52,232 
Lease, Cost
The components of lease costs recognized in the condensed consolidated statements of operations and comprehensive loss consist of the following for the three month periods ended March 31, 2024 and 2023 and are included in selling, general, and administrative expenses unless otherwise noted:
Three Months Ended March 31,
20242023
Operating lease costs$2,795 $2,870 
Finance lease costs
Amortization of finance lease right-of-use assets281110
Interest on finance lease liabilities (included in interest expense)8617
Variable lease costs586578
Total lease costs$3,748 $3,575 
The cash paid for amounts included in the measurement of lease liabilities for the three months ended March 31, 2024 and 2023 is as follows:
Three Months Ended
March 31,
20242023
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases$2,799 $2,845 
Operating cash flows from finance leases86 17 
Financing cash flows from finance leases291 105 
ROU assets obtained in exchange for new operating lease liabilities2,048 4,326 
Lessee, Operating Lease, Liability, to be Paid, Maturity
The following table reconciles the undiscounted cash flows expected to be paid in each of the next five years and thereafter recorded in the condensed consolidated balance sheets for operating and finance leases as of March 31, 2024:
Operating
Leases		Finance
Leases
2024 (remainder of year after March 31, 2024)$6,959 $1,132 
202510,014 1,487 
20269,620 1,249 
20278,370 1,185 
20286,271 948 
Thereafter19,147 261 
Total lease payments60,381 6,262 
Less: amount representing interest(13,880)(818)
Present value of lease liabilities46,501 5,444 
Less: current portion of lease liabilities(6,715)(1,205)
Long-term lease liabilities, net of current portion$39,786 $4,239 
Finance Lease, Liability, to be Paid, Maturity
The following table reconciles the undiscounted cash flows expected to be paid in each of the next five years and thereafter recorded in the condensed consolidated balance sheets for operating and finance leases as of March 31, 2024:
Operating
Leases		Finance
Leases
2024 (remainder of year after March 31, 2024)$6,959 $1,132 
202510,014 1,487 
20269,620 1,249 
20278,370 1,185 
20286,271 948 
Thereafter19,147 261 
Total lease payments60,381 6,262 
Less: amount representing interest(13,880)(818)
Present value of lease liabilities46,501 5,444 
Less: current portion of lease liabilities(6,715)(1,205)
Long-term lease liabilities, net of current portion$39,786 $4,239 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Related Parties (Tables)
 3 Months Ended
Mar. 31, 2024
Related Party Transactions [Abstract]  
Schedule of Related Party Transactions
As of March 31,
2024		As of
December 31,
2023		Original
Principal		Issue
Date		Maturity
Date
Notes receivable
Note 2$656 $656 $5,355 5/1/20194/30/2024
Note 3- 17 491 6/1/20195/31/2024
Note 81,999 2,081 2,816 5/1/20205/1/2025
Total notes receivables2,655 2,754 
Less:  Current portion of notes receivable$(2,498)(1,604)
Notes receivable, less current portion$157 $1,150 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Equity-Based Compensation (Tables)
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of RSU Activity
A summary of the RSU activity during the three month period ending March 31, 2024 is as follows:

Restricted Stock UnitsWeighted Average Grant Date Fair Value
Outstanding as of December 31, 2023— $— 
Granted3,759,459 $5.73 
Vested(2,289,181)$5.80 
Forfeited— $— 
Outstanding as of March 31, 20241,470,278 $5.67 
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Equity (Tables)
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Schedule of Reverse Recapitalization, Changes in Units
The following table summarizes the changes to AON LLC’s Class A, Class A-1, and Class B Units for the three months ended March 31, 2023.
in thousands, except for share and per share amountsThree Months Ended
March 31, 2023
Class A Units, value
Beginning of Period$7,725 
Issuance of Units— 
Impact of the Reverse Recapitalization— 
End of Period$7,725 
Class A Units, units
Beginning of Period19,495,376 
Issuance of Units— 
Impact of the Reverse Recapitalization— 
End of Period19,495,376 
Class A-1 Units, value
Beginning of Period$28,500 
Issuance of Units— 
Impact of the Reverse Recapitalization— 
End of Period$28,500 
Class A-1 Units, units
Beginning of Period1,842,520 
Issuance of Units— 
Impact of the Reverse Recapitalization— 
End of Period1,842,520 
Class B Units, value
Beginning of Period$80 
Equity based compensation— 
Impact of the Reverse Recapitalization— 
End of Period$80 
Class B Units, units
Beginning of Period4,703,628 
Units Vested— 
Impact of the Reverse Recapitalization— 
End of Period4,703,628 
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Net Loss Per Share (Tables)
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Schedule of Earnings Per Unit Net loss for diluted loss per share is adjusted for the Company’s share of AON LLC’s consolidated net loss, net of AON Inc. taxes, after giving effect to Class B Common Stock and Class B Prefunded Warrants that are exchanged into potential shares of Class A Common Stock, Public and Private Warrants that are liability classified, and Series A Preferred Stock that accrue dividends, to the extent it is dilutive.
Net loss attributable to Class A Common Stockholders for basic and diluted earnings per share$(7,841,000)
Series A Preferred Cumulative Dividends(1,360,180)
Undistributed loss for basic earnings per share$(9,201,180)
Weighted-average shares for basic earnings per share7,527,882 
Basic and Diluted loss per share of Class A Common Stock$(1.22)

The following table details the securities that have been excluded from the calculation of weighted-average shares for diluted loss per share for the period presented as they were anti-dilutive. Note that the Sponsor Earnouts are excluded from the calculation of weighted-average shares for diluted loss per share as the contingency had not been met as of the period end.

Series A Preferred Stock6,651,610 
Class B Common Stock23,725,998 
Class B Prefunded Warrants3,000,245 
Public and Private Warrants14,450,833 
Restricted Stock Units1,470,278 
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Redeemable Noncontrolling Interest (Tables)
 3 Months Ended
Mar. 31, 2024
Noncontrolling Interest [Abstract]  
Schedule of Reverse Recapitalization, Ownership Summary
The following table summarizes the economic ownership of AON LLC, for the period beginning December 31, 2023 and ending March 31, 2024.

 Period beginning December 31, 2023 and ending March 31, 2024
AON LLC Units
AON Inc.Legacy AON ShareholdersTotal
Beginning of Period13,330,051 28,109,796 41,439,847 
Issuances2,289,181 — 2,289,181 
Repurchases(16,441)— (16,441)
Redemptions 1,383,553 (1,383,553)— 
Total Units Issued16,986,344 26,726,243 43,712,587 
End of Period16,986,344 26,726,243 43,712,587 
Allocation of income to controlling and noncontrolling interests38.9 %61.1 %100 %
Allocation of losses to controlling and noncontrolling interests (1)
23.0 %77.0 %100 %
(1) As discussed in Note 13, Series A Preferred Stock are considered participating securities for basic and diluted loss per share, but do not participate in losses. As a result, the consolidated net loss of AON LLC, during the period of January 1, 2024 through March 31, 2024, were
allocated to the NCI to reflect the absorption of the Legacy AON Shareholders to a portion of the consolidated net loss of AON LLC. Net losses were not attributed to Series A Preferred Stock.
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Business (Details)
$ / shares in Units, $ in Millions
 3 Months Ended
Sep. 20, 2023
$ / shares
shares
Mar. 31, 2024
USD ($)
state
practice
$ / shares
shares
Mar. 31, 2023
USD ($)
Dec. 31, 2023
shares
Business Acquisition [Line Items]        
Number of oncology practices | practice   32    
Number of states in which entity operates | state   19    
Reverse recapitalization, equity conversion ratio   1    
Number of securities called by each warrant (in shares)   1    
AON LLC        
Business Acquisition [Line Items]        
Reverse recapitalization costs | $   $ 0.4 $ 1.9  
New AON (AON Inc.)        
Business Acquisition [Line Items]        
Reverse recapitalization costs | $   $ 0.4 $ 1.9  
Common Class A        
Business Acquisition [Line Items]        
Shares issued (in shares) 1,047,343      
Common stock, shares outstanding (in shares)   10,334,734   9,517,816
Series A Preferred Stock        
Business Acquisition [Line Items]        
Stock price (in usd per share) | $ / shares   $ 10.00    
Class B Common Stock        
Business Acquisition [Line Items]        
Common stock, shares outstanding (in shares)   23,725,998   25,109,551
Legacy AON Shareholders | Class B Prefunded Warrants        
Business Acquisition [Line Items]        
Class of warrant outstanding (in shares) 3,000,245      
Legacy AON Shareholders | AON LLC        
Business Acquisition [Line Items]        
Common unit, units outstanding (in units) 28,109,796      
Legacy AON Shareholders | Class B Common Stock        
Business Acquisition [Line Items]        
Common stock, shares outstanding (in shares) 25,109,551      
New AON (AON Inc.) | AON LLC        
Business Acquisition [Line Items]        
Common unit, units outstanding (in units) 9,532,354      
New AON (AON Inc.) | AON LLC | Series A Preferred Stock        
Business Acquisition [Line Items]        
Preferred units, outstanding (in units) 6,651,610      
Digital Transformation Opportunities Corp. (“DTOC”) | Class B Common Stock        
Business Acquisition [Line Items]        
Reverse recapitalization, equity conversion ratio 1      
DTOC Unredeemed Shareholders | Common Class A        
Business Acquisition [Line Items]        
Common stock, shares outstanding (in shares) 147,511      
DTOC Sponsor | Private Placement Warrants        
Business Acquisition [Line Items]        
Class of warrant outstanding (in shares) 6,113,333      
DTOC Sponsor | Public Warrant        
Business Acquisition [Line Items]        
Class of warrant outstanding (in shares) 8,337,500      
Warrant, exercise period, after initial public offering 12 months      
Warrant, exercise period, after business combination 30 days      
Warrant, term (in years) 5 years      
DTOC Sponsor | Common Class A        
Business Acquisition [Line Items]        
Common stock, shares outstanding (in shares) 5,498,125      
Earnout shares not outstanding (in shares) 2,839,375      
Stock price (in usd per share) | $ / shares $ 11.50      
DTOC Sponsor | Common Class A | Public Warrant        
Business Acquisition [Line Items]        
Number of securities called by each warrant (in shares) 1      
AEA Growth Management LP | Series A Preferred Stock        
Business Acquisition [Line Items]        
Shares issued (in shares) 6,651,610      
Common stock, shares outstanding (in shares) 6,651,610      
AON LLC        
Business Acquisition [Line Items]        
Reverse recapitalization, equity conversion ratio 1      
AON LLC | Class B Prefunded Warrants        
Business Acquisition [Line Items]        
Class of warrant outstanding (in shares) 3,000,245      
AON LLC | Common Class A        
Business Acquisition [Line Items]        
Common stock, shares outstanding (in shares) 1,047,343      
AON LLC | Class B Common Stock        
Business Acquisition [Line Items]        
Stock price (in usd per share) | $ / shares $ 0.01      
AON LLC | Class B Common Stock | Class B Prefunded Warrants        
Business Acquisition [Line Items]        
Number of securities called by each warrant (in shares) 1      
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Basis of Presentation and Significant Accounting Policies (Details)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended 15 Months Ended
Sep. 30, 2023
May 31, 2023
USD ($)
Jan. 31, 2023
USD ($)
Mar. 31, 2024
USD ($)
segment
$ / shares
shares
Jun. 30, 2023
USD ($)
Mar. 31, 2023
USD ($)
$ / shares
Dec. 31, 2023
USD ($)
shares
Mar. 31, 2024
USD ($)
shares
Sep. 20, 2023
Description Of Business And Significant Accounting Policies [Line Items]                  
Recapitalization exchange ratio, units | shares       2,524,000       2,524,000  
Net income (loss) attributable to common shareholders       $ (7,800)          
Net loss attributable to redeemable noncontrolling interest       17,163          
Net loss and noncontrolling interest attributable to Legacy AON Stockholders prior to the reverse recapitalization       $ 0   $ 1,486      
Number of operating segments | segment       1          
Number of reportable segments | segment       1          
Revenue       $ 364,339   303,731      
Offering costs       $ 97   $ 0      
Shares repurchased (in shares) | shares       16,441     14,729 31,170  
Cost of shares repurchased (less than)       $ 100     $ 100    
Fair value of warrants       $ 4,913     $ 0 $ 4,913  
Number of securities called by each warrant (in shares) | shares       1       1  
Reverse recapitalization, equity conversion ratio       1       1  
Earnings (loss) per unit, diluted (in usd per share) | $ / shares       $ (1.22)   $ 0      
Earnings (loss) per unit, basic (in usd per share) | $ / shares       $ (1.22)   $ 0      
Accrued dividend rate (in percent)       8.00%          
Participating Threshold, 1                  
Description Of Business And Significant Accounting Policies [Line Items]                  
Recapitalization exchange ratio, units | shares       2,524,000       2,524,000  
Participating Threshold, 2                  
Description Of Business And Significant Accounting Policies [Line Items]                  
Recapitalization exchange ratio, units | shares       2,453,000       2,453,000  
Participating Threshold, 3                  
Description Of Business And Significant Accounting Policies [Line Items]                  
Recapitalization exchange ratio, units | shares       1,976,000       1,976,000  
AON LLC                  
Description Of Business And Significant Accounting Policies [Line Items]                  
Reverse recapitalization, equity conversion ratio                 1
AON LLC | Series A Preferred Stock                  
Description Of Business And Significant Accounting Policies [Line Items]                  
Recapitalization exchange ratio, units | shares       2,705,000       2,705,000  
Preferred Class A                  
Description Of Business And Significant Accounting Policies [Line Items]                  
Offering costs       $ 800          
Accrued dividend rate (in percent)       8.00%          
Public Warrant                  
Description Of Business And Significant Accounting Policies [Line Items]                  
Fair value of warrants       $ 2,800       $ 2,800  
Private Placement Warrants                  
Description Of Business And Significant Accounting Policies [Line Items]                  
Fair value of warrants       $ 2,100       $ 2,100  
Private Placement Warrants | Measurement Input, Expected Dividend Rate                  
Description Of Business And Significant Accounting Policies [Line Items]                  
Warrants, measurement input       0.000       0.000  
Private Placement Warrants | Measurement Input, Price Volatility                  
Description Of Business And Significant Accounting Policies [Line Items]                  
Warrants, measurement input       0.2640       0.2640  
Private Placement Warrants | Measurement Input, Risk Free Interest Rate                  
Description Of Business And Significant Accounting Policies [Line Items]                  
Warrants, measurement input       0.0431       0.0431  
Private Placement Warrants | Measurement Input, Expected Term                  
Description Of Business And Significant Accounting Policies [Line Items]                  
Warrants, measurement input       5       5  
Professional Malpractice Liability Insurance                  
Description Of Business And Significant Accounting Policies [Line Items]                  
Malpractice insurance, limit per policy period       $ 3,000          
Malpractice insurance, coverage per claim       1,000          
Directors and Officers Liability Insurance                  
Description Of Business And Significant Accounting Policies [Line Items]                  
Malpractice insurance, limit per policy period       4,000          
Malpractice insurance, coverage per claim       2,000          
OCP Management Arizona, LLP                  
Description Of Business And Significant Accounting Policies [Line Items]                  
Noncash consideration of equity method investment     $ 2,300            
Equity method investment (in percent)     49.00%            
Patient Visits                  
Description Of Business And Significant Accounting Policies [Line Items]                  
Revenue       246,100   $ 214,300      
Clinical Trials                  
Description Of Business And Significant Accounting Policies [Line Items]                  
Revenue       $ 500   $ 0      
MIBA                  
Description Of Business And Significant Accounting Policies [Line Items]                  
Allocation of income to controlling and noncontrolling interests (in percent)   56.00%              
Payments to acquire interest in subsidiary   $ 200     $ 200        
AON LLC | Legacy AON Shareholders                  
Description Of Business And Significant Accounting Policies [Line Items]                  
Allocation of income to controlling and noncontrolling interests (in percent) 77.00%     61.10%   100.00%      
AON LLC | AON Inc.                  
Description Of Business And Significant Accounting Policies [Line Items]                  
Allocation of income to controlling and noncontrolling interests (in percent)       23.00%          
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Reverse Recapitalization - Narrative (Details)
$ in Thousands
 3 Months Ended
Sep. 30, 2023
USD ($)
Sep. 20, 2023
USD ($)
Mar. 31, 2024
USD ($)
person
Mar. 31, 2023
USD ($)
Restructuring Cost and Reserve [Line Items]        
Gain (Loss) On Reverse Recapitalization     $ 18,200  
Transaction expenses   $ 13,000 $ 352 $ 1,971
Public and Private Warrants        
Restructuring Cost and Reserve [Line Items]        
Gain (loss) on issuance of warrants $ (5,200)      
Fair Value Adjustment of Warrants $ 4,300      
AON Inc.        
Restructuring Cost and Reserve [Line Items]        
Number of board of managers designated by company | person     3  
AON Common Unit        
Restructuring Cost and Reserve [Line Items]        
Number of board of managers designated by majority common unit holders | person     2  
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Reverse Recapitalization - Schedule of Historical Cost (Details)
Sep. 20, 2023
USD ($)
Reverse Recapitalization [Abstract]  
Cash and cash equivalents $ 1,493,000
Current Liabilities (13,295,000)
Long Term Liabilities (6,791,000)
Total Net Liabilities $ (18,593,000)
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Variable Interest Entities - Narrative (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended
May 31, 2023
Mar. 31, 2024
Jun. 30, 2023
AON Central      
Variable Interest Entity [Line Items]      
Ownership interest   20.00%  
MIBA      
Variable Interest Entity [Line Items]      
Payments to acquire interest in subsidiary $ 0.2   $ 0.2
Allocation of income to controlling and noncontrolling interests 56.00%    
MIBA | Variable Interest Entity, Primary Beneficiary      
Variable Interest Entity [Line Items]      
Allocation of income to controlling and noncontrolling interests     56.00%
Physician Owned | AON Central      
Variable Interest Entity [Line Items]      
Ownership interest   80.00%  
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Variable Interest Entities - Schedule of Assets and Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Assets    
Cash and cash equivalents $ 74,944 $ 28,539
Inventories 44,288 44,569
Goodwill and intangibles, net 1,230 1,230
Total assets 421,921 374,453
Liabilities    
Other long-term liabilities 11,342 14,251
Total liabilities 365,813 303,740
Variable Interest Entity, Primary Beneficiary    
Assets    
Cash and cash equivalents 75,796 26,574
Accounts receivable 132,300 129,151
Inventories 44,288 44,569
Prepaid expenses and other current assets 1,157 895
Goodwill and intangibles, net 180 180
Other receivables 34,297 33,809
Other assets 7,880 2,091
Total assets 295,898 237,269
Liabilities    
Accounts payable 184,314 122,324
Accrued compensation and benefits 25,713 21,380
Accrued other 14,972 16,723
Other long-term liabilities 1,078 273
Due to AON LLC and subsidiaries, net 107,144 117,194
Total liabilities $ 333,221 $ 277,894
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Marketable Securities - Schedule of Marketable Securities Measured at Fair Value (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Debt Securities, Available-for-Sale [Line Items]    
Cash and cash equivalents $ 74,944 $ 28,539
Gross Unrealized
Gains 377 402
Gross Unrealized
Losses (7) (9)
Estimated Fair
Value 30,105 35,389
Cash and cash equivalents and available-for-sale securities, amortized cost 105,194 64,312
Cash and cash equivalents and marketable securities, aggregate fair value 105,564 64,705
Level 1    
Debt Securities, Available-for-Sale [Line Items]    
Cash and cash equivalents 75,460 29,316
Cash and cash equivalents, estimated fair value 75,460 29,316
Level 1 | Overnight Repurchase Agreements    
Debt Securities, Available-for-Sale [Line Items]    
Cash and cash equivalents 73,938 28,593
Cash and cash equivalents, estimated fair value 73,938 28,593
Level 1 | Money market funds    
Debt Securities, Available-for-Sale [Line Items]    
Cash and cash equivalents 529 723
Cash and cash equivalents, estimated fair value 529 723
Level 1 | U.S. Treasury securities    
Debt Securities, Available-for-Sale [Line Items]    
Cash and cash equivalents 993  
Cash and cash equivalents, estimated fair value 993  
Level 2    
Debt Securities, Available-for-Sale [Line Items]    
Amortized 
Cost 29,734 34,996
Gross Unrealized
Gains 377 402
Gross Unrealized
Losses (7) (9)
Estimated Fair
Value 30,104 35,389
Level 2 | Corporate bonds    
Debt Securities, Available-for-Sale [Line Items]    
Amortized 
Cost 14,267 13,678
Gross Unrealized
Gains 172 191
Gross Unrealized
Losses (3) (9)
Estimated Fair
Value 14,436 13,860
Level 2 | U.S. Treasury securities    
Debt Securities, Available-for-Sale [Line Items]    
Amortized 
Cost 15,467 21,318
Gross Unrealized
Gains 205 211
Gross Unrealized
Losses (4)
Estimated Fair
Value $ 15,668 $ 21,529
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Marketable Securities - Remaining Contractual Maturities (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]    
Total $ 30,105 $ 35,389
Level 2    
Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]    
Due in one year or less 17,858  
Due in one to five years 12,246  
Total 30,104 35,389
Corporate bonds | Level 2    
Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]    
Due in one year or less 5,886  
Due in one to five years 8,550  
Total 14,436 13,860
U.S. Treasury securities | Level 2    
Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]    
Due in one year or less 11,972  
Due in one to five years 3,696  
Total $ 15,668 $ 21,529
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Supplemental Condensed Balance Sheet Information - Schedule of Other Receivables (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Rebates receivable $ 34,112 $ 33,708
Other 687 566
Other receivables $ 34,799 $ 34,274
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Supplemental Condensed Balance Sheet Information - Schedule of Inventory (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Inventory [Line Items]    
Inventories $ 44,288 $ 44,569
Intravenous drugs    
Inventory [Line Items]    
Inventories 33,972 32,388
Oral pharmaceuticals    
Inventory [Line Items]    
Inventories $ 10,316 $ 12,181
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Supplemental Condensed Balance Sheet Information - Schedule of Property and Equipment, net (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 67,804 $ 65,074
Accumulated depreciation and amortization (26,807) (24,635)
Property and equipment, net 40,997 40,439
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 33,985 32,490
Furniture, fixtures and equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 2,750 2,607
Medical equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 16,310 15,666
Computer equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 3,395 3,285
Signs    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 176 153
Automobiles    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 110 59
Software    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 9,231 7,829
Construction-in-progress    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 1,847 $ 2,985
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Supplemental Condensed Balance Sheet Information - Schedule of Accrued Other (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Refund liability $ 12,879 $ 15,078
Warrant liability 4,913 0
Excise taxes payable 2,700 2,700
Less: current portion of lease liabilities 1,205 1,189
Other 3,489 3,360
Accrued other $ 25,186 $ 22,327
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Accrued other Accrued other
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Long-term Debt - Schedule of Long-term Debt (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Debt Instrument [Line Items]    
Total $ 81,250 $ 81,250
Unamortized debt issuance costs (394) (609)
Total debt 80,856 80,641
PNC Loan Facility | Line of Credit    
Debt Instrument [Line Items]    
Total $ 81,250 $ 81,250
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Long-term Debt - Narrative (Details) - Line of Credit
 1 Months Ended 3 Months Ended 12 Months Ended
Feb. 14, 2022
USD ($)
Apr. 30, 2021
USD ($)
Jun. 30, 2023
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Aug. 15, 2022
USD ($)
Jul. 29, 2021
USD ($)
PNC Loan Facility              
Debt Instrument [Line Items]              
Proceeds from facility   $ 34,600,000          
Maximum borrowing capacity $ 125,000,000 65,000,000         $ 75,000,000
Pledged collateral   10,000,000          
Quarterly collateral released   $ 2,500,000          
Proceeds from lines of credit 16,300,000            
Unamortized debt issuance costs     $ 400,000        
PNC Loan Facility | Debt Instrument, Threshold Limit, Period One              
Debt Instrument [Line Items]              
Minimum funding threshold (in percent)   0.65 0.65        
PNC Loan Facility | Debt Instrument, Threshold Limit, Period Two              
Debt Instrument [Line Items]              
Minimum funding threshold (in percent)   0.75          
PNC Loan Facility | Alternate Base Rate              
Debt Instrument [Line Items]              
Basis spread (in percent)   1.45%          
Revolving Credit Facility | PNC Line of Credit              
Debt Instrument [Line Items]              
Maximum borrowing capacity $ 10,000,000 $ 5,000,000       $ 1,000,000  
Bank fee (in percent)   1.65%          
Unused line fee (in percent)   0.20%          
Proceeds from lines of credit       $ 0 $ 0    
Revolving Credit Facility | PNC Line of Credit | London Interbank Offered Rate (LIBOR) 1              
Debt Instrument [Line Items]              
Basis spread (in percent)   1.65%          
Revolving Credit Facility | PNC Line of Credit | Alternate Base Rate              
Debt Instrument [Line Items]              
Basis spread (in percent)   0.65%          
Revolving Credit Facility | PNC Line of Credit | Bloomberg Short-Term Bank Yield Index              
Debt Instrument [Line Items]              
Basis spread (in percent) 1.65%            
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Income Taxes (Details) - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Tax Disclosure [Abstract]    
Effective income tax rate (in percent) (13.10%) 0.00%
Income tax expense $ 2,894,000 $ 0
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Leases - Right-of-use Assets And Lease Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Assets    
Operating lease right-of-use assets, net [1] $ 43,358 $ 43,349
Finance lease right-of-use assets, net (included in property and equipment, net) 5,513 5,794
Total right-of-use assets 48,871 49,143
Current    
Current portion of operating lease liabilities [2] 6,715 6,692
Current portion of finance lease liabilities (included in accrued other) 1,205 1,189
Current portion of operating and finance lease liabilities 7,920 7,881
Long-term    
Long-term operating lease liabilities [3] 39,786 39,803
Long-term finance lease liabilities (included in other long-term liabilities) 4,239 4,548
Total lease liabilities $ 51,945 $ 52,232
[1] Includes related party operating right-of-use assets, net of $11,293 and $10,931 at March 31, 2024 and December 31, 2023, respectively
[2] Includes related party current portion of operating lease liabilities of $1,971 and $1,888 at March 31, 2024 and December 31, 2023, respectively
[3] Includes related party long-term operating lease liabilities of $9,772 and $9,472 at March 31, 2024 and December 31, 2023, respectively
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Leases - Lease Costs (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Leases [Abstract]    
Operating lease costs $ 2,795 $ 2,870
Amortization of finance lease right-of-use assets 281 110
Interest on finance lease liabilities (included in interest expense) 86 17
Variable lease costs 586 578
Total lease costs $ 3,748 $ 3,575
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Leases - Maturities of Operating and Financing Lease Liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Operating 
Leases    
2024 (remainder of year after March 31, 2024) $ 6,959  
2025 10,014  
2026 9,620  
2027 8,370  
2028 6,271  
Thereafter 19,147  
Total lease payments 60,381  
Less: amount representing interest (13,880)  
Present value of lease liabilities 46,501  
Less: current portion of lease liabilities [1] (6,715) $ (6,692)
Long-term lease liabilities, net of current portion [2] 39,786 39,803
Finance 
Leases    
2024 (remainder of year after March 31, 2024) 1,132  
2025 1,487  
2026 1,249  
2027 1,185  
2028 948  
Thereafter 261  
Total lease payments 6,262  
Less: amount representing interest (818)  
Present value of lease liabilities 5,444  
Less: current portion of lease liabilities (1,205) (1,189)
Long-term lease liabilities, net of current portion $ 4,239 $ 4,548
[1] Includes related party current portion of operating lease liabilities of $1,971 and $1,888 at March 31, 2024 and December 31, 2023, respectively
[2] Includes related party long-term operating lease liabilities of $9,772 and $9,472 at March 31, 2024 and December 31, 2023, respectively
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Leases - Narrative (Details)
Mar. 31, 2024
Dec. 31, 2023
Leases [Abstract]    
Weighted-average remaining lease term for operating leases (in years) 4 years 6 months 14 days 6 years 11 months 4 days
Weighted-average remaining lease term for finance leases (in years) 6 years 10 months 2 days 4 years 9 months 3 days
Weighted-average discount rate for operating leases (in percent) 6.33% 6.64%
Weighted-average discount rate for finance leases (in percent) 6.71% 6.30%
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Leases - Supplemental Cash Flow Information (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash paid for amounts included in the measurement of lease liabilities:    
Operating cash flows from operating leases $ 2,799 $ 2,845
Operating cash flows from finance leases 86 17
Financing cash flows from finance leases 291 105
ROU assets obtained in exchange for new lease liabilities    
ROU assets obtained in exchange for new operating lease liabilities $ 2,048 $ 4,326
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Related Parties - Narrative (Details)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2024
USD ($)
office
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Related Party Transaction [Line Items]      
Notes receivable, amortization period (in months) 60 months    
Incremental borrowing rate 7.09%   7.18%
Payments for operating leases $ 2,799 $ 2,845  
Cost of revenue $ 354,948 278,534  
Related Party      
Related Party Transaction [Line Items]      
Number of offices with operating lease | office 13    
Payments for operating leases $ 700 700  
Cost of revenue 310,877 178,166  
Related Party | Subsidiary Under Common Control of Class A-1 Member      
Related Party Transaction [Line Items]      
Cost of revenue 311,000 $ 243,000  
Accounts payable $ 183,000   $ 102,100
Related Party | Cost of Goods and Service Benchmark | Supplier Concentration Risk | Subsidiary Under Common Control of Class A-1 Member      
Related Party Transaction [Line Items]      
Concentration risk (in percentage) 88.00% 87.00%  
Related Party | Accounts Payable | Supplier Concentration Risk | Subsidiary Under Common Control of Class A-1 Member      
Related Party Transaction [Line Items]      
Concentration risk (in percentage) 97.00%   97.00%
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Related Parties - Notes Receivable (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
May 01, 2020
Jun. 01, 2019
May 01, 2019
Related Party Transaction [Line Items]          
Total notes receivables $ 2,655 $ 2,754      
Less:  Current portion of notes receivable (2,498) (1,604)      
Notes receivable - related parties 157 1,150      
Note 2          
Related Party Transaction [Line Items]          
Total notes receivables 656 656      
Original
Principal         $ 5,355
Note 3          
Related Party Transaction [Line Items]          
Total notes receivables 0 17      
Original
Principal       $ 491  
Note 8          
Related Party Transaction [Line Items]          
Total notes receivables $ 1,999 $ 2,081      
Original
Principal     $ 2,816    
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Equity-Based Compensation - Summary of RSU Activity (Details) - Restricted Stock - $ / shares
 3 Months Ended
Mar. 31, 2024
Mar. 28, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]    
Outstanding, beginning period (in shares) 0 0
Granted (in shares) 3,759,459 3,759,459
Vested (in shares) (2,289,181)  
Forfeited (in shares) 0  
Outstanding, ending period (in shares) 1,470,278  
Weighted Average Grant Date Fair Value    
Beginning Balance (usd per share) $ 0 $ 0
Granted (usd per share) 5.73  
Vested (usd per share) 5.80  
Forfeited (usd per share) 0  
Ending Balance (usd per share) $ 5.67  
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Equity-Based Compensation - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 28, 2024
Employee Stock | 2023 Incentive Equity Plan    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Shares authorized (in shares) 5,300,000  
Percentage of outstanding stock maximum (in percent) 5.00%  
Number of shares available for grant (in shares) 2,044,394  
Restricted Stock    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Granted (in shares) 3,759,459 3,759,459
Stock compensation expense $ 13.3  
Unrecognized compensation expense $ 8.2  
Cost not yet recognized, period for recognition (in years) 1 year 8 months 12 days  
Shares awarded upon vesting of RSUs (in shares) 1  
Minimum | Restricted Stock    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Vesting period (in years) 1 year  
Maximum | Restricted Stock    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Vesting period (in years) 2 years  
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Equity - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
 2 Months Ended 3 Months Ended 12 Months Ended
Sep. 20, 2023
Jun. 07, 2023
Mar. 04, 2020
Jul. 31, 2023
Mar. 31, 2024
Dec. 31, 2022
Dec. 31, 2023
Mar. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Invested capital contributions         $ 65.0      
Accrued dividend rate (in percent)         8.00%      
Stockholders' equity, conversion period (in years)         5 years      
Common Class A                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Common unit, units outstanding (in units)           19,495,376   19,495,376
Accrued dividend rate (in percent)     8.00%          
Payments of dividends   $ 4.0            
Common Class A-1                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Common unit, units outstanding (in units)           1,842,520   1,842,520
Accrued dividend rate (in percent)     4.00%          
Payments of dividends   $ 4.1            
Class B Common Stock                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Common unit, units outstanding (in units)           4,703,628   4,703,628
Class B-1                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Grants in period (in units)       415        
Class C                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Temporary equity, redeemable period         5 years      
AON Inc.                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Stockholders' equity, conversion, threshold volume weighted average price period         30 days      
Stockholders' equity, conversion, threshold stock price (in dollars per share) (less than) (greater than)         $ 16.00      
AON LLC                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Issuance of units (in units)         2,289,181      
AON LLC | Common Class A                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Common unit authorized (in units)           19,495,376    
Issuance of units (in units)           19,495,376    
Common unit, units outstanding (in units)           19,495,376    
AON LLC | Common Class A-1                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Common unit authorized (in units)           3,000,245    
Issuance of units (in units)           1,842,520    
Common unit, units outstanding (in units)           1,842,520    
AON LLC | Class B Common Stock                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Issuance of units (in units)             5,614,176  
Units vested (in units)           4,703,628    
Units vested upon consummation of business combination (in units)           910,548    
Common Class A                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Shares issued (in shares) 1,047,343              
Stockholders' equity, conversion, threshold volume weighted average price period         5 days      
Series A Preferred Stock                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Dividends         $ 2.1      
Class A-1 distribution (in shares) 151,610              
Stock price (in usd per share)         $ 10.00      
Series A Preferred Stock | Stockholders                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Number of days after five year anniversary         30 days      
Stockholders' equity, conversion period (in years)         5 years      
Stockholders' equity, conversion, threshold volume weighted average price period         30 days      
Stockholders' equity, conversion, threshold stock price (in dollars per share) (less than) (greater than)         $ 10.00      
Threshold stock price, conversion price adjustment (in usd per share)         $ 5.00      
Series A Preferred Stock | AEA Growth Management LP                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Shares issued (in shares) 6,651,610              
Series A Preferred Stock | Dividends Paid, Event Prior to June 7, 2024                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Accrued dividend rate (in percent)         125.00%      
Series A Preferred Stock | Dividends Paid, Event Prior to June 7, 2025, After June 7, 2024                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Accrued dividend rate (in percent)         120.00%      
Series A Preferred Stock | Dividends Paid, Event Prior to June 7, 2026, After June 7, 2025                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Accrued dividend rate (in percent)         115.00%      
Series A Preferred Stock | Dividends Paid, Event Prior to June 7, 2027, After June 7, 2026                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Accrued dividend rate (in percent)         110.00%      
Series A Preferred Stock | Dividends Paid, Event Prior to June 7, 2028, After June 7, 2027                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Accrued dividend rate (in percent)         105.00%      
Series A Preferred Stock | Dividends Paid, Event After June 7, 2028                
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]                
Accrued dividend rate (in percent)         100.00%      
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Equity - Schedule of Changes in Units (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
USD ($)
shares
Common Class A  
Reverse Recapitalization, Change In Value Of Units [Roll Forward]  
Beginning of Period | $ $ 7,725
Issuance of Units | $ 0
Impact of the Reverse Recapitalization | $ 0
End of Period | $ $ 7,725
Reverse Recapitalization, Change In Units [Roll Forward]  
Beginning balance (in units) | shares 19,495,376
Issuance of units (in units) | shares 0
Impact of the Reverse Recapitalization (in units) | shares 0
Ending balance (in units) | shares 19,495,376
Common Class A-1  
Reverse Recapitalization, Change In Value Of Units [Roll Forward]  
Beginning of Period | $ $ 28,500
Issuance of Units | $ 0
Impact of the Reverse Recapitalization | $ 0
End of Period | $ $ 28,500
Reverse Recapitalization, Change In Units [Roll Forward]  
Beginning balance (in units) | shares 1,842,520
Issuance of units (in units) | shares 0
Impact of the Reverse Recapitalization (in units) | shares 0
Ending balance (in units) | shares 1,842,520
Class B Common Stock  
Reverse Recapitalization, Change In Value Of Units [Roll Forward]  
Beginning of Period | $ $ 80
Issuance of Units | $ 0
Impact of the Reverse Recapitalization | $ 0
End of Period | $ $ 80
Reverse Recapitalization, Change In Units [Roll Forward]  
Beginning balance (in units) | shares 4,703,628
Issuance of units (in units) | shares 0
Impact of the Reverse Recapitalization (in units) | shares 0
Ending balance (in units) | shares 4,703,628
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Net Loss Per Share - Calculation Of Earnings Per Share (Details) - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]    
Net loss attributable to Class A Common Stockholders for basic earnings per share $ (7,841,000) $ 0
Net loss attributable to Class A Common Stockholders for diluted earnings per share (7,841,000) $ 0
Undistributed net earnings, basic $ (9,201,180)  
Weighted average shares for basic earnings per share (in shares) 7,527,882 0
Basic loss per share of Class A Common Stock (in dollars per share) $ (1.22) $ 0
Diluted loss per share of Class A Common Stock (in dollars per share) $ (1.22) $ 0
Series A Preferred Stock    
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]    
Series A Preferred Cumulative Dividends $ (1,360,180)  
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Net Loss Per Share - Antidilutive Securities (Details)
shares in Thousands
 3 Months Ended
Mar. 31, 2024
shares
Series A Preferred Stock  
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]  
Antidilutive shares excluded from computation of earnings per share (in shares) 6,651,610
Class B Common Stock  
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]  
Antidilutive shares excluded from computation of earnings per share (in shares) 23,725,998
Class B Prefunded Warrants  
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]  
Antidilutive shares excluded from computation of earnings per share (in shares) 3,000,245
Public and Private Warrants  
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]  
Antidilutive shares excluded from computation of earnings per share (in shares) 14,450,833
Restricted Stock Units  
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]  
Antidilutive shares excluded from computation of earnings per share (in shares) 1,470,278
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Redeemable Noncontrolling Interest - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended
Sep. 30, 2023
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Noncontrolling Interest [Line Items]        
Redemption ratio   1    
Number of days after redemption notice date that redemption must be settled   10 days    
Redemption value of noncontrolling interest   $ 157,700    
Excess redeemable noncontrolling interest over carrying amount   15,600    
Fair value adjustment to redeemable noncontrolling interest   15,636    
Additional Paid in Capital        
Noncontrolling Interest [Line Items]        
Fair value adjustment to redeemable noncontrolling interest   9,696    
Retained
Earnings (Deficit)        
Noncontrolling Interest [Line Items]        
Fair value adjustment to redeemable noncontrolling interest   $ 5,940    
Common Class A        
Noncontrolling Interest [Line Items]        
Common stock, shares outstanding (in shares)   10,334,734   9,517,816
Stockholders' equity, conversion, threshold volume weighted average price period   5 days    
Legacy AON Shareholders | AON LLC        
Noncontrolling Interest [Line Items]        
Common unit, units outstanding (in units)   26,726,243    
Allocation of income to controlling and noncontrolling interests (in percent) 77.00% 61.10% 100.00%  
Common stock, shares outstanding (in shares)   23,725,998    
Class of warrant outstanding (in shares)   3,000,245    
LLC ownership threshold, percentage   50.00%    
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Redeemable Noncontrolling Interest - Schedule of Ownership (Details) - AON LLC
 3 Months Ended
Mar. 31, 2024
shares
Equity, Attributable to Noncontrolling Interest [Roll Forward]  
Beginning balance (in units) 41,439,847
Issuances (in units) 2,289,181
Repurchases (in units) (16,441)
Redemptions (in units) 0
Total Units Issued (in units) 43,712,587
Ending balance (in units) 43,712,587
Allocation of income to controlling and noncontrolling interests (in percent) 1
Allocation of losses to controlling and noncontrolling interests (in percent) 1
AON Inc.  
Equity, Attributable to Noncontrolling Interest [Roll Forward]  
Beginning balance (in units) 13,330,051
Issuances (in units) 2,289,181
Repurchases (in units) (16,441)
Redemptions (in units) 1,383,553
Total Units Issued (in units) 16,986,344
Ending balance (in units) 16,986,344
Allocation of income to controlling and noncontrolling interests (in percent) 0.389
Allocation of losses to controlling and noncontrolling interests (in percent) 0.230
Legacy AON Shareholders  
Equity, Attributable to Noncontrolling Interest [Roll Forward]  
Beginning balance (in units) 28,109,796
Issuances (in units) 0
Repurchases (in units) 0
Redemptions (in units) 1,383,553
Total Units Issued (in units) 26,726,243
Ending balance (in units) 26,726,243
Allocation of income to controlling and noncontrolling interests (in percent) 0.611
Allocation of losses to controlling and noncontrolling interests (in percent) 0.770
EXCEL 78 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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ɔ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

,"2*S'MP[WT4-.^I8/-_VO%O4$L#!!0 ( M *:*KUB7BKL

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end XML 79 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 80 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 82 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 240 374 1 true 109 0 false 9 false false R1.htm 0000001 - Document - Cover Sheet http://www.aoncology.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statements of Mezzanine and Stockholders??? Deficit Sheet http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit Condensed Consolidated Statements of Mezzanine and Stockholders??? Deficit Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) Sheet http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) Statements 7 false false R8.htm 0000008 - Statement - Condensed Consolidated Statements of Cash Flows - Parenthetical Sheet http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical Condensed Consolidated Statements of Cash Flows - Parenthetical Statements 8 false false R9.htm 0000009 - Disclosure - Business Sheet http://www.aoncology.com/role/Business Business Notes 9 false false R10.htm 0000010 - Disclosure - Basis of Presentation and Significant Accounting Policies Sheet http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPolicies Basis of Presentation and Significant Accounting Policies Notes 10 false false R11.htm 0000011 - Disclosure - Reverse Recapitalization Sheet http://www.aoncology.com/role/ReverseRecapitalization Reverse Recapitalization Notes 11 false false R12.htm 0000012 - Disclosure - Variable Interest Entities Sheet http://www.aoncology.com/role/VariableInterestEntities Variable Interest Entities Notes 12 false false R13.htm 0000013 - Disclosure - Business Combinations Sheet http://www.aoncology.com/role/BusinessCombinations Business Combinations Notes 13 false false R14.htm 0000014 - Disclosure - Marketable Securities Sheet http://www.aoncology.com/role/MarketableSecurities Marketable Securities Notes 14 false false R15.htm 0000015 - Disclosure - Supplemental Condensed Balance Sheet Information Sheet http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformation Supplemental Condensed Balance Sheet Information Notes 15 false false R16.htm 0000016 - Disclosure - Long-term Debt Sheet http://www.aoncology.com/role/LongtermDebt Long-term Debt Notes 16 false false R17.htm 0000017 - Disclosure - Income Taxes Sheet http://www.aoncology.com/role/IncomeTaxes Income Taxes Notes 17 false false R18.htm 0000018 - Disclosure - Leases Sheet http://www.aoncology.com/role/Leases Leases Notes 18 false false R19.htm 0000019 - Disclosure - Related Parties Sheet http://www.aoncology.com/role/RelatedParties Related Parties Notes 19 false false R20.htm 0000020 - Disclosure - Equity-Based Compensation Sheet http://www.aoncology.com/role/EquityBasedCompensation Equity-Based Compensation Notes 20 false false R21.htm 0000021 - Disclosure - Equity Sheet http://www.aoncology.com/role/Equity Equity Notes 21 false false R22.htm 0000022 - Disclosure - Net Loss Per Share Sheet http://www.aoncology.com/role/NetLossPerShare Net Loss Per Share Notes 22 false false R23.htm 0000023 - Disclosure - Redeemable Noncontrolling Interest Sheet http://www.aoncology.com/role/RedeemableNoncontrollingInterest Redeemable Noncontrolling Interest Notes 23 false false R24.htm 9954471 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) Sheet http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies Basis of Presentation and Significant Accounting Policies (Policies) Policies http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPolicies 24 false false R25.htm 9954472 - Disclosure - Business (Tables) Sheet http://www.aoncology.com/role/BusinessTables Business (Tables) Tables http://www.aoncology.com/role/Business 25 false false R26.htm 9954473 - Disclosure - Reverse Recapitalization (Tables) Sheet http://www.aoncology.com/role/ReverseRecapitalizationTables Reverse Recapitalization (Tables) Tables http://www.aoncology.com/role/ReverseRecapitalization 26 false false R27.htm 9954474 - Disclosure - Variable Interest Entities (Tables) Sheet http://www.aoncology.com/role/VariableInterestEntitiesTables Variable Interest Entities (Tables) Tables http://www.aoncology.com/role/VariableInterestEntities 27 false false R28.htm 9954475 - Disclosure - Marketable Securities (Tables) Sheet http://www.aoncology.com/role/MarketableSecuritiesTables Marketable Securities (Tables) Tables http://www.aoncology.com/role/MarketableSecurities 28 false false R29.htm 9954476 - Disclosure - Supplemental Condensed Balance Sheet Information (Tables) Sheet http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationTables Supplemental Condensed Balance Sheet Information (Tables) Tables http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformation 29 false false R30.htm 9954477 - Disclosure - Long-term Debt (Tables) Sheet http://www.aoncology.com/role/LongtermDebtTables Long-term Debt (Tables) Tables http://www.aoncology.com/role/LongtermDebt 30 false false R31.htm 9954478 - Disclosure - Leases (Tables) Sheet http://www.aoncology.com/role/LeasesTables Leases (Tables) Tables http://www.aoncology.com/role/Leases 31 false false R32.htm 9954479 - Disclosure - Related Parties (Tables) Sheet http://www.aoncology.com/role/RelatedPartiesTables Related Parties (Tables) Tables http://www.aoncology.com/role/RelatedParties 32 false false R33.htm 9954480 - Disclosure - Equity-Based Compensation (Tables) Sheet http://www.aoncology.com/role/EquityBasedCompensationTables Equity-Based Compensation (Tables) Tables http://www.aoncology.com/role/EquityBasedCompensation 33 false false R34.htm 9954481 - Disclosure - Equity (Tables) Sheet http://www.aoncology.com/role/EquityTables Equity (Tables) Tables http://www.aoncology.com/role/EquityBasedCompensation 34 false false R35.htm 9954482 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.aoncology.com/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.aoncology.com/role/NetLossPerShare 35 false false R36.htm 9954483 - Disclosure - Redeemable Noncontrolling Interest (Tables) Sheet http://www.aoncology.com/role/RedeemableNoncontrollingInterestTables Redeemable Noncontrolling Interest (Tables) Tables http://www.aoncology.com/role/RedeemableNoncontrollingInterest 36 false false R37.htm 9954484 - Disclosure - Business (Details) Sheet http://www.aoncology.com/role/BusinessDetails Business (Details) Details http://www.aoncology.com/role/BusinessTables 37 false false R38.htm 9954485 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details) Sheet http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails Basis of Presentation and Significant Accounting Policies (Details) Details http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies 38 false false R39.htm 9954486 - Disclosure - Reverse Recapitalization - Narrative (Details) Sheet http://www.aoncology.com/role/ReverseRecapitalizationNarrativeDetails Reverse Recapitalization - Narrative (Details) Details 39 false false R40.htm 9954487 - Disclosure - Reverse Recapitalization - Schedule of Historical Cost (Details) Sheet http://www.aoncology.com/role/ReverseRecapitalizationScheduleofHistoricalCostDetails Reverse Recapitalization - Schedule of Historical Cost (Details) Details 40 false false R41.htm 9954488 - Disclosure - Variable Interest Entities - Narrative (Details) Sheet http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails Variable Interest Entities - Narrative (Details) Details 41 false false R42.htm 9954489 - Disclosure - Variable Interest Entities - Schedule of Assets and Liabilities (Details) Sheet http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails Variable Interest Entities - Schedule of Assets and Liabilities (Details) Details 42 false false R43.htm 9954490 - Disclosure - Marketable Securities - Schedule of Marketable Securities Measured at Fair Value (Details) Sheet http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails Marketable Securities - Schedule of Marketable Securities Measured at Fair Value (Details) Details 43 false false R44.htm 9954491 - Disclosure - Marketable Securities - Remaining Contractual Maturities (Details) Sheet http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails Marketable Securities - Remaining Contractual Maturities (Details) Details 44 false false R45.htm 9954492 - Disclosure - Supplemental Condensed Balance Sheet Information - Schedule of Other Receivables (Details) Sheet http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofOtherReceivablesDetails Supplemental Condensed Balance Sheet Information - Schedule of Other Receivables (Details) Details 45 false false R46.htm 9954493 - Disclosure - Supplemental Condensed Balance Sheet Information - Schedule of Inventory (Details) Sheet http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofInventoryDetails Supplemental Condensed Balance Sheet Information - Schedule of Inventory (Details) Details 46 false false R47.htm 9954494 - Disclosure - Supplemental Condensed Balance Sheet Information - Schedule of Property and Equipment, net (Details) Sheet http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails Supplemental Condensed Balance Sheet Information - Schedule of Property and Equipment, net (Details) Details 47 false false R48.htm 9954495 - Disclosure - Supplemental Condensed Balance Sheet Information - Schedule of Accrued Other (Details) Sheet http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails Supplemental Condensed Balance Sheet Information - Schedule of Accrued Other (Details) Details 48 false false R49.htm 9954496 - Disclosure - Long-term Debt - Schedule of Long-term Debt (Details) Sheet http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails Long-term Debt - Schedule of Long-term Debt (Details) Details 49 false false R50.htm 9954497 - Disclosure - Long-term Debt - Narrative (Details) Sheet http://www.aoncology.com/role/LongtermDebtNarrativeDetails Long-term Debt - Narrative (Details) Details 50 false false R51.htm 9954498 - Disclosure - Income Taxes (Details) Sheet http://www.aoncology.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.aoncology.com/role/IncomeTaxes 51 false false R52.htm 9954499 - Disclosure - Leases - Right-of-use Assets And Lease Liabilities (Details) Sheet http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails Leases - Right-of-use Assets And Lease Liabilities (Details) Details 52 false false R53.htm 9954500 - Disclosure - Leases - Lease Costs (Details) Sheet http://www.aoncology.com/role/LeasesLeaseCostsDetails Leases - Lease Costs (Details) Details 53 false false R54.htm 9954501 - Disclosure - Leases - Maturities of Operating and Financing Lease Liabilities (Details) Sheet http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails Leases - Maturities of Operating and Financing Lease Liabilities (Details) Details 54 false false R55.htm 9954502 - Disclosure - Leases - Narrative (Details) Sheet http://www.aoncology.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 55 false false R56.htm 9954503 - Disclosure - Leases - Supplemental Cash Flow Information (Details) Sheet http://www.aoncology.com/role/LeasesSupplementalCashFlowInformationDetails Leases - Supplemental Cash Flow Information (Details) Details 56 false false R57.htm 9954504 - Disclosure - Related Parties - Narrative (Details) Sheet http://www.aoncology.com/role/RelatedPartiesNarrativeDetails Related Parties - Narrative (Details) Details 57 false false R58.htm 9954505 - Disclosure - Related Parties - Notes Receivable (Details) Notes http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails Related Parties - Notes Receivable (Details) Details 58 false false R59.htm 9954506 - Disclosure - Equity-Based Compensation - Summary of RSU Activity (Details) Sheet http://www.aoncology.com/role/EquityBasedCompensationSummaryofRSUActivityDetails Equity-Based Compensation - Summary of RSU Activity (Details) Details 59 false false R60.htm 9954507 - Disclosure - Equity-Based Compensation - Narrative (Details) Sheet http://www.aoncology.com/role/EquityBasedCompensationNarrativeDetails Equity-Based Compensation - Narrative (Details) Details 60 false false R61.htm 9954508 - Disclosure - Equity - Narrative (Details) Sheet http://www.aoncology.com/role/EquityNarrativeDetails Equity - Narrative (Details) Details 61 false false R62.htm 9954509 - Disclosure - Equity - Schedule of Changes in Units (Details) Sheet http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails Equity - Schedule of Changes in Units (Details) Details 62 false false R63.htm 9954510 - Disclosure - Net Loss Per Share - Calculation Of Earnings Per Share (Details) Sheet http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails Net Loss Per Share - Calculation Of Earnings Per Share (Details) Details 63 false false R64.htm 9954511 - Disclosure - Net Loss Per Share - Antidilutive Securities (Details) Sheet http://www.aoncology.com/role/NetLossPerShareAntidilutiveSecuritiesDetails Net Loss Per Share - Antidilutive Securities (Details) Details 64 false false R65.htm 9954512 - Disclosure - Redeemable Noncontrolling Interest - Narrative (Details) Sheet http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails Redeemable Noncontrolling Interest - Narrative (Details) Details 65 false false R66.htm 9954513 - Disclosure - Redeemable Noncontrolling Interest - Schedule of Ownership (Details) Sheet http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails Redeemable Noncontrolling Interest - Schedule of Ownership (Details) Details 66 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: aonc:StockholdersEquityNumberOfDaysAfterTheRedemptionNoticeDateForRedemptionToBeSettled, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 - aonc-20240331.htm 4 aonc-20240331.htm aonc-20240331.xsd aonc-20240331_cal.xml aonc-20240331_def.xml aonc-20240331_lab.xml aonc-20240331_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 85 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "aonc-20240331.htm": { "nsprefix": "aonc", "nsuri": "http://www.aoncology.com/20240331", "dts": { "inline": { "local": [ "aonc-20240331.htm" ] }, "schema": { "local": [ "aonc-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "aonc-20240331_cal.xml" ] }, "definitionLink": { "local": [ "aonc-20240331_def.xml" ] }, "labelLink": { "local": [ "aonc-20240331_lab.xml" ] }, "presentationLink": { "local": [ "aonc-20240331_pre.xml" ] } }, "keyStandard": 298, "keyCustom": 76, "axisStandard": 31, "axisCustom": 3, "memberStandard": 45, "memberCustom": 51, "hidden": { "total": 9, "http://xbrl.sec.gov/dei/2023": 5, "http://fasb.org/us-gaap/2023": 3, "http://www.aoncology.com/20240331": 1 }, "contextCount": 240, "entityCount": 1, "segmentCount": 109, "elementCount": 621, "unitCount": 9, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 712, "http://xbrl.sec.gov/dei/2023": 34 }, "report": { "R1": { "role": "http://www.aoncology.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "unique": true } }, "R3": { "role": "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:TemporaryEquitySharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:TreasuryStockCommonShares", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "unique": true } }, "R4": { "role": "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CostsAndExpenses", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "unique": true } }, "R5": { "role": "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit", "longName": "0000005 - Statement - Condensed Consolidated Statements of Mezzanine and Stockholders\u2019 Deficit", "shortName": "Condensed Consolidated Statements of Mezzanine and Stockholders\u2019 Deficit", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-44", "name": "us-gaap:CommonUnitOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-44", "name": "us-gaap:CommonUnitOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows", "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "unique": true } }, "R7": { "role": "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical", "longName": "0000007 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CostOfRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "unique": true } }, "R8": { "role": "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical", "longName": "0000008 - Statement - Condensed Consolidated Statements of Cash Flows - Parenthetical", "shortName": "Condensed Consolidated Statements of Cash Flows - Parenthetical", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-21", "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "link:footnote", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "unique": true } }, "R9": { "role": "http://www.aoncology.com/role/Business", "longName": "0000009 - Disclosure - Business", "shortName": "Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPolicies", "longName": "0000010 - Disclosure - Basis of Presentation and Significant Accounting Policies", "shortName": "Basis of Presentation and Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.aoncology.com/role/ReverseRecapitalization", "longName": "0000011 - Disclosure - Reverse Recapitalization", "shortName": "Reverse Recapitalization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "aonc:ReverseRecapitalizationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "aonc:ReverseRecapitalizationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.aoncology.com/role/VariableInterestEntities", "longName": "0000012 - Disclosure - Variable Interest Entities", "shortName": "Variable Interest Entities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.aoncology.com/role/BusinessCombinations", "longName": "0000013 - Disclosure - Business Combinations", "shortName": "Business Combinations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.aoncology.com/role/MarketableSecurities", "longName": "0000014 - Disclosure - Marketable Securities", "shortName": "Marketable Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformation", "longName": "0000015 - Disclosure - Supplemental Condensed Balance Sheet Information", "shortName": "Supplemental Condensed Balance Sheet Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.aoncology.com/role/LongtermDebt", "longName": "0000016 - Disclosure - Long-term Debt", "shortName": "Long-term Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.aoncology.com/role/IncomeTaxes", "longName": "0000017 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.aoncology.com/role/Leases", "longName": "0000018 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeFinanceLeasesTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.aoncology.com/role/RelatedParties", "longName": "0000019 - Disclosure - Related Parties", "shortName": "Related Parties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.aoncology.com/role/EquityBasedCompensation", "longName": "0000020 - Disclosure - Equity-Based Compensation", "shortName": "Equity-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.aoncology.com/role/Equity", "longName": "0000021 - Disclosure - Equity", "shortName": "Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.aoncology.com/role/NetLossPerShare", "longName": "0000022 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.aoncology.com/role/RedeemableNoncontrollingInterest", "longName": "0000023 - Disclosure - Redeemable Noncontrolling Interest", "shortName": "Redeemable Noncontrolling Interest", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)", "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.aoncology.com/role/BusinessTables", "longName": "9954472 - Disclosure - Business (Tables)", "shortName": "Business (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "aonc:ScheduleOfAffiliationAgreementsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "aonc:ScheduleOfAffiliationAgreementsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.aoncology.com/role/ReverseRecapitalizationTables", "longName": "9954473 - Disclosure - Reverse Recapitalization (Tables)", "shortName": "Reverse Recapitalization (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "aonc:ScheduleOfReverseRecapitalizationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "aonc:ScheduleOfReverseRecapitalizationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.aoncology.com/role/VariableInterestEntitiesTables", "longName": "9954474 - Disclosure - Variable Interest Entities (Tables)", "shortName": "Variable Interest Entities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.aoncology.com/role/MarketableSecuritiesTables", "longName": "9954475 - Disclosure - Marketable Securities (Tables)", "shortName": "Marketable Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationTables", "longName": "9954476 - Disclosure - Supplemental Condensed Balance Sheet Information (Tables)", "shortName": "Supplemental Condensed Balance Sheet Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "aonc:ScheduleOfOtherReceivablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "aonc:ScheduleOfOtherReceivablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.aoncology.com/role/LongtermDebtTables", "longName": "9954477 - Disclosure - Long-term Debt (Tables)", "shortName": "Long-term Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.aoncology.com/role/LeasesTables", "longName": "9954478 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "aonc:LesseeAssetsAndLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "aonc:LesseeAssetsAndLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.aoncology.com/role/RelatedPartiesTables", "longName": "9954479 - Disclosure - Related Parties (Tables)", "shortName": "Related Parties (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.aoncology.com/role/EquityBasedCompensationTables", "longName": "9954480 - Disclosure - Equity-Based Compensation (Tables)", "shortName": "Equity-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.aoncology.com/role/EquityTables", "longName": "9954481 - Disclosure - Equity (Tables)", "shortName": "Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "aonc:ScheduleOfReverseRecapitalizationChangesInUnitsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "aonc:ScheduleOfReverseRecapitalizationChangesInUnitsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.aoncology.com/role/NetLossPerShareTables", "longName": "9954482 - Disclosure - Net Loss Per Share (Tables)", "shortName": "Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.aoncology.com/role/RedeemableNoncontrollingInterestTables", "longName": "9954483 - Disclosure - Redeemable Noncontrolling Interest (Tables)", "shortName": "Redeemable Noncontrolling Interest (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "aonc:ScheduleOfReverseRecapitalizationOwnershipSummaryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "aonc:ScheduleOfReverseRecapitalizationOwnershipSummaryTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.aoncology.com/role/BusinessDetails", "longName": "9954484 - Disclosure - Business (Details)", "shortName": "Business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-6", "name": "aonc:NumberOfOncologyPractices", "unitRef": "practice", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "aonc:NumberOfOncologyPractices", "unitRef": "practice", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "longName": "9954485 - Disclosure - Basis of Presentation and Significant Accounting Policies (Details)", "shortName": "Basis of Presentation and Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-6", "name": "aonc:RecapitalizationExchangeRatioUnits", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "unique": true } }, "R39": { "role": "http://www.aoncology.com/role/ReverseRecapitalizationNarrativeDetails", "longName": "9954486 - Disclosure - Reverse Recapitalization - Narrative (Details)", "shortName": "Reverse Recapitalization - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "aonc:GainLossOnReverseRecapitalization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "aonc:GainLossOnReverseRecapitalization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.aoncology.com/role/ReverseRecapitalizationScheduleofHistoricalCostDetails", "longName": "9954487 - Disclosure - Reverse Recapitalization - Schedule of Historical Cost (Details)", "shortName": "Reverse Recapitalization - Schedule of Historical Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-108", "name": "aonc:CashAndCashEquivalentsAcquiredThroughReverseRecapitalization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "aonc:ScheduleOfReverseRecapitalizationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-108", "name": "aonc:CashAndCashEquivalentsAcquiredThroughReverseRecapitalization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "aonc:ScheduleOfReverseRecapitalizationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails", "longName": "9954488 - Disclosure - Variable Interest Entities - Narrative (Details)", "shortName": "Variable Interest Entities - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-112", "name": "us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-112", "name": "us-gaap:LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails", "longName": "9954489 - Disclosure - Variable Interest Entities - Schedule of Assets and Liabilities (Details)", "shortName": "Variable Interest Entities - Schedule of Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-115", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "unique": true } }, "R43": { "role": "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails", "longName": "9954490 - Disclosure - Marketable Securities - Schedule of Marketable Securities Measured at Fair Value (Details)", "shortName": "Marketable Securities - Schedule of Marketable Securities Measured at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "unique": true } }, "R44": { "role": "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails", "longName": "9954491 - Disclosure - Marketable Securities - Remaining Contractual Maturities (Details)", "shortName": "Marketable Securities - Remaining Contractual Maturities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-123", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "unique": true } }, "R45": { "role": "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofOtherReceivablesDetails", "longName": "9954492 - Disclosure - Supplemental Condensed Balance Sheet Information - Schedule of Other Receivables (Details)", "shortName": "Supplemental Condensed Balance Sheet Information - Schedule of Other Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-6", "name": "aonc:RebatesReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "aonc:ScheduleOfOtherReceivablesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "aonc:RebatesReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "aonc:ScheduleOfOtherReceivablesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofInventoryDetails", "longName": "9954493 - Disclosure - Supplemental Condensed Balance Sheet Information - Schedule of Inventory (Details)", "shortName": "Supplemental Condensed Balance Sheet Information - Schedule of Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:InventoryNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-130", "name": "us-gaap:InventoryNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "unique": true } }, "R47": { "role": "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails", "longName": "9954494 - Disclosure - Supplemental Condensed Balance Sheet Information - Schedule of Property and Equipment, net (Details)", "shortName": "Supplemental Condensed Balance Sheet Information - Schedule of Property and Equipment, net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails", "longName": "9954495 - Disclosure - Supplemental Condensed Balance Sheet Information - Schedule of Accrued Other (Details)", "shortName": "Supplemental Condensed Balance Sheet Information - Schedule of Accrued Other (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CustomerRefundLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "aonc:ScheduleOfOtherAccruedLiabilitiesCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:CustomerRefundLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "aonc:ScheduleOfOtherAccruedLiabilitiesCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails", "longName": "9954496 - Disclosure - Long-term Debt - Schedule of Long-term Debt (Details)", "shortName": "Long-term Debt - Schedule of Long-term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.aoncology.com/role/LongtermDebtNarrativeDetails", "longName": "9954497 - Disclosure - Long-term Debt - Narrative (Details)", "shortName": "Long-term Debt - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-152", "name": "us-gaap:ProceedsFromLongTermLinesOfCredit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-152", "name": "us-gaap:ProceedsFromLongTermLinesOfCredit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.aoncology.com/role/IncomeTaxesDetails", "longName": "9954498 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails", "longName": "9954499 - Disclosure - Leases - Right-of-use Assets And Lease Liabilities (Details)", "shortName": "Leases - Right-of-use Assets And Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:FinanceLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "aonc:LesseeAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "unique": true } }, "R53": { "role": "http://www.aoncology.com/role/LeasesLeaseCostsDetails", "longName": "9954500 - Disclosure - Leases - Lease Costs (Details)", "shortName": "Leases - Lease Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails", "longName": "9954501 - Disclosure - Leases - Maturities of Operating and Financing Lease Liabilities (Details)", "shortName": "Leases - Maturities of Operating and Financing Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.aoncology.com/role/LeasesNarrativeDetails", "longName": "9954502 - Disclosure - Leases - Narrative (Details)", "shortName": "Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.aoncology.com/role/LeasesSupplementalCashFlowInformationDetails", "longName": "9954503 - Disclosure - Leases - Supplemental Cash Flow Information (Details)", "shortName": "Leases - Supplemental Cash Flow Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeasePayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FinanceLeaseInterestPaymentOnLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "unique": true } }, "R57": { "role": "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails", "longName": "9954504 - Disclosure - Related Parties - Narrative (Details)", "shortName": "Related Parties - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-1", "name": "aonc:FinancingReceivableAmortizationPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "aonc:FinancingReceivableAmortizationPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails", "longName": "9954505 - Disclosure - Related Parties - Notes Receivable (Details)", "shortName": "Related Parties - Notes Receivable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:NotesReceivableNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:NotesReceivableNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.aoncology.com/role/EquityBasedCompensationSummaryofRSUActivityDetails", "longName": "9954506 - Disclosure - Equity-Based Compensation - Summary of RSU Activity (Details)", "shortName": "Equity-Based Compensation - Summary of RSU Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-191", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-192", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "unique": true } }, "R60": { "role": "http://www.aoncology.com/role/EquityBasedCompensationNarrativeDetails", "longName": "9954507 - Disclosure - Equity-Based Compensation - Narrative (Details)", "shortName": "Equity-Based Compensation - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-188", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-188", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.aoncology.com/role/EquityNarrativeDetails", "longName": "9954508 - Disclosure - Equity - Narrative (Details)", "shortName": "Equity - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:MembersCapital", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:MembersCapital", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails", "longName": "9954509 - Disclosure - Equity - Schedule of Changes in Units (Details)", "shortName": "Equity - Schedule of Changes in Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-200", "name": "us-gaap:CommonUnitIssuanceValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-200", "name": "us-gaap:CommonUnitIssuanceValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails", "longName": "9954510 - Disclosure - Net Loss Per Share - Calculation Of Earnings Per Share (Details)", "shortName": "Net Loss Per Share - Calculation Of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:UndistributedEarnings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "unique": true } }, "R64": { "role": "http://www.aoncology.com/role/NetLossPerShareAntidilutiveSecuritiesDetails", "longName": "9954511 - Disclosure - Net Loss Per Share - Antidilutive Securities (Details)", "shortName": "Net Loss Per Share - Antidilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-228", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-228", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails", "longName": "9954512 - Disclosure - Redeemable Noncontrolling Interest - Narrative (Details)", "shortName": "Redeemable Noncontrolling Interest - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-1", "name": "aonc:StockholdersEquityRedemptionRatio", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "aonc:StockholdersEquityRedemptionRatio", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails", "longName": "9954513 - Disclosure - Redeemable Noncontrolling Interest - Schedule of Ownership (Details)", "shortName": "Redeemable Noncontrolling Interest - Schedule of Ownership (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-237", "name": "aonc:LimitedLiabilityCompanyLLCUnitsOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "aonc:ScheduleOfReverseRecapitalizationOwnershipSummaryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-237", "name": "aonc:LimitedLiabilityCompanyLLCUnitsOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "aonc:ScheduleOfReverseRecapitalizationOwnershipSummaryTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "aonc-20240331.htm", "first": true, "unique": true } } }, "tag": { "aonc_A2023IncentiveEquityPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "A2023IncentiveEquityPlanMember", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2023 Incentive Equity Plan", "label": "2023 Incentive Equity Plan [Member]", "documentation": "2023 Incentive Equity Plan" } } }, "auth_ref": [] }, "aonc_A2024NotesReceivableNote2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "A2024NotesReceivableNote2Member", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Note 2", "label": "2024 Notes Receivable, Note 2 [Member]", "documentation": "2024 Notes Receivable, Note 2" } } }, "auth_ref": [] }, "aonc_A2024NotesReceivableNote3Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "A2024NotesReceivableNote3Member", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Note 3", "label": "2024 Notes Receivable, Note 3 [Member]", "documentation": "2024 Notes Receivable, Note 3" } } }, "auth_ref": [] }, "aonc_A2025NotesReceivableNote8Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "A2025NotesReceivableNote8Member", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Note 8", "label": "2025 Notes Receivable, Note 8 [Member]", "documentation": "2025 Notes Receivable, Note 8" } } }, "auth_ref": [] }, "aonc_AEAGrowthManagementLPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "AEAGrowthManagementLPMember", "presentation": [ "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AEA Growth Management LP", "label": "AEA Growth Management LP [Member]", "documentation": "AEA Growth Management LP" } } }, "auth_ref": [] }, "aonc_AONCentralMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "AONCentralMember", "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AON Central", "label": "AON Central [Member]", "documentation": "AON Central" } } }, "auth_ref": [] }, "aonc_AONCommonUnitholdersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "AONCommonUnitholdersMember", "presentation": [ "http://www.aoncology.com/role/ReverseRecapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AON Common Unit", "label": "AON Common Unitholders [Member]", "documentation": "AON Common Unitholders" } } }, "auth_ref": [] }, "aonc_AONIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "AONIncMember", "presentation": [ "http://www.aoncology.com/role/ReverseRecapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AON Inc.", "label": "AON Inc. [Member]", "documentation": "AON Inc." } } }, "auth_ref": [] }, "aonc_AONLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "AONLLCMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AON LLC", "label": "AON LLC [Member]", "documentation": "AON LLC" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r22", "r760" ] }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails", "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r101", "r894" ] }, "us-gaap_AccountsPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableMember", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Payable", "label": "Accounts Payable [Member]", "documentation": "Obligations incurred and payable to vendors for goods and services received." } } }, "auth_ref": [ "r17" ] }, "us-gaap_AccountsReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNet", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": [ "r662", "r724", "r766", "r896" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Patient accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r280", "r281" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r33", "r34", "r119", "r184", "r592", "r617", "r618" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r13", "r34", "r481", "r484", "r523", "r613", "r614", "r801", "r802", "r803", "r810", "r811", "r812" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r111", "r760", "r899" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r447", "r448", "r449", "r632", "r810", "r811", "r812", "r878", "r901" ] }, "aonc_AdjustmentsToAdditionalPaidInCapitalFairValueAdjustmentRedeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "AdjustmentsToAdditionalPaidInCapitalFairValueAdjustmentRedeemableNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value adjustment to redeemable noncontrolling interest", "negatedTerseLabel": "Fair value adjustment to redeemable noncontrolling interest", "label": "Adjustments To Additional Paid In Capital, Fair Value Adjustment, Redeemable Noncontrolling Interest", "documentation": "Adjustments To Additional Paid In Capital, Fair Value Adjustment, Redeemable Noncontrolling Interest" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Equity-based compensation and NCI rebalancing", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r70", "r71", "r410" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash provided by operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r442", "r455" ] }, "aonc_AlternateBaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "AlternateBaseRateMember", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Alternate Base Rate", "label": "Alternate Base Rate [Member]", "documentation": "Alternate Base Rate" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of debt issuance costs", "label": "Amortization of Debt Issuance Costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r122", "r368", "r504", "r805" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.aoncology.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive shares excluded from computation of earnings per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r246" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.aoncology.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r46" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.aoncology.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.aoncology.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r46" ] }, "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI", "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]", "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r13", "r34", "r801", "r802", "r803" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r150", "r178", "r208", "r255", "r271", "r275", "r320", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r474", "r478", "r496", "r590", "r667", "r760", "r773", "r842", "r843", "r885" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r174", "r186", "r208", "r320", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r474", "r478", "r496", "r760", "r842", "r843", "r885" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AutomobilesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AutomobilesMember", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Automobiles", "label": "Automobiles [Member]", "documentation": "Vehicles that are used primarily for transporting people." } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails_1": { "parentTag": "aonc_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost", "weight": -1.0, "order": 1.0 }, "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized\u2028Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r289" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 }, "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails_1": { "parentTag": "aonc_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross Unrealized\u2028Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r290" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails": { "parentTag": "aonc_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Amortized \u2028Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r286", "r329", "r588" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available-for-Sale Securities, Debt Maturities [Abstract]", "label": "Available-for-Sale Securities, Debt Maturities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due in one to five years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r294", "r587" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]", "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due in one year or less", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r293", "r586" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails": { "parentTag": "aonc_CashCashEquivalentsAndAvailableForSaleDebtSecurities", "weight": 1.0, "order": 1.0 }, "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 }, "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails", "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term marketable securities", "verboseLabel": "Estimated Fair\u2028Value", "totalLabel": "Total", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r287", "r329", "r580", "r816" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationNarrativeDetails", "http://www.aoncology.com/role/EquityBasedCompensationSummaryofRSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r413", "r414", "r415", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r437", "r438", "r439", "r440", "r441" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "aonc_BloombergShortTermBankYieldIndexMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "BloombergShortTermBankYieldIndexMember", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bloomberg Short-Term Bank Yield Index", "label": "Bloomberg Short-Term Bank Yield Index [Member]", "documentation": "Bloomberg Short-Term Bank Yield Index" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r471" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.aoncology.com/role/BusinessCombinations" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combinations", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r143", "r472" ] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combinations", "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r72" ] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://www.aoncology.com/role/Business" ], "lang": { "en-us": { "role": { "terseLabel": "Business", "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r105", "r133", "r134" ] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Changes in accounts payable for capital additions to property and equipment", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r42", "r43", "r44" ] }, "aonc_CapitalUnitClassA1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "CapitalUnitClassA1Member", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Capital Unit, Class A-1", "label": "Capital Unit, Class A-1 [Member]", "documentation": "Capital Unit, Class A-1" } } }, "auth_ref": [] }, "us-gaap_CapitalUnitClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalUnitClassAMember", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Capital Unit, Class A", "label": "Capital Unit, Class A [Member]", "documentation": "Class A of capital units, which are a type of ownership interest in a corporation." } } }, "auth_ref": [] }, "us-gaap_CapitalUnitClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalUnitClassBMember", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Capital Unit, Class B", "label": "Capital Unit, Class B [Member]", "documentation": "Class B of capital units, which are a type of ownership interest in a corporation." } } }, "auth_ref": [] }, "us-gaap_CapitalUnitClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalUnitClassDomain", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital Unit, Class [Domain]", "label": "Capital Unit, Class [Domain]", "documentation": "Description of the type or class of capital units or capital shares." } } }, "auth_ref": [] }, "us-gaap_CapitalUnitsByClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalUnitsByClassAxis", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Capital Units by Class [Axis]", "label": "Capital Units by Class [Axis]", "documentation": "Information by type or class of the entity's capital units." } } }, "auth_ref": [] }, "aonc_CashAndCashEquivalentsAcquiredThroughReverseRecapitalization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "CashAndCashEquivalentsAcquiredThroughReverseRecapitalization", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/ReverseRecapitalizationScheduleofHistoricalCostDetails": { "parentTag": "aonc_ReverseRecapitalizationNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/ReverseRecapitalizationScheduleofHistoricalCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash And Cash Equivalents Acquired Through Reverse Recapitalization", "documentation": "Cash And Cash Equivalents Acquired Through Reverse Recapitalization" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails": { "parentTag": "aonc_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost", "weight": 1.0, "order": 1.0 }, "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails", "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r41", "r176", "r731" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Axis]", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r176" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails": { "parentTag": "aonc_CashCashEquivalentsAndAvailableForSaleDebtSecurities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents, estimated fair value", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "aonc_CashCashEquivalentsAndAvailableForSaleDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "CashCashEquivalentsAndAvailableForSaleDebtSecurities", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails_1": { "parentTag": "aonc_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost", "weight": 1.0, "order": 2.0 }, "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Cash and cash equivalents and marketable securities, aggregate fair value", "label": "Cash, Cash Equivalents And Available-For-Sale Debt Securities", "documentation": "Cash, Cash Equivalents And Available-For-Sale Debt Securities" } } }, "auth_ref": [] }, "aonc_CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "CashCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCost", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Cash and cash equivalents and available-for-sale securities, amortized cost", "label": "Cash, Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost", "documentation": "Cash, Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning of period", "periodEndLabel": "End of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r41", "r130", "r206" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r130" ] }, "aonc_CashFlowLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "CashFlowLesseeAbstract", "presentation": [ "http://www.aoncology.com/role/LeasesSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:", "label": "Cash Flow, Lessee [Abstract]", "documentation": "Cash Flow, Lessee" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "aonc_ClassBPrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "ClassBPrefundedWarrantsMember", "presentation": [ "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class B Prefunded Warrants", "label": "Class B Prefunded Warrants [Member]", "documentation": "Class B Prefunded Warrants" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit", "http://www.aoncology.com/role/Cover", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r169", "r180", "r181", "r182", "r208", "r233", "r234", "r242", "r245", "r253", "r254", "r320", "r344", "r346", "r347", "r348", "r351", "r352", "r373", "r374", "r377", "r380", "r387", "r496", "r621", "r622", "r623", "r624", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r653", "r676", "r699", "r717", "r718", "r719", "r720", "r721", "r780", "r806", "r814" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/ReverseRecapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Axis]", "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r68" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/ReverseRecapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Domain]", "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "aonc_ClassOfWarrantOrRightExercisePeriodAfterInitialPublicOffering": { "xbrltype": "durationItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "ClassOfWarrantOrRightExercisePeriodAfterInitialPublicOffering", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant, exercise period, after initial public offering", "label": "Class Of Warrant Or Right, Exercise Period, After Initial Public Offering", "documentation": "Class Of Warrant Or Right, Exercise Period, After Initial Public Offering" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of securities called by each warrant (in shares)", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of warrant outstanding (in shares)", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "aonc_ClassOfWarrantOrRightOutstandingExercisePeriodAfterBusinessCombination": { "xbrltype": "durationItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "ClassOfWarrantOrRightOutstandingExercisePeriodAfterBusinessCombination", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant, exercise period, after business combination", "label": "Class Of Warrant Or Right Outstanding, Exercise Period, After Business Combination", "documentation": "Class Of Warrant Or Right Outstanding, Exercise Period, After Business Combination" } } }, "auth_ref": [] }, "aonc_ClinicalTrialsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "ClinicalTrialsMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Clinical Trials", "label": "Clinical Trials [Member]", "documentation": "Clinical Trials" } } }, "auth_ref": [] }, "aonc_CommonClassA1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "CommonClassA1Member", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Class A-1", "label": "Common Class A-1 [Member]", "documentation": "Common Class A-1" } } }, "auth_ref": [] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassAMember", "presentation": [ "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit", "http://www.aoncology.com/role/Cover", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Common Class A", "terseLabel": "Common Class A", "label": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r901" ] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassBMember", "presentation": [ "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit", "http://www.aoncology.com/role/Cover", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails", "http://www.aoncology.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class B Common Stock", "label": "Common Class B [Member]", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": [ "r901" ] }, "us-gaap_CommonClassCMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassCMember", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class C", "label": "Common Class C [Member]", "documentation": "Classification of common stock that has different rights than provided to Class A or B shares, representing ownership interest in a corporation." } } }, "auth_ref": [] }, "aonc_CommonStockClassB1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "CommonStockClassB1Member", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class B-1", "label": "Common Stock, Class B-1 [Member]", "documentation": "Common Stock, Class B-1" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r763", "r764", "r765", "r767", "r768", "r769", "r770", "r810", "r811", "r878", "r898", "r901" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in usd per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r110" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r110", "r653" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r110" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r14", "r110", "r653", "r673", "r901", "r902" ] }, "us-gaap_CommonStockValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValueOutstanding", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, value", "label": "Common Stock, Value, Outstanding", "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares." } } }, "auth_ref": [ "r110", "r653" ] }, "us-gaap_CommonUnitAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonUnitAuthorized", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common unit authorized (in units)", "label": "Common Unit, Authorized", "documentation": "Maximum number of common units of ownership permitted to be issued by a limited liability company (LLC)." } } }, "auth_ref": [] }, "us-gaap_CommonUnitIssuanceValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonUnitIssuanceValue", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning of Period", "periodEndLabel": "End of Period", "label": "Common Unit, Issuance Value", "documentation": "Stated value of common units of ownership issued by a limited liability company (LLC)." } } }, "auth_ref": [] }, "us-gaap_CommonUnitIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonUnitIssued", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of units (in units)", "terseLabel": "Issuances (in units)", "label": "Common Unit, Issued", "documentation": "Number of common units issued of limited liability company (LLC)." } } }, "auth_ref": [ "r141" ] }, "aonc_CommonUnitIssuedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "CommonUnitIssuedDuringPeriod", "presentation": [ "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of units (in units)", "label": "Common Unit, Issued During Period", "documentation": "Common Unit, Issued During Period" } } }, "auth_ref": [] }, "us-gaap_CommonUnitOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonUnitOutstanding", "presentation": [ "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in units)", "periodEndLabel": "Ending balance (in units)", "terseLabel": "Common unit, units outstanding (in units)", "label": "Common Unit, Outstanding", "documentation": "Number of common units of ownership outstanding of a limited liability company (LLC)." } } }, "auth_ref": [] }, "aonc_CommonUnitRedemptions": { "xbrltype": "sharesItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "CommonUnitRedemptions", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redemptions (in units)", "label": "Common Unit, Redemptions", "documentation": "Common Unit, Redemptions" } } }, "auth_ref": [] }, "aonc_CommonUnitRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "CommonUnitRepurchased", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchases (in units)", "label": "Common Unit, Repurchased", "documentation": "Common Unit, Repurchased" } } }, "auth_ref": [] }, "aonc_CommonUnitUnitImpactOfTheReverseRecapitalization": { "xbrltype": "sharesItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "CommonUnitUnitImpactOfTheReverseRecapitalization", "presentation": [ "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of the Reverse Recapitalization (in units)", "label": "Common Unit, Unit Impact Of The Reverse Recapitalization", "documentation": "Common Unit, Unit Impact Of The Reverse Recapitalization" } } }, "auth_ref": [] }, "aonc_CommonUnitUnitsIssuedValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "CommonUnitUnitsIssuedValue", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Units", "label": "Common Unit, Units Issued, Value", "documentation": "Common Unit, Units Issued, Value" } } }, "auth_ref": [] }, "aonc_CommonUnitValueImpactOfTheReverseRecapitalization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "CommonUnitValueImpactOfTheReverseRecapitalization", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impact of the Reverse Recapitalization", "label": "Common Unit, Value, Impact Of The Reverse Recapitalization", "documentation": "Common Unit, Value, Impact Of The Reverse Recapitalization" } } }, "auth_ref": [] }, "aonc_ComprehensiveIncomeLossNetOfTaxAttributableToCommonStockholders": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "ComprehensiveIncomeLossNetOfTaxAttributableToCommonStockholders", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive loss attributable to Class A Common Stockholders", "label": "Comprehensive Income (Loss), Net Of Tax, Attributable To Common Stockholders", "documentation": "Comprehensive Income (Loss), Net Of Tax, Attributable To Common Stockholders" } } }, "auth_ref": [] }, "aonc_ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestBeforeRecapitalization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestBeforeRecapitalization", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "aonc_ComprehensiveIncomeLossNetOfTaxAttributableToCommonStockholders", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive loss attributable to Legacy AON Shareholders", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest, Before Recapitalization", "documentation": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest, Before Recapitalization" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss):", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "aonc_ComprehensiveIncomeLossNetOfTaxAttributableToCommonStockholders", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive loss attributable to noncontrolling interests", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r77", "r87", "r192", "r194", "r200", "r583", "r602" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "aonc_ComprehensiveIncomeLossNetOfTaxAttributableToCommonStockholders", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r87", "r145", "r192", "r194", "r199", "r582", "r601" ] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer equipment", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r50", "r52", "r92", "r93", "r279", "r725" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r50", "r52", "r92", "r93", "r279", "r619", "r725" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r50", "r52", "r92", "r93", "r279", "r725", "r784" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk (in percentage)", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r50", "r52", "r92", "r93", "r279" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r50", "r52", "r92", "r93", "r279", "r725" ] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails", "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Axis]", "label": "Consolidated Entities [Axis]" } } }, "auth_ref": [ "r215", "r474", "r475", "r478", "r479", "r532", "r726", "r841", "r844", "r845" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails", "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidated Entities [Domain]", "label": "Consolidated Entities [Domain]" } } }, "auth_ref": [ "r215", "r474", "r475", "r478", "r479", "r532", "r726", "r841", "r844", "r845" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r78", "r736" ] }, "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interests", "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest." } } }, "auth_ref": [ "r162" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Construction-in-progress", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_CorporateBondSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateBondSecuritiesMember", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails", "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate bonds", "label": "Corporate Bond Securities [Member]", "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)." } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsTotalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsTotalMember", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Goods and Service Benchmark", "label": "Cost of Goods and Service Benchmark [Member]", "documentation": "Cost of product sold and service rendered, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r783" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical", "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of revenue", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r125", "r208", "r320", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r496", "r842" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total costs and expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r123" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/ReverseRecapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r212", "r213", "r356", "r375", "r530", "r733", "r735" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "aonc_CurrentLiabilitiesAssumedInReverseRecapitalization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "CurrentLiabilitiesAssumedInReverseRecapitalization", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/ReverseRecapitalizationScheduleofHistoricalCostDetails": { "parentTag": "aonc_ReverseRecapitalizationNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/ReverseRecapitalizationScheduleofHistoricalCostDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Current Liabilities", "label": "Current Liabilities Assumed In Reverse Recapitalization", "documentation": "Current Liabilities Assumed In Reverse Recapitalization" } } }, "auth_ref": [] }, "us-gaap_CustomerRefundLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRefundLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Refund liability", "label": "Customer Refund Liability, Current", "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment." } } }, "auth_ref": [] }, "aonc_DTOCSponsorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "DTOCSponsorMember", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "DTOC Sponsor", "label": "DTOC Sponsor [Member]", "documentation": "DTOC Sponsor" } } }, "auth_ref": [] }, "aonc_DTOCUnredeemedShareholdersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "DTOCUnredeemedShareholdersMember", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "DTOC Unredeemed Shareholders", "label": "DTOC Unredeemed Shareholders [Member]", "documentation": "DTOC Unredeemed Shareholders" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails", "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r19", "r106", "r107", "r151", "r152", "r215", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r505", "r744", "r745", "r746", "r747", "r748", "r807" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis spread (in percent)", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r19", "r152", "r370" ] }, "us-gaap_DebtInstrumentCollateralAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCollateralAmount", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pledged collateral", "label": "Debt Instrument, Collateral Amount", "documentation": "Amount of assets pledged to secure a debt instrument." } } }, "auth_ref": [ "r104" ] }, "aonc_DebtInstrumentCollateralReleasedQuarterly": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "DebtInstrumentCollateralReleasedQuarterly", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Quarterly collateral released", "label": "Debt Instrument, Collateral Released, Quarterly", "documentation": "Debt Instrument, Collateral Released, Quarterly" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails", "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r215", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r505", "r744", "r745", "r746", "r747", "r748", "r807" ] }, "aonc_DebtInstrumentMinimumFundingThresholdPercentage": { "xbrltype": "pureItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "DebtInstrumentMinimumFundingThresholdPercentage", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum funding threshold (in percent)", "label": "Debt Instrument, Minimum Funding Threshold, Percentage", "documentation": "Debt Instrument, Minimum Borrowing Threshold, Percentage" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails", "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r28", "r215", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r505", "r744", "r745", "r746", "r747", "r748", "r807" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails", "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-Term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r28", "r63", "r64", "r95", "r96", "r98", "r103", "r139", "r140", "r215", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r505", "r744", "r745", "r746", "r747", "r748", "r807" ] }, "aonc_DebtInstrumentThresholdLimitPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "DebtInstrumentThresholdLimitPeriodAxis", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Threshold Limit, Period [Axis]", "label": "Debt Instrument, Threshold Limit, Period [Axis]", "documentation": "Debt Instrument, Threshold Limit, Period" } } }, "auth_ref": [] }, "aonc_DebtInstrumentThresholdLimitPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "DebtInstrumentThresholdLimitPeriodDomain", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Threshold Limit, Period [Domain]", "label": "Debt Instrument, Threshold Limit, Period [Domain]", "documentation": "Debt Instrument, Threshold Limit, Period [Domain]" } } }, "auth_ref": [] }, "aonc_DebtInstrumentThresholdLimitPeriodOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "DebtInstrumentThresholdLimitPeriodOneMember", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Threshold Limit, Period One", "label": "Debt Instrument, Threshold Limit, Period One [Member]", "documentation": "Debt Instrument, Threshold Limit, Period One" } } }, "auth_ref": [] }, "aonc_DebtInstrumentThresholdLimitPeriodTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "DebtInstrumentThresholdLimitPeriodTwoMember", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Threshold Limit, Period Two", "label": "Debt Instrument, Threshold Limit, Period Two [Member]", "documentation": "Debt Instrument, Threshold Limit, Period Two" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails", "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828" ] }, "us-gaap_DeferredChargesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredChargesPolicyTextBlock", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Offering Costs", "label": "Deferred Charges, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges." } } }, "auth_ref": [ "r177" ] }, "us-gaap_DeferredFinanceCostsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsGross", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unamortized debt issuance costs", "label": "Debt Issuance Costs, Gross", "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r97" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Unamortized debt issuance costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r97", "r847" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax asset, net", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r457", "r458" ] }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes", "label": "Deferred Income Taxes and Tax Credits", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": [ "r132" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r7", "r260" ] }, "aonc_DerivativeInstrumentContingentConsiderationLiabilityShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "DerivativeInstrumentContingentConsiderationLiabilityShares", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnout shares not outstanding (in shares)", "label": "Derivative Instrument, Contingent Consideration, Liability, Shares", "documentation": "Derivative Instrument, Contingent Consideration, Liability, Shares" } } }, "auth_ref": [] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant Liabilities", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r15", "r88", "r89", "r90", "r91", "r214" ] }, "aonc_DescriptionOfBusinessAndSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "DescriptionOfBusinessAndSignificantAccountingPoliciesLineItems", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Description Of Business And Significant Accounting Policies [Line Items]", "label": "Description Of Business And Significant Accounting Policies [Line Items]", "documentation": "Description Of Business And Significant Accounting Policies [Line Items]" } } }, "auth_ref": [] }, "aonc_DescriptionOfBusinessAndSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "DescriptionOfBusinessAndSignificantAccountingPoliciesTable", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Description Of Business And Significant Accounting Policies [Table]", "label": "Description Of Business And Significant Accounting Policies [Table]", "documentation": "Description Of Business And Significant Accounting Policies [Table]" } } }, "auth_ref": [] }, "aonc_DigitalTransformationOpportunitiesCorpDTOCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "DigitalTransformationOpportunitiesCorpDTOCMember", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Digital Transformation Opportunities Corp. (\u201cDTOC\u201d)", "label": "Digital Transformation Opportunities Corp. (\u201cDTOC\u201d) [Member]", "documentation": "Digital Transformation Opportunities Corp. (\u201cDTOC\u201d)" } } }, "auth_ref": [] }, "us-gaap_DirectorsAndOfficersLiabilityInsuranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DirectorsAndOfficersLiabilityInsuranceMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Directors and Officers Liability Insurance", "label": "Directors and Officers Liability Insurance [Member]", "documentation": "Professional liability coverage for legal expenses and liability to shareholders, bondholders, creditors or others due to actions or omissions by a director or officer of a corporation or nonprofit organization." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Equity-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r408", "r412", "r443", "r444", "r446", "r755" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DistributedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DistributedEarnings", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails": { "parentTag": "us-gaap_UndistributedEarnings", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Series A Preferred Cumulative Dividends", "label": "Distributed Earnings", "documentation": "The total amount of dividends declared in the period for each class of stock and the contractual amount of dividends (or interest on participating income bonds) that must be paid for the period (for example, unpaid cumulative dividends). Dividends declared in the current period do not include dividends declared in respect of prior-period unpaid cumulative dividends. Preferred dividends that are cumulative only if earned are deducted only to the extent that they are earned." } } }, "auth_ref": [ "r239" ] }, "us-gaap_Dividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Dividends", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends", "label": "Dividends", "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock." } } }, "auth_ref": [ "r3", "r141" ] }, "us-gaap_DividendsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsAxis", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends [Axis]", "label": "Dividends [Axis]", "documentation": "Information about distribution of earnings to shareholders including, but not limited to, cash, property or capital stock." } } }, "auth_ref": [] }, "us-gaap_DividendsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsDomain", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends [Domain]", "label": "Dividends [Domain]", "documentation": "Distributions of earnings to shareholders including but not limited to cash, property or capital stock." } } }, "auth_ref": [] }, "aonc_DividendsPaidEventAfterJune72028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "DividendsPaidEventAfterJune72028Member", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends Paid, Event After June 7, 2028", "label": "Dividends Paid, Event After June 7, 2028 [Member]", "documentation": "Dividends Paid, Event After June 7, 2028" } } }, "auth_ref": [] }, "aonc_DividendsPaidEventPriorToJune72024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "DividendsPaidEventPriorToJune72024Member", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends Paid, Event Prior to June 7, 2024", "label": "Dividends Paid, Event Prior to June 7, 2024 [Member]", "documentation": "Dividends Paid, Event Prior to June 7, 2024" } } }, "auth_ref": [] }, "aonc_DividendsPaidEventPriorToJune72025AfterJune72024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "DividendsPaidEventPriorToJune72025AfterJune72024Member", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends Paid, Event Prior to June 7, 2025, After June 7, 2024", "label": "Dividends Paid, Event Prior to June 7, 2025, After June 7, 2024 [Member]", "documentation": "Dividends Paid, Event Prior to June 7, 2025, After June 7, 2024" } } }, "auth_ref": [] }, "aonc_DividendsPaidEventPriorToJune72026AfterJune72025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "DividendsPaidEventPriorToJune72026AfterJune72025Member", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends Paid, Event Prior to June 7, 2026, After June 7, 2025", "label": "Dividends Paid, Event Prior to June 7, 2026, After June 7, 2025 [Member]", "documentation": "Dividends Paid, Event Prior to June 7, 2026, After June 7, 2025" } } }, "auth_ref": [] }, "aonc_DividendsPaidEventPriorToJune72027AfterJune72026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "DividendsPaidEventPriorToJune72027AfterJune72026Member", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends Paid, Event Prior to June 7, 2027, After June 7, 2026", "label": "Dividends Paid, Event Prior to June 7, 2027, After June 7, 2026 [Member]", "documentation": "Dividends Paid, Event Prior to June 7, 2027, After June 7, 2026" } } }, "auth_ref": [] }, "aonc_DividendsPaidEventPriorToJune72028AfterJune72027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "DividendsPaidEventPriorToJune72028AfterJune72027Member", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends Paid, Event Prior to June 7, 2028, After June 7, 2027", "label": "Dividends Paid, Event Prior to June 7, 2028, After June 7, 2027 [Member]", "documentation": "Dividends Paid, Event Prior to June 7, 2028, After June 7, 2027" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r777" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r778" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Loss per share of Class A Common Stock:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Earnings (loss) per unit, basic (in usd per share)", "terseLabel": "Basic loss per share of Class A Common Stock (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r201", "r221", "r222", "r223", "r224", "r225", "r230", "r233", "r242", "r244", "r245", "r249", "r489", "r490", "r584", "r603", "r738" ] }, "us-gaap_EarningsPerShareBasicLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicLineItems", "presentation": [ "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r233", "r234", "r242" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Earnings (loss) per unit, diluted (in usd per share)", "terseLabel": "Diluted loss per share of Class A Common Stock (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r201", "r221", "r222", "r223", "r224", "r225", "r233", "r242", "r244", "r245", "r249", "r489", "r490", "r584", "r603", "r738" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r46", "r47" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.aoncology.com/role/NetLossPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r229", "r246", "r247", "r248" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.aoncology.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective income tax rate (in percent)", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r460" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation related costs", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r26" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation and benefits", "label": "Employee-related Liabilities", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r101", "r894" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r445" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost not yet recognized, period for recognition (in years)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r445" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockMember", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r775" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails", "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r775" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r775" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r779" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r775" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r775" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r775" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r775" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r14", "r171", "r195", "r196", "r197", "r216", "r217", "r218", "r220", "r226", "r228", "r250", "r321", "r322", "r388", "r447", "r448", "r449", "r464", "r465", "r480", "r481", "r482", "r483", "r484", "r485", "r488", "r497", "r498", "r499", "r500", "r501", "r502", "r523", "r613", "r614", "r615", "r632", "r699" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r317", "r318", "r319" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investment (in percent)", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r317" ] }, "us-gaap_EquityMethodInvestmentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsPolicy", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Investment in Affiliate", "label": "Equity Method Investments [Policy Text Block]", "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received." } } }, "auth_ref": [ "r5", "r94", "r318" ] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/ReverseRecapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Adjustment of Warrants", "label": "Fair Value Adjustment of Warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r0", "r7" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails", "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r361", "r400", "r401", "r402", "r403", "r404", "r405", "r491", "r536", "r537", "r538", "r745", "r746", "r751", "r752", "r753" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r361", "r400", "r405", "r491", "r536", "r751", "r752", "r753" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails", "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r361", "r400", "r405", "r491", "r537", "r745", "r746", "r751", "r752", "r753" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails", "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r361", "r400", "r401", "r402", "r403", "r404", "r405", "r536", "r537", "r538", "r745", "r746", "r751", "r752", "r753" ] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r10", "r16" ] }, "aonc_FinanceAndOperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "FinanceAndOperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails": { "parentTag": "aonc_LeaseLiability", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Current portion of operating and finance lease liabilities", "label": "Finance and Operating Lease Liability, Current", "documentation": "Finance and Operating Lease Liability, Current" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/LeasesLeaseCostsDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest on finance lease liabilities (included in interest expense)", "label": "Finance Lease, Interest Expense", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": [ "r510", "r515", "r759" ] }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/LeasesSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows from finance leases", "label": "Finance Lease, Interest Payment on Liability", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": [ "r512", "r518" ] }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance \u2028Leases", "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiability", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Present value of lease liabilities", "label": "Finance Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r508", "r522" ] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails": { "parentTag": "aonc_FinanceAndOperatingLeaseLiabilityCurrent", "weight": 1.0, "order": 2.0 }, "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0, "order": 2.0 }, "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails", "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails", "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Less: current portion of lease liabilities", "verboseLabel": "Current portion of finance lease liabilities (included in accrued other)", "negatedTerseLabel": "Less: current portion of lease liabilities", "label": "Finance Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r508" ] }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current finance lease liability." } } }, "auth_ref": [ "r509" ] }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.aoncology.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Finance Lease, Liability, to be Paid, Maturity", "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r883" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails": { "parentTag": "aonc_LeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails", "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-term finance lease liabilities (included in other long-term liabilities)", "terseLabel": "Long-term lease liabilities, net of current portion", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r508" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Finance Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r522" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finance Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r522" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finance Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r522" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finance Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r522" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finance Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r522" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 (remainder of year after March 31, 2024)", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r883" ] }, "aonc_FinanceLeaseLiabilityToBePaidDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "FinanceLeaseLiabilityToBePaidDueAfterYearFour", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finance Lease, Liability, to be Paid, Due after Year Four", "documentation": "Finance Lease, Liability, to be Paid, Due after Year Four" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: amount representing interest", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r522" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/LeasesSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financing cash flows from finance leases", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r511", "r518" ] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails": { "parentTag": "aonc_LeaseRightOfUseAsset", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finance lease right-of-use assets, net (included in property and equipment, net)", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r507" ] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/LeasesLeaseCostsDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of finance lease right-of-use assets", "label": "Finance Lease, Right-of-Use Asset, Amortization", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": [ "r510", "r515", "r759" ] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.aoncology.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate for finance leases (in percent)", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": [ "r521", "r759" ] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.aoncology.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term for finance leases (in years)", "label": "Finance Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r520", "r759" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails", "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r323", "r324", "r325", "r326", "r327", "r330", "r331", "r332", "r369", "r385", "r486", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r600", "r743", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r828", "r829", "r830", "r831" ] }, "aonc_FinancingReceivableAfterAllowanceForCreditLossOriginalPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "FinancingReceivableAfterAllowanceForCreditLossOriginalPrincipal", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Original\u2028Principal", "label": "Financing Receivable, After allowance For Credit Loss, Original Principal", "documentation": "Financing Receivable, After allowance For Credit Loss, Original Principal" } } }, "auth_ref": [] }, "aonc_FinancingReceivableAmortizationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "FinancingReceivableAmortizationPeriod", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes receivable, amortization period (in months)", "label": "Financing Receivable, Amortization Period", "documentation": "Financing Receivable, Amortization Period" } } }, "auth_ref": [] }, "aonc_FinancingReceivableBorrowingRate": { "xbrltype": "percentItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "FinancingReceivableBorrowingRate", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incremental borrowing rate", "label": "Financing Receivable, Borrowing Rate", "documentation": "Financing Receivable, Borrowing Rate" } } }, "auth_ref": [] }, "aonc_FurnitureFixturesAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "FurnitureFixturesAndEquipmentMember", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture, fixtures and equipment", "label": "Furniture, Fixtures and Equipment [Member]", "documentation": "Furniture, Fixtures and Equipment" } } }, "auth_ref": [] }, "us-gaap_GainLossOnDispositionOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnDispositionOfAssets", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gain on sale of property and equipment", "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property." } } }, "auth_ref": [ "r805", "r833", "r837" ] }, "aonc_GainLossOnIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "GainLossOnIssuanceOfWarrants", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/ReverseRecapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Gain (loss) on issuance of warrants", "label": "Gain (Loss) On Issuance Of Warrants", "documentation": "Gain (Loss) On Issuance Of Warrants" } } }, "auth_ref": [] }, "aonc_GainLossOnReverseRecapitalization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "GainLossOnReverseRecapitalization", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/ReverseRecapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (Loss) On Reverse Recapitalization", "label": "Gain (Loss) On Reverse Recapitalization", "documentation": "Gain (Loss) On Reverse Recapitalization" } } }, "auth_ref": [] }, "aonc_GainLossOnWarrantAndDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "GainLossOnWarrantAndDerivativeNet", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Changes in fair value adjustments of warrants and derivative liabilities", "label": "Gain (Loss) On Warrant And Derivative, Net", "documentation": "Gain (Loss) On Warrant And Derivative, Net" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative expenses", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r126", "r678" ] }, "aonc_IncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "IncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsNetOfTax", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before equity loss in affiliate and noncontrolling interest", "label": "Income (Loss) From Continuing Operations Before Equity Method Investments, Net Of Tax", "documentation": "Income (Loss) From Continuing Operations Before Equity Method Investments, Net Of Tax" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "aonc_IncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income taxes, equity loss in affiliate, and noncontrolling interest", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." } } }, "auth_ref": [ "r255", "r270", "r274", "r276", "r604", "r740" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 }, "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Equity in loss of affiliate", "negatedTerseLabel": "Equity in loss of affiliate", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r7", "r120", "r155", "r261", "r316", "r596" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.aoncology.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r209", "r456", "r461", "r462", "r463", "r466", "r468", "r469", "r470", "r626" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "aonc_IncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.aoncology.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r161", "r167", "r227", "r228", "r262", "r459", "r467", "r605" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Patient accounts receivable, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation related costs", "label": "Increase (Decrease) in Employee Related Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r786", "r804" ] }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 18.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued other", "label": "Increase (Decrease) in Other Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherReceivables", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 19.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other receivables", "label": "Increase (Decrease) in Other Receivables", "documentation": "Amount of increase (decrease) in receivables classified as other." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r6" ] }, "aonc_IncreaseDecreaseInRedeemableNoncontrollingInterestRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "IncreaseDecreaseInRedeemableNoncontrollingInterestRollForward", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) In Noncontrolling Interest [Roll Forward]", "label": "Increase (Decrease) In Redeemable Noncontrolling Interest [Roll Forward]", "documentation": "Increase (Decrease) In Redeemable Noncontrolling Interest" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable Preferred Stock", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsNetIncludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetIncludingGoodwill", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and intangibles, net", "label": "Intangible Assets, Net (Including Goodwill)", "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance." } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r97", "r157", "r198", "r259", "r503", "r684", "r771", "r900" ] }, "aonc_IntravenousDrugsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "IntravenousDrugsMember", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intravenous drugs", "label": "Intravenous Drugs [Member]", "documentation": "Intravenous Drugs" } } }, "auth_ref": [] }, "us-gaap_InventoryCurrentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryCurrentTable", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory, Current [Table]", "label": "Inventory, Current [Table]", "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_InventoryLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryLineItems", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory [Line Items]", "label": "Inventory [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 }, "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofInventoryDetails", "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r185", "r732", "r760" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r127", "r258" ] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://www.aoncology.com/role/MarketableSecurities" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r148", "r158", "r159", "r170", "r282", "r284", "r494", "r495" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/LeasesLeaseCostsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease costs", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r514", "r759" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.aoncology.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Lease, Cost", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r882" ] }, "aonc_LeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "LeaseLiability", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease liabilities", "label": "Lease, Liability", "documentation": "Lease, Liability" } } }, "auth_ref": [] }, "aonc_LeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "LeaseLiabilityAbstract", "presentation": [ "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Lease, Liability [Abstract]", "documentation": "Lease, Liability" } } }, "auth_ref": [] }, "aonc_LeaseLiabilityCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "LeaseLiabilityCurrentAbstract", "presentation": [ "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current", "label": "Lease Liability, Current [Abstract]", "documentation": "Lease Liability, Current" } } }, "auth_ref": [] }, "aonc_LeaseLiabilityNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "LeaseLiabilityNoncurrentAbstract", "presentation": [ "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term", "label": "Lease Liability, Noncurrent [Abstract]", "documentation": "Lease Liability, Noncurrent" } } }, "auth_ref": [] }, "aonc_LeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "LeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total right-of-use assets", "label": "Lease, Right-Of-Use Asset", "documentation": "Lease, Right-Of-Use Asset" } } }, "auth_ref": [] }, "aonc_LeaseRightOfUseAssetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "LeaseRightOfUseAssetAbstract", "presentation": [ "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Lease, Right-Of-Use Asset [Abstract]", "documentation": "Lease, Right-Of-Use Asset" } } }, "auth_ref": [] }, "aonc_LeaseRightOfUseAssetAndLiabilityReductionFromLeaseTerminations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "LeaseRightOfUseAssetAndLiabilityReductionFromLeaseTerminations", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Right-of-use assets and lease liabilities removed in termination of lease", "label": "Lease, Right-Of-Use Asset And Liability Reduction From Lease Terminations", "documentation": "Lease, Right-Of-Use Asset And Liability Reduction From Lease Terminations" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r136" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "aonc_LegacyAONShareholdersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "LegacyAONShareholdersMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legacy AON Shareholders", "label": "Legacy AON Shareholders [Member]", "documentation": "Legacy AON Shareholders" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails", "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "aonc_LesseeAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "LesseeAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.aoncology.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Assets And Liabilities", "label": "Lessee, Assets And Liabilities [Table Text Block]", "documentation": "Lessee, Assets And Liabilities" } } }, "auth_ref": [] }, "us-gaap_LesseeFinanceLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeFinanceLeasesTextBlock", "presentation": [ "http://www.aoncology.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Finance Leases [Text Block]", "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability." } } }, "auth_ref": [ "r506" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.aoncology.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Operating Lease, Liability, to be Paid, Maturity", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r883" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r522" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r522" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r522" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r522" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r522" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 (remainder of year after March 31, 2024)", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r883" ] }, "aonc_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, Due after Year Four", "documentation": "Lessee, Operating Lease, Liability, to be Paid, Due after Year Four" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: amount representing interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r522" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.aoncology.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r506" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 }, "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r25", "r208", "r320", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r475", "r478", "r479", "r496", "r652", "r739", "r773", "r842", "r885", "r886" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities, mezzanine equity, noncontrolling interest, and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r115", "r154", "r595", "r760", "r808", "r832", "r881" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities, Mezzanine Equity, and Stockholders' Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r27", "r175", "r208", "r320", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r475", "r478", "r479", "r496", "r760", "r842", "r885", "r886" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "aonc_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerAllocationOfIncome": { "xbrltype": "pureItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerAllocationOfIncome", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allocation of income to controlling and noncontrolling interests (in percent)", "label": "Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Allocation Of Income", "documentation": "Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Allocation Of Income" } } }, "auth_ref": [] }, "aonc_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerAllocationOfLosses": { "xbrltype": "pureItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerAllocationOfLosses", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allocation of losses to controlling and noncontrolling interests (in percent)", "label": "Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Allocation Of Losses", "documentation": "Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Allocation Of Losses" } } }, "auth_ref": [] }, "us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails", "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Allocation of income to controlling and noncontrolling interests (in percent)", "terseLabel": "Allocation of income to controlling and noncontrolling interests", "label": "Limited Liability Company (LLC) or Limited Partnership (LP), Managing Member or General Partner, Ownership Interest", "documentation": "Percentage investment held by the managing member or general partner of the limited liability company (LLC) or limited partnership (LP)." } } }, "auth_ref": [ "r49" ] }, "us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest", "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership interest", "label": "Limited Liability Company or Limited Partnership, Members or Limited Partners, Ownership Interest", "documentation": "Percentage investment held by members or limited partners of limited liability company (LLC) or limited partnership (LP)." } } }, "auth_ref": [ "r49" ] }, "aonc_LimitedLiabilityCompanyLLCOwnershipThresholdPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "LimitedLiabilityCompanyLLCOwnershipThresholdPercentage", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "LLC ownership threshold, percentage", "label": "Limited Liability Company (LLC), Ownership Threshold, Percentage", "documentation": "Limited Liability Company (LLC), Ownership Threshold, Percentage" } } }, "auth_ref": [] }, "aonc_LimitedLiabilityCompanyLLCUnitsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "LimitedLiabilityCompanyLLCUnitsIssued", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Units Issued (in units)", "label": "Limited Liability Company (LLC) Units, Issued", "documentation": "Limited Liability Company (LLC) Units, Issued" } } }, "auth_ref": [] }, "aonc_LimitedLiabilityCompanyLLCUnitsOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "LimitedLiabilityCompanyLLCUnitsOutstanding", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in units)", "periodEndLabel": "Ending balance (in units)", "label": "Limited Liability Company (LLC), Units, Outstanding", "documentation": "Limited Liability Company (LLC), Units, Outstanding" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bank fee (in percent)", "label": "Line of Credit Facility, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r23" ] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unused line fee (in percent)", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditMember", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails", "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "aonc_LondonInterbankOfferedRateLIBOR1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "LondonInterbankOfferedRateLIBOR1Member", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "London Interbank Offered Rate (LIBOR) 1", "label": "London Interbank Offered Rate (LIBOR) 1 [Member]", "documentation": "London Interbank Offered Rate (LIBOR) 1" } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r19", "r152", "r360", "r371", "r745", "r746", "r895" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, net", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r179" ] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtTextBlock", "presentation": [ "http://www.aoncology.com/role/LongtermDebt" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt", "label": "Long-Term Debt [Text Block]", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r137" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails", "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r28" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails", "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r28", "r57" ] }, "aonc_MIBAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "MIBAMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MIBA", "label": "MIBA [Member]", "documentation": "MIBA" } } }, "auth_ref": [] }, "us-gaap_MalpracticeInsuranceAnnualCoverageLimit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MalpracticeInsuranceAnnualCoverageLimit", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Malpractice insurance, limit per policy period", "label": "Malpractice Insurance, Annual Coverage Limit", "documentation": "Annual coverage limit provided by the insurance arrangement for malpractice claims." } } }, "auth_ref": [] }, "us-gaap_MalpracticeInsuranceMaximumCoveragePerIncident": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MalpracticeInsuranceMaximumCoveragePerIncident", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Malpractice insurance, coverage per claim", "label": "Malpractice Insurance, Maximum Coverage Per Incident", "documentation": "Maximum coverage per malpractice claim provided by the insurance arrangement." } } }, "auth_ref": [ "r160" ] }, "us-gaap_MalpracticeLossContingencyPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MalpracticeLossContingencyPolicy", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Professional Liability", "label": "Malpractice Loss Contingency, Policy [Policy Text Block]", "documentation": "Disclosure of the accounting policy for malpractice loss contingencies accrual (general and professional liability) which may include the method for calculating incurred but not reported (IBNR) claims, the use of actuarial and individual case-based assumptions, whether the accrual has been discounted, the types of costs included in the accrual (for example, legal costs) and other significant estimates used to determine the accrued liability." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesPolicy", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term Marketable Securities", "label": "Marketable Securities, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": [ "r102" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r340", "r341", "r342", "r343", "r407", "r566", "r612", "r644", "r645", "r708", "r710", "r713", "r714", "r715", "r727", "r728", "r742", "r749", "r754", "r762", "r846", "r887", "r888", "r889", "r890", "r891", "r892" ] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input, Expected Dividend Rate", "label": "Measurement Input, Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": [ "r879" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input, Expected Term", "label": "Measurement Input, Expected Term [Member]", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r879" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input, Price Volatility", "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r879" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input, Risk Free Interest Rate", "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r879" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r492" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "aonc_MedicalEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "MedicalEquipmentMember", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medical equipment", "label": "Medical Equipment [Member]", "documentation": "Medical Equipment" } } }, "auth_ref": [] }, "us-gaap_MemberUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MemberUnitsMember", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Common Units", "label": "Member Units [Member]", "documentation": "Ownership interest in limited liability company (LLC)." } } }, "auth_ref": [] }, "us-gaap_MembersCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MembersCapital", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Invested capital contributions", "label": "Members' Capital", "documentation": "Amount of member capital in limited liability company (LLC)." } } }, "auth_ref": [ "r141" ] }, "us-gaap_MembersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MembersEquity", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Members' Equity", "documentation": "Amount of ownership interest in limited liability company (LLC), attributable to the parent entity." } } }, "auth_ref": [ "r141", "r251", "r252", "r253", "r254" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r340", "r341", "r342", "r343", "r407", "r566", "r612", "r644", "r645", "r708", "r710", "r713", "r714", "r715", "r727", "r728", "r742", "r749", "r754", "r762", "r846", "r887", "r888", "r889", "r890", "r891", "r892" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interest", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r32", "r153", "r208", "r320", "r344", "r346", "r347", "r348", "r351", "r352", "r496", "r594", "r655" ] }, "us-gaap_MinorityInterestDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestDisclosureTextBlock", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterest" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable Noncontrolling Interest", "label": "Noncontrolling Interest Disclosure [Text Block]", "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock." } } }, "auth_ref": [ "r144" ] }, "us-gaap_MinorityInterestLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestLineItems", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Line Items]", "label": "Noncontrolling Interest [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestTable", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Table]", "label": "Noncontrolling Interest [Table]", "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock." } } }, "auth_ref": [ "r32", "r76", "r79", "r124" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r851" ] }, "us-gaap_MovementInMinorityInterestRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MovementInMinorityInterestRollForward", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity, Attributable to Noncontrolling Interest [Roll Forward]", "label": "Equity, Attributable to Noncontrolling Interest [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r205" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r205" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r130", "r131", "r132" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss)", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r121", "r132", "r156", "r173", "r190", "r193", "r197", "r208", "r219", "r221", "r222", "r223", "r224", "r227", "r228", "r239", "r255", "r270", "r274", "r276", "r320", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r490", "r496", "r599", "r675", "r697", "r698", "r740", "r771", "r842" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss)", "negatedTerseLabel": "Net loss attributable to redeemable noncontrolling interest", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r86", "r147", "r190", "r193", "r227", "r228", "r598", "r803" ] }, "us-gaap_NetIncomeLossAttributableToNonredeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNonredeemableNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "aonc_NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest", "weight": -1.0, "order": 1.0 }, "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss_1": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Net income attributable to noncontrolling interest", "label": "Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest", "documentation": "Portion of net income (loss) attributable to nonredeemable noncontrolling interest." } } }, "auth_ref": [ "r124" ] }, "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 2.0 }, "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss_1": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss attributable to redeemable noncontrolling interest", "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest." } } }, "auth_ref": [ "r124" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 1.0 }, "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails": { "parentTag": "us-gaap_UndistributedEarnings", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to Class A Common Stockholders, Basic", "verboseLabel": "Net loss attributable to Class A Common Stockholders for basic earnings per share", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r202", "r221", "r222", "r223", "r224", "r230", "r231", "r241", "r245", "r255", "r270", "r274", "r276", "r740" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to Class A Common Stockholders, Diluted", "verboseLabel": "Net loss attributable to Class A Common Stockholders for diluted earnings per share", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r202", "r232", "r235", "r236", "r237", "r238", "r241", "r245" ] }, "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) attributable to common shareholders", "label": "Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders." } } }, "auth_ref": [ "r231", "r245" ] }, "aonc_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestBeforeRecapitalization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestBeforeRecapitalization", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 4.0 }, "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss_1": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss and noncontrolling interest attributable to Legacy AON Stockholders prior to the reverse recapitalization", "verboseLabel": "Net loss attributable to Legacy AON Shareholders", "negatedLabel": "Net loss and noncontrolling interest attributable to Legacy AON Stockholders prior to the reverse recapitalization", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Before Recapitalization", "documentation": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Before Recapitalization" } } }, "auth_ref": [] }, "aonc_NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss before redeemable noncontrolling interest", "label": "Net Income (Loss), Including Portion Attributable To Redeemable Noncontrolling Interest", "documentation": "Net Income (Loss), Including Portion Attributable To Redeemable Noncontrolling Interest" } } }, "auth_ref": [] }, "aonc_NewAONAONIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "NewAONAONIncMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AON Inc.", "verboseLabel": "New AON (AON Inc.)", "label": "New AON (AON Inc.) [Member]", "documentation": "New AON (AON Inc.)" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Adopted Accounting Pronouncements\u00a0 and Recently Issued Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "aonc_NoncashConsiderationFairValueOfConsiderationForEquityMethodInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "NoncashConsiderationFairValueOfConsiderationForEquityMethodInvestment", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncash consideration of equity method investment", "label": "Noncash Consideration, Fair Value Of Consideration For Equity Method Investment", "documentation": "Noncash Consideration, Fair Value Of Consideration For Equity Method Investment" } } }, "auth_ref": [] }, "aonc_NoncashContributionsFromNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "NoncashContributionsFromNoncontrollingInterest", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Contribution from noncontrolling interest", "label": "Noncash Contributions From Noncontrolling Interest", "documentation": "Noncash Contributions From Noncontrolling Interest" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestAbstract", "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Capital contributions from noncontrolling interest member", "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance", "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders." } } }, "auth_ref": [ "r11", "r65", "r146" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r75", "r388", "r810", "r811", "r812", "r901" ] }, "aonc_NoncurrentLiabilitiesAssumedInReverseRecapitalization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "NoncurrentLiabilitiesAssumedInReverseRecapitalization", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/ReverseRecapitalizationScheduleofHistoricalCostDetails": { "parentTag": "aonc_ReverseRecapitalizationNet", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/ReverseRecapitalizationScheduleofHistoricalCostDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Long Term Liabilities", "label": "Noncurrent Liabilities Assumed In Reverse Recapitalization", "documentation": "Noncurrent Liabilities Assumed In Reverse Recapitalization" } } }, "auth_ref": [] }, "us-gaap_NotesAndLoansReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesAndLoansReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails": { "parentTag": "us-gaap_NotesReceivableNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of notes receivable - related parties", "negatedLabel": "Less:\u00a0\u00a0Current portion of notes receivable", "label": "Financing Receivable, after Allowance for Credit Loss, Current", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease." } } }, "auth_ref": [ "r280", "r281", "r581" ] }, "us-gaap_NotesAndLoansReceivableNetNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesAndLoansReceivableNetNoncurrent", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails": { "parentTag": "us-gaap_NotesReceivableNet", "weight": 1.0, "order": 1.0 }, "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes receivable - related parties", "label": "Financing Receivable, after Allowance for Credit Loss, Noncurrent", "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent." } } }, "auth_ref": [] }, "us-gaap_NotesIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesIssued1", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Promissory note issued in connection with acquisition", "label": "Notes Issued", "documentation": "The fair value of notes issued in noncash investing and financing activities." } } }, "auth_ref": [ "r42", "r43", "r44" ] }, "us-gaap_NotesReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesReceivableNet", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total notes receivables", "label": "Financing Receivable, after Allowance for Credit Loss", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease." } } }, "auth_ref": [ "r280", "r328", "r662" ] }, "aonc_NumberOfBoardOfManagersDesignatedByCompany": { "xbrltype": "integerItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "NumberOfBoardOfManagersDesignatedByCompany", "presentation": [ "http://www.aoncology.com/role/ReverseRecapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of board of managers designated by company", "label": "Number Of Board Of Managers Designated By Company", "documentation": "Number Of Board Of Managers Designated By Company" } } }, "auth_ref": [] }, "aonc_NumberOfBoardOfManagersDesignatedByMajorityCommonUnitHolders": { "xbrltype": "integerItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "NumberOfBoardOfManagersDesignatedByMajorityCommonUnitHolders", "presentation": [ "http://www.aoncology.com/role/ReverseRecapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of board of managers designated by majority common unit holders", "label": "Number Of Board Of Managers Designated By Majority Common Unit Holders", "documentation": "Number Of Board Of Managers Designated By Majority Common Unit Holders" } } }, "auth_ref": [] }, "aonc_NumberOfOfficesWithOperatingLeases": { "xbrltype": "integerItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "NumberOfOfficesWithOperatingLeases", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of offices with operating lease", "label": "Number Of Offices With Operating Leases", "documentation": "Number Of Offices With Operating Leases" } } }, "auth_ref": [] }, "aonc_NumberOfOncologyPractices": { "xbrltype": "integerItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "NumberOfOncologyPractices", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of oncology practices", "label": "Number Of Oncology Practices", "documentation": "Number Of Oncology Practices" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r815" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r815" ] }, "us-gaap_NumberOfStatesInWhichEntityOperates": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfStatesInWhichEntityOperates", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of states in which entity operates", "label": "Number of States in which Entity Operates", "documentation": "The number of states the entity operates in as of the balance sheet date." } } }, "auth_ref": [] }, "aonc_OCPManagementArizonaLLPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "OCPManagementArizonaLLPMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "OCP Management Arizona, LLP", "label": "OCP Management Arizona, LLP [Member]", "documentation": "OCP Management Arizona, LLP" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Costs and expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r255", "r270", "r274", "r276", "r740" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/LeasesLeaseCostsDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease costs", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r516", "r759" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating \u2028Leases", "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Present value of lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r508" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails": { "parentTag": "aonc_FinanceAndOperatingLeaseLiabilityCurrent", "weight": 1.0, "order": 1.0 }, "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails", "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of operating lease liabilities", "negatedLabel": "Less: current portion of lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r508" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 }, "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails": { "parentTag": "aonc_LeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/LeasesMaturitiesofOperatingandFinancingLeaseLiabilitiesDetails", "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Long-term operating lease liabilities", "terseLabel": "Long-term lease liabilities, net of current portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r508" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/LeasesSupplementalCashFlowInformationDetails", "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows from operating leases", "verboseLabel": "Payments for operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r513", "r518" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails": { "parentTag": "aonc_LeaseRightOfUseAsset", "weight": 1.0, "order": 2.0 }, "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/LeasesRightofuseAssetsAndLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "verboseLabel": "Operating lease right-of-use assets, net", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r507" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of operating right-of-use assets", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r805" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.aoncology.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate for operating leases (in percent)", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r521", "r759" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.aoncology.com/role/LeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term for operating leases (in years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r520", "r759" ] }, "aonc_OralPharmaceuticalsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "OralPharmaceuticalsMember", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Oral pharmaceuticals", "label": "Oral Pharmaceuticals [Member]", "documentation": "Oral Pharmaceuticals" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Significant Accounting Policies", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": [ "r105", "r133", "r134", "r144" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 }, "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued other", "totalLabel": "Accrued other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r26" ] }, "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued other", "label": "Other Accrued Liabilities", "documentation": "Amount of expenses incurred but not yet paid classified as other." } } }, "auth_ref": [ "r101" ] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssets", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": [ "r149", "r177", "r589", "r773" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r177" ] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "aonc_OtherComprehensiveIncomeLossNetOfTaxIncludingRedeemableNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on marketable securities", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r187", "r188", "r189" ] }, "aonc_OtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestBeforeRecapitalization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "OtherComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestBeforeRecapitalization", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "negatedLabel": "Other comprehensive income attributable to Legacy AON Shareholders", "label": "Other Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest, Before Recapitalization", "documentation": "Other Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest, Before Recapitalization" } } }, "auth_ref": [] }, "aonc_OtherComprehensiveIncomeLossNetOfTaxIncludingRedeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "OtherComprehensiveIncomeLossNetOfTaxIncludingRedeemableNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive gain (loss)", "label": "Other Comprehensive Income (Loss), Net Of Tax, Including Redeemable Noncontrolling Interest", "documentation": "Other Comprehensive Income (Loss), Net Of Tax, Including Redeemable Noncontrolling Interest" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive loss attributable to noncontrolling interests", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests." } } }, "auth_ref": [ "r4", "r12", "r145", "r191", "r194" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "verboseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r4", "r12", "r145", "r191", "r194" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due to AON LLC and subsidiaries, net", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r26", "r760" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 }, "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r29" ] }, "aonc_OtherMiscellaneousReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "OtherMiscellaneousReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofOtherReceivablesDetails": { "parentTag": "us-gaap_OtherReceivablesNetCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Miscellaneous Receivables, Net, Current", "documentation": "Other Miscellaneous Receivables, Net, Current" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other (expense) income, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r128" ] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense)", "label": "Other Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivables", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Other Receivables", "documentation": "Amount due from parties in nontrade transactions, classified as other." } } }, "auth_ref": [ "r183", "r661" ] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofOtherReceivablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "totalLabel": "Other receivables", "label": "Other Receivables, Net, Current", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherSundryLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherSundryLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Sundry Liabilities, Current", "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date." } } }, "auth_ref": [ "r26", "r56" ] }, "aonc_OvernightRepurchaseAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "OvernightRepurchaseAgreementsMember", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Overnight Repurchase Agreements", "label": "Overnight Repurchase Agreements [Member]", "documentation": "Overnight Repurchase Agreements" } } }, "auth_ref": [] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails", "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestScheduleofOwnershipDetails", "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "aonc_PNCLineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "PNCLineOfCreditMember", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PNC Line of Credit", "label": "PNC Line Of Credit [Member]", "documentation": "PNC Line Of Credit" } } }, "auth_ref": [] }, "aonc_PNCLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "PNCLoanFacilityMember", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails", "http://www.aoncology.com/role/LongtermDebtScheduleofLongtermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "PNC Loan Facility", "label": "PNC Loan Facility [Member]", "documentation": "PNC Loan Facility" } } }, "auth_ref": [] }, "aonc_ParticipatingThreshold1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "ParticipatingThreshold1Member", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Participating Threshold, 1", "label": "Participating Threshold, 1 [Member]", "documentation": "Participating Threshold, 1" } } }, "auth_ref": [] }, "aonc_ParticipatingThreshold2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "ParticipatingThreshold2Member", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Participating Threshold, 2", "label": "Participating Threshold, 2 [Member]", "documentation": "Participating Threshold, 2" } } }, "auth_ref": [] }, "aonc_ParticipatingThreshold3Member": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "ParticipatingThreshold3Member", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Participating Threshold, 3", "label": "Participating Threshold, 3 [Member]", "documentation": "Participating Threshold, 3" } } }, "auth_ref": [] }, "aonc_ParticipatingThresholdAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "ParticipatingThresholdAxis", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Participating Threshold [Axis]", "label": "Participating Threshold [Axis]", "documentation": "Participating Threshold" } } }, "auth_ref": [] }, "aonc_ParticipatingThresholdDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "ParticipatingThresholdDomain", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Participating Threshold [Domain]", "label": "Participating Threshold [Domain]", "documentation": "Participating Threshold [Domain]" } } }, "auth_ref": [] }, "aonc_PatientServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "PatientServiceMember", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Patient service revenue, net", "label": "Patient Service [Member]", "documentation": "Patient Service" } } }, "auth_ref": [] }, "aonc_PatientVisitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "PatientVisitsMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patient Visits", "label": "Patient Visits [Member]", "documentation": "Patient Visits And Shipments Of Prescriptions" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDividends", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments of dividends", "label": "Payments of Dividends", "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests." } } }, "auth_ref": [ "r40" ] }, "us-gaap_PaymentsOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfFinancingCosts", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments on finance lease liabilities", "label": "Payments of Financing Costs", "documentation": "The cash outflow for loan and debt issuance costs." } } }, "auth_ref": [ "r39" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchases of Class A Common Stock", "terseLabel": "Offering costs", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r39" ] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of marketable securities", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r36", "r203", "r283" ] }, "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments to acquire interest in subsidiary", "label": "Payments to Acquire Interest in Subsidiaries and Affiliates", "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity)." } } }, "auth_ref": [ "r37" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r129" ] }, "aonc_PhysiciansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "PhysiciansMember", "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Physician Owned", "label": "Physicians [Member]", "documentation": "Physician Owned" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r852", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877" ] }, "us-gaap_PreferredClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredClassAMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Class A", "label": "Preferred Class A [Member]", "documentation": "Outstanding nonredeemable preferred class A stock or outstanding convertible preferred class A stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer." } } }, "auth_ref": [] }, "us-gaap_PreferredStockDividendRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockDividendRatePercentage", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued dividend rate (in percent)", "label": "Preferred Stock, Dividend Rate, Percentage", "documentation": "The percentage rate used to calculate dividend payments on preferred stock." } } }, "auth_ref": [ "r374", "r709", "r711", "r712", "r716" ] }, "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Mezzanine equity", "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PreferredUnitsOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredUnitsOutstanding", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred units, outstanding (in units)", "label": "Preferred Units, Outstanding", "documentation": "The number of preferred units outstanding." } } }, "auth_ref": [ "r142" ] }, "us-gaap_PrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r800" ] }, "aonc_PrivatePlacementWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "PrivatePlacementWarrantsMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private Placement Warrants", "label": "Private Placement Warrants [Member]", "documentation": "Private Placement Warrants" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromCollectionOfNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromCollectionOfNotesReceivable", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Collections on notes receivable - related parties", "label": "Proceeds from Collection of Notes Receivable", "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r35" ] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from lines of credit", "label": "Proceeds from Lines of Credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r38", "r807" ] }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLongTermLinesOfCredit", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from facility", "label": "Proceeds from Long-Term Lines of Credit", "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": [ "r38" ] }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sales of marketable securities", "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r35", "r203", "r283", "r315" ] }, "us-gaap_ProductAndServiceOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductAndServiceOtherMember", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other revenue", "label": "Product and Service, Other [Member]", "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other." } } }, "auth_ref": [ "r850" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r277", "r567", "r606", "r607", "r608", "r609", "r610", "r611", "r730", "r750", "r761", "r787", "r839", "r840", "r849", "r897" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r277", "r567", "r606", "r607", "r608", "r609", "r610", "r611", "r730", "r750", "r761", "r787", "r839", "r840", "r849", "r897" ] }, "us-gaap_ProfessionalMalpracticeLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfessionalMalpracticeLiabilityMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Professional Malpractice Liability Insurance", "label": "Professional Malpractice Liability Insurance [Member]", "documentation": "Business insurance coverage for professionals, such as doctors, lawyers, insurance agents, accountants, real estate agents, veterinarians, and others. This liability coverage insures losses for claims arising from mistakes and errors or omissions in the course of professional activities." } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 3.0 }, "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss_1": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 3.0 }, "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss before noncontrolling interest", "terseLabel": "Net loss before noncontrolling interest", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r173", "r190", "r193", "r204", "r208", "r219", "r227", "r228", "r255", "r270", "r274", "r276", "r320", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r473", "r476", "r477", "r490", "r496", "r585", "r597", "r631", "r675", "r697", "r698", "r740", "r757", "r758", "r772", "r803", "r842" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated depreciation and amortization", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization", "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease." } } }, "auth_ref": [ "r782", "r785", "r836" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 }, "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": [ "r785", "r834" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, gross", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization", "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": [ "r781", "r796", "r835" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment, net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r136" ] }, "aonc_PublicAndPrivateWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "PublicAndPrivateWarrantsMember", "presentation": [ "http://www.aoncology.com/role/NetLossPerShareAntidilutiveSecuritiesDetails", "http://www.aoncology.com/role/ReverseRecapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Public and Private Warrants", "label": "Public And Private Warrants [Member]", "documentation": "Public And Private Warrants" } } }, "auth_ref": [] }, "us-gaap_PublicUtilitiesInventoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PublicUtilitiesInventoryAxis", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory [Axis]", "label": "Inventory [Axis]", "documentation": "Information by type of inventory held." } } }, "auth_ref": [ "r799" ] }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PublicUtilitiesInventoryTypeDomain", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory [Domain]", "label": "Inventory [Domain]", "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale." } } }, "auth_ref": [ "r799" ] }, "aonc_PublicWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "PublicWarrantMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Public Warrant", "label": "Public Warrant [Member]", "documentation": "Public Warrant" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r340", "r341", "r342", "r343", "r399", "r407", "r438", "r439", "r440", "r539", "r566", "r612", "r644", "r645", "r708", "r710", "r713", "r714", "r715", "r727", "r728", "r742", "r749", "r754", "r762", "r765", "r838", "r846", "r888", "r889", "r890", "r891", "r892" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r340", "r341", "r342", "r343", "r399", "r407", "r438", "r439", "r440", "r539", "r566", "r612", "r644", "r645", "r708", "r710", "r713", "r714", "r715", "r727", "r728", "r742", "r749", "r754", "r762", "r765", "r838", "r846", "r888", "r889", "r890", "r891", "r892" ] }, "aonc_RebatesReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "RebatesReceivableCurrent", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofOtherReceivablesDetails": { "parentTag": "us-gaap_OtherReceivablesNetCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rebates receivable", "label": "Rebates Receivable, Current", "documentation": "Rebates Receivable, Current" } } }, "auth_ref": [] }, "aonc_RecapitalizationExchangeRatioUnits": { "xbrltype": "sharesItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "RecapitalizationExchangeRatioUnits", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recapitalization exchange ratio, units", "label": "Recapitalization Exchange Ratio, Units", "documentation": "Recapitalization Exchange Ratio, Shares" } } }, "auth_ref": [] }, "aonc_RedeemableNoncontrollingInterestEquityBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "RedeemableNoncontrollingInterestEquityBasedCompensation", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Equity-based compensation and NCI rebalancing", "label": "Redeemable Noncontrolling Interest, Equity Based Compensation", "documentation": "Redeemable Noncontrolling Interest, Equity Based Compensation" } } }, "auth_ref": [] }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "verboseLabel": "Redeemable noncontrolling interest", "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount", "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity." } } }, "auth_ref": [ "r59", "r60", "r61", "r62" ] }, "aonc_RedeemableNoncontrollingInterestEquityExcessOverCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "RedeemableNoncontrollingInterestEquityExcessOverCarryingAmount", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Excess redeemable noncontrolling interest over carrying amount", "label": "Redeemable Noncontrolling Interest, Equity, Excess Over Carrying Amount", "documentation": "Redeemable Noncontrolling Interest, Equity, Excess Over Carrying Amount" } } }, "auth_ref": [] }, "aonc_RedeemableNoncontrollingInterestEquityFairValueAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "RedeemableNoncontrollingInterestEquityFairValueAdjustment", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value adjustment to redeemable noncontrolling interest", "label": "Redeemable Noncontrolling Interest, Equity, Fair Value Adjustment", "documentation": "Redeemable Noncontrolling Interest, Equity, Fair Value Adjustment" } } }, "auth_ref": [] }, "us-gaap_RedeemableNoncontrollingInterestEquityRedemptionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RedeemableNoncontrollingInterestEquityRedemptionValue", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption value of noncontrolling interest", "label": "Redeemable Noncontrolling Interest, Equity, Redemption Value", "documentation": "Redemption value, as if currently redeemable, of redeemable noncontrolling interest classified as temporary equity and the election has been made to accrete changes in redemption value to the earliest redemption date." } } }, "auth_ref": [ "r20" ] }, "aonc_RedeemableNoncontrollingInterestStockRedeemed": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "RedeemableNoncontrollingInterestStockRedeemed", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Redemption of Class B Common Stock to Class A Common Stock", "label": "Redeemable Noncontrolling Interest, Stock Redeemed", "documentation": "Redeemable Noncontrolling Interest, Stock Redeemed" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical", "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party, Type [Domain]", "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r406", "r527", "r528", "r647", "r648", "r649", "r650", "r651", "r672", "r674", "r707" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical", "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r210", "r211", "r527", "r528", "r529", "r530", "r647", "r648", "r649", "r650", "r651", "r672", "r674", "r707" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Axis]", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r527", "r528", "r884" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Domain]", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails", "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r679", "r680", "r683" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical", "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party, Type [Axis]", "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r406", "r527", "r528", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r647", "r648", "r649", "r650", "r651", "r672", "r674", "r707", "r884" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.aoncology.com/role/RelatedParties" ], "lang": { "en-us": { "role": { "terseLabel": "Related Parties", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r524", "r525", "r526", "r528", "r531", "r627", "r628", "r629", "r681", "r682", "r683", "r704", "r706" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/ReverseRecapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r212", "r213", "r356", "r375", "r530", "r734", "r735" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Domain]", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r176" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationNarrativeDetails", "http://www.aoncology.com/role/EquityBasedCompensationSummaryofRSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r46" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.aoncology.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.aoncology.com/role/ReverseRecapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r333", "r334", "r335", "r336", "r337", "r338", "r339" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Retained deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r112", "r141", "r593", "r616", "r618", "r625", "r654", "r760" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Retained\u2028Earnings (Deficit)", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r171", "r216", "r217", "r218", "r220", "r226", "r228", "r321", "r322", "r447", "r448", "r449", "r464", "r465", "r480", "r482", "r483", "r485", "r488", "r613", "r615", "r632", "r901" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Total revenue", "terseLabel": "Revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r256", "r257", "r269", "r272", "r273", "r277", "r278", "r279", "r397", "r398", "r567" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r168", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r729" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "aonc_ReverseRecapitalizationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "ReverseRecapitalizationAbstract", "lang": { "en-us": { "role": { "label": "Reverse Recapitalization [Abstract]", "documentation": "Reverse Recapitalization" } } }, "auth_ref": [] }, "aonc_ReverseRecapitalizationChangeInUnitsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "ReverseRecapitalizationChangeInUnitsRollForward", "presentation": [ "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reverse Recapitalization, Change In Units [Roll Forward]", "label": "Reverse Recapitalization, Change In Units [Roll Forward]", "documentation": "Reverse Recapitalization, Change In Units" } } }, "auth_ref": [] }, "aonc_ReverseRecapitalizationChangeInValueOfUnitsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "ReverseRecapitalizationChangeInValueOfUnitsRollForward", "presentation": [ "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reverse Recapitalization, Change In Value Of Units [Roll Forward]", "label": "Reverse Recapitalization, Change In Value Of Units [Roll Forward]", "documentation": "Reverse Recapitalization, Change In Value Of Units" } } }, "auth_ref": [] }, "aonc_ReverseRecapitalizationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "ReverseRecapitalizationDisclosureTextBlock", "presentation": [ "http://www.aoncology.com/role/ReverseRecapitalization" ], "lang": { "en-us": { "role": { "terseLabel": "Reverse Recapitalization", "label": "Reverse Recapitalization Disclosure [Text Block]", "documentation": "Reverse Recapitalization Disclosure" } } }, "auth_ref": [] }, "aonc_ReverseRecapitalizationEquityConversionRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "ReverseRecapitalizationEquityConversionRatio", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reverse recapitalization, equity conversion ratio", "label": "Reverse Recapitalization, Equity Conversion Ratio", "documentation": "Reverse Recapitalization, Equity Conversion Ratio" } } }, "auth_ref": [] }, "aonc_ReverseRecapitalizationExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "ReverseRecapitalizationExpenses", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reverse recapitalization costs", "label": "Reverse Recapitalization Expenses", "documentation": "Reverse Recapitalization Expenses" } } }, "auth_ref": [] }, "aonc_ReverseRecapitalizationNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "ReverseRecapitalizationNet", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/ReverseRecapitalizationScheduleofHistoricalCostDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/ReverseRecapitalizationScheduleofHistoricalCostDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total Net Liabilities", "label": "Reverse Recapitalization, Net", "documentation": "Reverse Recapitalization, Net" } } }, "auth_ref": [] }, "aonc_ReverseRecapitalizationTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "ReverseRecapitalizationTransactionCosts", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.aoncology.com/role/ReverseRecapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction expenses", "label": "Reverse Recapitalization Transaction Costs", "documentation": "Reverse Recapitalization Transaction Costs" } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "aonc_RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiabilityAbstract", "presentation": [ "http://www.aoncology.com/role/LeasesSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ROU assets obtained in exchange for new lease liabilities", "label": "Right-Of-Use Asset Obtained In Exchange For Lease Liability [Abstract]", "documentation": "Right-Of-Use Asset Obtained In Exchange For Lease Liability" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/LeasesSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ROU assets obtained in exchange for new operating lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r519", "r759" ] }, "us-gaap_SalesAndExciseTaxPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesAndExciseTaxPayableCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Excise taxes payable", "label": "Sales and Excise Tax Payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax." } } }, "auth_ref": [ "r101" ] }, "aonc_ScheduleOfAffiliationAgreementsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "ScheduleOfAffiliationAgreementsTableTextBlock", "presentation": [ "http://www.aoncology.com/role/BusinessTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Affiliation Agreements", "label": "Schedule Of Affiliation Agreements [Table Text Block]", "documentation": "Schedule Of Affiliation Agreements" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.aoncology.com/role/NetLossPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r46" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails", "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r73", "r74", "r471" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.aoncology.com/role/LongtermDebtTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-Term Debt Instruments", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r28", "r63", "r64", "r95", "r96", "r98", "r103", "r139", "r140", "r745", "r747", "r809" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "presentation": [ "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share." } } }, "auth_ref": [ "r45", "r48", "r233", "r234", "r242" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock", "presentation": [ "http://www.aoncology.com/role/NetLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Unit", "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]", "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share." } } }, "auth_ref": [ "r45", "r48", "r813" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r317", "r318", "r319" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r21", "r116", "r117", "r118" ] }, "us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Insurance Type and Tier Identifier [Axis]", "label": "Insurance Type and Tier Identifier [Axis]", "documentation": "Information by type of insurance coverage or layer of insurance that covers malpractice claims." } } }, "auth_ref": [ "r160" ] }, "aonc_ScheduleOfOtherAccruedLiabilitiesCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "ScheduleOfOtherAccruedLiabilitiesCurrentTableTextBlock", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Accrued Liabilities, Current", "label": "Schedule Of Other Accrued Liabilities, Current [Table Text Block]", "documentation": "Schedule Of Other Accrued Liabilities, Current" } } }, "auth_ref": [] }, "aonc_ScheduleOfOtherReceivablesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "ScheduleOfOtherReceivablesTableTextBlock", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Receivables", "label": "Schedule Of Other Receivables [Table Text Block]", "documentation": "Schedule Of Other Receivables" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails", "http://www.aoncology.com/role/RelatedPartiesNotesReceivableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r99", "r100", "r679", "r680", "r683" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions", "label": "Schedule of Related Party Transactions [Table Text Block]", "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.aoncology.com/role/ReverseRecapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Schedule of Restructuring and Related Costs [Table]", "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring." } } }, "auth_ref": [ "r333", "r334", "r335", "r336", "r337", "r338", "r339" ] }, "aonc_ScheduleOfReverseRecapitalizationChangesInUnitsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "ScheduleOfReverseRecapitalizationChangesInUnitsTableTextBlock", "presentation": [ "http://www.aoncology.com/role/EquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reverse Recapitalization, Changes in Units", "label": "Schedule Of Reverse Recapitalization, Changes In Units [Table Text Block]", "documentation": "Schedule Of Reverse Recapitalization, Changes In Units" } } }, "auth_ref": [] }, "aonc_ScheduleOfReverseRecapitalizationOwnershipSummaryTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "ScheduleOfReverseRecapitalizationOwnershipSummaryTableTextBlock", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reverse Recapitalization, Ownership Summary", "label": "Schedule Of Reverse Recapitalization, Ownership Summary [Table Text Block]", "documentation": "Schedule Of Reverse Recapitalization, Ownership Summary" } } }, "auth_ref": [] }, "aonc_ScheduleOfReverseRecapitalizationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "ScheduleOfReverseRecapitalizationTableTextBlock", "presentation": [ "http://www.aoncology.com/role/ReverseRecapitalizationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reverse Recapitalization", "label": "Schedule Of Reverse Recapitalization [Table Text Block]", "documentation": "Schedule Of Reverse Recapitalization" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationNarrativeDetails", "http://www.aoncology.com/role/EquityBasedCompensationSummaryofRSUActivityDetails", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r409", "r411", "r413", "r414", "r415", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r437", "r438", "r439", "r440", "r441" ] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of RSU Activity", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfVariableInterestEntitiesTable", "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails", "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Variable Interest Entities [Table]", "label": "Schedule of Variable Interest Entities [Table]", "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide." } } }, "auth_ref": [ "r80", "r81", "r82", "r83", "r84", "r474", "r475", "r478", "r479", "r547", "r548", "r549" ] }, "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfVariableInterestEntitiesTextBlock", "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Variable Interest Entities", "label": "Schedule of Variable Interest Entities [Table Text Block]", "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide." } } }, "auth_ref": [ "r80", "r81", "r82", "r83", "r84" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r774" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r776" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Segments", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r263", "r264", "r265", "r266", "r267", "r268", "r278", "r741" ] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/NetLossPerShareAntidilutiveSecuritiesDetails", "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series A Preferred Stock", "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } }, "auth_ref": [ "r797", "r798", "r848" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Equity-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r755" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationSummaryofRSUActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r430" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationSummaryofRSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r430" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationNarrativeDetails", "http://www.aoncology.com/role/EquityBasedCompensationSummaryofRSUActivityDetails", "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted (in shares)", "terseLabel": "Grants in period (in units)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r428" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationSummaryofRSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r428" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationSummaryofRSUActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning period (in shares)", "periodEndLabel": "Outstanding, ending period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r425", "r426" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationSummaryofRSUActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance (usd per share)", "periodEndLabel": "Ending Balance (usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r425", "r426" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationSummaryofRSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationSummaryofRSUActivityDetails", "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Vested (in shares)", "terseLabel": "Units vested (in units)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r429" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationSummaryofRSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested (usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r429" ] }, "aonc_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedUponConsummationOfBusinessCombination": { "xbrltype": "sharesItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedUponConsummationOfBusinessCombination", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Units vested upon consummation of business combination (in units)", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested Upon Consummation Of Business Combination", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested Upon Consummation Of Business Combination" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationNarrativeDetails", "http://www.aoncology.com/role/EquityBasedCompensationSummaryofRSUActivityDetails", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/EquityScheduleofChangesinUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r409", "r411", "r413", "r414", "r415", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r437", "r438", "r439", "r440", "r441" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationSummaryofRSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r756" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares available for grant (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r69" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of outstanding stock maximum (in percent)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Equity-based compensation and NCI rebalancing (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": [ "r69" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationNarrativeDetails", "http://www.aoncology.com/role/EquityBasedCompensationSummaryofRSUActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All Award Types", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r413", "r414", "r415", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r437", "r438", "r439", "r440", "r441" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Equity-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r408", "r416", "r435", "r436", "r437", "r438", "r441", "r450", "r451", "r452", "r453" ] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier [Axis]", "label": "Supplier [Axis]", "documentation": "Information by supplier." } } }, "auth_ref": [] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier [Domain]", "label": "Supplier [Domain]", "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received." } } }, "auth_ref": [] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock price (in usd per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "aonc_SharesAwardedUponVesting": { "xbrltype": "sharesItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "SharesAwardedUponVesting", "presentation": [ "http://www.aoncology.com/role/EquityBasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares awarded upon vesting of RSUs (in shares)", "label": "Shares Awarded Upon Vesting", "documentation": "Shares Awarded Upon Vesting" } } }, "auth_ref": [] }, "aonc_SignsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "SignsMember", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Signs", "label": "Signs [Member]", "documentation": "Signs" } } }, "auth_ref": [] }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofPropertyandEquipmentnetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Software", "label": "Software and Software Development Costs [Member]", "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit", "http://www.aoncology.com/role/Cover", "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r169", "r180", "r181", "r182", "r208", "r233", "r234", "r242", "r245", "r253", "r254", "r320", "r344", "r346", "r347", "r348", "r351", "r352", "r373", "r374", "r377", "r380", "r387", "r496", "r621", "r622", "r623", "r624", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r653", "r676", "r699", "r717", "r718", "r719", "r720", "r721", "r780", "r806", "r814" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r14", "r30", "r171", "r195", "r196", "r197", "r216", "r217", "r218", "r220", "r226", "r228", "r250", "r321", "r322", "r388", "r447", "r448", "r449", "r464", "r465", "r480", "r481", "r482", "r483", "r484", "r485", "r488", "r497", "r498", "r499", "r500", "r501", "r502", "r523", "r613", "r614", "r615", "r632", "r699" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r216", "r217", "r218", "r250", "r567", "r620", "r643", "r646", "r647", "r648", "r649", "r650", "r651", "r653", "r656", "r657", "r658", "r659", "r660", "r663", "r664", "r665", "r666", "r668", "r669", "r670", "r671", "r672", "r674", "r677", "r678", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r699", "r766" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlowsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r216", "r217", "r218", "r250", "r567", "r620", "r643", "r646", "r647", "r648", "r649", "r650", "r651", "r653", "r656", "r657", "r658", "r659", "r660", "r663", "r664", "r665", "r666", "r668", "r669", "r670", "r671", "r672", "r674", "r677", "r678", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r699", "r766" ] }, "us-gaap_StockDividendsShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockDividendsShares", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class A-1 distribution (in shares)", "label": "Stock Dividends, Shares", "documentation": "Number of shares of common and preferred stock issued as dividends during the period. Excludes stock splits." } } }, "auth_ref": [ "r14" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.aoncology.com/role/BusinessDetails", "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r14", "r109", "r110", "r141", "r621", "r699", "r718" ] }, "us-gaap_StockRedeemedOrCalledDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRedeemedOrCalledDuringPeriodShares", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "negatedLabel": "Redemption of Class B Common Stock to Class A Common Stock (in shares)", "label": "Stock Redeemed or Called During Period, Shares", "documentation": "Number of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": [ "r14" ] }, "us-gaap_StockRedeemedOrCalledDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRedeemedOrCalledDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Redemption of Class B Common Stock to Class A Common Stock", "label": "Stock Redeemed or Called During Period, Value", "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price." } } }, "auth_ref": [ "r14" ] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchases of Class A Common Stock (in shares)", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r14", "r109", "r110", "r141", "r624", "r699", "r720" ] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchases of Class A Common Stock", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r14", "r109", "r110", "r141", "r632", "r699", "r720", "r772" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total AON stockholders' deficit", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r110", "r113", "r114", "r135", "r655", "r673", "r700", "r701", "r760", "r773", "r808", "r832", "r881", "r901" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "aonc_StockholdersEquityConversionNumberOfDaysAfterFiveYearAnniversary": { "xbrltype": "durationItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "StockholdersEquityConversionNumberOfDaysAfterFiveYearAnniversary", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of days after five year anniversary", "label": "Stockholders' Equity, Conversion, Number Of Days After Five Year Anniversary", "documentation": "Stockholders' Equity, Conversion, Number Of Days After Five Year Anniversary" } } }, "auth_ref": [] }, "aonc_StockholdersEquityConversionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "StockholdersEquityConversionPeriod", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity, conversion period (in years)", "label": "Stockholders' Equity, Conversion Period", "documentation": "Stockholders' Equity, Conversion Period" } } }, "auth_ref": [] }, "aonc_StockholdersEquityConversionRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "StockholdersEquityConversionRightDomain", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity, Conversion Right [Domain]", "label": "Stockholders' Equity, Conversion Right [Domain]", "documentation": "Stockholders' Equity, Conversion Right [Domain]" } } }, "auth_ref": [] }, "aonc_StockholdersEquityConversionRightsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "StockholdersEquityConversionRightsAxis", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity, Conversion Right [Axis]", "label": "Stockholders' Equity, Conversion Rights [Axis]", "documentation": "Stockholders' Equity, Conversion Rights" } } }, "auth_ref": [] }, "aonc_StockholdersEquityConversionStockPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "StockholdersEquityConversionStockPrice", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Threshold stock price, conversion price adjustment (in usd per share)", "label": "Stockholders' Equity, Conversion, Stock Price", "documentation": "Stockholders' Equity, Conversion, Stock Price" } } }, "auth_ref": [] }, "aonc_StockholdersEquityConversionThresholdStockPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "StockholdersEquityConversionThresholdStockPrice", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity, conversion, threshold stock price (in dollars per share) (less than) (greater than)", "label": "Stockholders' Equity, Conversion, Threshold Stock Price", "documentation": "Stockholders' Equity, Conversion, Threshold Stock Price" } } }, "auth_ref": [] }, "aonc_StockholdersEquityConversionThresholdVolumeWeightedAveragePricePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "StockholdersEquityConversionThresholdVolumeWeightedAveragePricePeriod", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails", "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity, conversion, threshold volume weighted average price period", "label": "Stockholders' Equity, Conversion, Threshold Volume Weighted Average Price Period", "documentation": "Stockholders' Equity, Conversion, Threshold Volume Weighted Average Price Period" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Total deficit", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r75", "r76", "r85", "r171", "r172", "r196", "r216", "r217", "r218", "r220", "r226", "r321", "r322", "r388", "r447", "r448", "r449", "r464", "r465", "r480", "r481", "r482", "r483", "r484", "r485", "r488", "r497", "r498", "r502", "r523", "r614", "r615", "r630", "r655", "r673", "r700", "r701", "r722", "r772", "r808", "r832", "r881", "r901" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.aoncology.com/role/Equity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r138", "r207", "r372", "r374", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r386", "r388", "r487", "r702", "r705", "r723" ] }, "aonc_StockholdersEquityNumberOfDaysAfterTheRedemptionNoticeDateForRedemptionToBeSettled": { "xbrltype": "durationItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "StockholdersEquityNumberOfDaysAfterTheRedemptionNoticeDateForRedemptionToBeSettled", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of days after redemption notice date that redemption must be settled", "label": "Stockholders' Equity, Number Of Days After The Redemption Notice Date For Redemption To Be Settled", "documentation": "Stockholders Equity, Number Of Days After The Redemption Notice Date For Redemption To Be Settled" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityPolicyTextBlock", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Mezzanine Equity and Treasury Stock", "label": "Stockholders' Equity, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income." } } }, "auth_ref": [ "r9", "r703" ] }, "aonc_StockholdersEquityRedemptionRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "StockholdersEquityRedemptionRatio", "presentation": [ "http://www.aoncology.com/role/RedeemableNoncontrollingInterestNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption ratio", "label": "Stockholders' Equity, Redemption Ratio", "documentation": "Stockholders' Equity, Redemption Ratio" } } }, "auth_ref": [] }, "aonc_StockholdersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "StockholdersMember", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders", "label": "Stockholders [Member]", "documentation": "Stockholders" } } }, "auth_ref": [] }, "aonc_SubsidiaryUnderCommonControlOfClassA1MemberMember": { "xbrltype": "domainItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "SubsidiaryUnderCommonControlOfClassA1MemberMember", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsidiary Under Common Control of Class A-1 Member", "label": "Subsidiary Under Common Control Of Class A-1 Member [Member]", "documentation": "Subsidiary Under Common Control Of Class A-1 Member" } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Condensed Balance Sheet Information", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r795" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental noncash investing and financing activities", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplierConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplierConcentrationRiskMember", "presentation": [ "http://www.aoncology.com/role/RelatedPartiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier Concentration Risk", "label": "Supplier Concentration Risk [Member]", "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services." } } }, "auth_ref": [ "r51" ] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Income tax payable", "label": "Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r24" ] }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityCarryingAmountAttributableToParent", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Series A convertible preferred stock; $0.0001 par value; 7,500,000 shares authorized; 6,651,610 issued and outstanding at March 31, 2024 and December 31, 2023, with an aggregate liquidation preference of $69,369,195 and $68,009,015 at March 31, 2024 and December 31, 2023, respectively.", "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r344", "r346", "r347", "r348", "r351", "r352", "r454", "r591" ] }, "us-gaap_TemporaryEquityLiquidationPreference": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityLiquidationPreference", "crdr": "credit", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Liquidation preference", "label": "Temporary Equity, Liquidation Preference", "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityParOrStatedValuePerShare", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Par value (dollars per share)", "label": "Temporary Equity, Par or Stated Value Per Share", "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable." } } }, "auth_ref": [ "r18", "r58" ] }, "aonc_TemporaryEquityRedeemablePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.aoncology.com/20240331", "localname": "TemporaryEquityRedeemablePeriod", "presentation": [ "http://www.aoncology.com/role/EquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary equity, redeemable period", "label": "Temporary Equity, Redeemable Period", "documentation": "Temporary Equity, Redeemable Period" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquitySharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesAuthorized", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Shares authorized (shares)", "label": "Temporary Equity, Shares Authorized", "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r108" ] }, "us-gaap_TemporaryEquitySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesIssued", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued (in shares)", "label": "Temporary Equity, Shares Issued", "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r108" ] }, "us-gaap_TemporaryEquitySharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesOutstanding", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable convertible preferred stock, shares outstanding (in shares)", "periodStartLabel": "Beginning Balance (in shares)", "periodEndLabel": "Ending Balance (in shares)", "label": "Temporary Equity, Shares Outstanding", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r108" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails", "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r369", "r385", "r486", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r600", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r828", "r829", "r830", "r831" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofMezzanineandStockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r66" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, common, shares (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r66" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock, at cost, 31,170 shares at March 31, 2024 and 14,729 shares at December 31, 2023", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r31", "r66", "r67" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares repurchased (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r14", "r110", "r141" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of shares repurchased (less than)", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r14", "r66", "r141" ] }, "us-gaap_TypeAndTierIdentifierDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeAndTierIdentifierDomain", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Type and Tier Identifier [Domain]", "label": "Type and Tier Identifier [Domain]", "documentation": "Name of the type of insurance coverage or layer of insurance that covers malpractice claims." } } }, "auth_ref": [ "r160" ] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://www.aoncology.com/role/MarketableSecuritiesRemainingContractualMaturitiesDetails", "http://www.aoncology.com/role/MarketableSecuritiesScheduleofMarketableSecuritiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Treasury securities", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r737", "r751", "r753", "r893" ] }, "us-gaap_UndistributedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UndistributedEarnings", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Undistributed net earnings, basic", "label": "Undistributed Earnings, Basic", "documentation": "The earnings that is allocated to common stock and participating securities to the extent that each security may share in earnings as if all of the earnings for the period had been distributed." } } }, "auth_ref": [ "r240", "r243" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Estimates and Assumptions", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r53", "r54", "r55", "r163", "r164", "r165", "r166" ] }, "us-gaap_VariableInterestEntityDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableInterestEntityDisclosureTextBlock", "presentation": [ "http://www.aoncology.com/role/VariableInterestEntities" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entities", "label": "Variable Interest Entity Disclosure [Text Block]", "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss." } } }, "auth_ref": [ "r144" ] }, "us-gaap_VariableInterestEntityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableInterestEntityLineItems", "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails", "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entity [Line Items]", "label": "Variable Interest Entity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r474", "r475", "r478", "r479", "r547", "r548", "r549" ] }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "presentation": [ "http://www.aoncology.com/role/VariableInterestEntitiesNarrativeDetails", "http://www.aoncology.com/role/VariableInterestEntitiesScheduleofAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Interest Entity, Primary Beneficiary", "label": "Variable Interest Entity, Primary Beneficiary [Member]", "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity." } } }, "auth_ref": [ "r80", "r474", "r475", "r478", "r479" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://www.aoncology.com/role/LeasesLeaseCostsDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.aoncology.com/role/LeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable lease costs", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r517", "r759" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.aoncology.com/role/LongtermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://www.aoncology.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r763", "r764", "r767", "r768", "r769", "r770" ] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "calculation": { "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails": { "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails", "http://www.aoncology.com/role/SupplementalCondensedBalanceSheetInformationScheduleofAccruedOtherDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of warrants", "verboseLabel": "Warrant liability", "label": "Warrants and Rights Outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://www.aoncology.com/role/BasisofPresentationandSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, measurement input", "label": "Warrants and Rights Outstanding, Measurement Input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r493" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://www.aoncology.com/role/BusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant, term (in years)", "label": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r880" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "verboseLabel": "Weighted average shares for diluted loss per share (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r232", "r245" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.aoncology.com/role/NetLossPerShareCalculationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares for basic loss per share (in shares)", "verboseLabel": "Weighted average shares for basic earnings per share (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r230", "r245" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.aoncology.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares of Class A Common Stock Outstanding:", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(19)", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(27)", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "24(b)", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "272", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-10" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(12)(c)", "Section": "S99", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(16)(c)", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "14", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "15", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)-(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479515/805-10-05-4" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-6" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-9" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "320", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 4.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-5" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//805/tableOfContent" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-23" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//940-320/tableOfContent" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//942-320/tableOfContent" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//946-320/tableOfContent" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "(b)", "Publisher": "SEC" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "66", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-66" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-4" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.E.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481058/954-310-45-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r780": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//210/tableOfContent" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 86 0001839998-24-000040-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001839998-24-000040-xbrl.zip M4$L#!!0 ( *:*KUB7;U")AGX! 'ZO$0 1 86]N8RTR,#(T,#,S,2YH M=&WLO6MWVSJ2*/I]?@6O>I_I9"U)YOOA9.LLQ7'V^$YBNVVG>_I^F061D,4. M1:I)RK;VK[\HD'I+%BF2$BBAU^[8Y@,$ZEV%0M7G__LV](07'$9NX/_^5ZDM M_E7 OATXKO_\^U^[CU1 MTA=;&NII+=7!_98I&:CEF+8F._V>9%EF\_E2%"7%L/1>2\0Z;JDR$EL]0T2HDH.,F1)L215T11D8BRJCR M+7)_;PSB>'1Y^N% MWG3>R@7<[J%H-EL'S]=(GXRPW7X.7B[(#9BK,GW0?=LVJJ1 M(++8$N66),^00EYR5@"33ER_2&Y.'XW"^??Z*.K1Y\C%)>#!*^Y[L%BAH7'4 M>D9HM#YP>F,^^*6'"#,VL-_Z^=CH?!Y@Y'0^#W&,!'BUA?\]=E]^;UP%?DP8 ML_4T&9%OV,E?OS=B_!9?4.*YZ/S'?_S'Y]B-/=P!>FU-R?3S17+Q\T4R="]P M)IW/COLB1/'$P[\W'#<:>6ARZ0<^)A-PWR[A01PFO[J.@WWZ*[E_2Z1#Z-K) M]]_B!]S_O6&W".9\-(21L'MY[9//3:[([$+DW?@.?OMO/&D(KO-[H]]2Q$9' M),QG*H3JS<\72Z/F^,A43GUS(QMY_\0H_$:N1+//2(T.++^L#]R3QP-G^1-R MH_,W:?\/7(W#<&D!U[[SE8C\-P@:7#KG2&I)1!BT'S:&H-#J2W%(* M?+Y+%N?0!7KH>?F;??<-.ZT^\D#$I!]4&YUOW>^/U[D^:$P_F)+\Y3?7!Q;Y MCHGT^NZBGNL!I22 >(S)4F%"=_WD,9> /8A<8._K-T+LD=OSR%M1/)V49AF- MSGO<]9<[HKC"KFV'8^Q,O^?B*/UBKK7H5:_%/-Q:)$M=71@/"%O]7!XU_^*)E&W'^/P:8 ?L(.'(YCP;1"[ M-@8V^A:$\\M/P1?\B&,B!)WIY$S-@LF)7]=F=[$L]$+C<7(",0'YO'H[=R#>93AME",2/R:[ZIX6=@_2V32V[F M&G!$.#OPMP"/WLLU7-#O;\5%Q]2TF?Y%2(/\W7=Q*% 1 M@#<:OE#$1A?'D?!L[8CN]"8B.^ MN#9.X$Q#KOJ7)'L_8. U)%9M8%9AQ=1^(N]AWH).,( M$J("G_P9;7*BL\1!\W_YM()3,K.N>[FQDN-1&#NH9C9&D!'F7<>A:9K(NT>N M<^-?H9$;(Z\V\&1QZY(:L/<51!YDY%"&(N+) 3034'/W-N M?T[P/^ 8N3YVKE'H$_A'=0&\PO[V=UT$$P-^KL)L6.*,'2<6Z(+9^ =KIC<+ MR*I[].,@=CH+B&(_=L&&S<@"KNH>?*C>P&0!2^R'*,XO&L@"7=0]?'**=FTU MF60*^X&8\Q,!%:&Z[D&?8VP(E A_M>ZQGT-O")0)^[I':MB)NU6$H+J'3&H. M_KH'00ZZ(5 FX)D-:J3:]:?OQM&726+5+IM \PB6OV@RMEP;PZF5+MF;@RL5WWD$G7ML?#,37:N] MFW\,*XIXN/%G%/=>;B"M XYCM^1MXUG4]>B5>4[^'3]H1\BO:8 M2-N"U(;7F LV[(#V+7XEH";_$0.T*&(+$@X[2*Q?#*%( 5].0A60$'.AB3*, MV?HH]HJPREP(8I<-3:SCGSZ1 YC,RT\P%.#)@^G$4^%&PJUS=V:.6 M_72*PQQ+.&D[G+E@4L5=& KK_^ON'V'P&@]^(!\ES2"_W]<&V\S%MF;\FB Y M;7YU%SY #^W%;3_*R8#IL>]@)WVNL'8^9=8VF MG'5XU[R*K^W&/C%!9R[6* M$,M<)*S>B#UW0\^H6RR.<7JJ9WS=8"Z8QR 5A.X+@>^]AVPJ!S*:(>QP^GE' MVZHQ,MG!;MVB;G7 ;D7&06TVQ8VZ!?B.&:"O#U:9B^T=?D.+@2(_!G/1M^UH MR+%[65-D,!<<.S)/'.<8BLE)\V,X! >UG,1>W M8 @EQQ%4%G/1BQTHN?)+O!-E$^9"&RSAY$A\PES< W#R2+[HC#U\ MUT]*%/S \2!P;OP7',4PS/I5C%<<];NK^WF:;C=T_PQ\]+V*=-T"2)3*0B*3 M490Z(7%YJU4J*0!B,1< R;&W/8LYG7"G.*ORL$6E F2IO&(A.+!0,F5?.)1) M#\RYMS.&G0G3'\@;A#0!T_C 8_&9(8HPMWG$--X5'U<=XG9C(G:4,,L,!KX>/(#A;]P_&WL M.S6B 6:S+&I' S\?GT(:'Y\\8GL<4GU2&SJ0F8WP'((.&,(#IW(?+N!R@<(AN/8ZB642-R9S8VPB#@ M2Z5X9H,A]V% 5A)/[CVR..)Z@MLY@C&^3-:/,GPG9@XM)G+3]6$'9L, = M'1,_L ,JN89LP*P#S"CPRZ1\E5VO-X]*O@J&HW&,P_I1O\JN \PN DKE '9] MX^!_TSB[Z^.[_E6( M'7>7XY7YB_"EU82+I$#![=7W /G?D%U1&=>*6$QCUM,^4^26RKG,>O'GA-RE M\_,2G)]7,E7]67FTT/EYC=GHPO1@-A0>7"PSXA'R\"&E$D6XS**$)='!X2F] MKI3';)3EG&30@H)906XQ!<-<'(>";+W!$>'@B/$Y'5TEG=N/E M?,/?1DNV2G&R=;ZWP19RY98HMR2U'.0RM[?!U<>Q(G.ETA5S6Q)G2%=;HA)? MO"" 5YX?!T$80RN\+\C_]4\7>\Z-[^"W4R#K):MHA;#?LXI6'BUF%3&[ZW%. MBI,)2N#[%,>7ANQH6;,E:>5H669C_^IE;6X:S,6X>=H1,P)E->JC M'Z%=E<%L_/L!>] DZ1YZUSZ%R(\0/9:RN#,'8=C;(,;1 [:Q^P)F,OQ9GQK? M!K.!7U:A7^:A X/9B">CT)>LEJ@M"*EBT&C\$00.E(&\#7P\''G!!.-''+ZX-HX6T/)E\C@>D4%QN%A5:=R+ M7 >:T_[T'1Q>!<-AX%\1$(2!1]QH#T51-\T9+LM_WT(UT9?)XIW5F.C\SFDF M%)G,>O69)4VAOX(\/4'-_KU!7J/VX,A"G^MUHR) MXKL^A?)3$".OPAELJ.24(FWMX1.5Z\Q&K#B_<7X[0?W&;(R2\QOC80Z3V0 K M)QW&8S0FL]%A3CJ'TO)=VP[&?AS=HPF$NBLX^=ZRG!Q8._"2>9O03G>6S3$*]L;R@VE ?<%0YW>I&IO?4Q> M9O>6S@:S+.A3B]E-KBUD\("C.'1MHGVR$,*AL2*;Y6"%V2VA8V&E(N_-8G9/ MI);D7Y908C9RS@#YEVD$6,R&3$L!],ZO16%\^8#\Y_0K\.'X^&),A:S M<<[CX1N]G3"^F0U.7J&1&R/OI^_&T9=)$MA8;7((H0]ZHRC:'>Q>?L?/R+NF M0%@T]N]NOW^_JE1>RV6:*\Q&O[;BDX)Y$9F%ZU">#C:9#:[DX4KS MXV61V8!)>78A0Z*'V:C)4:'-A.!A-L#!"B.4*G9.(KRPR^!E2/#4S_T_#+R9 M$#UGXGN%A) M\R(KQ5'W/L1]'(8E[CY<0>8:#D>0.;>:>'+=_2,,7N/!#^2C9SK![_?5TX9% M6"DC;2P^6HPV3L)YKSJ2=9Q-(UEBUGFOB''KBB=FG7Y&\70L8<=( M0VU('$9)EN-5X+^0/VA"\_,@7C1:%A\N*_>2'2JI)KM&EI@+1G#$,RC&F0NB MY*>26_S:O;LE_]WX=GW8D[EH"FN 9X(]F VK',N-G%5?=E]@&)BI@9D*X\60PYSL3\F$I&80 US 3<6^2;)&C R;I8L/EH, M.,X+C>& IV/&)['+HQ,4"NWVQO[&#G6Q@,"7I&XY@6 MZ[GK7Z/0=_WGZ!Z'2=&FR>8!SM?+93::=A!,'S!7\4@(5I@-?56*X$124[P" M&X]],N0_4!@B/]ZUN5E71#,;KZH>T??C'IE#UW?N0_>%0/#$,?YXHKIF+#FT_\PM7[4GW[I8BLZ1,$LBDO7OUR4@#=W38 ^-E9B H MS$5P3AR/3# O MOI5JDS 7^SD18T]E+N9RXM:7^W890IUZ*&9/%BB@T X#;QFZ\$H[")\O9%%4 M+M(G+OK(CEO]((C](,8-H4]'HV/!:IS>:I53=/2X=Y6D:!>>JS>>J5S5,1 9Z* M6 2>QFR>1G7SE$28IR05F*M_(?H\?R>*)S"[H>NW!AA.,EPJ M4EL;Q9]>72<>7$JB^'\:],G.YVB$_.GS=N %X>5?B.X3^_U/?2+>6WTT=+W) MY5^?B#*+!&)G"0_!$/E_;4;(CUH140CI@Y'[)R8#DV_0/U^3SZJB^(E 4^G M(GIF@4X2WDN<_^)5U'1LAQ7/_Y4A0D,LST&Q=T\9NX,P%''(PN=0(+NO@$#M 1 M X>-KU<'7WX\?-X^/-W2WS2_@'(DK*?XX#ORE\;5^U M!5G45&OKM!?(ADJ'ZI>A9UK&M[N''P*H7C_P;\=#,H@MI![" \@@&^QQ'X'3 M!8[\U\ >@S\#E<@;5,GUR0,=26S]C2K"^2B=XV'0R"!]&QUA.L%2O[T*]1W? MKIN(EMN&8;TKH3,+>ZTMRIM?61'VVR3[5'#+HS<0W8LLY>'^.@R"479"^P<9 M& :/BFCX1B<_8_UM3/Q\8@9,'O H"&-BS ;A$,7$F'R++_ON&W9:<3B>\9[< MZ+QM9;S8.0;HLO&)E4DZ_>UG]^'I^N'[/X6'Z_N[AR?A_N?#X\_N[9/P="<0 M)?)$-(4@*<+=@R!I'YR/PMTWX>F_KH4%_3+3+=VK)[@M68JZ!*'WU7WUY'-YLX$"G3Y$-%[[&D\N&MZ6Q2&C)CW0AV M#X2^2Z2(/Z9["MG)+]DC^T;>O:6O3JE+@[T-J26JBBQE%K,'=U6SN1QYH?& MG]THAM1$* @XA8C>Z'3I &0!=S[,_7E"9AB_!N&OIG#CVVV&U=%FP'RX?D-V M3-A<$+C#,W2HU&YROVT"L*<;DNT0E ^ F]W:0[X3:%\K)Z,1L=4VLIEJFJ MLO$N\,JU!61 MC.ECX3/RW3_IWRMRNCSGG%48;M%Q-^V']F-;2+M5A\(R60JW07L3I/+'_=?" M^AD?JY[ 64%%7AG2=9P01U'ZXSL93YK*#ZO1D51-580_O*"'/.$>A;]>T615 MDC1S6\+KWY1G86>QT7D[\"EXG:D5J,7\C7B P@]"KE%I M'Z*RY"Z\)VJ,R(WL6@ZJ#W\C!.(ZZ'T#]VQU70K@^X! T/O_W%%B1*304QH= M1;$DI2(E=U3P;=%:*3Q 0]V'A-;<$>'0ZS=LTP-#PEV?"%\(RUH?OXO MC1_@$#O":!Q&8P@DQ(% GJ"6EB1_Z'T$H0#;"ET[OIRNK!8!<-5LZU(YWKDD MMS6UG&"ZHK4UY?VA=NB6%-Y@2UY"/#@*/->9Y:JD=RF-K=W,+9UI!/G)C9,< M*(SL@6##X>_W5$ U\]L>WV909CR%B(J$Q\FP%WB9C:Y,D N3[QP"\4>!W6T: MVZ3$AM_L 32;%X@T>AVXY,I<9.6QQP[.,TM0PX.L(;!_-841"H47Y(VQ\!N5QE(3MI>%:+!?+(TC9!DAJ<1( M!,8,&T:CT[V[O:H*OJ>0NY!R!"__OL0L.//';>SA] M@ PZ\^$5V&9*DFQ23WXA #!%"WCW$-FX/'DB9Y=G2=->Z,OI&CY^(N+4$3[(R1I[ MA S(_=Z_R K@>?HH>0EFD8X#Z5<1G02=)(IBP1(%!TVB=NY@^]4X#,EP20X7 MB)(8Q>-H1H=RH_-/O!;3SYL97E*2VELE">D9/R[=,.8&"RX)T1NC)N"VR4D5-1 ##_AYG!RS%!Y;3\(' M2.(U/LF*W$X?B GJ$8P_!^%D0^R!/D1IP4X?6@A#J(W.[2;=R^XYGK+-SN.OJ-SLAVV6 M"COK/?B)MH1/*&2^C",R4!3M/%6L[3I6G%'RY$V^/1U*O"9 >P8"? Z#UWC MZ3"EPRE<_J!@N4J@LO-P);0D>O]T92W"PGVZL[29,B#9;*.KZ?8WQ9AH9(GH M*S^@\9UQE/B"!/;)@?!X=GYU&HR!( U\RYO QU]=\FGR6<$G:PM 8KZX$=5_ M/O)M%WE@!L,A''@8JCHZ*'0B ?*176=;1IGR 7W?6SH#5S,+0>$\[LTGI71J:^H$F M@J0FQ2*:ZU+-$8)Q3&4-")T4AM]H/)=(E['O)A"DN^_$AEF&JMH@G&"[Q,R) M?F_E-1Y2DNIE/M) D"T;84@S2O.(*0_G37;A3X$1'#T-R# "$=H$FC<#D! MH1T4$%:C(RM-0]::M.CN+D!\60)$.^/1];I$!6M1P&ZYM.0H2*R$M/3F"UXK M-CF?!YV .'\%]:+ &\?KKR0RIO.Y%UYL+$F8MTRF,2N3.0CG9O(S;O5"C'ZU M$#2SO43>*YI$L/[-M3157DF35](L6DF3]6-"3]TOWZ^AH,K5W>W3]>W3]E*0 MZW9!+42LN5O$9AXJJ[#>*IF1_8LX<83:6BE^;1MC0NC[GG0X#LTL;__N/L=P M&JN^[_YQO?V@>?;%]^G_:K;XC1*ZPB^N26AB)"X(9UE1D.Z8HJYJNNH8R+)5 MA'!/1CU5LFQ#(J(9C>$]%$Z(4T<JZ8=S=@K[SD,F,H3T3)&&(!SL MPT;<%02$/=>A62E?D$WPA'D"'P1IANH M:=-H. DA&9^$K[@/34"YAJXS+:A<0]\,I5<:V1K;&LBF6#H]J:+2I*&E:6V\(/Y*-GRIA_C82O;F2/DTXX8"MW?>1-(IFF:*4:GTX$:_N*ZN M,_XUF2OK&B#24ON:A61)UU5+13T9&7U91IJC$UOMZW]*P MU=.1)IM4"DU)>(?:29"C)MU9&QI>-^ MS]"QJ$O$1C*ME$NU-@\0GQ9:N1:M!2+%OFBI$C+ZV'94N=^W'$LQU+XA(4MW M9'O*GWI;N'X;N#V7GZ.M-S:949L<7V#FH)ZCBSV%(,@A9HYE6@BI8E]2Q9Z& M9*77Z#P2H*&X!'.5J\.CXE%[-WE_5RE#M3:%#"615S(\_%QX)<-W*AENK5Q( M*7IWG:;#%'C>+.?VJPJV"(X,@-C$_9M?^]W,8*.?-Y$2'I@0N-! IRA((FMOPD?:*N_M,W7['+:UNMC6J<8 -JD!>,A MI==SAS3?-_";9$&S@W244&DIXP&F37MGPU9R+Q@QJ'R/7I_U"*<:]%.,+ MA^P*%VA>Z MJWXG/YZ3-HH/&-SR>9M52UL W>),$,V*AN'G=?;MZ6J;0CA?:C!?JH!1Z%.( MDI=A>4FSQ#"(1MA.GN[2(N"$Q.Y\H*YGP@\X?@W"7TWAQK?;T..1XJ)[=YL" MKCE%#Q#;ALOD$GUU=CUMQYK>OEIJ />Q33 Y65PH[?Q(!!8 ,X"Y_BOI$4!6 M0T"%;13!Q$,AH&$-FR "V81,W3_1K(]=?PR&'73!])-G;3>TQT,H5&W#;N$< MP% )/Q&4M+4!BJ+Q<)1^#3I];R>-]DQ0;" ;>#6>C-+>G2ZPL]MWDP:\!+9. ME/2J1#-*'WG(7^VOU\.>2Y:P>AF_ >[6FO&1+]CNB,Q@]8X+\MQ9O9K2P]K@ M1 P--PPRA?SJ]10]JY>!M5Q_O#:,'8R]M:D,T63M$LBBM6\%A/N)AEV_#@J+ M\,/ZY+#CKD\N&FR:Q2M<7.Q@F-!71&26A\(4:W"=P)\P6Y302"_E26(&8M^> MUF2/BI!6LG30J M%1*R6*@7LL YJ?!89@MXY@6%;C".%NF^#2PM$($ ,WLF*H!0%NT62>;NQD26 M>]#?(QXG76GM 9!HTN&5D##E+8H-"AW">4O3I-@+"38 MHG B7R @)NPZANK_GDOK&A$0I#)(,CZ]-^*\DTA>12QK;66FBFNLTX$NWX&X MZ[\$'IS-$?SQL$=HGQ!SZ$:_""+'!-(A*$NJOCX,06R2NZ\#%Z08D".>$%U$ MZ0!X/PP\JEON;C\VY[)Z@

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end XML 88 aonc-20240331_htm.xml IDEA: XBRL DOCUMENT 0001839998 2024-01-01 2024-03-31 0001839998 us-gaap:CommonClassAMember 2024-01-01 2024-03-31 0001839998 us-gaap:WarrantMember 2024-01-01 2024-03-31 0001839998 us-gaap:CommonClassAMember 2024-05-14 0001839998 us-gaap:CommonClassBMember 2024-05-14 0001839998 2024-03-31 0001839998 2023-12-31 0001839998 us-gaap:SeriesAPreferredStockMember 2024-03-31 0001839998 us-gaap:SeriesAPreferredStockMember 2023-12-31 0001839998 us-gaap:CommonClassAMember 2024-03-31 0001839998 us-gaap:CommonClassAMember 2023-12-31 0001839998 us-gaap:CommonClassBMember 2024-03-31 0001839998 us-gaap:CommonClassBMember 2023-12-31 0001839998 us-gaap:RelatedPartyMember 2024-03-31 0001839998 us-gaap:RelatedPartyMember 2023-12-31 0001839998 aonc:PatientServiceMember 2024-01-01 2024-03-31 0001839998 aonc:PatientServiceMember 2023-01-01 2023-03-31 0001839998 us-gaap:ProductAndServiceOtherMember 2024-01-01 2024-03-31 0001839998 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-03-31 0001839998 2023-01-01 2023-03-31 0001839998 us-gaap:RelatedPartyMember 2024-01-01 2024-03-31 0001839998 us-gaap:RelatedPartyMember 2023-01-01 2023-03-31 0001839998 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-12-31 0001839998 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-12-31 0001839998 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001839998 us-gaap:TreasuryStockCommonMember 2023-12-31 0001839998 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-12-31 0001839998 us-gaap:NoncontrollingInterestMember 2023-12-31 0001839998 us-gaap:RetainedEarningsMember 2023-12-31 0001839998 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-01-01 2024-03-31 0001839998 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001839998 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001839998 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0001839998 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0001839998 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001839998 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001839998 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-03-31 0001839998 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-03-31 0001839998 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001839998 us-gaap:TreasuryStockCommonMember 2024-03-31 0001839998 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-03-31 0001839998 us-gaap:NoncontrollingInterestMember 2024-03-31 0001839998 us-gaap:RetainedEarningsMember 2024-03-31 0001839998 us-gaap:CapitalUnitClassAMember us-gaap:MemberUnitsMember 2022-12-31 0001839998 aonc:CapitalUnitClassA1Member us-gaap:MemberUnitsMember 2022-12-31 0001839998 us-gaap:CapitalUnitClassBMember us-gaap:MemberUnitsMember 2022-12-31 0001839998 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001839998 us-gaap:RetainedEarningsMember 2022-12-31 0001839998 2022-12-31 0001839998 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001839998 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001839998 us-gaap:CapitalUnitClassAMember us-gaap:MemberUnitsMember 2023-03-31 0001839998 aonc:CapitalUnitClassA1Member us-gaap:MemberUnitsMember 2023-03-31 0001839998 us-gaap:CapitalUnitClassBMember us-gaap:MemberUnitsMember 2023-03-31 0001839998 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001839998 us-gaap:RetainedEarningsMember 2023-03-31 0001839998 2023-03-31 0001839998 aonc:AONLLCMember 2023-09-20 0001839998 aonc:DigitalTransformationOpportunitiesCorpDTOCMember us-gaap:CommonClassBMember 2023-09-20 0001839998 us-gaap:CommonClassAMember 2023-09-20 2023-09-20 0001839998 aonc:LegacyAONShareholdersMember aonc:AONLLCMember 2023-09-20 0001839998 aonc:NewAONAONIncMember aonc:AONLLCMember 2023-09-20 0001839998 aonc:NewAONAONIncMember us-gaap:SeriesAPreferredStockMember aonc:AONLLCMember 2023-09-20 0001839998 aonc:AONLLCMember us-gaap:CommonClassAMember 2023-09-20 0001839998 aonc:DTOCUnredeemedShareholdersMember us-gaap:CommonClassAMember 2023-09-20 0001839998 aonc:DTOCSponsorMember us-gaap:CommonClassAMember 2023-09-20 0001839998 aonc:LegacyAONShareholdersMember us-gaap:CommonClassBMember 2023-09-20 0001839998 aonc:AEAGrowthManagementLPMember us-gaap:SeriesAPreferredStockMember 2023-09-20 0001839998 aonc:LegacyAONShareholdersMember aonc:ClassBPrefundedWarrantsMember 2023-09-20 0001839998 aonc:DTOCSponsorMember aonc:PublicWarrantMember 2023-09-20 0001839998 aonc:DTOCSponsorMember aonc:PublicWarrantMember us-gaap:CommonClassAMember 2023-09-20 0001839998 aonc:DTOCSponsorMember aonc:PublicWarrantMember 2023-09-20 2023-09-20 0001839998 aonc:DTOCSponsorMember aonc:PrivatePlacementWarrantsMember 2023-09-20 0001839998 aonc:AONLLCMember aonc:ClassBPrefundedWarrantsMember 2023-09-20 0001839998 aonc:AONLLCMember aonc:ClassBPrefundedWarrantsMember us-gaap:CommonClassBMember 2023-09-20 0001839998 aonc:AONLLCMember us-gaap:CommonClassBMember 2023-09-20 0001839998 aonc:AONLLCMember 2024-01-01 2024-03-31 0001839998 aonc:NewAONAONIncMember 2024-01-01 2024-03-31 0001839998 aonc:AONLLCMember 2023-01-01 2023-03-31 0001839998 aonc:NewAONAONIncMember 2023-01-01 2023-03-31 0001839998 aonc:ParticipatingThreshold1Member 2024-03-31 0001839998 aonc:ParticipatingThreshold2Member 2024-03-31 0001839998 aonc:ParticipatingThreshold3Member 2024-03-31 0001839998 aonc:AONLLCMember us-gaap:SeriesAPreferredStockMember 2024-03-31 0001839998 aonc:AONLLCMember aonc:NewAONAONIncMember 2024-01-01 2024-03-31 0001839998 aonc:AONLLCMember aonc:LegacyAONShareholdersMember 2023-09-21 2023-09-30 0001839998 aonc:AONLLCMember aonc:LegacyAONShareholdersMember 2023-01-01 2023-03-31 0001839998 aonc:MIBAMember 2023-05-01 2023-05-31 0001839998 aonc:PatientVisitsMember 2024-01-01 2024-03-31 0001839998 aonc:PatientVisitsMember 2023-01-01 2023-03-31 0001839998 aonc:ClinicalTrialsMember 2024-01-01 2024-03-31 0001839998 aonc:ClinicalTrialsMember 2023-01-01 2023-03-31 0001839998 aonc:OCPManagementArizonaLLPMember 2023-01-01 2023-01-31 0001839998 aonc:OCPManagementArizonaLLPMember 2023-01-31 0001839998 us-gaap:PreferredClassAMember 2024-01-01 2024-03-31 0001839998 2023-01-01 2023-12-31 0001839998 2023-01-01 2024-03-31 0001839998 us-gaap:ProfessionalMalpracticeLiabilityMember 2024-01-01 2024-03-31 0001839998 us-gaap:DirectorsAndOfficersLiabilityInsuranceMember 2024-01-01 2024-03-31 0001839998 aonc:PublicWarrantMember 2024-03-31 0001839998 aonc:PrivatePlacementWarrantsMember 2024-03-31 0001839998 aonc:PrivatePlacementWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2024-03-31 0001839998 aonc:PrivatePlacementWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2024-03-31 0001839998 aonc:PrivatePlacementWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-03-31 0001839998 aonc:PrivatePlacementWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2024-03-31 0001839998 aonc:AONIncMember 2024-03-31 0001839998 aonc:AONCommonUnitholdersMember 2024-03-31 0001839998 2023-09-20 0001839998 2023-09-20 2023-09-20 0001839998 aonc:PublicAndPrivateWarrantsMember 2023-09-21 2023-09-30 0001839998 aonc:AONCentralMember aonc:PhysiciansMember 2024-01-01 2024-03-31 0001839998 aonc:AONCentralMember 2024-01-01 2024-03-31 0001839998 aonc:MIBAMember 2023-04-01 2023-06-30 0001839998 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember aonc:MIBAMember 2023-04-01 2023-06-30 0001839998 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2024-03-31 0001839998 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2023-12-31 0001839998 aonc:OvernightRepurchaseAgreementsMember us-gaap:FairValueInputsLevel1Member 2024-03-31 0001839998 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2024-03-31 0001839998 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2024-03-31 0001839998 us-gaap:FairValueInputsLevel1Member 2024-03-31 0001839998 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember 2024-03-31 0001839998 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2024-03-31 0001839998 us-gaap:FairValueInputsLevel2Member 2024-03-31 0001839998 aonc:OvernightRepurchaseAgreementsMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001839998 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2023-12-31 0001839998 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001839998 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001839998 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasurySecuritiesMember 2023-12-31 0001839998 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001839998 aonc:IntravenousDrugsMember 2024-03-31 0001839998 aonc:IntravenousDrugsMember 2023-12-31 0001839998 aonc:OralPharmaceuticalsMember 2024-03-31 0001839998 aonc:OralPharmaceuticalsMember 2023-12-31 0001839998 us-gaap:LeaseholdImprovementsMember 2024-03-31 0001839998 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001839998 aonc:FurnitureFixturesAndEquipmentMember 2024-03-31 0001839998 aonc:FurnitureFixturesAndEquipmentMember 2023-12-31 0001839998 aonc:MedicalEquipmentMember 2024-03-31 0001839998 aonc:MedicalEquipmentMember 2023-12-31 0001839998 us-gaap:ComputerEquipmentMember 2024-03-31 0001839998 us-gaap:ComputerEquipmentMember 2023-12-31 0001839998 aonc:SignsMember 2024-03-31 0001839998 aonc:SignsMember 2023-12-31 0001839998 us-gaap:AutomobilesMember 2024-03-31 0001839998 us-gaap:AutomobilesMember 2023-12-31 0001839998 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-03-31 0001839998 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-12-31 0001839998 us-gaap:ConstructionInProgressMember 2024-03-31 0001839998 us-gaap:ConstructionInProgressMember 2023-12-31 0001839998 aonc:PNCLoanFacilityMember us-gaap:LineOfCreditMember 2024-03-31 0001839998 aonc:PNCLoanFacilityMember us-gaap:LineOfCreditMember 2023-12-31 0001839998 aonc:PNCLoanFacilityMember us-gaap:LineOfCreditMember 2021-04-30 2021-04-30 0001839998 aonc:PNCLoanFacilityMember us-gaap:LineOfCreditMember aonc:AlternateBaseRateMember 2021-04-30 2021-04-30 0001839998 aonc:PNCLoanFacilityMember us-gaap:LineOfCreditMember 2021-04-30 0001839998 aonc:PNCLoanFacilityMember us-gaap:LineOfCreditMember aonc:DebtInstrumentThresholdLimitPeriodOneMember 2021-04-30 2021-04-30 0001839998 aonc:PNCLoanFacilityMember us-gaap:LineOfCreditMember aonc:DebtInstrumentThresholdLimitPeriodTwoMember 2021-04-30 2021-04-30 0001839998 us-gaap:RevolvingCreditFacilityMember aonc:PNCLineOfCreditMember us-gaap:LineOfCreditMember 2021-04-30 0001839998 us-gaap:RevolvingCreditFacilityMember aonc:PNCLineOfCreditMember us-gaap:LineOfCreditMember aonc:LondonInterbankOfferedRateLIBOR1Member 2021-04-30 2021-04-30 0001839998 us-gaap:RevolvingCreditFacilityMember aonc:PNCLineOfCreditMember us-gaap:LineOfCreditMember aonc:AlternateBaseRateMember 2021-04-30 2021-04-30 0001839998 us-gaap:RevolvingCreditFacilityMember aonc:PNCLineOfCreditMember us-gaap:LineOfCreditMember 2021-04-30 2021-04-30 0001839998 us-gaap:RevolvingCreditFacilityMember aonc:PNCLineOfCreditMember us-gaap:LineOfCreditMember 2024-01-01 2024-03-31 0001839998 us-gaap:RevolvingCreditFacilityMember aonc:PNCLineOfCreditMember us-gaap:LineOfCreditMember 2023-01-01 2023-12-31 0001839998 aonc:PNCLoanFacilityMember us-gaap:LineOfCreditMember 2021-07-29 0001839998 aonc:PNCLoanFacilityMember us-gaap:LineOfCreditMember 2022-02-14 0001839998 us-gaap:RevolvingCreditFacilityMember aonc:PNCLineOfCreditMember us-gaap:LineOfCreditMember 2022-02-14 0001839998 us-gaap:RevolvingCreditFacilityMember aonc:PNCLineOfCreditMember us-gaap:LineOfCreditMember aonc:BloombergShortTermBankYieldIndexMember 2022-02-14 2022-02-14 0001839998 aonc:PNCLoanFacilityMember us-gaap:LineOfCreditMember 2022-02-14 2022-02-14 0001839998 us-gaap:RevolvingCreditFacilityMember aonc:PNCLineOfCreditMember us-gaap:LineOfCreditMember 2022-08-15 0001839998 aonc:PNCLoanFacilityMember us-gaap:LineOfCreditMember 2023-06-30 0001839998 aonc:PNCLoanFacilityMember us-gaap:LineOfCreditMember aonc:DebtInstrumentThresholdLimitPeriodOneMember 2023-06-01 2023-06-30 0001839998 aonc:A2024NotesReceivableNote2Member 2024-03-31 0001839998 aonc:A2024NotesReceivableNote2Member 2023-12-31 0001839998 aonc:A2024NotesReceivableNote2Member 2019-05-01 0001839998 aonc:A2024NotesReceivableNote3Member 2024-03-31 0001839998 aonc:A2024NotesReceivableNote3Member 2023-12-31 0001839998 aonc:A2024NotesReceivableNote3Member 2019-06-01 0001839998 aonc:A2025NotesReceivableNote8Member 2024-03-31 0001839998 aonc:A2025NotesReceivableNote8Member 2023-12-31 0001839998 aonc:A2025NotesReceivableNote8Member 2020-05-01 0001839998 us-gaap:RelatedPartyMember aonc:SubsidiaryUnderCommonControlOfClassA1MemberMember 2024-01-01 2024-03-31 0001839998 us-gaap:RelatedPartyMember aonc:SubsidiaryUnderCommonControlOfClassA1MemberMember 2023-01-01 2023-03-31 0001839998 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember aonc:SubsidiaryUnderCommonControlOfClassA1MemberMember 2024-01-01 2024-03-31 0001839998 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember aonc:SubsidiaryUnderCommonControlOfClassA1MemberMember 2023-01-01 2023-03-31 0001839998 us-gaap:RelatedPartyMember aonc:SubsidiaryUnderCommonControlOfClassA1MemberMember 2024-03-31 0001839998 us-gaap:RelatedPartyMember aonc:SubsidiaryUnderCommonControlOfClassA1MemberMember 2023-12-31 0001839998 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember aonc:SubsidiaryUnderCommonControlOfClassA1MemberMember 2024-01-01 2024-03-31 0001839998 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember aonc:SubsidiaryUnderCommonControlOfClassA1MemberMember 2023-01-01 2023-12-31 0001839998 us-gaap:EmployeeStockMember aonc:A2023IncentiveEquityPlanMember 2024-03-31 0001839998 us-gaap:EmployeeStockMember aonc:A2023IncentiveEquityPlanMember 2024-01-01 2024-03-31 0001839998 us-gaap:RestrictedStockMember 2024-01-01 2024-03-28 0001839998 us-gaap:RestrictedStockMember 2023-12-31 0001839998 us-gaap:RestrictedStockMember 2024-01-01 2024-03-31 0001839998 us-gaap:RestrictedStockMember 2024-03-31 0001839998 srt:MinimumMember us-gaap:RestrictedStockMember 2024-01-01 2024-03-31 0001839998 srt:MaximumMember us-gaap:RestrictedStockMember 2024-01-01 2024-03-31 0001839998 us-gaap:CommonClassAMember aonc:AONLLCMember 2022-12-31 0001839998 aonc:CommonClassA1Member aonc:AONLLCMember 2022-12-31 0001839998 us-gaap:CommonClassBMember aonc:AONLLCMember 2023-12-31 0001839998 us-gaap:CommonClassBMember aonc:AONLLCMember 2022-01-01 2022-12-31 0001839998 us-gaap:CommonClassAMember 2022-12-31 0001839998 us-gaap:CommonClassAMember 2023-01-01 2023-03-31 0001839998 us-gaap:CommonClassAMember 2023-03-31 0001839998 aonc:CommonClassA1Member 2022-12-31 0001839998 aonc:CommonClassA1Member 2023-01-01 2023-03-31 0001839998 aonc:CommonClassA1Member 2023-03-31 0001839998 us-gaap:CommonClassBMember 2022-12-31 0001839998 us-gaap:CommonClassBMember 2023-01-01 2023-03-31 0001839998 us-gaap:CommonClassBMember 2023-03-31 0001839998 aonc:CommonStockClassB1Member 2023-06-01 2023-07-31 0001839998 aonc:AEAGrowthManagementLPMember us-gaap:SeriesAPreferredStockMember 2023-09-20 2023-09-20 0001839998 us-gaap:CommonClassCMember 2024-01-01 2024-03-31 0001839998 us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-03-31 0001839998 us-gaap:SeriesAPreferredStockMember 2023-09-20 2023-09-20 0001839998 us-gaap:SeriesAPreferredStockMember aonc:StockholdersMember 2024-03-31 0001839998 us-gaap:SeriesAPreferredStockMember aonc:StockholdersMember 2024-01-01 2024-03-31 0001839998 aonc:NewAONAONIncMember 2024-03-31 0001839998 aonc:NewAONAONIncMember 2024-01-01 2024-03-31 0001839998 aonc:DividendsPaidEventPriorToJune72024Member us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-03-31 0001839998 aonc:DividendsPaidEventPriorToJune72025AfterJune72024Member us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-03-31 0001839998 aonc:DividendsPaidEventPriorToJune72026AfterJune72025Member us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-03-31 0001839998 aonc:DividendsPaidEventPriorToJune72027AfterJune72026Member us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-03-31 0001839998 aonc:DividendsPaidEventPriorToJune72028AfterJune72027Member us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-03-31 0001839998 aonc:DividendsPaidEventAfterJune72028Member us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-03-31 0001839998 us-gaap:CommonClassAMember 2020-03-04 2020-03-04 0001839998 aonc:CommonClassA1Member 2020-03-04 2020-03-04 0001839998 us-gaap:CommonClassAMember 2023-06-07 2023-06-07 0001839998 aonc:CommonClassA1Member 2023-06-07 2023-06-07 0001839998 us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-03-31 0001839998 us-gaap:CommonClassBMember 2024-01-01 2024-03-31 0001839998 aonc:ClassBPrefundedWarrantsMember 2024-01-01 2024-03-31 0001839998 aonc:PublicAndPrivateWarrantsMember 2024-01-01 2024-03-31 0001839998 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001839998 aonc:AONLLCMember aonc:LegacyAONShareholdersMember 2024-03-31 0001839998 aonc:AONLLCMember aonc:LegacyAONShareholdersMember 2024-01-01 2024-03-31 0001839998 aonc:AONLLCMember aonc:NewAONAONIncMember 2023-12-31 0001839998 aonc:AONLLCMember aonc:LegacyAONShareholdersMember 2023-12-31 0001839998 aonc:AONLLCMember 2023-12-31 0001839998 aonc:AONLLCMember aonc:NewAONAONIncMember 2024-03-31 0001839998 aonc:AONLLCMember 2024-03-31 0001839998 aonc:AONLLCMember 2024-01-01 2024-03-31 shares iso4217:USD iso4217:USD shares aonc:practice aonc:state pure aonc:segment aonc:person aonc:office 0001839998 2024 Q1 --12-31 false http://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesCurrent P1Y P10D 10-Q true 2024-03-31 false 001-04321 American Oncology Network, Inc. DE 85-3984427 14543 Global Parkway Suite 110 Fort Myers FL 33913 833 886-1725 Class A common stock, par value $0.0001, per share AONC NASDAQ Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50 per share AONCW NASDAQ Yes Yes Non-accelerated Filer true false false 13046342 23725998 74944000 28539000 30105000 35389000 132300000 129151000 44288000 44569000 34799000 34274000 5029000 4277000 2498000 1604000 323963000 277803000 40997000 40439000 43358000 43349000 157000 1150000 12216000 7588000 1230000 1230000 0 2894000 421921000 374453000 188329000 127645000 12628000 11410000 25186000 22327000 971000 971000 6715000 6692000 233829000 169045000 80856000 80641000 39786000 39803000 11342000 14251000 365813000 303740000 0.0001 7500000 6651610 6651610 69369195 68009015 64986000 64986000 157716000 167025000 0.0001 200000000 10334734 10334734 9517816 9517816 1000 1000 0.0001 100000000 23725998 23725998 25109551 25109551 3000 3000 8164000 0 31170 14729 97000 0 77000 81000 -175594000 -161812000 -167446000 -161727000 852000 429000 -166594000 -161298000 421921000 374453000 11293000 10931000 182697000 120857000 1971000 1888000 9772000 9472000 361508000 301773000 2831000 1958000 364339000 303731000 354948000 278534000 28277000 23717000 352000 1971000 383577000 304222000 -19238000 -491000 1763000 1417000 793000 57000 -1908000 466000 -22116000 -1385000 2894000 0 -25010000 -1385000 49000 -101000 -24961000 -1486000 43000 0 -25004000 -1486000 0 -1486000 -17163000 0 -7841000 -7841000 0 0 -1.22 0 -1.22 0 7527882 0 7527882 0 -22000 64000 -22000 64000 -25026000 -1422000 0 -1422000 -17180000 0 -7846000 0 310877000 178166000 706000 679000 6652000 64986000 167025000 6678441000 1000 25109551000 3000 0 0 81000 429000 -161812000 -161298000 -17000 -4000 -4000 399000 2289181000 9696000 9696000 16441000 97000 97000 380000 380000 -17163000 43000 -7842000 -7799000 15636000 -9696000 -5940000 -15636000 8164000 1383553000 1383553000 -8164000 -8164000 6652000 64986000 157716000 10334734000 1000 23725998000 3000 8164000 -97000 77000 852000 -175594000 -166594000 19495000 7725000 1843000 28500000 80000 -117000 25828000 62016000 -1486000 -1486000 -64000 -64000 19495000 7725000 1843000 28500000 80000 -53000 24342000 60594000 -24961000 -1486000 2506000 2207000 215000 176000 2894000 0 2040000 2224000 1611000 0 10094000 0 49000 -101000 -393000 0 3149000 16711000 -281000 -4854000 752000 342000 525000 -3442000 4579000 2826000 61675000 5316000 1218000 2757000 4241000 -296000 -2042000 -1777000 -2752000 2032000 45137000 -329000 4132000 2777000 7069000 1442000 12624000 1423000 99000 153000 1522000 -2643000 157000 105000 97000 0 -254000 -105000 46405000 -3077000 28539000 26926000 74944000 23849000 1420000 0 -380000 0 0 -1023000 1055000 0 2146000 528000 7688000 -4610000 80584000 3669000 -2381000 -797000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.5pt">Business</span><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">American Oncology Network, Inc. (“AON”, “New AON”, “AON Inc.”, or the “Company”), through its subsidiary companies and variable interest entities (together, “its subsidiaries”), is an alliance of physicians and seasoned healthcare leaders who provide comprehensive oncology services across 32 oncology practices located in nineteen states (Arizona, Arkansas, Florida, Georgia, Iowa, Idaho, Indiana, Louisiana, Maryland, Missouri, Michigan, North Carolina, Nevada, Nebraska, Ohio, South Carolina, Texas, Virginia, Washington, and the District of Columbia). The Company also provides expertise in drug procurement and payor contracting, along with practice diversification through centralized laboratory and pathology services, as well as specialty pharmacy services, clinical research, radiation oncology, and imaging. During the three months ended March 31, 2024 and 2023, the Company entered into affiliation agreements with or acquired the following oncology practices.</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.090%"><tr><td style="width:1.0%"></td><td style="width:48.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.126%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">State</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">State</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maryland (a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Texas (a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;padding-left:49.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">The Company entered into affiliation agreements with the physicians for these respective practices. The Company evaluated each of the affiliation agreements and determined that the transactions did not represent a business combination.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operations of the practices above have been included in the Company’s condensed consolidated financial statements.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combination Agreements</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Digital Transformation Opportunities Corp. (“DTOC”), American Oncology Network, LLC (“AON LLC”), GEF AON Holdings Corp. (“AON Class C Preferred Investor”), and DTOC Merger Sub, Inc., a direct, wholly owned subsidiary of DTOC (“Merger Sub”) entered into a Business Combination Agreement (the “Business Combination Agreement”), dated as of June 14, 2023 (which further amended and restated the Business Combination Agreement entered into by DTOC and AON as of October 5, 2022, and amended and restated on January 6, 2023, and April 27, 2023), pursuant to which, among other transactions, on September 20, 2023 (the “Closing Date”), DTOC and AON undertook a series of transactions (the “Business Combination” or “Reverse Recapitalization”) resulting in the organization of the combined post-business combination company as an umbrella partnership C corporation, in which substantially all of the assets and the business of the combined company are held by AON LLC, and DTOC became a member of AON LLC. In connection with the closing of the Business Combination (“the Closing”), DTOC changed its name to “American Oncology Network, Inc.”. The Business Combination was completed on September 20, 2023.</span></div><div><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of, and in connection with, the Closing, among other things, (i) AON LLC amended and restated its operating agreement (the “Amended and Restated AON LLC Agreement”) to reclassify its existing Class A units, Class A-1 units and Class B units into a single class of AON LLC common units (“AON LLC Common Units”) that can be exchanged on a one-to-one basis for shares of New AON Class A common stock (“New AON Class A Common Stock”) and its existing AON LLC Class C units into AON LLC Series A preferred units (AON LLC Series A Preferred Units”); (ii) AON LLC converted profit pool units of certain of AON LLC’s subsidiaries into an equal number of AON LLC Common Units and shares of New AON Class B common stock (“New AON Class B Common Stock”), which together are exchangeable into shares of New AON Class A Common Stock (together with the New AON Class B Common Stock, the “New AON Common Stock”); (iii) New AON amended and restated its charter (the “Charter”) to provide for (a) the conversion of all existing shares of DTOC Class B common stock into shares of New AON Class A Common Stock on a one-to-one basis, (b) amendment of the terms </span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of New AON Class B Common Stock to provide holders voting rights but no economic rights and (c) designation of a new series of New AON preferred stock as Series A convertible preferred stock (the “New AON Series A </span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred Stock” or “Series A Preferred Stock") with such rights and preferences as provided for in the certificate of designation of the New Aon Series A Preferred Stock (the “New AON Series A Certificate of Designation”); and (iv) among other things, (a) AON LLC issued common units to New AON in exchange for a combination of cash </span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and shares of New AON Class B Common Stock and warrants to acquire shares of New AON Class B Common Stock (the “Class B Prefunded Warrants”), (b) New AON was admitted as a member of AON LLC, (c) AON LLC distributed shares of New AON Class B common stock or Class B Prefunded Warrants, as applicable, to AON LLC equity holders, (d) New AON reserved a specified number of additional shares of New AON Class A Common Stock after the Closing for issuance to eligible participants, (e) Merger Sub merged with and into the AON Class C Preferred Investor whereby the separate existence of Merger Sub ceased and New AON issued a number of shares of New AON Series A Preferred Stock equal to the number of AON LLC Series A preferred units held by the AON Class C Preferred Investor to AEA Growth Management LP, the parent of AON Class C Preferred Investor (“AEA Growth”) in exchange for all the shares of common stock held by AEA Growth in the AON Class C Preferred Investor (the “First Step”), (f) promptly after the First Step, the AON Class C Preferred Investor merged with and into New AON whereby the separate existence of the AON Class C Preferred Investor ceased and New AON held all the AON LLC Series A preferred units and (g) from and after the Closing (but subject to lock-up restrictions), the AON LLC common equity holders (other than New AON), referred to herein as “Legacy AON Shareholders” (former AON LLC Class A, Class A-1, and Class B unit holders), will have the right (but not the obligation) to exchange AON LLC Common Units together with an equal number of shares of New AON Class B Common Stock (whether held directly or indirectly through Class B Prefunded Warrants) for shares of New AON Class A Common Stock. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in connection with the Closing, DTOC completed the offer to the holders of AON LLC Class B-1 units to exchange their AON LLC Class B-1 units for such number of newly issued shares of New AON Class A Common Stock equal to the ratio set forth in the Business Combination Agreement (such offer, the “Exchange Offer”). DTOC and AON LLC solicited consents from the holders of AON LLC Class B-1 units to make certain amendments to the terms of the awards and the unit grant agreements pursuant to which the AON LLC Class B-1 units were granted, which provided for the automatic exchange, as of immediately prior to the adoption of the Amended and Restated AON LLC Agreement, of all outstanding AON LLC Class B-1 units into shares of New AON Class A Common Stock (collectively, the “Proposed Amendments”). The requisite number of holders of Class B-1 units provided their consent to the Proposed Amendments, and as a result, in connection with the Closing, all AON LLC Class B-1 units were exchanged for an aggregate of 1,047,343 shares of New AON Class A Common Stock.</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the consummation of the Business Combination, the outstanding membership units in AON LLC and the outstanding shares in AON Inc. (New AON) are as follows:</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">AON LLC Common Units held by the Legacy AON Shareholders - 28,109,796</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">AON LLC Common Units held by New AON - 9,532,354</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">AON LLC Series A Preferred Units held by New AON - 6,651,610</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Class A Common Stock held by the former AON LLC Class B-1 unit holders - 1,047,343</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Class A Common Stock held by the DTOC unredeemed shareholders - 147,511</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Class A Common Stock held by the DTOC Sponsor and their permitted transferees - 5,498,125</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Class B Common Stock held by Legacy AON Shareholders - 25,109,551</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div><div style="padding-left:67.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">New AON Series A Preferred Stock held by AEA Growth Management LP - 6,651,610</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sponsor Earnout Shares of 2,839,375 are subject to vesting and forfeiture provisions and are not outstanding for GAAP purposes as of the Closing Date. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(b) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain Legacy AON Shareholders hold 3,000,245 Class B Prefunded Warrants, which underlying shares of Class B common stock are not outstanding as of the Closing Date.</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Warrants</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the Closing Date, New AON assumed the outstanding warrants (Public Warrants and Private Placement Warrants) that were issued by DTOC as part of DTOC’s IPO. Further, New AON issued the Class B Prefunded Warrants to former Class A-1 unit holders, in lieu of New AON Class B Common Stock. The accounting treatment for the Public Warrants, the Private Placement Warrants, and the Class B Prefunded Warrants, collectively referred to as “the Warrants”, is disclosed in Note 2. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Public Warrants</span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the Closing Date, New AON assumed 8,337,500 public warrants (the “Public Warrants”) issued by DTOC in its IPO. Each whole warrant entitles the holder to purchase one share of New AON Class A Common Stock at a price of $11.50 per share, subject to adjustment. The warrants will become exercisable on the later of 12 months from the closing of the DTOC Initial Public Offering or 30 days after the completion of its initial business combination and will expire five years after the Closing of the Business Combination, or earlier upon redemption or liquidation.</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private Warrants</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the Closing Date, New AON assumed 6,113,333 Private Placement Warrants held by the DTOC Sponsor (the “Private Placement Warrants” or “Private Warrants”). The Private Placement Warrants will be</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">non-redeemable in certain circumstances so long as they are held by the Sponsor or its permitted transferees. The Private Placement Warrants may also be exercised by the Sponsor and its permitted transferees for cash or on a cashless basis. Otherwise, the Private Placement Warrants have terms and provisions that are identical to those of the Public Warrants, including as to exercise price, exercisability, and exercise period. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Class B Prefunded Warrants</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the Closing Date, New AON issued 3,000,245 of Class B Prefunded Warrants to former AON Class A-1 unitholders. Because the Class B Warrants are prefunded, there was not any cash consideration exchanged as part of the Class B Warrant issuance. Each Class B Prefunded Warrant entitles the holder to purchase one share of New AON Class B common stock at a price of $0.01 per share. The exercise term of the Class B Warrant shall continue indefinitely so long as the holder of the Class B Warrant is also the holder of an AON LLC Common Unit, provided that the number of shares of Common Stock that this Warrant is exercisable for shall not exceed the number of AON LLC Common Units held by holder. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Transaction Expenses</span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Reverse Recapitalization, AON LLC and New AON incurred costs of $0.4 million and $1.9 million during the three months ended March 31, 2024 and 2023, respectively, which were reported as transaction expenses in the condensed consolidated statements of operations and comprehensive loss.</span></div> 32 19 During the three months ended March 31, 2024 and 2023, the Company entered into affiliation agreements with or acquired the following oncology practices.<div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:39.090%"><tr><td style="width:1.0%"></td><td style="width:48.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.126%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">State</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">State</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maryland (a)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Texas (a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;padding-left:49.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">The Company entered into affiliation agreements with the physicians for these respective practices. The Company evaluated each of the affiliation agreements and determined that the transactions did not represent a business combination.</span></div> 1 1 1047343 28109796 9532354 6651610 1047343 147511 5498125 25109551 6651610 2839375 3000245 8337500 1 11.50 P12M P30D P5Y 6113333 3000245 1 0.01 400000 400000 1900000 1900000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24pt">Basis of Presentation and Significant Accounting Policies</span><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of the Company were prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. Management believes the unaudited condensed consolidated financial statements for the interim periods presented contain all necessary adjustments, of a normal recurring nature, to state fairly, in all material respects, the Company’s financial position, results of operations and cash flows for the interim periods presented. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements were prepared on the same basis as and should be read in conjunction with such audited consolidated financial statements and related notes thereto of AON Inc. and its wholly-owned subsidiaries, included in the Annual Report on Form 10-K, dated and filed on March 28, 2024 with the SEC (the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> “Annual Report 2023")</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results the Company expects for the entire year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, these unaudited condensed consolidated financial statements reflect the consolidated results of operations, comprehensive loss, cash flows and changes in equity of AON Inc. and its wholly-owned subsidiaries. The condensed consolidated balance sheet at March 31, 2024 presents the financial condition of AON Inc. and its consolidated subsidiaries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023, these unaudited condensed consolidated financial statements present the consolidated results of operations, comprehensive loss, cash flows and changes in equity of AON LLC. The condensed consolidated balance sheet as of December 31, 2023 presents the financial condition of AON Inc. and its consolidated subsidiaries after the Reverse Recapitalization. All intercompany balances and transactions of AON LLC have been eliminated. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification (“ASC”) Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the historical equity of AON LLC has been recasted in all periods up to the Closing Date, to reflect the number of shares of New AON’s Class A Common Stock and Class B Common Stock issued to Legacy AON Shareholders in connection with the Reverse Recapitalization. The Company recasted the units outstanding related to the historical AON LLC Class A, Class A-1, and Class B units prior to the Reverse Recapitalization (“Historical AON LLC Equity”) as common equity of New AON, equal to the Per Company Class Unit Exchange Ratio, pursuant to the Business Combination Agreement. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Per Company Unit Exchange Ratio at which AON LLC Class A units and Class A-1 units were reclassified is equal to 2,524 AON Common Units. The Per Company Unit Exchange Ratio at which AON LLC Class B units were reclassified varied depending on participation threshold, and is equal to 2,524, 2,453, or 1,976, AON Common Units. The Per Company Unit Exchange Ratio at which Class C units were reclassified is equal to 2,705 AON LLC Series A Preferred Units.</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements and related notes thereto give effect to the conversion for all periods presented, without any change to par value or per unit amounts. The condensed consolidated financial statements do not necessarily represent the capital structure of New AON had the Reverse Recapitalization occurred in prior periods. The Company has not made retroactive adjustments related to the historical book values of Historical AON LLC Equity as the adjustments were considered immaterial.</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, $7.8 million of the consolidated net loss of AON LLC were attributable to the Class A Common Stockholders, and reflects the Class A Common Stockholders’ absorption of 23.0% of the consolidated net loss of AON LLC. For the three months ended March 31, 2024, $17.2 million of the consolidated net losses of AON LLC were attributable to noncontrolling interest, and reflects the Legacy AON Stockholders’ absorption of 77.0% of the consolidated net losses of AON LLC.</span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023, $1.5 million of the consolidated net losses of AON LLC were attributable to the Legacy AON Stockholders, to reflect their absorption of 100% of the consolidated net losses of AON LLC pertaining to the days prior to the Reverse Recapitalization. </span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the period of January 1, 2024 through March 31, 2024, the condensed consolidated financial statements include the accounts of the Company, American Oncology Network, LLC (“AON LLC”), and its wholly owned subsidiary American Oncology Management Company, LLC (“AOMC”), and its consolidated variable interest entities (“VIEs”) American Oncology Partners, P.A. (“AON Partners”), American Oncology Partners of Maryland, P.A. (“Partners of Maryland”), AON Central Services, LLC (“AON Central Services”), and Meaningful Insights Biotech Analytics, LLC (“MIBA”). All intercompany accounts and transactions between the entities have been eliminated in consolidation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting treatment of the Business Combination was a Reverse Recapitalization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the periods prior to the Reverse Recapitalization, the consolidated financial statements of the Company comprise the accounts of AON LLC and its wholly-owned subsidiaries. All intercompany accounts and transactions among AON LLC and its consolidated subsidiaries were eliminated.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for American Oncology Network, LLC, AON Partners, Partners of Maryland, AON Central Services, and MIBA in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company determines whether it has a controlling financial interest in an entity by first evaluating whether the entity is a VIE. A VIE is broadly defined as an entity that has any of the following three characteristics: (i) the equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (ii) substantially all of the entity’s activities either involve or are conducted on behalf of an investor that has disproportionately few voting rights; or (iii) the equity investors as a group lack any of the following, the power through voting or similar rights to direct the activities of the entity that most significantly impact the entity’s economic performance, the obligation to absorb the expected losses of the entity, or the right to receive the expected residual returns of the entity. The Company consolidates a VIE if it has both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and an obligation to absorb losses or the right to receive benefits that could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively, if any. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AON LLC has contractual relationships with AON Partners, Partners of Maryland and AON Central Services and the physician owners through management service agreements (“MSAs”) and other contractual agreements to provide all practice management services outside of medical services provided by the physicians. In addition, despite not being required by the contractual relationships, AON LLC regularly provides funding to support AON Partners and Partners of Maryland’s operations and acquisitions of physician practices. AON Central Services was formed July 15, 2022 and, effective January 1, 2023, entered into an agreement with AOMC to provide qualified non-clinical and non-medical employees to AOMC to support the operation of the physician practices. MIBA was established during the first quarter of 2023 for the purpose of developing intellectual property to synergize the collection, de-identification, and dissemination of the Company’s patient data for sale to external parties for research, development, and clinical decisions. In May 2023, the Company contributed $0.2 million for a 56% interest in the equity of MIBA. As of March 31, 2024, MIBA had no significant operating activity. The Company concluded that AON LLC had a controlling financial interest in MIBA and has consolidated the entity at March 31, 2024 and recorded the noncontrolling interest in equity. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has concluded that AON Partners, Partners of Maryland, AON Central Services, and MIBA are all VIEs in which AON LLC has the characteristics of a controlling financial interest and is deemed to be the primary beneficiary. The variable interest subjects AON LLC to all potential losses in the entities and, therefore, requires AON LLC, and in turn AON Inc., to consolidate the results of AON Partners, Partners of Maryland, AON Central Services, and MIBA in its condensed consolidated financial statements. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 4 for further information on the VIEs. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies included below should be read in conjunction with the annual consolidated financial statements.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Estimates and Assumptions </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segments </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (the “CODM”). The Company’s CODM is its chief executive officer who reviews financial information together with certain operating metrics principally to make decisions about how to allocate resources and to measure the Company’s performance. The Company has one operating segment and one reportable segment that are structured around the organizational management of oncology practice operations. All revenue and assets are in the United States. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized under Accounting Standards Update (“ASU”) 2014-09 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“Topic 606”). The Company determines the transaction price based upon standard charges for goods and services with anticipated consideration due from patients, third-party payors (including health insurers and government agencies) and others. The Company’s revenue is primarily derived from patient service revenues, which encompass oncology services provided during patient visits and shipments of pharmacy prescriptions. Performance obligations for the Company’s services provided to patients and most procedures, are satisfied over the time of visit which is the same day services are performed. Performance obligations relating to pharmacy revenue are considered fully satisfied at a point in time upon the customer receiving delivery of the prescription. Accordingly, the Company does not anticipate a significant amount of revenue from performance obligations satisfied (or partially satisfied) in previous periods, and any such revenue recognized during the three month periods ended March 31, 2024 and 2023 was immaterial. Additionally, the Company does not expect to recognize material revenue in the future related to performance obligations that are unsatisfied (or partially satisfied) as of March 31, 2024 and December 31, 2023. Approximately $246.1 million and $214.3 million and of the Company’s revenues are generated from services performed during patient visits with the remainder primarily generated from shipments of pharmacy prescriptions for the three month periods ended March 31, 2024 and 2023, respectively.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As services are performed and prescriptions are shipped, timely billing occurs for services rendered and prescriptions shipped less discounts provided to uninsured patients and contractual adjustments to third-party payors based upon prospectively determined rates and discounted charges. Payment is requested at the time of service for self-paying patients and for patients covered by third-party payors that are responsible for paying deductibles and coinsurance.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors revenue and receivables to prepare estimated contractual allowances for the anticipated differences between billed and reimbursed amounts. Payments from third-party payors and Government programs including Medicare and Medicaid may be subject to audit and other retrospective adjustments. Such amounts are considered on an estimated basis when net patient revenue is recorded and are adjusted as final adjustments are determined. For the three month periods ended March 31, 2024 and 2023, such resulting historic adjustments have been immaterial to the condensed consolidated financial statements. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing who is the principal in providing patient services and pharmacy prescriptions, the Company considered who controls the provision of services and prescriptions. The Company has determined they are acting as a principal in these relationships. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the Company entered into a long-term arrangement to sponsor and manage a clinical trial. The Company subsequently contracted with a third-party to provide the clinical research services and is the principal in this arrangement. The performance of clinical research services are considered a single performance obligation because the Company provides a highly-integrated service. Revenue is recognized for the single performance obligation over time due to the Company’s right to payment for work performed to date. The contract provides for invoices based on predetermined milestones. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the cost-to-cost measure of progress for the Company’s contract because it best depicts the transfer of control to the customer as the performance obligation is fulfilled. For this method, the Company </span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compares the contract costs incurred to date to the estimated total contract costs through completion. As part of the client proposal and contract negotiation process, the Company develops a detailed project budget for the direct costs and reimbursable costs based on the scope of the work, the complexity of the study, the geographical location involved and the Company’s historical experience. The estimated total contract costs at the project level are reviewed and revised periodically throughout the life of the contract, with adjustments to revenue resulting from such revisions being recorded on a cumulative basis in the period in which the revisions are identified. Contract costs consist primarily of direct labor and other reimbursable project-related costs such as travel, third-party vendor costs and investigator fees. The Company establishes pricing based on the Company’s internal pricing guidelines, discount agreements, if any, and negotiations with the client. The transaction price is the contractually defined amount. Revenue related to the clinical trial, which is included within other revenue, was $0.5 million and $0 million for the three months ended March 31, 2024 and 2023, respectively. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a system and estimation process for recording Medicare net patient service revenue and estimated recoupments as it relates to value-based care (“VBC”) revenue included in patient service revenue in the condensed consolidated statements of operations and comprehensive loss. The Company’s VBC revenue is primarily generated through its participation in the CMS Oncology Care Model (“OCM”) which is an episode-based payment model to promote high-quality cancer care. Participants enter six-month episode periods, and the Company bills a monthly fee during the six-month period based on a fixed rate per participant per month and the total number of participants. Certain quality and compliance metrics are tracked as part of the program and submitted to CMS at the end of the episode period which may result in recoupment of funds. The Company estimates the recoupment amount by developing a recoupment percentage for each period based on historical known recoupment from CMS and applies the recoupment percentage against total fees for the period. Based on the estimate, the Company accrues a liability representing the expected final recoupments based on historical settlement trends.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-term Marketable Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable securities consist of corporate bonds and U.S. Treasury securities.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management determines the appropriate classification of investments at the time of purchase and reevaluates such determination at each balance sheet date. Marketable securities are classified as available-for-sale and are carried at fair value in the consolidated balance sheets. The marketable securities are classified as short-term based on management’s intent to convert such securities within one year and the ability to convert them within two to three days.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our available-for-sale securities are debt securities. For an available-for-sale debt security with an amortized cost that exceeds its fair value, the Company first determines if it intends to sell or will more-likely-than-not be required to sell the security before the expected recovery of its amortized cost. If it intends to sell or will more-likely-than-not be required to sell the security, then the Company recognizes the impairment as a credit loss in the condensed consolidated statements of operations and comprehensive loss by writing down the security’s amortized cost to its fair value. If it does not intend to sell or it is not more-likely-than-not that it will be required to sell the security before the expected recovery of its amortized cost, the Company recognizes the portion of the impairment that is due to a credit loss, if any, in the condensed consolidated statements of operations and comprehensive loss through an allowance. The portion of the impairment that is due to factors other than a credit loss is recognized in other comprehensive income (loss) in the condensed consolidated statements of operations and comprehensive loss as an unrealized loss.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Investment in Affiliate</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company contributed noncash consideration, with a fair value of approximately $2.3 million, in return for a 49% equity interest in OCP Management Arizona, LLP. Investments in entities over which the Company has the ability to exercise significant influence but does not control the entity are accounted for using the equity method. Equity method investments are included with other assets in the condensed consolidated balance sheets. The carrying amount of the investment is adjusted to reflect the Company’s proportionate share of the net earnings or losses and reduced by any dividends received. The Company’s share of income or loss related to this investment is reported as an equity in loss of affiliate in the condensed consolidated statements of operations and comprehensive loss.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Noncontrolling Interests</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company consolidates the results of entities in which it has a controlling financial interest. Refer to Note 15 for additional considerations and presentation for noncontrolling interest. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mezzanine Equity</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#060606;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New AON Series A Preferred Stock is redeemable for cash or the value of the property, rights or securities to be paid or distributed in the event of a Deemed Liquidation Event (which is outside of the Company’s control). As a result, Management has determined that the New AON Series A Preferred Stock should be classified as mezzanine equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of March 31, 2024, the Preferred Stock are recorded at their initial carrying value, net of offering costs of $0.8 million. The Series A Preferred Stock are not being accreted to redemption value, as the redemption is not probable. The Series A Preferred Stock are classified outside of members’ equity on the consolidated balance sheets. Refer to Note 14 for mezzanine equity presentation considerations for redeemable noncontrolling interest. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#060606;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for treasury stock purchased under the cost method and include treasury stock as a component of</span></div><div style="padding-left:31.5pt"><span style="color:#060606;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accumulated paid in capital. Treasury stock purchased with intent to retire (whether or not the retirement is actually accomplished) is charged to common stock. The company repurchased 14,729 shares of class A common stock at the spot rate as of each transaction date for a total cost of less than $0.1 million for the year ended December 31, 2023. For the three months ended March 31, 2024 the Company repurchased an additional 16,441 shares of class A common stock at the spot rate as of each transaction date for a total cost of less than $0.1 million. To date, the Company has repurchased a total of 31,170 shares.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity-Based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#060606;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues stock-based awards to employees and directors in the form of stock options and restricted stock units. The Company measures and recognizes compensation expense for its stock-based awards granted to its employees and directors based on the estimated grant date fair value in accordance with ASC 718, Compensation-Stock Compensation, and determines the fair value of restricted stock units based on the fair value of its common stock. The Company measures all share-based options granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. Compensation expense of those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company records the expense for awards with service-based conditions using the straight-line method over the requisite service period, net of any actual forfeitures. The Company classifies share-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates acquired practices in accordance with ASU 2017-01</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Business Combinations (Topic 805)-Clarifying the Definition of a Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. Because substantially all of the value of each acquired practice did not relate to a similar group of assets and as each acquired practice contained both inputs and processes necessary to provide economic benefits to the Company, it was determined that each acquisition represents a business combination. Therefore, the transactions have been accounted for using the acquisition method of accounting, which requires, with limited exceptions, that assets acquired, and liabilities assumed be recognized at their estimated fair values as of the acquisition date. Any excess of the consideration transferred over the estimated fair values of the net assets acquired is recorded as goodwill. Transaction costs related to business combinations are expensed in the period in which they are incurred.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Offering Costs</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defers specific incremental costs directly attributable to proposed offerings of securities. These costs consist of legal, accounting, and other similar expenses incurred through the balance sheet date that are directly related to a potential offering. If the offering is completed, these costs will be charged against the gross proceeds of the offering. These offering costs will be allocated to the separable financial instruments issued in the transaction on a relative fair value basis of the securities issued, compared to total proceeds received. Offering costs associated </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with any instruments classified as liabilities will be expensed as incurred, presented as non-operating expenses in the condensed consolidated statement of operations and comprehensive loss.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Professional Liability</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains insurance policies for exposure to professional malpractice insurance risk. The limits of malpractice insurance provide each physician/advanced practice provider with a dedicated $1.0 million limit per claim and a $3.0 million limit in the aggregate per policy period – on a first dollar basis, as no deductible applies. The policy further then extends coverage to the Company, by providing a $2.0 million limit per claim and a $4.0 million limit in the aggregate per policy period - on a first dollar basis, additionally, as no deductible applies. Reserves are established for estimates of the loss that will ultimately be incurred on claims that have been reported but not paid and claims that have been incurred but not reported. These reserves are established based on consultation with a third-party actuary. The actuarial valuations consider a number of factors, including historical claims payment patterns, changes in case reserves and the assumed rate of increase in healthcare costs. Management believes the use of actuarial methods to account for these reserves provides a consistent and effective way to measure these subjective accruals. However, due to the sensitive nature of this estimation technique, recorded reserves could differ from ultimate costs related to these claims due to changes in claims reporting, claims payment and settlement practices and differences in assumed future cost increases. Accrued unpaid claims and expenses that are expected to be paid within the next twelve months are classified as current liabilities and included in accrued other. All other accrued unpaid claims and expenses are classified as long-term liabilities and included in other long-term liabilities. Insurance recoveries associated with the unpaid claims are classified as long-term assets included in other assets.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting guidance establishes a three-level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:6.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.134%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model-derived valuations in which all significant inputs are observable for substantially the full term of the asset or liability.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. </span></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement of assets and liabilities being measured within the fair value hierarchy.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments include cash, short-term marketable securities, accounts receivable, notes receivable, accounts payable, accrued expenses, long-term debt and contractual agreements that resulted in derivative liabilities. Our nonfinancial assets such as property and equipment are not measured at fair value on a recurring basis; however, they are subject to fair value adjustments in certain circumstances, such as when there is evidence that impairment may exist.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash, accounts receivable, accounts payable, notes receivable, and accrued expenses approximate their fair value because of the short-term maturity and highly liquid nature of these instruments. We </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determine the fair value of long-term debt and marketable securities based on various factors including maturity schedules and current market rates.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 6 for a discussion of the Company’s Level 1 and Level 2 Marketable Securities as of March 31, 2024. See below for a discussion of the Company’s Level 1 and Level 3 warrant liabilities as of March 31, 2024. As of March 31, 2024 and December 31, 2023, there were no Level 3 financial instruments. There were no transfers between any levels of the hierarchy during any periods presented.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrant Liabilities</span></div><div><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon Closing of the Business Combination, on September 20, 2023, the Company evaluated the Public Warrants and Private Placement Warrants and the Class B Prefunded Warrants, collectively referred to herein as “Warrants”, in accordance with ASC 815-40, “Derivatives and Hedging —- Contracts in Entity’s Own Equity”, and concluded that a provision in the warrant agreements related to potential net cash settlement of the warrants upon an exchange or tender offer that may not result in a change in control of the entity precludes the warrants from being accounted for as components of equity. As the Warrants meet the definition of a derivative as contemplated in ASC 815, the Warrants are recorded as current liabilities within accrued other on the condensed consolidated balance sheets and measured at fair value at inception and at each reporting date in accordance with ASC 820, “Fair Value Measurement”, with changes in fair value recognized in other income (expense), net on the condensed consolidated statements of operations and comprehensive loss in the period of change.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the Public Warrants were trading separately from the Class A Common Stock and the quoted market price was used to establish fair value. As such, the Public Warrants fair value was determined using a Level 1 input. The fair value of the Public Warrants as of March 31, 2024 is $2.8 million and recorded in other long-term liabilities on the condensed consolidated balance sheets.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has utilized the public warrant price to value the private warrants and believes the public and private warrants have materially consistent fair values given the existence of the make-whole redemption feature. As of March 31, 2024, a valuation of the private warrants was performed which confirmed the private warrant value was materially consistent with the public warrants. The details of this valuation are included in the paragraph below.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Private Placement warrants was determined using Level 3 inputs. As of March 31, 2024, the fair value of the Private Placement Warrants was estimated to be $2.1 million and recorded in other long-term liabilities on the condensed consolidated balance sheets. The fair value was estimated at March 31, 2024, using the Black-Scholes Option Pricing model using the following assumptions:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected annual dividend yield – 0.0% </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                 Expected volatility – 26.40%</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                 Risk-free rate of return – 4.31%</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                 Expected Option Term – 5.0 years</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                 </span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AON Class B Prefunded Warrants are exercisable into one share of New AON Class B Common Stock. A share of New AON Class B Common Stock, together with an AON LLC Common Unit, may be exchanged for one share of New AON Class A Common Stock. Considering New AON Class B Common Stock has no economic rights and limited liquidity or value if the holder does not also possess an AON LLC Common Unit, and because the AON Class B Prefunded Warrants are exercisable into New AON Class B Common Stock, the Company has estimated fair value of the Class B Prefunded Warrants to be immaterial.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Earnings Per Share </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recast Historical AON LLC Equity as AON Inc. common equity for all periods prior to the Reverse Recapitalization, refer to Note 2. However, as 100% of the net losses of AON LLC prior to the Reverse Recapitalization were absorbed by the Legacy AON Shareholders, basic and diluted earnings (loss) per share is zero for the three months ended March 31, 2023. Basic and diluted earnings (loss) per share for the three months ended March 31, 2024 represents the period where the Company had earnings (loss) attributable to Class A Common Stockholders. Class B Common Stock does not have economic rights in AON Inc., including rights to dividends or distributions upon liquidation, and as a result, is not considered a participating security for basic and diluted earnings (loss) per share. As such, basic and diluted earnings (loss) per share of Class B Common Stock has not been presented.</span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued and outstanding Sponsor Earnouts, which are subject to forfeiture if the achievement of certain stock price thresholds are not met. In accordance with ASC Topic 260, “Earnings Per Share,” the Sponsor Earnouts are excluded from weighted-average shares outstanding to calculate basic earnings (loss) per share as they are considered contingently issuable shares due to their potential forfeiture. Sponsor Earnouts will be included in weighted-average shares outstanding to calculate basic earnings (loss) per share as of the date of their stock price thresholds are met and they are no longer subject to forfeiture. </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted earnings (loss) per share is computed by use of the two-class method as a result of outstanding Series A Preferred Stock, which accrue dividends at the annual rate of 8% of the original price per share, participate with common stock on all other dividends, and accordingly have participation rights in undistributed earnings as if all such earnings had been distributed during the period (see Note 12). Under such method income available to common shareholders is computed by deducting both dividends declared or, if not declared, accumulated on Series A Preferred Stock from net income. Loss attributable to common shareholders is computed by increasing net loss by such dividends. Since the participating Series A Preferred Stock has no contractual obligation to share in the losses of the Company, there is no loss allocation between Class A Common Stock and Series A Preferred Stock.</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share is based on the weighted-average number of shares of Class A Common Stock outstanding during the period. Diluted earnings (loss) per share is based on the weighted-average number of shares of Class A Common Stock used for the basic earnings (loss) per share calculation, adjusted for the dilutive effect of the Public and Private Warrants and Sponsor Earnout, if any, using the “treasury stock” method and the convertible Series A Preferred Stock and, exchangeable Class B Common Stock and Class B Prefunded Warrants, if any, using the “if-converted” method. Net earnings (loss) for diluted loss per share is adjusted for the Company’s share of AON LLC’s consolidated net earnings (loss), net of AON Inc. taxes, after giving effect to the Class B Common Stock and Class B Prefunded Warrants that are exchanged into potential shares of Class A Common Stock, Public and Private Warrants that are liability classified, and Series A Preferred Stock, to the extent it is dilutive.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">‘‘Financial instruments-Credit Losses’’ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2016- 13”). ASU 2016-13 requires entities to report ‘‘expected’’ credit losses on financial instruments and other commitments to extend credit rather than the current ‘‘incurred loss’’ model. These expected credit losses for financial assets held at the reporting date are to be based on historical experience, current conditions, and reasonable and supportable forecasts. This ASU will also require enhanced disclosures relating to significant estimates and judgments used in estimating credit losses, as well as the credit quality. ASU 2016-13 is effective for the Company for annual reporting periods beginning after December 15, 2022. ASU 2016-13 was adopted by the Company effective January 1, 2023, with no material impact on the Company’s consolidated financial statements and related disclosures. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers”,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which provides that an acquirer must recognize, and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606. The guidance is effective for the Company for annual reporting periods beginning after December 15, 2023, with early adoption permitted. The adoption of this standard as of January 1, 2024, did not have a material impact on the Company’s consolidated financial statements and related disclosures.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">“Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The amendments in this update are intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses. The ASU requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker, a description of other segment items by reportable segment, and any additional measures of a segment's profit or loss used by the chief operating decision maker when deciding how to allocate resources. The ASU also requires all annual disclosures currently required by Topic 280, “Segment Reporting,” to be included in interim periods. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and retrospective application is required for all </span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">periods presented. The Company is evaluating the impact this will have on the Company's consolidated financial statements and related disclosures.</span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">“Income Taxes (Topic 740): Improvements to Income Tax Disclosures.”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The amendments in this upgrade enhance the transparency and decision usefulness of income tax disclosures. This ASU requires disclosures of specific categories and disaggregation of information in the rate reconciliation table. The ASU also requires disclosure of disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit, and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December 15, 2024. Early adoption is permitted and the amendments should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating the effect that ASU 2023-09 will have on its disclosures.</span></div> <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of the Company were prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. Management believes the unaudited condensed consolidated financial statements for the interim periods presented contain all necessary adjustments, of a normal recurring nature, to state fairly, in all material respects, the Company’s financial position, results of operations and cash flows for the interim periods presented. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements were prepared on the same basis as and should be read in conjunction with such audited consolidated financial statements and related notes thereto of AON Inc. and its wholly-owned subsidiaries, included in the Annual Report on Form 10-K, dated and filed on March 28, 2024 with the SEC (the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> “Annual Report 2023")</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating results for the three months ended March 31, 2024 are not necessarily indicative of the results the Company expects for the entire year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, these unaudited condensed consolidated financial statements reflect the consolidated results of operations, comprehensive loss, cash flows and changes in equity of AON Inc. and its wholly-owned subsidiaries. The condensed consolidated balance sheet at March 31, 2024 presents the financial condition of AON Inc. and its consolidated subsidiaries.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023, these unaudited condensed consolidated financial statements present the consolidated results of operations, comprehensive loss, cash flows and changes in equity of AON LLC. The condensed consolidated balance sheet as of December 31, 2023 presents the financial condition of AON Inc. and its consolidated subsidiaries after the Reverse Recapitalization. All intercompany balances and transactions of AON LLC have been eliminated. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification (“ASC”) Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the historical equity of AON LLC has been recasted in all periods up to the Closing Date, to reflect the number of shares of New AON’s Class A Common Stock and Class B Common Stock issued to Legacy AON Shareholders in connection with the Reverse Recapitalization. The Company recasted the units outstanding related to the historical AON LLC Class A, Class A-1, and Class B units prior to the Reverse Recapitalization (“Historical AON LLC Equity”) as common equity of New AON, equal to the Per Company Class Unit Exchange Ratio, pursuant to the Business Combination Agreement. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Per Company Unit Exchange Ratio at which AON LLC Class A units and Class A-1 units were reclassified is equal to 2,524 AON Common Units. The Per Company Unit Exchange Ratio at which AON LLC Class B units were reclassified varied depending on participation threshold, and is equal to 2,524, 2,453, or 1,976, AON Common Units. The Per Company Unit Exchange Ratio at which Class C units were reclassified is equal to 2,705 AON LLC Series A Preferred Units.</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements and related notes thereto give effect to the conversion for all periods presented, without any change to par value or per unit amounts. The condensed consolidated financial statements do not necessarily represent the capital structure of New AON had the Reverse Recapitalization occurred in prior periods. The Company has not made retroactive adjustments related to the historical book values of Historical AON LLC Equity as the adjustments were considered immaterial.</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024, $7.8 million of the consolidated net loss of AON LLC were attributable to the Class A Common Stockholders, and reflects the Class A Common Stockholders’ absorption of 23.0% of the consolidated net loss of AON LLC. For the three months ended March 31, 2024, $17.2 million of the consolidated net losses of AON LLC were attributable to noncontrolling interest, and reflects the Legacy AON Stockholders’ absorption of 77.0% of the consolidated net losses of AON LLC.</span></div>For the three months ended March 31, 2023, $1.5 million of the consolidated net losses of AON LLC were attributable to the Legacy AON Stockholders, to reflect their absorption of 100% of the consolidated net losses of AON LLC pertaining to the days prior to the Reverse Recapitalization. 2524000 2524000 2453000 1976000 2705000 -7800000 0.230 -17200000 0.770 -1500000 1 <div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the period of January 1, 2024 through March 31, 2024, the condensed consolidated financial statements include the accounts of the Company, American Oncology Network, LLC (“AON LLC”), and its wholly owned subsidiary American Oncology Management Company, LLC (“AOMC”), and its consolidated variable interest entities (“VIEs”) American Oncology Partners, P.A. (“AON Partners”), American Oncology Partners of Maryland, P.A. (“Partners of Maryland”), AON Central Services, LLC (“AON Central Services”), and Meaningful Insights Biotech Analytics, LLC (“MIBA”). All intercompany accounts and transactions between the entities have been eliminated in consolidation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting treatment of the Business Combination was a Reverse Recapitalization.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the periods prior to the Reverse Recapitalization, the consolidated financial statements of the Company comprise the accounts of AON LLC and its wholly-owned subsidiaries. All intercompany accounts and transactions among AON LLC and its consolidated subsidiaries were eliminated.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for American Oncology Network, LLC, AON Partners, Partners of Maryland, AON Central Services, and MIBA in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 810, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company determines whether it has a controlling financial interest in an entity by first evaluating whether the entity is a VIE. A VIE is broadly defined as an entity that has any of the following three characteristics: (i) the equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (ii) substantially all of the entity’s activities either involve or are conducted on behalf of an investor that has disproportionately few voting rights; or (iii) the equity investors as a group lack any of the following, the power through voting or similar rights to direct the activities of the entity that most significantly impact the entity’s economic performance, the obligation to absorb the expected losses of the entity, or the right to receive the expected residual returns of the entity. The Company consolidates a VIE if it has both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and an obligation to absorb losses or the right to receive benefits that could potentially be significant to the VIE. Management performs ongoing reassessments of whether changes in the facts and circumstances regarding the Company’s involvement with a VIE will cause the consolidation conclusion to change. Changes in consolidation status are applied prospectively, if any. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AON LLC has contractual relationships with AON Partners, Partners of Maryland and AON Central Services and the physician owners through management service agreements (“MSAs”) and other contractual agreements to provide all practice management services outside of medical services provided by the physicians. In addition, despite not being required by the contractual relationships, AON LLC regularly provides funding to support AON Partners and Partners of Maryland’s operations and acquisitions of physician practices. AON Central Services was formed July 15, 2022 and, effective January 1, 2023, entered into an agreement with AOMC to provide qualified non-clinical and non-medical employees to AOMC to support the operation of the physician practices. MIBA was established during the first quarter of 2023 for the purpose of developing intellectual property to synergize the collection, de-identification, and dissemination of the Company’s patient data for sale to external parties for research, development, and clinical decisions. In May 2023, the Company contributed $0.2 million for a 56% interest in the equity of MIBA. As of March 31, 2024, MIBA had no significant operating activity. The Company concluded that AON LLC had a controlling financial interest in MIBA and has consolidated the entity at March 31, 2024 and recorded the noncontrolling interest in equity. </span></div>The Company has concluded that AON Partners, Partners of Maryland, AON Central Services, and MIBA are all VIEs in which AON LLC has the characteristics of a controlling financial interest and is deemed to be the primary beneficiary. The variable interest subjects AON LLC to all potential losses in the entities and, therefore, requires AON LLC, and in turn AON Inc., to consolidate the results of AON Partners, Partners of Maryland, AON Central Services, and MIBA in its condensed consolidated financial statements. 200000 0.56 <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Estimates and Assumptions </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</span></div> <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segments </span></div>Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (the “CODM”). The Company’s CODM is its chief executive officer who reviews financial information together with certain operating metrics principally to make decisions about how to allocate resources and to measure the Company’s performance. The Company has one operating segment and one reportable segment that are structured around the organizational management of oncology practice operations. All revenue and assets are in the United States. 1 1 <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized under Accounting Standards Update (“ASU”) 2014-09 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“Topic 606”). The Company determines the transaction price based upon standard charges for goods and services with anticipated consideration due from patients, third-party payors (including health insurers and government agencies) and others. The Company’s revenue is primarily derived from patient service revenues, which encompass oncology services provided during patient visits and shipments of pharmacy prescriptions. Performance obligations for the Company’s services provided to patients and most procedures, are satisfied over the time of visit which is the same day services are performed. Performance obligations relating to pharmacy revenue are considered fully satisfied at a point in time upon the customer receiving delivery of the prescription. Accordingly, the Company does not anticipate a significant amount of revenue from performance obligations satisfied (or partially satisfied) in previous periods, and any such revenue recognized during the three month periods ended March 31, 2024 and 2023 was immaterial. Additionally, the Company does not expect to recognize material revenue in the future related to performance obligations that are unsatisfied (or partially satisfied) as of March 31, 2024 and December 31, 2023. Approximately $246.1 million and $214.3 million and of the Company’s revenues are generated from services performed during patient visits with the remainder primarily generated from shipments of pharmacy prescriptions for the three month periods ended March 31, 2024 and 2023, respectively.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As services are performed and prescriptions are shipped, timely billing occurs for services rendered and prescriptions shipped less discounts provided to uninsured patients and contractual adjustments to third-party payors based upon prospectively determined rates and discounted charges. Payment is requested at the time of service for self-paying patients and for patients covered by third-party payors that are responsible for paying deductibles and coinsurance.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors revenue and receivables to prepare estimated contractual allowances for the anticipated differences between billed and reimbursed amounts. Payments from third-party payors and Government programs including Medicare and Medicaid may be subject to audit and other retrospective adjustments. Such amounts are considered on an estimated basis when net patient revenue is recorded and are adjusted as final adjustments are determined. For the three month periods ended March 31, 2024 and 2023, such resulting historic adjustments have been immaterial to the condensed consolidated financial statements. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing who is the principal in providing patient services and pharmacy prescriptions, the Company considered who controls the provision of services and prescriptions. The Company has determined they are acting as a principal in these relationships. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the Company entered into a long-term arrangement to sponsor and manage a clinical trial. The Company subsequently contracted with a third-party to provide the clinical research services and is the principal in this arrangement. The performance of clinical research services are considered a single performance obligation because the Company provides a highly-integrated service. Revenue is recognized for the single performance obligation over time due to the Company’s right to payment for work performed to date. The contract provides for invoices based on predetermined milestones. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the cost-to-cost measure of progress for the Company’s contract because it best depicts the transfer of control to the customer as the performance obligation is fulfilled. For this method, the Company </span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compares the contract costs incurred to date to the estimated total contract costs through completion. As part of the client proposal and contract negotiation process, the Company develops a detailed project budget for the direct costs and reimbursable costs based on the scope of the work, the complexity of the study, the geographical location involved and the Company’s historical experience. The estimated total contract costs at the project level are reviewed and revised periodically throughout the life of the contract, with adjustments to revenue resulting from such revisions being recorded on a cumulative basis in the period in which the revisions are identified. Contract costs consist primarily of direct labor and other reimbursable project-related costs such as travel, third-party vendor costs and investigator fees. The Company establishes pricing based on the Company’s internal pricing guidelines, discount agreements, if any, and negotiations with the client. The transaction price is the contractually defined amount. Revenue related to the clinical trial, which is included within other revenue, was $0.5 million and $0 million for the three months ended March 31, 2024 and 2023, respectively. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a system and estimation process for recording Medicare net patient service revenue and estimated recoupments as it relates to value-based care (“VBC”) revenue included in patient service revenue in the condensed consolidated statements of operations and comprehensive loss. The Company’s VBC revenue is primarily generated through its participation in the CMS Oncology Care Model (“OCM”) which is an episode-based payment model to promote high-quality cancer care. Participants enter six-month episode periods, and the Company bills a monthly fee during the six-month period based on a fixed rate per participant per month and the total number of participants. Certain quality and compliance metrics are tracked as part of the program and submitted to CMS at the end of the episode period which may result in recoupment of funds. The Company estimates the recoupment amount by developing a recoupment percentage for each period based on historical known recoupment from CMS and applies the recoupment percentage against total fees for the period. Based on the estimate, the Company accrues a liability representing the expected final recoupments based on historical settlement trends.</span></div> 246100000 214300000 500000 0 <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-term Marketable Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable securities consist of corporate bonds and U.S. Treasury securities.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management determines the appropriate classification of investments at the time of purchase and reevaluates such determination at each balance sheet date. Marketable securities are classified as available-for-sale and are carried at fair value in the consolidated balance sheets. The marketable securities are classified as short-term based on management’s intent to convert such securities within one year and the ability to convert them within two to three days.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our available-for-sale securities are debt securities. For an available-for-sale debt security with an amortized cost that exceeds its fair value, the Company first determines if it intends to sell or will more-likely-than-not be required to sell the security before the expected recovery of its amortized cost. If it intends to sell or will more-likely-than-not be required to sell the security, then the Company recognizes the impairment as a credit loss in the condensed consolidated statements of operations and comprehensive loss by writing down the security’s amortized cost to its fair value. If it does not intend to sell or it is not more-likely-than-not that it will be required to sell the security before the expected recovery of its amortized cost, the Company recognizes the portion of the impairment that is due to a credit loss, if any, in the condensed consolidated statements of operations and comprehensive loss through an allowance. The portion of the impairment that is due to factors other than a credit loss is recognized in other comprehensive income (loss) in the condensed consolidated statements of operations and comprehensive loss as an unrealized loss.</span></div> <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Investment in Affiliate</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company contributed noncash consideration, with a fair value of approximately $2.3 million, in return for a 49% equity interest in OCP Management Arizona, LLP. Investments in entities over which the Company has the ability to exercise significant influence but does not control the entity are accounted for using the equity method. Equity method investments are included with other assets in the condensed consolidated balance sheets. The carrying amount of the investment is adjusted to reflect the Company’s proportionate share of the net earnings or losses and reduced by any dividends received. The Company’s share of income or loss related to this investment is reported as an equity in loss of affiliate in the condensed consolidated statements of operations and comprehensive loss.</span></div> 2300000 0.49 <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Noncontrolling Interests</span></div>The Company consolidates the results of entities in which it has a controlling financial interest. Refer to Note 15 for additional considerations and presentation for noncontrolling interest. <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mezzanine Equity</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#060606;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New AON Series A Preferred Stock is redeemable for cash or the value of the property, rights or securities to be paid or distributed in the event of a Deemed Liquidation Event (which is outside of the Company’s control). As a result, Management has determined that the New AON Series A Preferred Stock should be classified as mezzanine equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of March 31, 2024, the Preferred Stock are recorded at their initial carrying value, net of offering costs of $0.8 million. The Series A Preferred Stock are not being accreted to redemption value, as the redemption is not probable. The Series A Preferred Stock are classified outside of members’ equity on the consolidated balance sheets. Refer to Note 14 for mezzanine equity presentation considerations for redeemable noncontrolling interest. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#060606;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for treasury stock purchased under the cost method and include treasury stock as a component of</span></div><div style="padding-left:31.5pt"><span style="color:#060606;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accumulated paid in capital. Treasury stock purchased with intent to retire (whether or not the retirement is actually accomplished) is charged to common stock. The company repurchased 14,729 shares of class A common stock at the spot rate as of each transaction date for a total cost of less than $0.1 million for the year ended December 31, 2023. For the three months ended March 31, 2024 the Company repurchased an additional 16,441 shares of class A common stock at the spot rate as of each transaction date for a total cost of less than $0.1 million. To date, the Company has repurchased a total of 31,170 shares.</span></div> 800000 14729 100000 16441 100000 31170 <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity-Based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#060606;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues stock-based awards to employees and directors in the form of stock options and restricted stock units. The Company measures and recognizes compensation expense for its stock-based awards granted to its employees and directors based on the estimated grant date fair value in accordance with ASC 718, Compensation-Stock Compensation, and determines the fair value of restricted stock units based on the fair value of its common stock. The Company measures all share-based options granted to employees and directors based on the fair value on the date of grant using the Black-Scholes option-pricing model. Compensation expense of those awards is recognized over the requisite service period, which is generally the vesting period of the respective award. The Company records the expense for awards with service-based conditions using the straight-line method over the requisite service period, net of any actual forfeitures. The Company classifies share-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified.</span></div> <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates acquired practices in accordance with ASU 2017-01</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, Business Combinations (Topic 805)-Clarifying the Definition of a Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This standard clarifies the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. Because substantially all of the value of each acquired practice did not relate to a similar group of assets and as each acquired practice contained both inputs and processes necessary to provide economic benefits to the Company, it was determined that each acquisition represents a business combination. Therefore, the transactions have been accounted for using the acquisition method of accounting, which requires, with limited exceptions, that assets acquired, and liabilities assumed be recognized at their estimated fair values as of the acquisition date. Any excess of the consideration transferred over the estimated fair values of the net assets acquired is recorded as goodwill. Transaction costs related to business combinations are expensed in the period in which they are incurred.</span></div> <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Offering Costs</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defers specific incremental costs directly attributable to proposed offerings of securities. These costs consist of legal, accounting, and other similar expenses incurred through the balance sheet date that are directly related to a potential offering. If the offering is completed, these costs will be charged against the gross proceeds of the offering. These offering costs will be allocated to the separable financial instruments issued in the transaction on a relative fair value basis of the securities issued, compared to total proceeds received. Offering costs associated </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with any instruments classified as liabilities will be expensed as incurred, presented as non-operating expenses in the condensed consolidated statement of operations and comprehensive loss.</span></div> <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Professional Liability</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains insurance policies for exposure to professional malpractice insurance risk. The limits of malpractice insurance provide each physician/advanced practice provider with a dedicated $1.0 million limit per claim and a $3.0 million limit in the aggregate per policy period – on a first dollar basis, as no deductible applies. The policy further then extends coverage to the Company, by providing a $2.0 million limit per claim and a $4.0 million limit in the aggregate per policy period - on a first dollar basis, additionally, as no deductible applies. Reserves are established for estimates of the loss that will ultimately be incurred on claims that have been reported but not paid and claims that have been incurred but not reported. These reserves are established based on consultation with a third-party actuary. The actuarial valuations consider a number of factors, including historical claims payment patterns, changes in case reserves and the assumed rate of increase in healthcare costs. Management believes the use of actuarial methods to account for these reserves provides a consistent and effective way to measure these subjective accruals. However, due to the sensitive nature of this estimation technique, recorded reserves could differ from ultimate costs related to these claims due to changes in claims reporting, claims payment and settlement practices and differences in assumed future cost increases. Accrued unpaid claims and expenses that are expected to be paid within the next twelve months are classified as current liabilities and included in accrued other. All other accrued unpaid claims and expenses are classified as long-term liabilities and included in other long-term liabilities. Insurance recoveries associated with the unpaid claims are classified as long-term assets included in other assets.</span></div> 1000000 3000000 2000000 4000000 <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting guidance establishes a three-level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability on the measurement date. The three levels are defined as follows:</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:6.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.134%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model-derived valuations in which all significant inputs are observable for substantially the full term of the asset or liability.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. </span></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement of assets and liabilities being measured within the fair value hierarchy.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments include cash, short-term marketable securities, accounts receivable, notes receivable, accounts payable, accrued expenses, long-term debt and contractual agreements that resulted in derivative liabilities. Our nonfinancial assets such as property and equipment are not measured at fair value on a recurring basis; however, they are subject to fair value adjustments in certain circumstances, such as when there is evidence that impairment may exist.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash, accounts receivable, accounts payable, notes receivable, and accrued expenses approximate their fair value because of the short-term maturity and highly liquid nature of these instruments. We </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">determine the fair value of long-term debt and marketable securities based on various factors including maturity schedules and current market rates.</span></div> <div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrant Liabilities</span></div><div><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon Closing of the Business Combination, on September 20, 2023, the Company evaluated the Public Warrants and Private Placement Warrants and the Class B Prefunded Warrants, collectively referred to herein as “Warrants”, in accordance with ASC 815-40, “Derivatives and Hedging —- Contracts in Entity’s Own Equity”, and concluded that a provision in the warrant agreements related to potential net cash settlement of the warrants upon an exchange or tender offer that may not result in a change in control of the entity precludes the warrants from being accounted for as components of equity. As the Warrants meet the definition of a derivative as contemplated in ASC 815, the Warrants are recorded as current liabilities within accrued other on the condensed consolidated balance sheets and measured at fair value at inception and at each reporting date in accordance with ASC 820, “Fair Value Measurement”, with changes in fair value recognized in other income (expense), net on the condensed consolidated statements of operations and comprehensive loss in the period of change.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the Public Warrants were trading separately from the Class A Common Stock and the quoted market price was used to establish fair value. As such, the Public Warrants fair value was determined using a Level 1 input. The fair value of the Public Warrants as of March 31, 2024 is $2.8 million and recorded in other long-term liabilities on the condensed consolidated balance sheets.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has utilized the public warrant price to value the private warrants and believes the public and private warrants have materially consistent fair values given the existence of the make-whole redemption feature. As of March 31, 2024, a valuation of the private warrants was performed which confirmed the private warrant value was materially consistent with the public warrants. The details of this valuation are included in the paragraph below.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Private Placement warrants was determined using Level 3 inputs. As of March 31, 2024, the fair value of the Private Placement Warrants was estimated to be $2.1 million and recorded in other long-term liabilities on the condensed consolidated balance sheets. The fair value was estimated at March 31, 2024, using the Black-Scholes Option Pricing model using the following assumptions:</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected annual dividend yield – 0.0% </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                 Expected volatility – 26.40%</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                 Risk-free rate of return – 4.31%</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                 Expected Option Term – 5.0 years</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                 </span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AON Class B Prefunded Warrants are exercisable into one share of New AON Class B Common Stock. A share of New AON Class B Common Stock, together with an AON LLC Common Unit, may be exchanged for one share of New AON Class A Common Stock. Considering New AON Class B Common Stock has no economic rights and limited liquidity or value if the holder does not also possess an AON LLC Common Unit, and because the AON Class B Prefunded Warrants are exercisable into New AON Class B Common Stock, the Company has estimated fair value of the Class B Prefunded Warrants to be immaterial.</span></div> 2800000 2100000 0.000 0.2640 0.0431 5 1 1 <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Earnings Per Share </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recast Historical AON LLC Equity as AON Inc. common equity for all periods prior to the Reverse Recapitalization, refer to Note 2. However, as 100% of the net losses of AON LLC prior to the Reverse Recapitalization were absorbed by the Legacy AON Shareholders, basic and diluted earnings (loss) per share is zero for the three months ended March 31, 2023. Basic and diluted earnings (loss) per share for the three months ended March 31, 2024 represents the period where the Company had earnings (loss) attributable to Class A Common Stockholders. Class B Common Stock does not have economic rights in AON Inc., including rights to dividends or distributions upon liquidation, and as a result, is not considered a participating security for basic and diluted earnings (loss) per share. As such, basic and diluted earnings (loss) per share of Class B Common Stock has not been presented.</span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued and outstanding Sponsor Earnouts, which are subject to forfeiture if the achievement of certain stock price thresholds are not met. In accordance with ASC Topic 260, “Earnings Per Share,” the Sponsor Earnouts are excluded from weighted-average shares outstanding to calculate basic earnings (loss) per share as they are considered contingently issuable shares due to their potential forfeiture. Sponsor Earnouts will be included in weighted-average shares outstanding to calculate basic earnings (loss) per share as of the date of their stock price thresholds are met and they are no longer subject to forfeiture. </span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted earnings (loss) per share is computed by use of the two-class method as a result of outstanding Series A Preferred Stock, which accrue dividends at the annual rate of 8% of the original price per share, participate with common stock on all other dividends, and accordingly have participation rights in undistributed earnings as if all such earnings had been distributed during the period (see Note 12). Under such method income available to common shareholders is computed by deducting both dividends declared or, if not declared, accumulated on Series A Preferred Stock from net income. Loss attributable to common shareholders is computed by increasing net loss by such dividends. Since the participating Series A Preferred Stock has no contractual obligation to share in the losses of the Company, there is no loss allocation between Class A Common Stock and Series A Preferred Stock.</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share is based on the weighted-average number of shares of Class A Common Stock outstanding during the period. Diluted earnings (loss) per share is based on the weighted-average number of shares of Class A Common Stock used for the basic earnings (loss) per share calculation, adjusted for the dilutive effect of the Public and Private Warrants and Sponsor Earnout, if any, using the “treasury stock” method and the convertible Series A Preferred Stock and, exchangeable Class B Common Stock and Class B Prefunded Warrants, if any, using the “if-converted” method. Net earnings (loss) for diluted loss per share is adjusted for the Company’s share of AON LLC’s consolidated net earnings (loss), net of AON Inc. taxes, after giving effect to the Class B Common Stock and Class B Prefunded Warrants that are exchanged into potential shares of Class A Common Stock, Public and Private Warrants that are liability classified, and Series A Preferred Stock, to the extent it is dilutive.</span></div> 1 0 0 0 0 0.08 <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">‘‘Financial instruments-Credit Losses’’ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASU 2016- 13”). ASU 2016-13 requires entities to report ‘‘expected’’ credit losses on financial instruments and other commitments to extend credit rather than the current ‘‘incurred loss’’ model. These expected credit losses for financial assets held at the reporting date are to be based on historical experience, current conditions, and reasonable and supportable forecasts. This ASU will also require enhanced disclosures relating to significant estimates and judgments used in estimating credit losses, as well as the credit quality. ASU 2016-13 is effective for the Company for annual reporting periods beginning after December 15, 2022. ASU 2016-13 was adopted by the Company effective January 1, 2023, with no material impact on the Company’s consolidated financial statements and related disclosures. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers”,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which provides that an acquirer must recognize, and measure contract assets and contract liabilities acquired in a business combination in accordance with ASC 606. The guidance is effective for the Company for annual reporting periods beginning after December 15, 2023, with early adoption permitted. The adoption of this standard as of January 1, 2024, did not have a material impact on the Company’s consolidated financial statements and related disclosures.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">“Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The amendments in this update are intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant expenses. The ASU requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker, a description of other segment items by reportable segment, and any additional measures of a segment's profit or loss used by the chief operating decision maker when deciding how to allocate resources. The ASU also requires all annual disclosures currently required by Topic 280, “Segment Reporting,” to be included in interim periods. This update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and retrospective application is required for all </span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">periods presented. The Company is evaluating the impact this will have on the Company's consolidated financial statements and related disclosures.</span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">“Income Taxes (Topic 740): Improvements to Income Tax Disclosures.”</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The amendments in this upgrade enhance the transparency and decision usefulness of income tax disclosures. This ASU requires disclosures of specific categories and disaggregation of information in the rate reconciliation table. The ASU also requires disclosure of disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit, and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December 15, 2024. Early adoption is permitted and the amendments should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating the effect that ASU 2023-09 will have on its disclosures.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24pt">Reverse Recapitalization</span><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1, AON LLC merged with DTOC, with AON LLC surviving the Merger. AON LLC is governed by a board of managers composed of three (3) persons that were designated by New AON and two (2) persons that were designated by holders of a majority of the AON LLC Common Units, held by members of AON LLC other than New AON. Management determined AON LLC was not a variable interest entity (Refer to Note 2), and as result, identified AON LLC as the accounting acquirer of the Merger in accordance ASC Topic 805. Management concluded that AON LLC was the accounting acquirer due to (i) the Legacy AON Shareholders, defined as the former AON Class A, Class A-1, and Class B unit holders, receiving the largest portion of the voting rights in the combined company, New AON, (ii) significantly all of the Legacy AON Shareholders retained their equity interest as stockholders in New AON, (iii) AON LLC’s operations prior to the Reverse Recapitalization comprising the only ongoing operations of New AON, (iv) the Legacy AON Shareholders have the right to appoint a majority of the directors of New AON, (v) the executive management of AON LLC will become the executive management of New AON and (vi) AON LLC is significantly larger than New AON in terms of revenue, total assets, and employees. Therefore, the Merger was accounted for as a reverse recapitalization, with no goodwill or other intangible assets recorded, in accordance with ASC Topic 805. New AON was treated as the “acquired” company for financial reporting purposes, and for accounting purposes, the Reverse Recapitalization was treated as the equivalent of AON LLC issuing stock for the net assets of New AON, accompanied by a recapitalization. The net assets of New AON were recorded at historical cost on the condensed consolidated balance sheet as of September 20, 2023, the Closing Date of the Reverse Recapitalization, with no goodwill or other intangible assets recorded. For additional information on the capitalization of New AON and AON LLC immediately following the Closing of the Reverse Recapitalization, see Note 1.</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the historical cost of assets and liabilities of AON Inc. as of September 20, 2023.</span></div><div style="padding-left:31.5pt;text-indent:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:59.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.221%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of September 20, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,493 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current Liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,295)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long Term Liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,791)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Net Liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18,593)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a Day 1 expense as of the Closing of the Business Combination equal to $18.2 million. Of that total amount, $13.0 million was recorded in transaction expenses on the condensed consolidated statement of operations and comprehensive loss. The remaining $5.2 million was recorded in other income (expense) net on the condensed consolidated statement of operations and comprehensive loss. This amount represented the loss on the issuance of Public and Private Warrants, as of the Closing, net of cash received. The Company also recorded a $4.3 million gain in other income (expense), net related to the change in the fair value of the Public and Private Warrants d</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uring the period of September 21, 2023 through September 30, 2023</span>. 3 2 <div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the historical cost of assets and liabilities of AON Inc. as of September 20, 2023.</span></div><div style="padding-left:31.5pt;text-indent:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:59.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.221%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of September 20, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,493 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current Liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,295)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long Term Liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,791)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Net Liabilities</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18,593)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1493000 13295000 6791000 -18593000 18200000 13000000 -5200000 4300000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24pt">Variable Interest Entities</span><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AOMC is a wholly owned subsidiary of AON LLC and neither AOMC nor AON LLC has ownership interest in AON Partners and Partners of Maryland. Both AON Partners and Partners of Maryland are fully owned by physicians. AON LLC operates its physician practices through the MSAs and other contractual agreements between AOMC, AON Partners, and Partners of Maryland. The responsibilities of AOMC include, but are not limited to, negotiating provider and payor contracts, employment and compensation decisions, billing and collections, furnishing all supplies and equipment necessary for the respective practice’s operations as well as, necessary real estate, contracting on behalf of AON Partners and Partners of Maryland, entering into leases, holding a power of attorney to perform the above activities, preparing, maintaining and administering all accounting records (including financial reporting), expense payment, and maintenance of all information systems/software. AON LLC is paid a management fee to compensate AOMC for the services provided. AON Central Services is 80% physician owned and 20% owned by AON LLC. AOMC entered into an agreement with AON Central Services, effective January 1, 2023, to provide qualified non-clinical and non-medical employees to AOMC to support the operation of the physician practices. AOMC pays a monthly management fee to AON Central Services equal to the aggregate cost of compensation, benefits and all other costs related to these employees. AON LLC invested $0.2 million in MIBA, a newly formed LLC, during the second quarter of 2023 in exchange for 56% equity ownership. The Company evaluated AON LLC’s relationship with MIBA under the VIE model and determined it was a VIE and the Company is the primary beneficiary based on its financial controlling interest.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on various quantitative and qualitative factors, including assessment of certain services performed and relationships held above, management has determined that AON Partners, Partners of Maryland, AON Central Services, and MIBA are all variable interest entities and AOMC is the primary beneficiary who holds the decision-making rights over the activities that most significantly impact the economic performance of AON Partners, Partners of Maryland, AON Central Services, and MIBA through the MSAs and other contractual agreements. Accordingly, the results of AON Partners, Partners of Maryland, AON Central Services, and MIBA have been consolidated with the Company for the three month period ended March 31, 2024. The results of AON Partners, Partners of Maryland, and AON Central Services have been consolidated with the Company for the three month period ended March 31, 2023.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets of AON Partners, Partners of Maryland, AON Central Services, and MIBA as of March 31, 2024 and December 31, 2023, are as follows:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:59.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75,796 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,574 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129,151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">895 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and intangibles, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,809 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,880 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,091 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">295,898 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">237,269 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The liabilities of AON Partners, Partners of Maryland, AON Central Services, and MIBA as of March 31, 2024 and December 31, 2023, are as follows:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:59.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.319%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184,314 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122,324 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,713 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,380 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,972 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,078 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to AON LLC and subsidiaries, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107,144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117,194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333,221 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">277,894 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All intercompany transactions and balances with the VIEs are eliminated in consolidation.</span></div> 0.80 0.20 200000 0.56 <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets of AON Partners, Partners of Maryland, AON Central Services, and MIBA as of March 31, 2024 and December 31, 2023, are as follows:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:59.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75,796 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,574 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132,300 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129,151 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">895 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and intangibles, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,297 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,809 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,880 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,091 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">295,898 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">237,269 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The liabilities of AON Partners, Partners of Maryland, AON Central Services, and MIBA as of March 31, 2024 and December 31, 2023, are as follows:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:59.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.319%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184,314 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122,324 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,713 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,380 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,972 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,078 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">273 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to AON LLC and subsidiaries, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107,144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117,194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333,221 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">277,894 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 75796000 26574000 132300000 129151000 44288000 44569000 1157000 895000 180000 180000 34297000 33809000 7880000 2091000 295898000 237269000 184314000 122324000 25713000 21380000 14972000 16723000 1078000 273000 107144000 117194000 333221000 277894000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24pt">Business Combinations </span><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2024 Acquisitions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any ASC 805 acquisitions during the three months ended March 31, 2024.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">2023 Acquisitions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any ASC 805 acquisitions during the three months ended March 31, 2023.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24pt">Marketable Securities</span><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s marketable securities financial assets that are measured at fair value on a recurring basis:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:40.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash equivalents (1)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overnight repurchase agreements (2)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73,938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73,938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury Bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75,460 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75,460 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,267 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">172 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,436 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,734 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">377 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,104 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105,194 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">377 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105,564 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:40.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash equivalents (1)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overnight repurchase agreements (2)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,593 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,593 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,316 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,316 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,678 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,860 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,529 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,996 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">402 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,389 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,312 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">402 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,705 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.18pt">Included in cash and cash equivalents in the consolidated balance sheets at March 31, 2024 and December 31, 2023.</span></div><div style="padding-left:45pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.18pt">Cash equivalents as of March 31, 2024 included U.S. Treasury Bills with an initial maturity of 3 months or less and overnight repurchase agreements in which cash from the Company's main operating checking account is invested overnight in highly liquid, short-term investments sponsored by a large financial institution. The company had overnight repurchase agreements as of March 31, 2024 and December 31, 2023.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses quoted prices in active markets for identical assets to determine the fair value of its Level 1 investments. The fair value of the Company’s Level 2 investments is determined using pricing based on quoted market prices or alternative market observable inputs. </span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company’s marketable securities as of March 31, 2024, by remaining contractual maturities, were as follows:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:55.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.980%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Bonds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Treasuries</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,886 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,972 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,858 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in one to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,550 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,696 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 40pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,436 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,668 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,104 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s marketable securities financial assets that are measured at fair value on a recurring basis:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:40.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash equivalents (1)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overnight repurchase agreements (2)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73,938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73,938 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">529 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury Bills</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">993 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75,460 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75,460 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,267 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">172 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,436 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,467 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,734 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">377 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,104 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105,194 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">377 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105,564 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:40.647%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash equivalents (1)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overnight repurchase agreements (2)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,593 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,593 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">723 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,316 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,316 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,678 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">191 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,860 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,318 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,529 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,996 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">402 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,389 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,312 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">402 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,705 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:45pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.18pt">Included in cash and cash equivalents in the consolidated balance sheets at March 31, 2024 and December 31, 2023.</span></div><div style="padding-left:45pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:4.18pt">Cash equivalents as of March 31, 2024 included U.S. Treasury Bills with an initial maturity of 3 months or less and overnight repurchase agreements in which cash from the Company's main operating checking account is invested overnight in highly liquid, short-term investments sponsored by a large financial institution. The company had overnight repurchase agreements as of March 31, 2024 and December 31, 2023.</span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company’s marketable securities as of March 31, 2024, by remaining contractual maturities, were as follows:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:55.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.980%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Bonds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">U.S. Treasuries</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,886 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,972 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,858 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due in one to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,550 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,696 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 40pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,436 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,668 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,104 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 73938000 73938000 529000 529000 993000 993000 75460000 75460000 14267000 172000 3000 14436000 15467000 205000 4000 15668000 29734000 377000 7000 30104000 105194000 377000 7000 105564000 28593000 28593000 723000 723000 29316000 29316000 13678000 191000 9000 13860000 21318000 211000 21529000 34996000 402000 9000 35389000 64312000 402000 9000 64705000 5886000 11972000 17858000 8550000 3696000 12246000 14436000 15668000 30104000 Supplemental Condensed Balance Sheet Information<div style="margin-top:10pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other receivables</span></div><div style="margin-top:10pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables consisted of the following at March 31, 2024 and December 31, 2023:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:59.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.319%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,112 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,708 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">687 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">566 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 40pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other receivables</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,799 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,274 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-top:10pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following at March 31, 2024 and December 31, 2023:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:59.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.319%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intravenous drugs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,972 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32,388 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oral pharmaceuticals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,316 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventories</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,288 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,569 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment, net</span></div><div style="margin-top:10pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following at March 31, 2024 and December 31, 2023:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:59.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,985 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32,490 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture, fixtures and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,666 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Signs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Automobiles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,829 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction-in-progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,847 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,985 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67,804 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65,074 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,807)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24,635)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,997 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,439 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued Other</span></div><div><span><br/></span></div><div style="text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued other consisted of the following at March 31, 2024 and December 31, 2023:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:59.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.319%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refund liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,879 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,078 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,913 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excise taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-597"><span style="-sec-ix-hidden:f-598">Current portion of finance lease liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,489 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,360 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued other</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,186 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,327 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:10pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables consisted of the following at March 31, 2024 and December 31, 2023:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:59.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.319%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates receivable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,112 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,708 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">687 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">566 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 40pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other receivables</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,799 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,274 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 34112000 33708000 687000 566000 34799000 34274000 <div style="margin-top:10pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following at March 31, 2024 and December 31, 2023:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:59.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.319%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intravenous drugs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,972 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32,388 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oral pharmaceuticals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,316 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventories</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,288 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,569 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 33972000 32388000 10316000 12181000 44288000 44569000 <div style="margin-top:10pt;padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following at March 31, 2024 and December 31, 2023:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:59.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,985 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32,490 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furniture, fixtures and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,607 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,666 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Computer equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,395 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Signs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Automobiles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,829 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction-in-progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,847 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,985 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, gross</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67,804 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65,074 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,807)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24,635)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,997 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,439 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 33985000 32490000 2750000 2607000 16310000 15666000 3395000 3285000 176000 153000 110000 59000 9231000 7829000 1847000 2985000 67804000 65074000 26807000 24635000 40997000 40439000 <div style="text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued other consisted of the following at March 31, 2024 and December 31, 2023:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:59.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.319%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refund liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,879 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,078 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,913 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excise taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-597"><span style="-sec-ix-hidden:f-598">Current portion of finance lease liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,489 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,360 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued other</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,186 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,327 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 12879000 15078000 4913000 0 2700000 2700000 1205000 1189000 3489000 3360000 25186000 22327000 Long-term Debt<div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt consisted of the following at March 31, 2024 and December 31, 2023: </span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:59.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.319%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PNC Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,250 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,250 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,250 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,250 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(394)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(609)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80,856 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80,641 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Facilities</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 30, 2021, the Company entered into a Loan Facility with PNC (“PNC Loan Facility”) collateralized by the Company’s assets and outstanding patient accounts receivable. The PNC Loan Facility is guaranteed on a limited basis by the Company and shareholder of AON Partners and Partners of Maryland. $34.6 million of proceeds from the PNC Loan Facility was used to pay off the Company’s previous term loans and revolver with Truist Bank. The remaining funds were made available for working capital and acquisition of additional physician practices.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PNC Loan Facility is interest-only with total principal due at an initial maturity on April 30, 2024. Interest originally accrued at one-month LIBOR or an alternate base rate plus 1.45%. The maximum balance of the PNC Loan Facility (“Borrowing Base”) is limited to the lesser of the Facility Limit ($65.0 million) or the fair value of the Company’s patient accounts receivable. The Company must maintain a balance of the lesser of the Borrowing Base or 65% of the Facility Limit in the first year and 75% of the Facility Limit in subsequent years (“minimum funding threshold”). The Company can repay the PNC Loan Facility up to the minimum funding threshold at any time without penalty. In accordance with the PNC Loan Facility, the Company pledged $10.0 million of collateral as restricted cash to be released quarterly in increments of $2.5 million. The restricted cash was fully released as of March 31, 2024 and December 31, 2023.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 30, 2021, the Company entered into a $5.0 million revolving line of credit agreement (“PNC Line of Credit”). The PNC Line of Credit has an expiration date of April 30, 2024 and originally bore interest at a rate per annum equal to the sum of the daily LIBOR rate plus 1.65% or an alternate base rate plus 0.65% and is due on the first day of each month beginning June 1, 2021. Any outstanding principal and accrued interest will be due on the expiration date. Beginning July 1, 2021, quarterly bank fees equal to 1.65% per day per annum are due in arrears and will continue on the first day of each quarter thereafter. All debt related to the PNC Line of Credit is collateralized by the Company’s assets. As of March 31, 2024 and December 31 2023, no draws had been made on the PNC Line of Credit. The Company is also subject to a 0.20% unused line fee calculated per annum on the unused balance of the PNC Line of Credit. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2021, the Company amended the PNC Loan Facility increasing the Facility Limit to $75.0 million. On February 14, 2022, the Company further amended the PNC Loan Facility and Line of Credit agreements. The primary changes included an increase of the Facility limit from $75.0 million to $125.0 million, an increase of the PNC Line of Credit availability from $5.0 million to $10.0 million, interest charges to be calculated based on the Bloomberg Short-Term Bank Yield Index plus 1.65% and certain financial covenants. As part of the amendment, the Company drew an additional $16.3 million in proceeds under the Loan Facility. On August 15, 2022, the PNC Loan Facility and Line of Credit agreements were amended again to reduce the availability under the PNC Line of Credit from $10.0 million to $1.0 million. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective November 23, 2022, the Company entered into Waiver and Amendment No. 6 (“Waiver and Amendment”) under its PNC Loan Facility as the Company was not in compliance with the Delinquency Ratio financial covenant for the period ending October 31, 2022 and the requirement to provide certain annual financial statements. The Waiver and Amendment waives each event of default and also revised future delinquency percentages and financial statement requirements. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2023, the Company entered into Amendment No. 7 (“Amendment 7”) to its PNC Loan Facility which extended the maturity date from April 30, 2024 to June 30, 2026. In connection with Amendment 7, the Company paid additional debt issuance costs of $0.4 million which will be amortized over the revised remaining life of the </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loan Facility. In addition, Amendment 7 revised the definition of the minimum funding threshold to limit the threshold multiplier to 65% of the Facility Limit. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2024, the Company entered into Amendment No. 8 (“Amendment 8”) to its PNC Loan Facility to modify certain definitions such as “change in control”. In addition, the Amendment 8 also amended the delinquency ratio threshold used to calculate certain debt covenants. The effective date of Amendment 8 was January 16, 2024.</span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 16, 2024, the Company also entered into Amendment No. 3 (“Amendment 3”) to its PNC Line of Credit to modify certain definitions such as “change in control”. In addition, the Amendment 3 also amended certain debt covenants, such as EBITDA thresholds. The effective date of Amendment 3 was December 31, 2023. </span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PNC Loan Facility and PNC Line of Credit nonfinancial covenants include restrictions related to unpermitted property liens and the requirement of audited financial statements. Both agreements also contain several financial covenants, including the following ratios: accounts receivable default, delinquency, dilution, days sales outstanding, leverage, and fixed charge coverage. As of March 31, 2024, the Company was in compliance with all financial and nonfinancial debt covenants as required by both loan agreements.</span></div> <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt consisted of the following at March 31, 2024 and December 31, 2023: </span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:59.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.319%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PNC Facility</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,250 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,250 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,250 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,250 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(394)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(609)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80,856 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80,641 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 81250000 81250000 81250000 81250000 394000 609000 80856000 80641000 34600000 0.0145 65000000 0.65 0.75 10000000 2500000 5000000 0.0165 0.0065 0.0165 0 0 0.0020 75000000 75000000 125000000 5000000 10000000 0.0165 16300000 10000000 1000000 400000 0.65 Income Taxes<div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a member of American Oncology Network, LLC, which is treated as a partnership for U.S. federal and certain state and local income taxes. As a partnership, American Oncology Network, LLC is not subject to U.S. federal and certain state and local income taxes. Any taxable income or loss generated by American Oncology Network, LLC is passed through to and included in the taxable income or loss of its members, including the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal income taxes, in addition to state and local income taxes with respect to the allocable share of any taxable income of American Oncology Network, LLC. Additionally, other corporate entities within the Company's structure are subject to income taxes. These corporate entities continue to generate losses and continue to maintain a valuation allowance against their net deferred tax assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s effective income tax rate was (13.1)% and —% for the three months ended March 31, 2024 and 2023, respectively. The provision for income taxes was $2.9 million and $0 for the three months ended March 31, 2024 and 2023, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change to the income tax provision for the three months ended March 31, 2024 compared to the income tax provision for the three months ended March 31, 2023 was primarily a result of the transaction closing on September 20, 2023, resulting in a portion of the Company's consolidated pre-tax earnings, which were previously not subject to income taxes, flowing into a taxable corporation included in the Company's post transaction structure. As of December 31, 2023, the Company recognized a deferred tax asset related to its investment in the American Oncology Network, LLC partnership. As of March 31, 2024, the Company updated its valuation allowance assessment based on new factors including its year-to-date loss and forecasted loss at the American Oncology Network, LLC partnership legal entity. Based on its updated valuation allowance assessment, the Company recorded a discrete valuation allowance against its investment in partnership deferred tax asset during the three months ending March 31, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective income tax rate for the three months ended March 31, 2024 and 2023 differed from the federal statutory rate primarily due to certain legal entities in the Company's structure being treated as partnerships for income tax purposes and, therefore, a significant portion of its income not being subject to income tax. Additionally, certain corporate entities within the Company's structure continue to maintain a full valuation allowance against their net deferred tax assets.</span></div> -0.131 0 2900000 0 Leases<div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently leases office facilities and equipment for its practices under noncancelable operating and finance lease agreements expiring on various dates through 2038. Certain of the leases contain renewal options which are exercisable at the Company’s discretion. These renewal options are considered in determining the lease term if it is reasonably certain that the Company will exercise such options. Additionally, the Company leases certain other office and medical equipment under month-to-month lease agreements. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and lease liabilities consist of the following at March 31, 2024 and December 31, 2023:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.457%"><tr><td style="width:1.0%"></td><td style="width:58.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,358 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease right-of-use assets, net (included in property and equipment, net)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,513 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,794 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total right-of-use assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,871 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,143 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,692 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of finance lease liabilities (included in accrued other)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,920 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,881 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,786 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term finance lease liabilities (included in other long-term liabilities)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51,945 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,232 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs recognized in the condensed consolidated statements of operations and comprehensive loss consist of the following for the three month periods ended March 31, 2024 and 2023 and are included in selling, general, and administrative expenses unless otherwise noted:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.457%"><tr><td style="width:1.0%"></td><td style="width:58.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,795 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,870 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of finance lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">281</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on finance lease liabilities (included in interest expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">586</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">578</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease costs</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,748 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,575 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the undiscounted cash flows expected to be paid in each of the next five years and thereafter recorded in the condensed consolidated balance sheets for operating and finance leases as of March 31, 2024:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.457%"><tr><td style="width:1.0%"></td><td style="width:58.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating <br/>Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024 (remainder of year after March 31, 2024)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,959 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,132 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,014 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,620 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">948 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,262 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: amount representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,880)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(818)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,501 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,444 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,715)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities, net of current portion</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,786 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,239 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease term as of March 31, 2024 and December 31, 2023 was 4.54 years and 6.93 years for operating leases and 6.84 years and 4.76 years for finance leases, respectively. The weighted-average discount rate as of March 31, 2024 and December 31, 2023 was 6.33% and 6.64% for operating leases and 6.71% and 6.30% for finance leases, respectively.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash paid for amounts included in the measurement of lease liabilities for the three months ended March 31, 2024 and 2023 is as follows:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.457%"><tr><td style="width:1.0%"></td><td style="width:58.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,799 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,845 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for new operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,048 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> Leases<div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently leases office facilities and equipment for its practices under noncancelable operating and finance lease agreements expiring on various dates through 2038. Certain of the leases contain renewal options which are exercisable at the Company’s discretion. These renewal options are considered in determining the lease term if it is reasonably certain that the Company will exercise such options. Additionally, the Company leases certain other office and medical equipment under month-to-month lease agreements. </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and lease liabilities consist of the following at March 31, 2024 and December 31, 2023:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.457%"><tr><td style="width:1.0%"></td><td style="width:58.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,358 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease right-of-use assets, net (included in property and equipment, net)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,513 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,794 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total right-of-use assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,871 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,143 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,692 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of finance lease liabilities (included in accrued other)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,920 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,881 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,786 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term finance lease liabilities (included in other long-term liabilities)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51,945 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,232 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs recognized in the condensed consolidated statements of operations and comprehensive loss consist of the following for the three month periods ended March 31, 2024 and 2023 and are included in selling, general, and administrative expenses unless otherwise noted:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.457%"><tr><td style="width:1.0%"></td><td style="width:58.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,795 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,870 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of finance lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">281</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on finance lease liabilities (included in interest expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">586</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">578</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease costs</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,748 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,575 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the undiscounted cash flows expected to be paid in each of the next five years and thereafter recorded in the condensed consolidated balance sheets for operating and finance leases as of March 31, 2024:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.457%"><tr><td style="width:1.0%"></td><td style="width:58.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating <br/>Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024 (remainder of year after March 31, 2024)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,959 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,132 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,014 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,620 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">948 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,262 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: amount representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,880)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(818)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,501 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,444 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,715)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities, net of current portion</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,786 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,239 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease term as of March 31, 2024 and December 31, 2023 was 4.54 years and 6.93 years for operating leases and 6.84 years and 4.76 years for finance leases, respectively. The weighted-average discount rate as of March 31, 2024 and December 31, 2023 was 6.33% and 6.64% for operating leases and 6.71% and 6.30% for finance leases, respectively.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash paid for amounts included in the measurement of lease liabilities for the three months ended March 31, 2024 and 2023 is as follows:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.457%"><tr><td style="width:1.0%"></td><td style="width:58.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,799 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,845 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for new operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,048 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and lease liabilities consist of the following at March 31, 2024 and December 31, 2023:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.457%"><tr><td style="width:1.0%"></td><td style="width:58.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,358 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,349 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease right-of-use assets, net (included in property and equipment, net)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,513 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,794 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total right-of-use assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,871 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,143 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,692 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of finance lease liabilities (included in accrued other)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,920 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,881 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,786 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,803 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term finance lease liabilities (included in other long-term liabilities)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,548 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51,945 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52,232 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 43358000 43349000 5513000 5794000 48871000 49143000 6715000 6692000 1205000 1189000 7920000 7881000 39786000 39803000 4239000 4548000 51945000 52232000 <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs recognized in the condensed consolidated statements of operations and comprehensive loss consist of the following for the three month periods ended March 31, 2024 and 2023 and are included in selling, general, and administrative expenses unless otherwise noted:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.457%"><tr><td style="width:1.0%"></td><td style="width:58.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,795 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,870 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of finance lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">281</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on finance lease liabilities (included in interest expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">586</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">578</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease costs</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,748 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,575 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash paid for amounts included in the measurement of lease liabilities for the three months ended March 31, 2024 and 2023 is as follows:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.457%"><tr><td style="width:1.0%"></td><td style="width:58.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,799 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,845 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for new operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,048 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,326 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2795000 2870000 281000 110000 86000 17000 586000 578000 3748000 3575000 <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the undiscounted cash flows expected to be paid in each of the next five years and thereafter recorded in the condensed consolidated balance sheets for operating and finance leases as of March 31, 2024:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.457%"><tr><td style="width:1.0%"></td><td style="width:58.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating <br/>Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024 (remainder of year after March 31, 2024)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,959 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,132 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,014 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,620 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">948 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,262 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: amount representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,880)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(818)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,501 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,444 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,715)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities, net of current portion</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,786 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,239 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the undiscounted cash flows expected to be paid in each of the next five years and thereafter recorded in the condensed consolidated balance sheets for operating and finance leases as of March 31, 2024:</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.457%"><tr><td style="width:1.0%"></td><td style="width:58.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating <br/>Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024 (remainder of year after March 31, 2024)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,959 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,132 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,014 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,620 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,185 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">948 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,147 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">261 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60,381 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,262 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: amount representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,880)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(818)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,501 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,444 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,715)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities, net of current portion</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39,786 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,239 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 6959000 1132000 10014000 1487000 9620000 1249000 8370000 1185000 6271000 948000 19147000 261000 60381000 6262000 13880000 818000 46501000 5444000 6715000 1205000 39786000 4239000 P4Y6M14D P6Y11M4D P6Y10M2D P4Y9M3D 0.0633 0.0664 0.0671 0.0630 2799000 2845000 86000 17000 291000 105000 2048000 4326000 Related Parties<div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transactions Notes Receivable</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into promissory notes with physicians of the Company. The notes receivable balances are satisfied through cash payments or settlements through the physicians’ compensation as part of their employee agreement. The notes receivable are amortized over a 60-month period as a reduction of compensation. The notes bear interest at the Company’s incremental borrowing rate (7.09% at March 31, 2024 and 7.18% at December 31, 2023, respectively).</span></div><div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:23.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.404%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.982%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of <br/>December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Original<br/>Principal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issue <br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturity<br/>Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes receivable</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 2</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">656 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">656 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/1/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4/30/2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 3</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">491 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6/1/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/31/2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 8</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,999 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,081 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,816 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/1/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/1/2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total notes receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,655 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,754 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:  Current portion of notes receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,498)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,604)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes receivable, less current portion</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,150 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for thirteen of the office facilities owned by employees of the Company. Total cash was approximately $0.7 million and $0.7 million paid for leases to related parties for the three months ended March 31, 2024 and 2023, respectively.</span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory Purchases/Concentration Risk </span></div><div style="margin-top:10pt;padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company purchases the majority of pharmaceuticals inventory from a subsidiary under common control of a Legacy AON Shareholder. During the three months ended March 31, 2024 and 2023, the Company purchased from the related party approximately $311.0 million and $243.0 million, respectively. These purchases were approximately 88% and 87% as a percentage of cost of revenue for the three months ended March 31, 2024 and 2023, respectively. At March 31, 2024 and December 31, 2023, the Company had $183.0 million and $102.1 million, respectively, included in accounts payable for invoices from the related party, representing 97% of accounts payable at each period-end.</span></div> P60M 0.0709 0.0718 <div style="margin-top:10pt;padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:23.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.404%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.982%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of <br/>December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Original<br/>Principal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issue <br/>Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturity<br/>Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes receivable</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 2</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">656 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">656 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/1/2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4/30/2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 3</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">491 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6/1/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/31/2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Note 8</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,999 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,081 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,816 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/1/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5/1/2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total notes receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,655 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,754 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:  Current portion of notes receivable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,498)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,604)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes receivable, less current portion</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,150 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div> 656000 656000 5355000 0 17000 491000 1999000 2081000 2816000 2655000 2754000 2498000 1604000 157000 1150000 13 700000 700000 311000000 243000000 0.88 0.87 183000000 102100000 0.97 0.97 quity-Based Compensation<div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a single equity incentive plan, the “2023 Incentive Equity Plan”, which was adopted by the Board of Directors and approved by stockholders in connection with the Business Combination. A total of 5,300,000 shares were authorized under the 2023 Incentive Equity Plan. The number of shares of common stock available for issuance under the 2023 Incentive Equity Plan will be increased annually on the first day of each fiscal year during the term of the 2023 Incentive Equity Plan by an amount equal to the lesser of (a) 5% of the shares of common stock outstanding on the final day of the immediately preceding calendar year or (b) such smaller number of shares as determined by the Company’s board of directors. At March 31, 2024, 2,044,394 shares were available for grant under the 2023 Incentive Equity Plan. The purpose of the 2023 Incentive Equity Plan is to attract and retain personnel for positions with the Company, to provide additional incentive to employees, directors, and consultants, and to promote the success of the Company’s business. The Plan permits the grant of Incentive Stock Options (“ISO”) to any ISO Employee and the grant of Non statutory stock options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, and Performance Awards to any Service Provider.</span></div><div style="padding-left:31.5pt;text-indent:36pt"><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="padding-left:31.5pt;text-indent:36pt"><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted 3,759,459 Restricted Stock Units (“RSUs”) to employees during the three months ended March 31, 2024.</span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU activity during the three month period ending March 31, 2024 is as follows:</span></div><div style="padding-left:31.5pt;text-indent:36pt"><span><br/></span></div><div style="padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:45.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.789%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,759,459 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,289,181)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,470,278 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.67 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt;text-indent:36pt"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $13.3 million in stock-based compensation expense related to outstanding RSUs during the three months ended March 31, 2024. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, there was approximately $8.2 million of total unrecognized compensation expense related to RSUs, which is expected to be recognized over a weighted-average period of approximately 1.7 years.</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the RSUs is determined on the date of the grant based on the market price of the Company’s common stock on that date. Each RSU represents the right to receive one share of the Company’s common stock, upon vesting. Portions of the RSUs granted vest immediately with others vesting over <span style="-sec-ix-hidden:f-768">one</span> to two years following the grant date, subject to the individual’s continued service to the Company through the applicable vesting date, and are subject to the terms and conditions on the Company’s form of RSU agreement under the 2023 Incentive Equity Plan.</span></div> 5300000 0.05 2044394 3759459 <div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU activity during the three month period ending March 31, 2024 is as follows:</span></div><div style="padding-left:31.5pt;text-indent:36pt"><span><br/></span></div><div style="padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:45.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.789%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,759,459 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,289,181)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding as of March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,470,278 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.67 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 0 3759459 5.73 2289181 5.80 0 0 1470278 5.67 13300000 8200000 P1Y8M12D 1 P2Y Equity<div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Prior Period Presentation</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods prior to the Reverse Recapitalization, AON LLC had equity and stock-based compensation described below authorized, issued and outstanding. As discussed in Note 1, upon the Closing of the Business Combination, Legacy AON Shareholders received Class A Common Stock, Class B Common Stock, or Class B Prefunded Warrants and AON LLC reclassified their existing Class A, Class A-1, and Class B Units into AON LLC Common Units, pursuant to the terms of the Business Combination Agreement.</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recasted Historical AON LLC Equity outstanding for the periods prior to the Reverse Recapitalization, equal to the Per Company Unit Exchange Ratio, pursuant to the Business Combination, that was applied to the Class A, Class A-1, and Class B Units. The historical AON LLC units disclosed in this note give effect to the conversion for all periods presented, as follows. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Class A Units</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AON LLC had authorized 19,495,376 units of Class A Units, of which 19,495,376 units were issued and were outstanding as of December 31, 2022. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Class A-1 Units</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AON LLC had authorized 3,000,245 units of Class A-1 Units, of which 1,842,520 units were issued and were outstanding as of December 31, 2022. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Class B Units (Profit Interest)</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Class B units were issued through the 2017 Profits Interest Plan adopted by the Company in October 2017. The Class B Units represented a non-voting equity interest in AON LLC that entitled the holder to appreciation in the equity value of AON LLC arising after the date of grant and after such time as an applicable hurdle amount is met. AON LLC recognized the cost of services received in exchange for Class B Units based on the grant-date fair value. That cost was recognized over the period during which the service provider is required to provide service in exchange for the award over the requisite service period or based on performance. AON LLC used the Black-Scholes-Merton pricing model to estimate the fair value of profits interest unit awards. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an as converted basis,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of December 31, 2022, AON LLC issued 5,614,176 Class B Units, of which 4,703,628 were vested and outstanding; the remaining 910,548 of Class B units vested upon consummation of the Business Combination. </span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes to AON LLC’s Class A, Class A-1, and Class B Units for the three months ended March 31, 2023. </span></div><div style="padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:68.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in thousands, except for share and per share amounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class A Units, value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning of Period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,725 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of Units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of the Reverse Recapitalization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,725 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class A Units, units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning of Period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,495,376 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of Units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of the Reverse Recapitalization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,495,376 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class A-1 Units, value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning of Period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of Units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of the Reverse Recapitalization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class A-1 Units, units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning of Period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,842,520 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of Units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of the Reverse Recapitalization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,842,520 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class B Units, value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning of Period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of the Reverse Recapitalization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class B Units, units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning of Period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,703,628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Units Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of the Reverse Recapitalization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,703,628 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Class B-1 Units </span></div><div style="text-align:justify;text-indent:28.8pt"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June and July of 2023, the Company granted a total of 415 AON LLC Class B-1 Units to certain employees under the 2017 Profits Interest Plan (the “Plan”). Upon the closing of the Business Combination, the vested Class B-1 Units were reclassified to AON LLC Common Units and exchanged for newly issued shares of Class A Common Stock equal to the Per Company Unit Exchange Ratio, pursuant to the Business Combination Agreement, which resulted in the issuance of 1,047,343 shares of New AON Class A Common Stock. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mezzanine Equity Class C Units</span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 1, the AON LLC Class C Units were converted into AON LLC Series A Preferred Units as of the Closing Date. Concurrently, New AON issued a number of shares of New AON Series A Preferred Stock equal </span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the number of AON LLC Series A Preferred Units held by the AON Class C Preferred Investor to AEA Growth Management LP, the parent of AON Class C Preferred Investor (“AEA Growth”) in exchange for all the shares of common stock held by AEA Growth in the AON Class C Preferred Investor. Promptly after the First Step, the AON Class C Preferred Investor merged with and into New AON whereby the separate existence of the AON Class C Preferred Investor ceased and New AON held all the AON LLC Series A Preferred Units. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an as converted basis,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of September 20, 2023, 6,651,610 Series A Preferred Stock were issued to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AEA Growth Management LP</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AON LLC Class C Units were contingently redeemable convertible preferred units and classified as mezzanine equity on the condensed consolidated balance sheet as of June 30, 2023 because the units were redeemable five years from the issuance date, at the option of the holder. As of June 30, 2023, the AON LLC Class C Units were recorded at their initial carrying value, net of offering costs. The Class C Units were not being accreted to redemption value, as the redemption was not probable due to the removal of the redemption right pursuant to the Business Combination. See discussion below. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Class C Units had materially the same rights as the Series A Preferred Stock issued by the Company to AEA Growth Management LP, the parent of the AON Class C Preferred Investor, with the exception of the “AON LLC Class C Unit Redemption Right” and the “Class C Option to Purchase Additional Shares”, discussed below. Further, the Class C Units did not contain a mandatory conversion feature that allowed AON LLC to force the Class C Investor to convert the Class C Units into another equity unit in AON LLC and the Class C Units did not have a one time conversion price adjustment. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Class C Unit Redemption Right</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the fifth anniversary of the Effective Date (June 7, 2028), the holders of a majority of the Class C Units had the right to cause the Company to redeem all of the Class C Units. The redemption price per Class C Unit was equal to the greater of (i) the Class C Liquidation Preference and (ii) the Fair Market Value of a Class C Unit (the “Class C Redemption Price”). The Class C Liquidation Preference is defined as an amount equal to the sum of (a) the Class C Preferred Return of such Class C Member and (b) the amount of such Class C Member’s Net Invested Capital Contributions of $65.0 million. The Class C Unit Preferred Return is defined as the cumulative, semiannually-compounded return of 8% per annum based on the original Net Invested Capital Contributions of $65.0 million. The Class C Unit Redemption Right was removed as of the Closing of the Business Combination. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Series A Preferred Stock (Mezzanine Equity) </span></div><div style="text-align:justify;text-indent:28.8pt"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#060606;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New AON Series A Preferred Stock is redeemable for cash or the value of the property, rights or securities to be paid or distributed in the event of a Deemed Liquidation Event (which outside of the Company’s control). As a result, the Company has determined that the New AON Series A Preferred Stock should be classified as mezzanine equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. At the closing of the Business Combination, the Company exchanged existing AON LLC Class C Units for Series A Preferred Stock in the Company. Based on the qualitative changes to the instrument, this exchange is considered an extinguishment for accounting purposes, with the Company recording a deemed dividend of $2.1 million to account for the difference between the carrying value of the Class C Units and the fair value of the Series A Preferred Stock at the transaction date. This amount is reflected in the December 31, 2023 condensed consolidated statements of mezzanine and stockholders’ equity as part of the reverse recapitalization, net. See further discussion on the PIK Dividend discussed below. </span></div><div><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A Preferred Stock are not being accreted to redemption value, as the Series A Preferred Stock are not redeemable, nor are they probable of becoming redeemable. </span></div><div style="text-align:justify;text-indent:28.8pt"><span><br/></span></div><div style="text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="text-align:justify;text-indent:28.8pt"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A Preferred Stock accrue dividends at a cumulative, semiannually-compounded return of 8% per annum based on the original Net Invested Capital Contributions from the Class C Units of $65.0 million. These dividends may be paid in cash or accumulate into the Accrued Value at the option of New AON. The accrual shall be calculated on June 30 and December 31 and with respect to the semiannually-compounded return, no interest is required to be paid on any present or future Series A Preferred Stock accrued dividends. The Series A Preferred Stock also participate in distributions with the Class A Common stockholders. </span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2023, the Company issued </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,651,610 Series A Preferred Stock to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AEA Growth Management LP. The number of Series A Preferred Stock shares issued at the Closing of the Business Combination was equal to the aggregate Class C Liquidation Preference pursuant to the Business Combination Agreement. As a result, the issuance of the Series A Preferred Stock effectively included an in-kind payout (“PIK”) of the accrued dividend since the calculation of the amount issued was based on the Class C Liquidation Preference. As of the Closing, the Company recorded a dividend of 151,610 Series A Preferred Stock PIK shares with respect to the accrued dividends on the Series A Preferred Stock (the "PIK Dividend") in the December 31, 2023 condensed consolidated statements of mezzanine and stockholders’ equity. </span></div><div style="text-align:justify;text-indent:28.8pt"><span><br/></span></div><div style="text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Voting </span></div><div style="text-align:justify;text-indent:28.8pt"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of the Preferred Stock are entitled to elect and appoint one of the directors (“Series A Director”) to the Board of Directors. All other directors are appointed by the Class A and Class B Common stockholders. There are no restrictions on which matters the Series A Preferred stockholders are entitled to vote. The Series A Preferred stockholders are entitled to the number of votes equal to the number of shares of Common Stock into which the Series A Preferred Stock would be convertible on the record date of the vote.</span></div><div style="text-align:justify;text-indent:28.8pt"><span><br/></span></div><div style="text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conversion Rights</span></div><div style="text-align:justify;text-indent:28.8pt"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A Preferred Stock is convertible, at the option of the holder, at any time, and without the payment of additional consideration by the holder, into such number of fully-paid Class A Common Stock as is determined by dividing the Accrued Value by the Conversion Price in effect at the time of conversion (“Conversion Ratio”). The Accrued Value is the Original Issue Price (which is $10.00 per share of Preferred Stock, as adjusted for any stock split, stock dividend, combination, or other recapitalization) plus any unpaid dividends, compounded semi-annually. The Conversion Price is initially $10.00 per Preferred Share subject to adjustment for dilutive issuances of additional shares, dividends to common stockholders, stock splits, mergers, and a five-year anniversary special adjustment based on the volume weighted average price of the common stock. These dividends may be paid in cash or accumulate into the Accrued Value, at the option of New AON, on June 30 and December 31 of each year. The Conversion Rights shall terminate at the close of business on the day prior to the date of a Change of Control.</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If at any time on or after the 30th day after the five-year anniversary of the issue date, any of the Series A Preferred Stock remain outstanding and the 30-Day VWAP of the Common Stock is less than $10.00 (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification), then the Conversion Price shall be adjusted to the greater of (x) the 30-Day VWAP on such date of determination and (y) $5.00 (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification).</span></div><div style="text-align:justify;text-indent:28.8pt"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New AON also has the right on or after the third-year anniversary of the date of issuance to cause all (but not less than all) of the outstanding shares of Series A Preferred Stock to be converted into shares of Class A Common Stock for each share of Series A Preferred Stock at the Conversion Ratio detailed above. The Company may only convert shares of Series A Preferred Stock into shares of Common Stock if the 30-Day VWAP of the Common Stock immediately prior to the Company Conversion Date is greater than $16.00 (as adjusted for any stock split, stock dividend, combination, or other recapitalization).</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidation Preferences</span></div><div style="text-align:justify;text-indent:28.8pt"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of voluntary or involuntary liquidation, dissolution or winding up of the Company or an Initial Public Offering (IPO) or Exit Event, the Series A Preferred Stock have preferential liquidation rights. If a Deemed Liquidation Event were to occur, each Series A Preferred stockholder is entitled to be paid out of the assets of the Company available for distribution, equal to the greater of the following: </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:49.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) The Original Issue Price of $10 per Series A Preferred Stock multiplied by the Applicable Percentage plus any Accrued Dividends on such share of Series A Preferred Stock; or</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:49.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) Such amount per share as would have been payable had all shares of Series A Preferred Stock been converted into Common Stock immediately prior to such Deemed Liquidation Event.</span></div><div style="padding-left:49.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A Preferred Stock Applicable Percentage is defined as a percentage equal to (a) one hundred twenty-five percent (125%) if an Exit Event, dissolution, liquidation, or winding-up occurs prior to June 7, 2024, (b) one </span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hundred twenty percent (120%) if an Exit Event, dissolution, liquidation, or winding up occurs after June 7, 2024, but prior to June 7, 2025, (c) one hundred fifteen percent (115%) if an Exit Event, dissolution, liquidation, or winding-up occurs after June 7, 2025, but prior to June 7, 2026, (d) one hundred ten percent (110%) if an Exit Event, dissolution, liquidation, or winding up occurs after June 7, 2026, but prior to June 7, 2027, (e) one hundred five percent (105%) if an Exit Event, dissolution, liquidation, or winding-up occurs after June 7, 2027, but prior to June 7, 2028, (f) one hundred percent (100%) if an Exit Event, dissolution, liquidation, or winding-up occurs after June 7, 2028.</span></div><div><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Distributions to Class A and Class A-1 Members </span></div><div style="text-align:justify;text-indent:28.8pt"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 4, 2020, the AON LLC entered into the Second Amended and Restated Limited Liability Agreement (“Second Operating Agreement”) which established another class of equity, Class A-1 Units. The Second Operating Agreement provided, among other things, that the Class A and A-1 Units would receive a cumulative, annually-compounded, preferred return of 8.0% and 4.0%, respectively, on capital contributions when and if distributions are declared by the Board of the Company. </span></div><div style="text-align:justify;text-indent:28.8pt"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the issuance of the Class C Units on June 7, 2023 as discussed above, the Class A and A-1 unitholders were paid a cash distribution of $4.0 million and $4.1 million, respectively, representing the cumulative accrued preferred return to June 7, 2023. </span></div><div style="text-align:justify;text-indent:28.8pt"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 7, 2023, in connection with the issuance of the Class C Units, AON LLC entered into the Third Amended and Restated Limited Liability Agreement (“Third Operating Agreement”) which, among other things, eliminated any provisions for future preferred returns on Class A and A-1 units.</span></div> 19495376 19495376 19495376 3000245 1842520 1842520 5614176 4703628 910548 <div style="padding-left:31.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes to AON LLC’s Class A, Class A-1, and Class B Units for the three months ended March 31, 2023. </span></div><div style="padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:68.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.836%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in thousands, except for share and per share amounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class A Units, value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning of Period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,725 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of Units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of the Reverse Recapitalization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,725 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class A Units, units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning of Period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,495,376 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of Units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of the Reverse Recapitalization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,495,376 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class A-1 Units, value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning of Period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of Units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of the Reverse Recapitalization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class A-1 Units, units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning of Period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,842,520 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of Units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of the Reverse Recapitalization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,842,520 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class B Units, value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning of Period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of the Reverse Recapitalization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Class B Units, units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning of Period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,703,628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Units Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impact of the Reverse Recapitalization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,703,628 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 7725000 0 0 7725000 19495376 0 0 19495376 28500000 0 0 28500000 1842520 0 0 1842520 80000 0 0 80000 4703628 0 0 4703628 415 1047343 6651610 P5Y 65000000 0.08 65000000 2100000 0.08 65000000 6651610 151610 10.00 10.00 P5Y P30D P5Y P30D 10.00 P30D 5.00 P30D 16.00 10 1.25 1.20 1.15 1.10 1.05 1 0.080 0.040 4000000 4100000 Net Loss Per Share<div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net loss per share of Class A Common Stock and represents the period from January 1, 2024 to March 31, 2024, the period where the Company had Class A and Class B common stock outstanding. Class B Common Stock does not have economic rights in AON Inc., including rights to dividends or distributions upon liquidation, and as a result, is not considered a participating security for basic and diluted loss per share. As such, basic and diluted loss per share of Class B Common Stock has not been presented. Series A Preferred Stock are considered participating securities for basic and diluted loss per share, but do not participate in losses. As such, basic and diluted loss per share is computed using the two-class method. For additional information, see Notes 1 and 2.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is based on the weighted-average number of shares of Class A Common Stock outstanding during the period. Diluted loss per share is based on the weighted-average number of shares of Class A Common Stock used for the basic loss per share calculation, adjusted for the dilutive effect of Public and Private Warrants, Restricted Stock Units, and Sponsor Earnouts, if any, using the “treasury stock” method and the convertible Series A Preferred Stock, Class B Common Stock, and Class B Prefunded Warrants, if any, using the “if-converted” method. Net loss for diluted loss per share is adjusted for the Company’s share of AON LLC’s consolidated net loss, net of AON Inc. taxes, after giving effect to Class B Common Stock and Class B Prefunded Warrants that are exchanged into potential shares of Class A Common Stock, Public and Private Warrants that are liability classified, and Series A Preferred Stock that accrue dividends, to the extent it is dilutive.</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:81.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.891%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to Class A Common Stockholders for basic and diluted earnings per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,841,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series A Preferred Cumulative Dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,360,180)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undistributed loss for basic earnings per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,201,180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares for basic earnings per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,527,882 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and Diluted loss per share of Class A Common Stock</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.22)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the securities that have been excluded from the calculation of weighted-average shares for diluted loss per share for the period presented as they were anti-dilutive. Note that the Sponsor Earnouts are excluded from the calculation of weighted-average shares for diluted loss per share as the contingency had not been met as of the period end.</span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:81.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.891%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 10pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series A Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,651,610 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 10pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class B Common Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,725,998 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 10pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class B Prefunded Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,000,245 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 10pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public and Private Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,450,833 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 10pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,470,278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> Net loss for diluted loss per share is adjusted for the Company’s share of AON LLC’s consolidated net loss, net of AON Inc. taxes, after giving effect to Class B Common Stock and Class B Prefunded Warrants that are exchanged into potential shares of Class A Common Stock, Public and Private Warrants that are liability classified, and Series A Preferred Stock that accrue dividends, to the extent it is dilutive.<div style="padding-left:31.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:81.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.891%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to Class A Common Stockholders for basic and diluted earnings per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,841,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series A Preferred Cumulative Dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,360,180)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undistributed loss for basic earnings per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,201,180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares for basic earnings per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,527,882 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and Diluted loss per share of Class A Common Stock</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.22)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table details the securities that have been excluded from the calculation of weighted-average shares for diluted loss per share for the period presented as they were anti-dilutive. Note that the Sponsor Earnouts are excluded from the calculation of weighted-average shares for diluted loss per share as the contingency had not been met as of the period end.</span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:81.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.891%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 10pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series A Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,651,610 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 10pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class B Common Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,725,998 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 10pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class B Prefunded Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,000,245 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 10pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public and Private Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,450,833 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 10pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted Stock Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,470,278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -7841000 -7841000 1360180 -9201180 7527882 -1.22 -1.22 6651610000 23725998000 3000245000 14450833000 1470278000 Redeemable Noncontrolling Interest<div style="padding-left:31.5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legacy AON Shareholders own 26,726,243 AON LLC Common Units, equal to a 61.1% of the economic interest in AON LLC. Legacy AON Shareholders also own 23,725,998 shares of Class B Common Stock and 3,000,245 Class B Prefunded Warrants, which, together with the AON LLC Common Units, may be redeemed at the option of the Legacy AON Shareholder on a one-for-one basis for shares of Class A Common Stock or the cash equivalent thereof (based on the market price of the shares of Class A Common Stock at the time of redemption) as determined by New AON. If New AON elects the redemption to be settled in cash, the cash used to settle the redemption must be funded through a private or public offering of Class A Common Stock no later than <span style="-sec-ix-hidden:f-859">ten</span> (10) business days after the redemption notice date. Upon the redemption of the AON LLC Common Units and Class B </span></div><div style="padding-left:31.5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common Stock for shares of Class A Common Stock or the equivalent thereof, all redeemed shares of Class B Common Stock will be cancelled. The redemption value is determined based on a five-day volume weighted average price (”VWAP”) of the Class A common shares, subject to customary conversion rate adjustments for share splits, share dividends, and similar events affecting Class A Common Stock.</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When applying SEC guidance concerning mezzanine classification, the Company understands that due to the NCI holders having control of the Board, if there is a sequence of remotely possible events that could trigger a redemption, this requires the instrument to be classified as temporary equity, without any regard to probability. Accordingly, though the redemption would require such a remotely possible sequence of events, and such remote sequence of events would also require, in management’s view, the Company to take extraordinary actions in order to allow such sequence of events to be remotely possible, the noncontrolling interest is currently classified as temporary equity. In the event that the Legacy AON Shareholders own less than 50% of the outstanding economic interest in AON LLC Common Units due to future redemptions, the noncontrolling interest will be presented as permanent equity. </span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The redeemable noncontrolling interest is recognized at the greater of (1) its initial fair value plus accumulated earnings/(losses) associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At March 31, 2024, the redeemable noncontrolling interest was recorded based on its redemption value of $157.7 million which exceeded its carrying value by $15.6 million. This measurement adjustment decreased additional paid in capital by $9.7 million and retained deficit by $5.9 million. At the end of each reporting period, AON LLC equity attributable to AON Inc. and the Legacy AON Shareholders is rebalanced to reflect AON Inc.’s and the Legacy AON Shareholder’s ownership in AON LLC.</span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the economic ownership of AON LLC, for the period beginning December 31, 2023 and ending March 31, 2024. </span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:40.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.479%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.479%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Period beginning December 31, 2023 and ending March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">AON LLC Units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AON Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legacy AON Shareholders</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Beginning of Period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,330,051 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,109,796 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,439,847 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,289,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,289,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repurchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16,441)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16,441)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Redemptions </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,383,553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,383,553)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Units Issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,986,344 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,726,243 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,712,587 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,986,344 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,726,243 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,712,587 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation of income to controlling and noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation of losses to controlling and noncontrolling interests </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.0 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77.0 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) As discussed in Note 13, Series A Preferred Stock are considered participating securities for basic and diluted loss per share, but do not participate in losses. As a result, the consolidated net loss of AON LLC, during the period of January 1, 2024 through March 31, 2024, were </span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">allocated to the NCI to reflect the absorption of the Legacy AON Shareholders to a portion of the consolidated net loss of AON LLC. Net losses were not attributed to Series A Preferred Stock.</span></div> 26726243 0.611 23725998 3000245 1 P5D 0.50 157700000 15600000 -9700000 -5900000 <div style="padding-left:31.5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the economic ownership of AON LLC, for the period beginning December 31, 2023 and ending March 31, 2024. </span></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="padding-left:31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.636%"><tr><td style="width:1.0%"></td><td style="width:40.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.479%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.479%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.480%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Period beginning December 31, 2023 and ending March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">AON LLC Units</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AON Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legacy AON Shareholders</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Beginning of Period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,330,051 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,109,796 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,439,847 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,289,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,289,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repurchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16,441)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16,441)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Redemptions </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,383,553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,383,553)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Units Issued</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,986,344 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,726,243 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,712,587 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">End of Period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,986,344 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,726,243 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,712,587 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation of income to controlling and noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation of losses to controlling and noncontrolling interests </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.0 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77.0 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100 </span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) As discussed in Note 13, Series A Preferred Stock are considered participating securities for basic and diluted loss per share, but do not participate in losses. As a result, the consolidated net loss of AON LLC, during the period of January 1, 2024 through March 31, 2024, were </span></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">allocated to the NCI to reflect the absorption of the Legacy AON Shareholders to a portion of the consolidated net loss of AON LLC. Net losses were not attributed to Series A Preferred Stock.</span></div> 13330051 28109796 41439847 2289181 0 2289181 16441 0 16441 1383553 1383553 0 16986344 26726243 43712587 16986344 26726243 43712587 0.389 0.611 1 0.230 0.770 1 Includes related party operating right-of-use assets, net of $11,293 and $10,931 at March 31, 2024 and December 31, 2023, respectively Includes amounts due to related party of $182,697 and $120,857 at March 31, 2024 and December 31, 2023, respectively Includes related party current portion of operating lease liabilities of $1,971 and $1,888 at March 31, 2024 and December 31, 2023, respectively Includes related party long-term operating lease liabilities of $9,772 and $9,472 at March 31, 2024 and December 31, 2023, respectively Includes related party amortization of operating right-of-use assets of $2,146 and $528 for the three months ended March 31, 2024 and 2023, respectively. Includes changes in related party balances of ($7,688) and $4,610 for the three months ended March 31, 2024 and 2023, respectively. Includes changes in related party balances of $80,584 and $3,669 for the three months ended March 31, 2024 and 2023, respectively. Includes changes in related party balances of ($2,381) and ($797) for the three months ended March 31, 2024 and 2023, respectively.

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î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